



Effective Health Care Program

Comparative Effectiveness Review
Number 93

Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Comparative Effectiveness Review

Number 93

Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10058-I

Prepared by:

Blue Cross and Blue Shield Association Technology Evaluation Center
Evidence-based Practice Center
Chicago, IL

Investigators:

Suzanne Belinson, M.P.H., Ph.D.
Ryan Chopra, M.P.H.
Yoojung Yang, M.S., Pharm.D.
Veena Shankaran, M.D.
Naomi Aronson, Ph.D.

This report is based on research conducted by the Blue Cross Blue Shield Association Technology Evaluation Center (BCBSA TEC) Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHS 290 2007 10058-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those copyrighted materials is prohibited without the specific permission of copyright holders.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EffectiveHealthCare@ahrq.hhs.gov.

| |
|---|
| None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. |
|---|

Suggested citation: Belinson S, Chopra R, Yang Y, Shankaran V, Aronson N. Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer. Comparative Effectiveness Review No. 93. (Prepared by Blue Cross and Blue Cross Blue Shield Association Technology Evaluation Center under Contract No. 290-2007-10058-I.) AHRQ Publication No. 13-EHC014-EF. Rockville, MD: Agency for Healthcare Research and Quality. December 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm

AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input from are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input.

We welcome comments on this systematic review. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director
Evidence-based Practice Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Supriya Janakiraman, M.D., M.P.H.
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

The authors gratefully acknowledge the following individuals for their contributions to this project: Claudia Bonnell, R.N., M.L.S.; Jennifer Brock, M.P.H.; Stacey C. Chapman Tobin, Ph.D., E.L.S.; Lisa Garofalo, B.A.; Jenna Khan, M.P.H., David Samson, M.S.; Lisa Sarsany, M.A.; Kathleen Ziegler, Pharm.D.

Key Informants

James Andrews, M.D.
Professor of Radiology
Mayo Clinic
Rochester, MN

Suzanne Lindley, M.S.W.
Patient Advocate
YES! Beat Liver Tumors
Canton, TX

Al Benson, M.D.
Professor of Medicine
Northwestern University
Chicago, IL

Mark Sands, M.D.
Vice Chair, Clinical Ops, Quality/Section
Head, Interventional Radiology
Cleveland Clinic
Cleveland, OH

Virginia Calega, M.D., M.B.A.
Vice President of Medical
Management/Policy
Highmark, Inc.
Camp Hill, PA

Technical Expert Panel

James Andrews, M.D.
Professor of Radiology
Mayo Clinic
Rochester, MN

Afsaneh Barzi, M.D., Ph.D.
Assistant Professor of Clinical
Medicine/Hematology and Oncology
University of Southern California Hospital
Los Angeles, CA

Al Benson, M.D.
Professor of Medicine
Northwestern University
Chicago, IL

Virginia Calega, M.D., M.B.A.
Vice President of Medical
Management/Policy
Highmark, Inc.
Camp Hill, PA

Nancy Kemeny, M.D.
Medical Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY

David C. Madoff, M.D.
New York Presbyterian Hospital/Weil
Cornell Medical Center
New York, NY

Mark Sands, M.D.
Vice Chair, Clinical Ops, Quality/Section
Head, Interventional Radiology
Cleveland Clinic
Cleveland, OH

Peer Reviewers

Stephen Alberts, M.D.
Professor of Oncology
Mayo Clinic
Rochester, MN

Cathy Eng, M.D.
Associate Professor, Department of
Gastrointestinal Medical Oncology
University of Texas
MD Anderson Cancer Center
Houston, TX

Todd Crocenzi, M.D.
Medical Oncologist
Providence Portland Medical Center
Portland, OR

Michael Soulen, M.D.
Professor of Radiology
The Hospital of the University of
Pennsylvania
Philadelphia, PA

Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer

Structured Abstract

Objectives. To characterize the comparative effectiveness and harms of various local hepatic therapies for metastases to the liver from unresectable colorectal cancer (CRC) in two distinct populations: patients with liver-dominant metastases (i.e., majority of disease located in the liver) who are not eligible for continued systemic chemotherapy because their disease is refractory (i.e., they have experienced disease progression while on therapy), and patients who are candidates for local liver therapies as an adjunct to systemic chemotherapy. Local hepatic therapies include ablation, embolization, and radiotherapy approaches.

Data sources. We searched MEDLINE® and Embase® from January 2000 to June 2012. We also searched for gray literature in databases with regulatory information, clinical trial registries, abstracts and conference papers, grants and federally funded research, and information from manufacturers.

Review methods. We sought studies reporting two outcomes—overall survival and quality of life—and various adverse events related to the different interventions for the two populations of interest. Data were dually abstracted by a team of reviewers. A third reviewer resolved conflicts when necessary. We assessed the quality of individual studies and graded the strength of the body of evidence according to prespecified methods.

Results. We identified 937 articles through the literature search and excluded 913 at various stages of screening; 24 articles were included in our review. We also included one hand-searched article from *Annals of Oncology*, two published articles from scientific information packets, and three articles identified from conference abstracts; the total number of articles was 30. Twenty-three articles addressed Key Questions (KQ) 1 (effectiveness) and 2 (harms) for patients ineligible for systemic chemotherapy, and seven addressed KQ3 (effectiveness) and KQ4 (harms) for patients who are candidates for systemic chemotherapy. One randomized controlled trial (RCT) was included but this was treated as a case-series because the comparator was not relevant to this comparative effectiveness review. All others articles were case series. Fifteen studies were of good quality, 12 studies were of fair quality, and 3 were rated as poor quality. No comparative studies met our inclusion criteria. Evidence was insufficient to determine the comparative effectiveness or harms of these interventions.

Conclusions. In the absence of comparative data, the evidence is insufficient to permit conclusions on the comparative effectiveness of these therapies for unresectable CRC metastases to the liver. Gaps in the research base, even for critical benefits or harms, are extensive, and the quality of studies is generally questionable. Conducting RCTs (ideally head-to-head comparisons) to answer many important questions is desirable, but challenging.

Contents

| | |
|---|-------------|
| Executive Summary | ES-1 |
| Introduction | 1 |
| Background | 1 |
| Condition | 1 |
| Diagnosis and Treatment of Colorectal Cancer | 1 |
| Scope and Key Questions | 9 |
| Scope of the Review | 9 |
| Key Questions | 11 |
| Organization of This Evidence Report | 13 |
| Uses of This Evidence Report | 14 |
| Methods | 15 |
| Topic Refinement and Review Protocol | 15 |
| Literature Search Strategy | 15 |
| Search Strategy | 15 |
| Inclusion and Exclusion Criteria | 16 |
| Risk of Bias Assessment of Individual Studies | 18 |
| Data Synthesis | 18 |
| Strength of the Body of Evidence | 18 |
| Assessing Applicability | 19 |
| Results | 20 |
| Results of Literature Searches | 20 |
| Overview of the Literature | 22 |
| Key Questions 1 and 2: Effectiveness and Harms of Therapies in Patients Refractory to Systemic Chemotherapy | 23 |
| Key Points | 23 |
| Description of Included Studies | 23 |
| Detailed Synthesis | 32 |
| Overall Survival | 33 |
| Quality of Life | 34 |
| Length of Stay | 34 |
| Time to Progression | 34 |
| Local Recurrence | 34 |
| Adverse Events | 35 |
| Multivariate Analyses | 42 |
| Key Questions 3 and 4 | 42 |
| Key Points | 42 |
| Description of Included Studies | 42 |
| Detailed Synthesis | 47 |
| Overall Survival | 47 |
| Quality of Life | 48 |
| Length of Stay | 48 |
| Time to Recurrence | 48 |
| Local Recurrence | 48 |
| Adverse Events | 48 |

| | |
|---|----|
| Multivariate Analyses | 52 |
| Overall Conclusions for Key Questions 1-4 | 52 |
| Discussion | 53 |
| Key Findings and Strength of Evidence | 53 |
| Findings in Relationship to What Is Already Known..... | 55 |
| Applicability | 56 |
| Implications for Clinical and Policy Decisionmaking..... | 57 |
| Limitations of the Comparative Effectiveness Review Process | 58 |
| Limitations of the Evidence Base | 58 |
| Research Gaps..... | 58 |
| Gaps | 59 |
| Study Designs To Address These Gaps | 60 |
| Patient Registries | 60 |
| Conclusions..... | 63 |
| References | 64 |
| Abbreviations and Acronyms | 70 |

Tables

| | |
|---|-------|
| Table A. Local nonsurgical therapies for CRC liver metastases reviewed in this report | ES-4 |
| Table B. PICOTS (patient, intervention, comparator, outcome, timing, and setting) for the KQs..... | ES-11 |
| Table C. Characteristics of studies included in this review by intervention..... | ES-14 |
| Table D. Strength of evidence for KQ1 and KQ2 | ES-15 |
| Table E. Strength of evidence for KQ3 and KQ4..... | ES-17 |
| Table F. Core dataset elements for local hepatic therapy registry by PICOTS | ES-23 |
| Table 1. Local nonsurgical therapies for CRC liver metastases reviewed in this report | 4 |
| Table 2. PICOTS (population, intervention, comparator, outcome, timing, and setting) for the Key Questions | 10 |
| Table 3. Inclusion and exclusion criteria | 17 |
| Table 4. Characteristics of studies included in this review by intervention | 22 |
| Table 5. Local hepatic therapies for CRC metastases to the liver: Summary of study characteristics KQ1 and KQ2 | 25 |
| Table 6. Local hepatic therapies for CRC metastases to the liver: Summary of tumor characteristics KQ1 and KQ2 | 29 |
| Table 7. Outcomes reported for Key Questions 1 and 2..... | 32 |
| Table 8. Local hepatic therapies for CRC metastases to the liver: Outcomes related to overall survival KQ1 and KQ2 | 36 |
| Table 9. Local hepatic therapies for unresectable CRC metastases to the liver: Adverse events KQ1 and KQ2..... | 39 |
| Table 10. Local hepatic therapies adjunctive to systemic chemotherapy for CRC metastases to the liver: Summary of study characteristics KQ3 and KQ4 | 44 |
| Table 11. Local hepatic therapies adjunctive to systemic chemotherapy for CRC metastases to the liver: Summary of patient characteristics KQ3 and KQ4 | 45 |
| Table 12. Local hepatic therapies adjunctive to systemic chemotherapy for CRC metastases to the liver: Summary of tumor characteristics KQ3 and KQ4 | 46 |

| | |
|--|----|
| Table 13. Outcomes reported for Key Questions 3 and 4..... | 47 |
| Table 14. Local hepatic therapies for CRC metastases to the liver: Outcomes related to overall survival for patients receiving local hepatic therapy as an adjunct to systemic therapy KQ3 and KQ4 | 49 |
| Table 15. Local hepatic therapies for unresectable CRC metastases to the liver: Adverse events for patients receiving local hepatic therapy as an adjunct to systemic therapy KQ3 and KQ4 | 50 |
| Table 16. Strength of evidence for KQ1 and KQ2 | 53 |
| Table 17. Strength of evidence for KQ3 and KQ4 | 55 |
| Table 18. Core dataset elements for local hepatic therapy registry by PICOTS | 62 |

Figures

| | |
|--|----|
| Figure 1. Analytic framework for comparative effectiveness of local hepatic therapies for unresectable CRC metastases to the liver in patients whose metastatic disease is refractory to systemic chemotherapy and who have no or minimal extrahepatic disease | 12 |
| Figure 2. Analytic framework for comparative effectiveness of local hepatic therapies for unresectable colorectal cancer metastases to the liver in patients receiving local hepatic therapy as an adjunct to systemic chemotherapy and who have no extrahepatic disease | 13 |
| Figure 3. PRISMA diagram for identified published literature | 21 |

Appendixes

| |
|---|
| Appendix A. Search Strategy |
| Appendix B. Contacted Authors |
| Appendix C. DistillerSR Screening and Abstraction Forms |
| Appendix D. Evidence Tables |
| Appendix E. Abbreviations and Acronyms |
| Appendix F. Excluded Studies |

Executive Summary

Background

This report aims to compare the effectiveness and harms of several local hepatic therapies for unresectable colorectal cancer (CRC) metastases to the liver. In the sections that follow, we describe CRC and its diagnosis and treatment to orient the reader to the disease. This is followed by a discussion of the treatment of CRC liver metastasis.

Condition

CRC is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.¹ It is a cancer that forms in the tissues of the colon and the rectum. Most colorectal cancers are adenocarcinomas, meaning that they are a cancer of the epithelium originating from glandular tissue. Adenocarcinomas develop from adenomas, which are noncancerous tumors in the epithelial tissue. Over time, adenomas can become cancerous. This progression from adenoma to adenocarcinoma occurs through a sequential process of accumulating genetic changes.² Although the most common type of CRC is adenocarcinoma, squamous carcinoma and adenosquamous carcinoma have been reported infrequently.³

An elevated risk of CRC has been associated with obesity, low physical activity, high dietary intake of refined sugars, low dietary intake of fiber, consumption of meat, and consumption of more than two alcoholic drinks per day.⁴ A reduction in risk has been linked to the intake of dietary calcium and diets high in fiber and potassium.^{5, 6}

Diagnosis and Treatment of Colorectal Cancer

The diagnosis of CRC requires pathologic review to characterize and stage the tumor.⁷ Approximately 39 percent of new cases are diagnosed in the localized state, (i.e., no metastases or spread to regional lymph nodes); 36 percent present with regional spread to lymph nodes; 20 percent present with distant, metastatic cancer; and 5 percent present with unstaged disease.⁸ The 5-year survival rate estimated by the National Cancer Institute Surveillance Epidemiology and End Results program (SEER) data analysis was found to be 74.1 percent for stage I, 64.5 percent for stage IIA, 51.6 percent for stage IIB, 32.3 percent for stage IIC, 74 percent for IIIA, 45 percent for IIIB, 33.4 percent for IIIC, and 6 percent for stage IV.⁹ Survival declines with increasing depth of tumor penetration, increasing tumor stage, and patient age. For the 20 percent of patients who are initially diagnosed with distant (i.e., metastatic) disease, the 5-year survival rate is 10 percent or less with treatment. Patients with untreated liver metastases have a 5-year survival rate of less than 3 percent.¹⁰ Survival differs by the extent of liver metastases.

Treatment of Localized Disease

For the 39 percent of patients who are diagnosed with localized disease, the cornerstone of treatment is surgery.⁸ Advances in surgical technique, such as total mesorectal excision (dissection of the entire intact vascular, lymphatic, and fatty tissues) rather than blunt dissection, have improved local recurrence rates. Local recurrence rates have decreased from as high as 50 percent to less than 10 percent in some cases.¹¹ Patients whose disease was entirely removed through surgery may be offered adjuvant (i.e., after surgery) chemotherapy or radiation therapy to lower their risk of cancer recurrence. Patients with stage III colon cancer who received

postsurgical FOLFOX chemotherapy had a 3-year survival rate of 75 percent compared with 25 percent in the pre-adjuvant chemotherapy era.¹¹

Treatment of Distant Disease

CRC is the most common malignancy that metastasizes to the liver: 25 percent of colon cancer patients present with primary CRC and synchronous liver metastases (i.e., the primary disease and liver metastases are diagnosed at the same time), and another 50 percent develop metachronous disease (i.e., liver metastases develop after the initial CRC diagnosis).¹² For some proportion of patients, the liver may be the only site of metastasis. Autopsy studies have shown that 38 percent of patients who died of metastatic CRC had liver-only metastasis.¹³ Thus, therapies directed at the liver (“local hepatic therapies”) have been used with the goal of extending survival in these patients.¹⁴

Surgical Resection

Although the prognosis for patients with metastatic CRC to the liver has been historically quite poor, advances in surgical technique have improved outcomes for patients with liver-confined metastases. In some situations, treatment of limited liver-only metastases may be curative. For example, in patients with resectable liver-only metastases, several studies have demonstrated durable long-term survival in selected patients, with 5-year survival estimates ranging between 30 percent and 58 percent.¹⁵⁻²¹ CRC liver metastases are defined as resectable when it is anticipated that disease can be completely resected with negative margins, two adjacent liver segments can be spared, adequate vascular inflow and outflow and biliary drainage can be preserved, and adequate liver volume (20 to 25 percent) will remain postsurgery.²²⁻²⁴ Approximately 20 to 30 percent of patients with CRC liver metastases are candidates for this approach. Some patients with lesions not well suited for resection may also receive radiofrequency ablation at the time of surgery.

In cases where patients may not have resectable liver metastases at diagnosis, systemic chemotherapy may be used to shrink the tumor and “convert” it to resectable disease.²⁵ Similar to patients with initially resectable liver metastases, these patients may also experience promising 5-year survival rates of approximately 30 percent.

Local Nonsurgical Treatment Strategies

Despite improved surgical techniques and systemic chemotherapy options, many patients may remain ineligible for resection because of anatomic constraints (tumor location or extent of metastatic lesions), inadequate hepatic functional reserve, or concurrent medical comorbidities such as poor performance status (functional impairment typically defined by a higher Eastern Cooperative Oncology Group [ECOG] grade or a lower Karnofsky score) and cardiac insufficiency.²⁶

For patients with unresectable metastatic disease, local hepatic therapy may be used in an attempt to prolong survival or to palliate symptoms (e.g., pain) in patients for whom a cure is no longer within reach. Local hepatic therapy may be used for the following care scenarios:

1. Patients with unresectable, liver-dominant metastases (i.e., majority of disease located in the liver) who are not eligible for continued systemic chemotherapy because their disease is refractory (i.e., they have experienced disease progression while on therapy). These patients generally have large-volume disease and may be offered treatment to debulk the tumor and palliate symptoms when present.²⁷ Regardless of the local hepatic therapy,

patients should have liver-only metastases or liver-dominant metastases. In general, it is acceptable to have minimal extrahepatic disease (e.g., a single lung nodule) and remain a treatment candidate.

2. Patients with unresectable liver metastases at diagnosis or with limited unresectable hepatic recurrence after previous resection and who are candidates for local hepatic therapy.²⁸ In these patients, local hepatic therapies can be used as an adjunct to systemic chemotherapy with curative intent. The volume of disease in these patients is small, either in terms of lesion size or number of lesions.²⁹ These treatments are only appropriate when the entire tumor can be ablated with clear margins. To be considered a candidate for ablation or radiation therapy, patients treated in this setting should have no extrahepatic spread.

This report aims to compare the effectiveness and harms of local hepatic therapies for the two indications above. Therefore, comparisons of ablation with surgery or systemic chemotherapy with local hepatic therapy are outside the scope of this report.

Treatment Strategies

Several local hepatic therapies have been developed to treat patients with hepatic metastases of CRC. In the continuum of care, use of a local hepatic therapy may occur before or after the use of systemic chemotherapy, but it is administered most often in conjunction with systemic chemotherapy. Local hepatic therapies are divided into three groups: (1) ablation (destruction of tissue through procedures involving heating or cooling); (2) embolization (the selective blockage of blood vessels, often with agents that carry a drug to the occluded site); and (3) radiotherapy (directed radiation to destroy abnormal cells). Table A describes the local hepatic therapies included in this review.

Guidelines from the National Comprehensive Cancer Network for metastatic CRC state that ablative therapy for the metastases can be considered when all measurable metastatic disease can in fact be treated.³⁰ However, the group provides no guidance on *which* ablative therapy is optimal or on the comparative benefits and harms of the various palliative treatments.³⁰ A perception of clinical equipoise and limited randomized controlled trial (RCT) data comparing local hepatic therapies^{31,32} contribute to uncertainty regarding which techniques, either alone or in combination, may be preferable for certain patient groups.

Table A. Local nonsurgical therapies for CRC liver metastases reviewed in this report

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|----------|-------------------------------|--|---|-------------------------------------|---|
| Ablation | Cryosurgical ablation | The mechanism of action is based on the rapid formation of intracellular ice crystals during the freezing process. The procedure uses repetitive freezing and thawing of the tissue to produce necrosis and irreversible tissue damage, which occurs at temperatures between -20 and -40°C. ^{33,34} | This type of treatment typically does not require a hospital stay if the percutaneous method is used. An open procedure requires an abdominal incision under general anesthesia and results in a longer recovery period. | Interventional Radiologist | Serious complications are uncommon but are possible, and for cryosurgical ablation include cryoshock phenomenon (acute renal failure, acute respiratory distress syndrome, disseminated intravascular coagulation, and liver failure); myoglobinuria leading to renal failure; bile leakage; hepatic abscess; pleural effusion; consumptive coagulopathy; thrombocytopenia; hepatic iceball fracture; organ failure; and biliary fistula. ^{35,36} |
| | Radiofrequency ablation (RFA) | RFA is performed by generating an alternating current between at least two electrodes in the radiofrequency range that generates heat without muscle contraction. The procedure generates tissue temperatures of 90 to 100°C, which causes protein denaturation and coagulative necrosis. ²² | The procedure is performed under intravenous narcotics for the percutaneous awake approach and does not require a hospital stay. For laparoscopic or open RFA, the procedure is performed under general anesthesia and results in a longer recovery period. ³⁷ Each RFA takes approximately 10 to 30 minutes, with additional time required if multiple ablations are performed. The entire procedure is usually completed within 1 to 3 hours. ³⁸ | Interventional Radiologist, Surgeon | Possible side effects after RFA therapy include abdominal pain, mild fever, increase in liver enzymes due to damage to the bile ducts, abscess, infection in the liver, skin burns, and bleeding into the chest cavity or abdomen. Serious complications are uncommon but are possible, including hepatic failure, hydrothorax, bile duct leaks, intraperitoneal bleeding, and tumor seeding (spill of tumor cells and subsequent growth in an adjacent site). ^{35,38} |

Table A. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--|----------------------------------|--|--|----------------------------|---|
| Ablation (continued) | Microwave ablation (MWA) | MWA uses high-frequency electromagnetic radiation to create heat through the excitation of water molecules. ²² The heat causes thermal damage that leads to coagulation necrosis. | This type of treatment typically does not require a hospital stay if the percutaneous method is used. An open procedure requires an abdominal incision under general anesthesia and results in a longer recovery period. | Interventional Radiologist | Very little has been published about complications associated with MWA. ³⁶ Many patients experience a low-grade fever and pain for a few days following MWA. Major complications include liver abscess, bile duct injury, pleural effusion, intestinal obstruction, infections, bleeding and skin burn, and potential inadvertent injury to adjacent structures. ^{35,36} |
| Embolization and Transarterial Therapy | Transarterial embolization (TAE) | TAE uses an embolizing agent for selective catheterization and obstruction of the arterial vessel that supplies blood to the tumor. ³⁹ | Most patients can be discharged several hours after treatment with TAE, but an overnight stay is typically required if postembolization syndrome occurs. | Interventional Radiologist | Side effects differ depending on the type of embolization used. Common complications reported are postembolization syndrome (fever, pain, extreme fatigue, nausea/vomiting); infection in the liver; hepatic abscess; gallbladder inflammation; and blood clots in the main blood vessels of the liver. Serious complications are uncommon but possible. Embolization also reduces some of the blood supply to normal liver tissue. This may be dangerous in patients with underlying diseases such as hepatitis or cirrhosis. ⁴⁰ |

Table A. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--|--|--|---|----------------------------|----------------|
| Embolization and Transarterial Therapy (continued) | Transarterial chemoembolization (TACE) | TACE involves administering a chemotherapeutic agent directly to the liver tumor to cause ischemia. A chemotherapeutic solution (frequently doxorubicin or cisplatin) is suspended in lipiodol (an oily contrast medium selectively retained within the tumor) and is injected via a catheter into the hepatic arteries that are directly supplying the tumor. Simultaneously, the feeding hepatic arteries are obstructed with an embolizing agent. Tumor ischemia raises the drug concentration, extends retention of the chemotherapeutic agent, and reduces systemic toxicity. | Most patients can be discharged several hours after treatment with TACE, but an overnight stay is typically required if postembolization syndrome occurs. | Interventional Radiologist | Same as above. |

Table A. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--|-------------------------------|--|---|---|--|
| Embolization and Transarterial Therapy (continued) | Hepatic artery infusion (HAI) | HAI uses a pump to deliver higher doses of chemotherapy to the tumor compared with systemic chemotherapy, while maintaining low levels of toxicity in the normal tissue. This is achieved by exploiting the unique blood supply to the liver: normal hepatocytes are perfused by the portal vein, whereas the metastases derive most of their blood supply via the hepatic artery. The first-pass effect (a phenomenon of drug metabolism whereby the concentration of a drug is greatly reduced before it reaches the systemic circulation) of drugs delivered to the liver is high. ^{12,34} | A surgeon intraoperatively places the hepatic artery pump as an indwelling device. The pump delivers chemotherapeutic agent at a slow, fixed rate over a period of several weeks. The pump drug chamber can be refilled percutaneously. Successful hepatic arterial infusion is dependent on surgeon experience with the procedure. ⁴¹ | Interventional Radiologist, Surgeon for placement of pump | <p>Complications related to insertion of the pump are rare;⁴¹ however, hepatic artery thrombosis, catheter displacement, hematomas, infections, and liver perfusion are all reported as pump-related complications.</p> <p>The side effects will differ depending upon the type of embolization used. The most common complications reported are postembolization syndrome (fever, pain, extreme fatigue, nausea/vomiting); infection in the liver; hepatic abscess; chemical hepatitis; biliary sclerosis; peptic ulceration; gallbladder inflammation; and blood clots in the main blood vessels of the liver. Serious complications are uncommon but possible.</p> <p>Embolization also reduces some of the blood supply to normal liver tissue. This may be dangerous in patients with underlying diseases such as hepatitis or cirrhosis.⁴⁰</p> |

Table A. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--|--|---|---|----------------------------|---|
| Embolization and Transarterial Therapy (continued) | Radioembolization or selective internal radiation therapy (SIRT) | SIRT involves loading the radionuclide Yttrium-90 into microspheres, which are then placed within the microvasculature of the liver metastases, thus targeting multiple hepatic metastases in a single procedure. ⁴² The loaded microspheres deliver high localized doses of β -radiation to the tumor while minimizing radiation exposure to the surrounding tissue. ⁴²⁻⁴⁴ | Patients are required to undergo a ^{99m} Tc-macro-aggregated albumin (MAA) scan prior to SIRT to assess eligibility. ⁴⁵ The SIRT procedure takes approximately 90 minutes, and patients can typically return home 4 to 6 hours following treatment. | Interventional Radiologist | <p>The side effects will differ depending on the type of embolization used. The most common complications reported are postembolization syndrome (fever, pain, extreme fatigue, nausea/vomiting); infection in the liver; hepatic abscess; gallbladder inflammation; and blood clots in the main blood vessels of the liver. Serious complications are uncommon but possible.⁴⁰</p> <p>Acute toxicity events include gastritis, ulceration, or pancreatitis due to microsphere deposition in vessels serving these organs.⁴⁵ Radiation-induced liver disease (jaundice, weight gain, painful hepatomegaly, and elevated liver enzymes); thrombocytopenia; encephalopathy; elevated results of liver function tests; ascites; and hypoalbuminemia.</p> |
| | Drug-eluting beads (DEB) | This transarterial embolization system uses a drug-loaded (typically with doxorubicin or cisplatin), superabsorbent polymer microsphere to release drug gradually into the tumor, allowing longer intratumoral exposure and less systemic exposure to the drug. ⁴⁶ | Most patients can be discharged several hours after treatment, but an overnight stay is typically required if postembolization syndrome occurs. | Interventional Radiologist | <p>The side effects will differ depending on the type of embolization used. The most common complications reported are postembolization syndrome (fever, pain, extreme fatigue, nausea/vomiting); infection in the liver; hepatic abscess; gallbladder inflammation; and blood clots in the main blood vessels of the liver. Serious complications are uncommon but possible.⁴⁰</p> |

Table A. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--------------|--|--|---|--|---|
| Radiotherapy | External-beam three-dimensional conformal radiation therapy (3D-CRT) | This type of radiotherapy uses computer-assisted tomography scans (CT or CAT scans), magnetic resonance imaging scans (MR or MRI scans), or both to create detailed, 3D representations of the tumor and the surrounding organs. The radiation oncologist uses these computer-generated images to shape radiation beams to the exact size and shape of the tumor, which is intended to spare nearby healthy tissues from exposure. | Each treatment lasts only a few minutes, although the setup time usually takes longer. Most often, radiation treatments are given 5 days a week for several weeks. The patient's diagnosis determines the total duration of treatment. ^{47,48} | Radiation Oncologist, Medical Physicist, Dosimetrist, Radiation Therapist, and Radiation Therapy Nurse | Possible side effects of external radiation therapy include sunburn-like skin problems, nausea, vomiting, and fatigue. These typically subside post-treatment. Radiation might also make the side effects of chemotherapy worse. ⁴⁰ Radiation-induced liver disease is the major dose-limiting toxicity. ⁴⁹ |
| | External-beam intensity-modulated radiotherapy (IMRT) | This approach to radiotherapy allows the radiation oncologist to vary both the intensity of a radiation beam and the angle at which it is delivered to the patient. This is intended to deliver a high dose of radiation to the tumor while significantly reducing the exposure of surrounding normal tissue. IMRT offers more refined radiation dosing compared with traditional 3D-CRT. | Same as 3D-CRT, but IMRT requires slightly longer daily treatment times and additional planning and safety checks before the patient can start the treatment. ⁵⁰ | Same as 3D-CRT | Same as 3D-CRT. |
| | Stereotactic body radiation therapy (SBRT) | This type of external-beam radiation therapy delivers a high dose of radiation with high targeting accuracy to an extracranial target within the body, in either a single dose or a small number of fractions. ⁵¹ | Before treatment, patients may be asked to undergo placement of a fiducial marker (an object used in concert with imaging to provide precise location information), which is commonly performed as an outpatient procedure. SBRT typically consists of one to five treatment sessions over the course of 1 to 2 weeks, and is usually performed as an outpatient procedure. ⁵² | Same as 3D-CRT and IMRT | Same as 3D-CRT and IMRT. |

Scope and Key Questions

The objective of this systematic review is to characterize the comparative effectiveness and harms of various local hepatic therapies for liver metastases from unresectable CRC in two distinct patient populations:

- Patients with unresectable, liver-dominant (i.e., majority of disease located in the liver) metastases who are not eligible for continued systemic chemotherapy because their disease is refractory (i.e., they have experienced disease progression while on therapy).
- Patients who are candidates for local liver therapies as an adjunct to systemic chemotherapy.

There is extensive uncertainty surrounding the optimal use of the various local hepatic therapies. Because of the prevalence of CRC and the high likelihood of metastases, especially to the liver, this topic is important to health care providers, patients, and policymakers.

We addressed four Key Questions (KQs) for the two patient populations described above:

KQ1. What is the comparative effectiveness of the various liver-directed therapies in patients whose disease is refractory to systemic therapy for unresectable CRC metastases to the liver and who have minimal evidence of extrahepatic disease?

KQ2. What are the comparative harms of the various liver-directed therapies in patients whose disease is refractory to systemic therapy for unresectable CRC metastases to the liver and who have minimal evidence of extrahepatic disease?

KQ3. What is the comparative effectiveness of the various liver-directed therapies in patients who are candidates for local hepatic therapy as an adjunct to systemic therapy for unresectable CRC metastases to the liver and have no evidence of extrahepatic disease?

KQ4. What are the comparative harms of the various liver-directed therapies in patients who are candidates for local hepatic therapy as an adjunct to systemic therapy for unresectable CRC metastases to the liver and have no evidence of extrahepatic disease?

Table B provides the PICOTS (population, intervention, comparator, outcome, timing, and setting) for the KQs.

Table B. PICOTS (patient, intervention, comparator, outcome, timing, and setting) for the KQs

| PICOTS | KQs 1 and 2 | KQs 3 and 4 |
|--------------|--|--|
| Population | <p>Patients with unresectable liver metastases from primary CRC who are refractory to systemic chemotherapy but are candidates for local hepatic therapy.</p> <ul style="list-style-type: none"> • Patients whose hepatic metastases are unresectable due to medical comorbidities, such as low hepatic reserve, cardiac insufficiency, or poor performance status • Patients whose hepatic metastases are unresectable because of certain characteristics of the metastases • Patients with no or minimal extrahepatic disease | <p>Patients with unresectable liver metastases from primary CRC who receive systemic chemotherapy with local hepatic therapy.</p> <ul style="list-style-type: none"> • Patients whose hepatic metastases are unresectable because of medical comorbidities, such as low hepatic reserve, cardiac insufficiency, or poor performance status • Patients whose hepatic metastases are unresectable because of certain characteristics of the metastases • Patients who have synchronous hepatic metastases • Patients whose hepatic metastases have recurred after resection • Patients with no extrahepatic disease |
| Intervention | <ul style="list-style-type: none"> • Cryosurgical ablation • Radiofrequency ablation (RFA) • Microwave ablation (MWA) • Transarterial embolization (TAE) • Transarterial chemoembolization (TACE) • Hepatic arterial infusion (HAI) • Radioembolization or selective internal radiation therapy (SIRT) • Drug-eluting beads (DEB) • External beam with 3D-CRT or IMRT • Stereotactic body radiation therapy (SBRT) | Same as KQs 1 and 2. |
| Comparator | All the therapies listed above compared with the intervention in question for patients not eligible for systemic chemotherapy for CRC. | All the therapies listed above compared with the intervention in question for patients receiving systemic chemotherapy for CRC. |
| Outcome | <p>KQ1: <u>Ultimate outcomes:</u> Survival and quality of life <u>Intermediate outcomes:</u> Time to progression, local recurrence, and length of stay</p> <p>KQ2: <u>Adverse outcomes:</u> biloma, hepatic abscess, hepatic hemorrhage, elevated alkaline phosphatase, elevated bilirubin, elevated transaminases, injury to adjacent organ(s), liver failure, rare adverse events, and steatohepatitis</p> | <p>KQ3: <u>Ultimate outcomes:</u> Same as KQs 1 and 2 <u>Intermediate outcomes:</u> Time to recurrence, local recurrence, and length of stay</p> <p>KQ4: <u>Adverse outcomes:</u> Same as KQs 1 and 2</p> |
| Timing | The relevant periods occur at the time of treatment of CRC hepatic metastases through followup over months or years. | Same as KQs 1 and 2. |
| Setting | Inpatient and outpatient. | Same as KQs 1 and 2. |

3D-CRT = three-dimensional conformal radiotherapy; CRC = colorectal cancer; IMRT = intensity-modulated radiation therapy; KQ = Key Question

Methods

Topic Refinement and Review Protocol

The topic for this report was nominated in a public process. With input from Key Informants, the Evidence-based Practice Center (EPC) drafted the initial KQs and, after approval from AHRQ, posted them to a public Web site for 4 weeks for comment. We modified the KQs and the PICOTS based on these comments and discussion with the Technical Expert Panel (TEP). The initial KQs and interventions were stratified by intent of treatment (palliative or curative). This stratification seemed clinically inappropriate and potentially confusing because some interventions could be applied to palliate symptoms and to eliminate (i.e., cure) the liver metastases. The final KQs are distinguished by the population receiving local hepatic therapy (i.e., liver-directed). To be consistent with clinical practice, we modified KQs 1 and 2 to include patients with minimal rather than no extrahepatic disease. In addition, we categorized the 12 interventions to apply to all KQs, we removed some interventions, and we added SBRT. Finally, we expanded the list of harms to be considered.

Data Sources and Selection

To ensure the applicability of the interventions and outcomes data to current clinical practice, MEDLINE[®] and Embase[®] were searched for randomized, nonrandomized comparative and observational studies that treated patients between January 1, 2000, and June 27, 2012. Date restrictions were selected to ensure applicability of the interventions. Prior to 2000, some interventions were in their infancy and based on current standards used outdated regimens.^{53,54,55} Thermal therapies were not used significantly until the late 1990s, and major changes in proton beam and stereotactic therapy occurred during that same period.⁵⁶ Chemoembolization drugs and embolic mixtures have also changed a great deal in the last 10 years and are more standard now. For these reasons, which the TEP strongly supported, we excluded studies where patient treatment preceded 2000. The searches were also limited to the English language.⁵⁷ It was thought that the exclusion of non-English-language articles from this review would not have an impact on the conclusions. The gray literature was also searched, including in databases with regulatory information, clinical trial registries, abstracts and conference papers, grants, federally funded research, and manufacturing information.

Titles and abstracts were screened in duplicate for studies that looked at overall survival, adverse events, and quality of life among our populations of interest. To be excluded, a study needed to be independently excluded by two team members. In cases where there was disagreement, a second-level abstract screening was completed by two independent reviewers. A third reviewer was consulted when necessary. Full-text review was performed when it was unclear if the abstract met study selection criteria.

Data Extraction and Quality (Risk of Bias) Assessment

Data extraction was performed directly into tables created in DistillerSR, with elements defined in an accompanying data dictionary. All team members extracted a training set of five articles into evidence tables to ensure uniform extraction procedures and test the utility of the table design. All data extractions were performed in duplicate, with discrepancies identified and resolved by consensus. The full research team met regularly during the period of article extraction to discuss any issues related to the extraction process. Extracted data included patient

and treatment characteristics, outcomes related to intervention effectiveness, and information on harms. Harms included specific negative effects, including the narrower definition of adverse effects. Data extraction forms used during this review are presented in the main report in Appendix C.

Where applicable, we followed the Methods Guide³⁹ in the assessment of risk of bias in individual studies. Our assessment of risk of bias in the included case-series intervention studies was based on a set of study characteristics proposed by Carey and Boden.⁵⁸ The Carey and Boden assessment tool does not conclude with an overall score of the individual study. We created thresholds for converting the Carey and Boden⁵⁸ risk assessment tool into AHRQ standard quality ratings (good, fair, and poor) to differentiate case-series studies of varied quality. These distinctions were used for differentiation within the group of case-series studies, but not for the overall body of evidence described below. The classification into these categories (i.e., good, fair, poor) is distinct for a specific study design. For a study to be ranked as good quality, each of the Carey and Boden⁵⁸ criteria must have been met. For a fair-quality rank, one criterion was not met, and a rank of poor quality was given to studies with more than one criterion not met. These quality ranking forms can be found in the main report in Appendix D.

Data Synthesis

Evidence tables were completed for all included studies, and data are presented in summary tables. Evidence is also presented in text organized by outcome and intervention. No direct comparisons are made. We considered whether formal data synthesis (e.g., meta-analysis) would be possible from the set of included studies. Because the literature was so heterogeneous in terms of the populations (e.g., prior treatments, reason for unresectability, and number and size of lesions) and interventions (e.g., drugs and dose) studied, we concluded that pooling data would be inappropriate for this review. Thus, all data synthesis is based on qualitative summaries and analyses.

Strength of the Body of Evidence

We graded the strength of evidence using two independent reviewers and resolved disagreements by consensus discussion or adjudication by a third reviewer. The system used for grading the strength of the overall body of evidence is outlined in the Methods Guide,^{39,59} which is based on a system developed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group.⁶⁰ This system explicitly addresses the following domains: risk of bias, consistency, directness, and precision. The strength of evidence grade can fall into one of four categories: high, moderate, low, and insufficient. The grade rating was made by independent reviewers, and disagreements were resolved by consensus adjudication.

In this review, consistency of the body of literature was graded as “not applicable.” The direction of effect cannot be assessed in noncomparative studies; therefore, consistency in the direction of effect across case series cannot be discerned. In the absence of a comparator, we do not know if the observed estimate is better or worse; therefore, we concluded that consistency was not applicable. Directness pertains to the whether the evidence links the interventions directly to a health outcome. Due to the absence of direct comparisons precision will be rated imprecise.

Results

Of the 937 records identified through the literature search, we excluded 913 at various stages of screening and included 24 records.⁶¹⁻⁸⁴ We included one hand-searched article,⁸⁵ two published studies from scientific information packets,^{86,87} and three articles from conference abstracts.⁸⁸⁻⁹⁰ A total of 30 articles were included in this report: 29 case series and one RCT⁸⁵ for which a single arm was abstracted as a case series. This RCT compared radiofrequency ablation (RFA) with systemic chemotherapy to systemic chemotherapy alone. The scope of the review was liver-directed therapy versus liver-directed therapy. Systemic chemotherapy alone was not a relevant intervention or comparator for this review. Only the RFA combined with systemic chemotherapy arm was abstracted and included in this report as it is relevant for KQ3 and KQ4 (Table C).

Table C. Characteristics of studies included in this review by intervention

| Characteristic | RFA | TACE | HAI | RE | DEB | SBRT | RFA With SC | HAI With SC | RE With SC | Total Arms* |
|-------------------------------|-----|----------------|-----|-----------------|-----|------|----------------|-------------|------------|-------------|
| Total | 1 | 2 ^a | 2 | 13 ^a | 3 | 3 | 3 | 2 | 2 | 31 |
| Study Design | | | | | | | | | | |
| Prospective Case Series | 0 | 0 | 0 | 6 | 2 | 1 | 2 ^b | 1 | 1 | 13 |
| Retrospective Case Series | 1 | 2 | 2 | 7 | 1 | 2 | 1 | 1 | 1 | 18 |
| Outcomes Reported | | | | | | | | | | |
| Overall Survival | 1 | 2 | 2 | 13 | 3 | 3 | 3 | 2 | 2 | 31 |
| Quality of Life | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Time to Recurrence | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Length of Stay | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Local Recurrence | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 6 |
| Adverse Events | 1 | 2 | 2 | 13 | 3 | 3 | 3 | 2 | 2 | 31 |
| Study Population | | | | | | | | | | |
| United States | 0 | 2 | 0 | 7 | 1 | 0 | 0 | 0 | 0 | 10 |
| Europe | 1 | 0 | 1 | 4 | 2 | 2 | 1 | 0 | 1 | 12 |
| Australia | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 3 |
| Asia | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 6 |
| Total Participants (N) | 68 | 142 | 67 | 454 | 157 | 43 | 101 | 36 | 159 | 1,227 |

DEB = drug-eluting beads; HAI = hepatic arterial infusion; N = number; RE = radioembolization; RFA= radiofrequency ablation; SBRT = stereotactic body radiotherapy; SC = systemic chemotherapy; TACE = transarterial chemoembolization
Note: No studies reporting on cryosurgical ablation, MWA, TAE, 3D-CRT, or IMRT met inclusion criteria for this review.

*The total number of articles included in this review is 30.

^aHong et al. reports on both TACE and RE interventions.

^bThe study by Ruers et al. is an RCT that was extracted as a case series.

KQs 1 and 2

KQs 1 and 2 focus on the comparative effectiveness (KQ1) and harms (KQ2) of the patient population that was ineligible for systematic therapy and had no or only minimal evidence of extrahepatic disease. The evidence base comprised 23 case series and 931 patients. No comparative study met inclusion criteria for this review.

Key Points

- The evidence is insufficient to draw conclusions about overall survival, quality of life, or adverse events (Table D). Due to the absence of comparative data, we are limited in drawing conclusions regarding the efficacy and effectiveness of these interventions. Risk of bias is a primary concern in observational studies. Intended effects are likely to be biased by preferential prescribing of the intervention based on the patients' prognosis.
- All studies were case series. Carey and Boden quality rankings were converted into AHRQ “good,” “fair,” and “poor” ratings. Eleven studies were rated as good quality,^{64, 66,67,69,71,73-75,80,88,90} nine studies as fair quality,^{61,63,76,81,82,84,86,87,89} and three studies as poor quality.^{65,69,72}
- The assessment of applicability of the study findings to clinical practice is limited by the poor characterization of the patient populations (e.g., number and size of metastases, performance status) and variations in the delivery of the interventions (e.g., surgical approach, dose and drugs delivered).

Table D. Strength of evidence for KQ1 and KQ2

| Outcome | Intervention | Strength of Evidence | Summary of Included Studies |
|------------------|---------------|----------------------|---|
| Overall Survival | TACE with DEB | Insufficient | Three studies reported overall survival for this intervention. ^{61,69,88} Two studies ^{73a,90} defined survival starting from the time of study treatment and reported a median survival of 25 and 19 months. One study ^{65b} did not report the point from which survival time was measured and reported a 1-year survival of 61%. |
| | TACE | Insufficient | Two studies reported overall survival for this intervention. ^{61,66} Both studies defined survival time from diagnosis of liver metastases and reported median survival times of 27 and 26.3 months. Albert and colleagues presented overall survival data out to 5 years and reported 6% survival. |
| | SBRT | Insufficient | Three studies reported overall survival for this intervention and all defined survival from time of study treatment. ^{69,80,86} Two studies reported median survival of 25 and 17 months. ^{71,88} One study did not report median survival but recorded a 2-year survival of 58%. ⁸⁰ |
| | HAI | Insufficient | Two studies reported overall survival for this intervention and both defined survival from time of study treatment. ^{81,90} Median survival was 9.7 months and 6.7 months (95% CI, 5 to 8.3 months). |
| | RE | Insufficient | Eight studies reported survival from time of study treatment. One study did not reach median survival but reported a 3-year survival of 77%. ⁸⁴ In the other seven studies, median survival ranged from 4 to 15.2 months. ^{78,70,73,75,86,89,91} Three studies reported overall survival from diagnosis of liver metastases, with median survival ranging from 31 to 34.6 months. ^{66,68,76} Two studies did not report the point from which survival was defined. One study reported a median survival of 11.8 months. ⁶⁵ The other study reported a 1-year survival of 20%. ⁷⁴ |
| | RFA | Insufficient | Only one study reported data on overall survival. Survival was defined from time of study treatment and 3-year survival was 68%. ⁶⁷ |

Table D. Strength of evidence for KQ1 and KQ2 (continued)

| Outcome | Intervention | Strength of Evidence | Summary of Included Studies |
|------------------|---------------|----------------------|--|
| Quality of Life | TACE with DEB | Insufficient | The authors report qualitatively that 18 or 20 patients reported improvement in quality of life post-treatment. ⁶⁵ |
| | RE | Insufficient | This study reported quality-of-life data for 14 of 50 participants using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and Hamilton Rating Scale for Depression. No information was given for why only 14 patients underwent the quality of life assessment. Quality of life was not adversely affected after RE and anxiety was significantly reduced from pretreatment levels. No significant difference was observed in depression scores pre- and post-treatment. ⁶⁴ |
| Length of Stay | TACE | Insufficient | Mean length of stay ranged from 1.3 to 3 days. ^{61,65} |
| Local Recurrence | SBRT | Insufficient | Both studies reported a local recurrence rate of 33.3%. ^{69,86} |
| | RFA | Insufficient | One study reported local recurrence of 18%. ⁶⁹ |
| Adverse Events | TACE with DEB | Insufficient | Liver failure of 3% was reported in one study of this intervention. ⁷³ Increased bilirubin was reported in 50% of patients in one study. Other adverse events are listed in Table 9 of the full report. |
| | TACE | Insufficient | One study reported elevated alkaline phosphatase of varying severity in 19% of patients and grade 1 elevated bilirubin in 1% of patients. ⁴ Other adverse events are reported in Table 9 of the full report. |
| | SBRT | Insufficient | One study reported no major complications. ⁶⁹ Other adverse events are reported in Table 9 of the full report. |
| | HAI | Insufficient | One study reported no major complications. ⁸¹ One study reported 1.8% increased bilirubin. ⁹⁰ |
| | RE | Insufficient | Two studies reported no major complications. ^{82,84} Liver failure was reported in 2% and 2.4% of patients in two studies. ^{63,64} Elevated alkaline phosphatase in 8% of patients was reported in one study. ⁷⁴ Two studies reported elevated bilirubin in 10% and 13% of patients. ^{74,89} All other adverse events are listed in Table 9 of the full report. |
| | RFA | Insufficient | One study reported no major complications. ⁶⁷ |

DEB = drug-eluting beads; HAI = hepatic arterial infusion; RE = radioembolization; SBRT = stereotactic body radiation therapy
TACE = trans-arterial chemoembolization

KQs 3 and 4

KQs 3 and 4 focus on the comparative effectiveness (KQ3) and harms (KQ4) of the various local hepatic therapies in patients who are received local hepatic therapy as an adjunct to systemic therapy for unresectable CRC metastases to the liver and who had no evidence of extrahepatic disease.

The body of evidence (seven studies) comprises case series with the exception of a single RCT⁸¹ that was included as a single-arm study. Two-hundred ninety-six patients were included from these seven studies. No comparative studies were available that met inclusion criteria.

- No conclusions on overall survival, quality of life, length of stay, time to recurrence, local recurrence, or adverse events can be drawn from the body of evidence comparing local hepatic therapies for unresectable CRC metastases to the liver (Table E).
- The literature base for this review is comprised of case series and one RCT⁸⁵ that was abstracted as a case-series study due to a nonrelevant comparator. Four studies were ranked as good quality^{62,70,78,85} and three were ranked as fair quality.^{77,79,83}

- The assessment of applicability of the study findings to clinical practice is limited by the poor characterization of the patient populations (e.g., number and size of metastases, performance status) and variations in the delivery of the interventions (e.g., surgical approach, dose and drugs delivered).

Table E. Strength of evidence for KQ3 and KQ4

| Outcome | Adjunctive Therapy | No. of Studies | Risk of Bias | Consistency | Directness* | Precision | Overall Grade |
|---------------------------|--------------------|-----------------------|--------------|----------------|-------------|-----------|---------------|
| Overall Survival | RFA | 3 ^{59,64,66} | High | Not applicable | Direct | Imprecise | Insufficient |
| | RE | 2 ^{39,47} | High | Not applicable | Direct | Imprecise | Insufficient |
| | HAI | 2 ^{58,60} | High | Not applicable | Direct | Imprecise | Insufficient |
| Quality of Life | RFA | 1 ⁶⁶ | High | Not applicable | Direct | Imprecise | Insufficient |
| Length of Stay | NR | 0 | High | Unknown | Indirect | Imprecise | Insufficient |
| Time to Recurrence | NR | 0 | High | Unknown | Indirect | Imprecise | Insufficient |
| Local Recurrence | RFA | 3 ^{39,64,66} | High | Not applicable | Indirect | Imprecise | Insufficient |
| Adverse Events | RFA | 3 ^{59,64,66} | High | Not applicable | Direct | Imprecise | Insufficient |
| | RE | 2 ^{39,47} | High | Not applicable | Direct | Imprecise | Insufficient |
| | HAI | 2 ^{58,60} | High | Not applicable | Direct | Imprecise | Insufficient |

HAI = hepatic arterial infusion; RE = radioembolization; RFA = radiofrequency ablation

*Directness: Evidence is indirect for all comparisons because there is no comparative data, but evidence is direct for assessment of some health outcomes.

Key Points

- No conclusions on overall survival, quality of life, or adverse events can be drawn from this body of evidence. The strength of evidence is insufficient.

Discussion

Key Findings and Strength of Evidence

No comparative studies met inclusion criteria for any of the four KQs about local hepatic therapy for the treatment of unresectable colorectal cancer (CRC) metastases to the liver. Thirty-one studies met our inclusion criteria and addressed local hepatic therapy for unresectable CRC metastases to the liver.

We assessed the strength of evidence for our primary health outcomes of overall survival and quality of life and for the intermediate outcomes of length of stay, local recurrence, and adverse events for all KQs. In addition, strength of evidence was assessed for the intermediate outcomes of time to progression (KQs 1 and 2) and time to recurrence (KQs 3 and 4). We judged the strength of evidence to be insufficient to draw conclusions for all outcomes. The body of evidence provided no comparative information about differences in effectiveness by type of intervention.

We are not aware of any published systematic reviews of the comparative effectiveness of local hepatic therapies for CRC metastases to the liver, as the literature base does not contain studies comparing one local hepatic therapy with another. Some systematic reviews of single local hepatic therapies have been published. Earlier reviews conforming to a high quality standard interpreted their findings similar to ours in the present review; that is, evidence was insufficient to permit conclusions.^{32,91}

This review sought evidence on the comparative benefits and harms of local hepatic therapies in two patient groups for CRC metastasis to the liver. Although we did not find this evidence the strength of the present review is in the identification of this important evidence gap. Distinct patient groups exist within the population receiving local hepatic therapies, yet data to analyze these differences are limited.

Applicability

It is challenging to comment on the applicability of findings from our CER because we found that the available evidence was insufficient for us to draw conclusions. The degree to which the data presented in this report are applicable to clinical practice hinges on the degree to which the populations in the included studies represent the patient populations receiving clinical care in diverse settings, as well as the availability of the interventions. We comment below on the relevance of included studies for population, intervention, comparator, outcomes, timing, and setting (PICOTS) elements. The PICOTS format provides a practical and useful structure to review applicability in a systematic manner and is employed in the subsections that follow.⁸⁸

The goal of any local hepatic therapy for unresectable CRC metastases to the liver is to prolong life by eliminating the metastases if possible or to palliate symptoms such as pain. This report has reviewed the literature on local hepatic therapies to achieve these goals. Due to the noncomparative nature of the literature base, both clinical and policymakers are limited in their ability to apply the published literature base to decisions on effectiveness and comparative effectiveness of these interventions. Survival estimates from individual studies of local hepatic therapies suggest that local hepatic therapies may provide some benefit in terms of survival and symptom relief for some patients, but without comparative data, it is not possible to choose the therapy that will produce the best outcomes for specific patients.

Population and Settings

The question of which subgroups of patients with CRC metastases to the liver may benefit from any particular local hepatic therapy compared with another remains unanswered. This uncertainty is reflected in the heterogeneity of the patient populations included in the published literature. Patient characteristics were often poorly characterized and not uniformly reported. Patients with varying degrees of resectability, extrahepatic disease, portal vein tumor thrombosis, and size and number of lesions are often grouped together and reported on as one group, even though it is uncertain whether these factors are likely to affect outcomes. Patient heterogeneity, combined with poor reporting of stratified or patient-level data, limited our ability to compare patient groups in any meaningful way. As a result, we are currently unable to determine which patients should be receiving which local hepatic therapies.

The setting in which treatment occurs is a major factor in the outcomes of local hepatic therapy. Expertise of both clinicians and centers varies. Based on the available clinical expertise and technology, the choice of a local hepatic therapy may be limited to one option in many centers. Local hepatic therapies, such as radioembolization⁹³ and hepatic arterial infusion,⁹⁴ often

require high levels of training and familiarity with the procedure. Lack of experience may not only affect patient outcomes but also result in adverse effects; patients treated by less-experienced clinicians and centers will likely experience poorer outcomes.

Detailed analysis of differences in outcomes by center has important implications for the relevance of the findings in the literature. Unfortunately, these data were unavailable as part of our systematic review of the published literature.

Interventions

Even for a single local hepatic therapy, variations in how the procedure is performed may be substantial. For instance, variations may occur in the approach (open vs. percutaneous), the choice of chemotherapy drugs delivered, and the schedule of delivery of chemotherapy and radiation therapy. Given the lack of comparative data, the present review did not allow for a more rigorous and systematic comparison of the relative performance of local hepatic therapies stratified by these factors. How these factors may alter health outcomes remains unclear.

Additional heterogeneity exists for the context in which the intervention was delivered. Patients often receive more than one local hepatic therapy over time or more than one session of the same therapy. This often results in variations of prior therapy at study enrollment. The complex treatment history of each patient can further limit the conclusions that can be drawn about the benefits attributable to any one component of the treatment plan.

Comparators

All studies in this review are observational (including the arm of one RCT that was extracted as a case series); as such, they report on the experience of a particular center with one or more local hepatic therapies. Although case series can be useful for hypothesis generation, this approach cannot provide the comparative data the field needs for evaluating effectiveness. The applicability of any case series to another study group is very limited.

Outcomes

Little controversy exists regarding the most appropriate direct health outcomes to measure in a study of local hepatic therapies for CRC metastases to the liver. Overall survival is the ultimate outcome; it was reported in all of the studies included in this review. Quality of life is also a very important patient-centered outcome, but is not routinely reported in the literature in this review.

The importance of outcomes such as disease-free survival or local progression-free survival can be debated, but few experts would suggest that these outcomes replace the need for data on overall survival.

Studies of a comparative design are needed to measure accurately the differences in overall survival, quality of life, and harms that may be attributed to a local hepatic therapy.

Timing

The timing of followup assessment was appropriate given the natural history of unresectable CRC liver metastases and the primary outcome of overall survival. Median survival was reached in 21 of 24 studies. We judged this to be an appropriate length of assessment. In addition, two of the studies that did not reach median survival followed patients for up to 3 years to assess overall survival rates.

Research Gaps

In this section, we first present a set of gaps focused on issues in the body of literature. Then we discuss the use of RCTs and observational studies to address these gaps, followed by an example of how a registry might overcome the drawbacks of single-center case series.

Gaps

This systematic review attempted to compare outcomes of local hepatic therapies for patients treated for unresectable CRC metastases to the liver. The review focused on two patient populations: those patients whose disease is refractory to systemic chemotherapy and patients who are receiving local hepatic therapy as an adjunct to systemic chemotherapy. Evidence on patient outcomes is limited, and the strength of evidence is insufficient for us to draw conclusions on effectiveness or harms for either patient population. As detailed above under applicability, there are specific evidence gaps that, if addressed, could enhance this literature base.

We identified four broad evidence gaps during this review. We present them organized by PICOTS framework. No gaps were identified for timing and setting.

- **Populations:** An objective of comparative effectiveness research is to understand the comparative effects for different population subgroups. To achieve this, we must fully delineate the population subgroups of interest. As detailed in the population and setting section above, these data are limited. Future studies must present data by subgroups of interest so that evidence can be interpreted by these variables. Based on published multivariate analyses, examples of patient or tumor characteristics found to be associated with improved overall survival include: ECOG status (0 vs. ≥ 1 and in another study 0 or 1 vs. ≥ 2), performance status (0 or 1 vs. ≥ 2), number of extrahepatic metastases sites (0 or 1 vs. ≥ 2), number of lines of previous chemotherapy (0–1 vs. ≥ 2), performance status (0 or 1 vs. ≥ 2), carcinoembryonic antigen response (Yes, No), and Response Evaluation Criteria in Solid Tumors (RECIST). These variables should be considered when designing future studies. Because there are so many variables being collated, clinical risk scores may be particularly beneficial as a summary measure.⁹⁵
- **Intervention:** There can be substantial variation in the role of local hepatic therapy in the overall treatment strategy for patient populations with unresectable CRC liver metastases reviewed in this report. A thorough delineation of prior and concurrent treatment is necessary to assess the incremental benefit of local hepatic therapy and the comparative outcomes of these therapies for the reviewed patient populations. All other therapies, systemic and local, should be taken into account when evaluating the effectiveness of the intervention under study, as these therapies may have an effect on patient survival. Previous resections and other local hepatic therapies were often not reported in the studies included in this review.
- **Comparator:** A major limitation of the current evidence review was that there was no comparative evidence at the time of publication of this report comparing the various liver-directed therapies with one another.
- **Outcomes:** Outcomes of interest to patients and their physicians include survival, quality of life, and adverse effects such as radiation-induced liver disease, liver failure, and local recurrence (i.e., treatment failure). Evidence comparing these outcomes of local hepatic therapies in the populations of interest for the review are needed. For survival and other

time-to-event outcomes, it is essential for authors to report the time point from which the event was measured (e.g., time from liver-directed therapy, time from CRC diagnosis, time from diagnosis of metastases).

Collection and reporting of quality-of-life data (e.g., pain) using standard measurement tools was inconsistently reported in the literature included in this review. These data are particularly important for the population of patients in which palliation of symptoms, rather than cure, is the intent of therapy.

Study Designs To Address These Gaps

RCTs are the gold standard of clinical evaluation, and there is an absence of randomized controlled clinical trial evidence on the use of local hepatic therapies for the included indications. Because we were unable to find comparative studies to answer any of our KQs, we conducted additional discussions with members of our Technical Expert Panel (TEP) to elicit ideas that could address the gaps in the literature. TEP members identified common barriers to conducting RCTs that would answer our KQs, including limited sources of research funding to support RCTs, reluctance of physicians to randomize patients, and reluctance of patients to be randomized.

In addition to the resistance to randomize, consensus around the most compelling hypothesis for a comparative RCT is lacking. Clinical investigators have competing hypotheses of which treatment is best suited for which patients, and these hypotheses are often based on their own institution's experience. TEP members agreed that certain broad categories of patients with CRC metastasis to the liver, such as the populations included in this review, may well benefit from local hepatic therapies, but they also recognized that the published literature did not permit analysis of patient subgroups to identify characteristics more favorable to one local hepatic therapy over another. RCTs with well-documented patient and treatment characteristics could address the lack of comparative evidence. Lack of funding sources will continue to be an issue under the current regulatory structure. Under this system, the FDA does not require the same level of evidence for device approval as it does for drug approval. Because device companies can obtain approval without data from RCTs, they have very little incentive to provide funding.⁹²

Regardless of the study design, we suggest that studies aiming to address the effectiveness or comparative effectiveness of local hepatic therapies take care to address potential confounders and effect measure modification that could obscure the results. This is particularly important for patient characteristics such as size and number of metastases and performance status, which could serve as both modifiers of the effectiveness and factors that are considered when choosing the best local hepatic therapy.

Although RCTs may not be possible for all comparisons in all centers, multivariate analyses from existing case series can aid in identifying additional factors that should be documented and potentially controlled for in the comparative analysis of these data. Several factors were identified in multivariate analyses in the literature base of this report that impacted overall survival. The following factors should be collected and considered in future studies: number and size of lesions, number of extrahepatic metastases, previous treatment history (i.e., number of lines of previous chemotherapy), CEA, performance status, and tumor response. These analyses can enhance the design of future RCTs or observational studies.

Patient Registries

In the absence of consensus regarding the most salient comparative research question, observational data could be useful in driving the generation and prioritization of hypotheses for future research. One approach is the use of a registry to systematically collect observational data. According to the Agency for Healthcare Research and Quality publication on registries for evaluating patient outcomes, patient registries are often constructed to study patient outcomes, the natural history of disease, and disease management under various treatment scenarios.⁹⁷ Registries need to be created with a question in mind, which will then guide the identification of the target patient population, the interventions of interest (e.g., a local hepatic therapy), the outcomes of interest, the number of patients (to be adequately powered for future analysis), and the length of followup.

The KQs from this CER could serve as guide for designing one or more registries focused on this clinical area. The aim would be to establish a prospective registry that tracks the outcomes, quality of life, and adverse events in those who receive local nonsurgical treatment for unresectable metastatic CRC to the liver in order to identify the most effective local hepatic therapy strategies. The effectiveness of any one local hepatic therapy is expected to vary by patient subgroup. Provider experience with the local hepatic therapy is also an important factor in patient outcomes. We have identified a core set of variables or core dataset, defined as the information set needed to address the critical questions the registry is developed to answer. This is presented in Table F, organized by PICOTS.

Table F. Core dataset elements for local hepatic therapy registry by PICOTS

| Population | Intervention | Comparators | Outcomes | Timing | Setting |
|---|--|----------------------|--|---------|--|
| Patient Characteristics Age Sex Race Ethnicity Performance status LDH CEA Clinical risk scores (e.g., Fong) ⁹⁵ Tumor Characteristics Location of tumor Size of lesions Number of lesions Tumor volume Portal vein obstruction Course of disease (stabilization, rapid progression) Other Treatments Number, dose, and duration for lines of prior therapy by drug Number, dose, and duration for lines of adjunctive therapy by drug Previous liver-directed therapy | Type of Local Hepatic Therapy Cryosurgical ablation RFA MWA TAE TACE HAI RE DEB 3D-CRT IMRT SBRT Characteristics of Local Hepatic Therapy Dose Duration Surgical site | Same as Intervention | Overall survival Quality of life Response (e.g., complete, partial, no response) Recovery time Length of stay Adverse effects (Short-term and long-term harms) Treatment holidays* | Ongoing | Hospital type Number of procedures by practitioner Type of practitioner Local hepatic therapy availability Inpatient or outpatient procedure |

3D-CRT = three-dimensional conformal radiation therapy; CEA = carcinoembryonic antigen; DEB = drug-eluting bead; HAI = hepatic artery infusion; IMRT = intensity-modulated radiation therapy; LDH = lactate dehydrogenase; RE = radioembolization; RFA = radiofrequency ablation; SBRT = stereotactic body radiation therapy; TACE = transarterial chemoembolization; TAE = transarterial embolization

*Treatment holidays refer to time away from systemic chemotherapy and may vary based on the success of treatment with a local hepatic therapy.

Conclusions

Due to the absence of comparative data, the evidence is insufficient for us to draw conclusions about the comparative effectiveness of local hepatic therapies for unresectable CRC metastases to the liver for the patient populations addressed in this review. Important outcomes of therapy include overall survival, quality of life, and adverse effects (harms). A patient registry is one tool for future research that may generate hypotheses for clinical trials or observational evidence on the comparative effectiveness of local hepatic therapies.

References

1. Bruckner HW. Adenocarcinoma of the colon and rectum. In: Bast RC, Kufe DW, Pollock RE, eds. *Holland-Frei Cancer Medicine* 5th edition. Ontario: B C Decker; 2000.
2. Tierney RP, Ballantyne GH, Modlin IM. The adenoma to carcinoma sequence. *Surg Gynecol Obstet*. 1990 Jul;171(1):81-94. PMID: 2163117.
3. Minsky BD, Cohen AM, Enker WE, et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. *Int J Radiat Oncol Biol Phys*. 1997 Jan 15;37(2):289-95. PMID: 9069299.
4. Steinbach G, Heymsfield S, Olansen NE, et al. Effect of caloric restriction on colonic proliferation in obese persons: implications for colon cancer prevention. *Cancer Res*. 1994 Mar 1;54(5):1194-7. PMID: 8118805.
5. DeCosse JJ, Tsioulis GJ, Jacobson JS. Colorectal cancer: detection, treatment, and rehabilitation. *CA Cancer J Clin*. 1994 Jan-Feb;44(1):27-42. PMID: 8281470.
6. Wargovich MJ. New dietary anticarcinogens and prevention of gastrointestinal cancer. *Dis Colon Rectum*. 1988 Jan;31(1):72-5. PMID: 3284725.
7. American Joint Committee on Cancer. *In Manual for Staging of Cancer*. 2nd ed. Philadelphia: Lippincott.
8. Surveillance Epidemiology and End Results. *Cancer of the Colon and Rectum - SEER Stat Fact Sheet*. 2012. seer.cancer.gov/statfacts/html/colorect.html. Accessed on August 3rd 2012.
9. American Joint Committee on Cancer. *AJCC Cancer Staging Manual*. 7 ed: Springer; 2010.
10. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. *Ann Surg*. 1984 May;199(5):502-8. PMID: 6721600.
11. Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. *Mayo Clin Proc*. 2007 Jan;82(1):114-29. PMID: 17285793.
12. Flanders VL, Gervais DA. Ablation of liver metastases: Current status. *J Vasc Interv Radiol*. 2010;21(8 Suppl):S214-S22. PMID: 20656231.
13. Gilbert HA, Kagan AR. Metastases: incidence, detection, and evaluation without histologic confirmation. In: Weiss L, ed. *Fundamental Aspects of Metastasis*. Netherlands: North Holland Publishing Co; 1976:385-405.
14. Feliberti EC, Wagman LD. Radiofrequency ablation of liver metastases from colorectal carcinoma. *Cancer Control*. 2006 Jan;13(1):48-51. PMID: 16508626.
15. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg*. 2004 Jun;239(6):818-25; discussion 25-7. PMID: 15166961.
16. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. *Ann Surg*. 2002 Jun;235(6):759-66. PMID: 12035031.
17. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. *Ann Surg*. 2009 Sep;250(3):440-8. PMID: 19730175.
18. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). *Ann Surg*. 2004 Sep;240(3):438-47; discussion 47-50. PMID: 15319715.
19. Fong Y, Blumgart LH, Cohen AM. Surgical treatment of colorectal metastases to the liver. *CA Cancer J Clin*. 1995 Jan-Feb;45(1):50-62. PMID: 7804899.
20. Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. *Br J Surg*. 2010 Jul;97(7):1110-8. PMID: 20632280.

21. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996 Apr 1;77(7):1254-62. PMID: 8608500.
22. Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. J Surg Oncol. 2009;100(8):619-34. PMID: 20017157.
23. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg. 2004 May;239(5):722-30; discussion 30-2. PMID: 15082977.
24. Vauthey J-N, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg. 2004;239(5):722-32. PMID: 15082977.
25. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 1;27(22):3677-83. PMID: 19470929.
26. Burak KW. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge? Oncology (Williston Park). 2011 Mar;25(3):296, 8, 300. PMID: 21548474.
27. Evans J. Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM). Eur J Surg Oncol. 2007;33(Suppl 2):S64-S75. PMID: 18061390.
28. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002 June 1, 2002;137(6):675-81. PMID: 12049538.
29. Alsina J, Choti MA. Liver-directed therapies in colorectal cancer. Semin Oncol. 2011;38(4):561-7. PMID: 21810515.
30. Benson AB, Engstrom P, Venook A, et al. National Comprehensive Cancer Network Guidelines Colon Cancer Version 3.2012. 2012.
31. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010 Aug 10;28(23):3687-94. PMID: 20567019.
32. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010 Jan 20;28(3):493-508. PMID: 19841322.
33. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37(3):171-86. PMID: 9787063.
34. Gage AA, Guest K, Montes M, et al. Effect of varying freezing and thawing rates in experimental cryosurgery. Cryobiology. 1985;22(2):175-82. PMID: 3979086.
35. Gueorguiev AL, Mackey R, Kowdley GC, et al. Minimally invasive evaluation and treatment of colorectal liver metastases. Int J Surg Oncol. 2011;2011:686030. PMID: 22312518.
36. Blazer DG, Anaya DA, Abdalla EK. Destructive therapies for colorectal cancer metastases. In: Vauthey JN, Audisio RA, Hoff PM, Poston G, eds. Liver Metastases. London: Springer-Verlag; 2009:39-49.
37. Nguyen KT, Geller DA. Radiofrequency ablation of hepatocellular carcinoma. In: Carr BI, ed Hepatocellular Carcinoma, Diagnosis and Treatment. New York, New York: Humana Press; 2010:421-51.
38. Radiologyinfo. Radiofrequency Abalation (RFA) of Liver Tumors. 2011. www.radiologyinfo.org/en/info.cfm?pg=rfaliver. Accessed on May, 10 2012.
39. Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253(3):453-69 PMID: 21263310.
40. American Cancer Society. Embolization therapy for liver cancer. 2012. www.cancer.org/Cancer/LiverCancer/Detail edGuide/liver-cancer-treating-embolization-therapy. Accessed on May 10 2012.

41. Leonard GD, Kemeny NE. Hepatic Directed Therapy. In: Cassidy J, Johnston P, Van Cutsem E, eds. Colorectal cancer. Informa Healthcare; 2007:253-85.
42. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of 90Y microspheres in man: Review of four explanted whole livers. *Int J Radiat Oncol Biol Phys.* 2004;60(5):1552-63. PMID: 15590187.
43. Campbell AM, Bailey IH, MA. B. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. *Phys Med Biol.* 2001;46(2):487-98. PMID: 11229728.
44. Lau WY, Leung T, Ho S, et al. Diagnostic pharmaco-scintigraphy with hepatic intraarterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma. *Br J Radiol.* 1994;67(794):136-9. PMID: 8130973.
45. Coldwell DM, Kennedy AS. Internal Radiation for the Treatment of Liver Metastases. In: Vauthey JN, Audisio RA, Hoff PM, Poston G, eds. *Liver Metastases.* London: Springer-Verlag; 2009:98-109.
46. Meza-Junco J, Montano-Loza AJ, Liu DM, et al. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? *Cancer Treat Rev.* 2011;In Press, Corrected Proof. PMID: 21726960.
47. Radiologyinfo. External Beam Therapy (EBT). "American College of Radiology and the Radiological Society of North America"; 2012. www.radiologyinfo.org/en/info.cfm?pg=ebt. Accessed May 10, 2012.
48. American Cancer Society. Radiation therapy for liver cancer. 2012. www.cancer.org/Cancer/LiverCancer/DetailedGuide/liver-cancer-treating-radiation-therapy. Accessed on May 10 2012.
49. Blazer DG, Anaya DA, Abdalla EK. Destructive therapies for colorectal cancer metastases. In: Vauthey JN, ed *Liver Metastases.* London: Springer-Verlag; 2009:39-50.
50. Radiologyinfo. Intensity-Modulated Radiation Therapy (IMRT). "American College of Radiology and the Radiological Society of North America"; 2012. www.radiologyinfo.org/en/info.cfm?pg=imrt. Accessed on May 10 2012.
51. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. *Clin Ther.* 2010 Dec;32(13):2117-38. PMID: 21316532.
52. Radiologyinfo. Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotehrapy (SBRT). "American College of Radiology and the Radiological Society of North America"; 2012. www.radiologyinfo.org/en/info.cfm?pg=stereotactic. Accessed May 10, 2012.
53. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? *J Clin Oncol.* 2009 Apr 10;27(11):1829-35. PMID: 19273699.
54. Kern W, Beckert B, Lang N, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. *Ann Oncol.* 2001 May;12(5):599-603. PMID: 11432616.
55. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. *J Clin Oncol.* 2001 May 15;19(10):2687-95. PMID: 11352961.
56. Meyers MO, Sasson AR, Sigurdson ER. Locoregional strategies for colorectal hepatic metastases. *Clin Colorectal Cancer.* 2003 May;3(1):34-44. PMID: 12777190.
57. Moher D, Pham B, Lawson ML, et al. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. *Health Technol Assess.* 2003;7(41):1-90. PMID: 14670218.
58. Carey TS, SD B. A critical guide to case series reports. *Spine.* 2003;28:1631-4. PMID: 12897483.

59. Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. *American Journal of Pathology*. 2010 May;176 (5):2292-301. PMID: 2010268740.
60. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol*. 2010;63:513-23. PMID: 19595577.
61. Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. *Cancer*. 2011 Jan 15;117(2):343-52. PMID: 20830766.
62. Chua TC, Bester L, Saxena A, et al. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. *J Cancer Res Clin Oncol*. 2011 May;137(5):865-73. PMID: 20859640.
63. Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. *Cardiovasc Intervent Radiol*. 2009 Nov;32(6):1179-86. PMID: 19680720.
64. Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. *Br J Cancer*. 2010 Jul 27;103(3):324-31. PMID: 20628388.
65. Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study. *In Vivo*. 2007;21(6):1085-92.
66. Hong K, McBride JD, Georgiades CS, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. *J Vasc Interv Radiol*. 2009 Mar;20(3):360-7. PMID: 19167245.
67. Jakobs TF, Hoffmann RT, Trumm C, et al. Radiofrequency ablation of colorectal liver metastases: Mid-term results in 68 patients. *Anticancer Research*. 2006;26(1 B):671-80.
68. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. *Eur J Surg Oncol*. 2007 Jun;33(5):597-602. PMID: 17433608.
69. Kim MS, Kang JK, Cho CK, et al. Three-fraction stereotactic body radiation therapy for isolated liver recurrence from colorectal cancer. *Tumori*. 2009 Jul-Aug;95(4):449-54. PMID: 19856655.
70. Kosmider S, Tan TH, Yip D, et al. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. *J Vasc Interv Radiol*. 2011 Jun;22(6):780-6. PMID: 21515072.
71. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. *J Vasc Interv Radiol*. 2005 Dec;16(12):1641-51. PMID: 16371530.
72. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. *BMC Cancer*. 2005;5:132. PMID: 16225697.
73. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. *Ann Surg Oncol*. 2011 Jan;18(1):192-8. PMID: 20740319.
74. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. *Cancer*. 2009 May 1;115(9):1849-58. PMID: 19267416.

75. Rowe BP, Weiner R, Foster J, et al. 90Yttrium microspheres for nonresectable liver cancer: the University of Connecticut Health Center experience. *Conn Med*. 2007 Oct;71(9):523-8. PMID: 17966721.
76. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. *Radiology*. 2008 May;247(2):507-15. PMID: 18349311.
77. Seki H, Ozaki T, Shiina M. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. *Cardiovasc Intervent Radiol*. 2009 Jul;32(4):679-86. PMID: 19296157.
78. Sgouros J, Cast J, Garadi KK, et al. Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases. *World J Gastrointest Oncol*. 2011 Apr 15;3(4):60-6. PMID: 21528091.
79. Tsutsumi S, Yamaguchi S, Tsuboi K, et al. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer. *Hepatogastroenterology*. 2008 Jul-Aug;55(85):1419-22. PMID: 18795703.
80. Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: Is there a dose response relationship? *Int J Radiat Oncol Biol Phys*. Epub 2011 Mar 4. PMID: 21377292.
81. Vogl TJ, Zangos S, Eichler K, et al. Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. *Eur Radiol*. 2008 Mar;18(3):468-76. PMID: 17938935.
82. Kucuk ON, Soydal C, Lacin S, et al. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. *World J Surg Oncol*. 2011;9:86. PMID: 21819613.
83. Lee KH, Kim HO, Yoo CH, et al. Comparison of radiofrequency ablation and resection for hepatic metastasis from colorectal cancer. *Korean J Gastroenterol*. 2012 Mar;59(3):218-23. PMID: 22460570.
84. Martin LK, Cucci A, Wei L, et al. Yttrium-90 Radioembolization as salvage therapy for colorectal cancer with liver metastases. *Clin Colorectal Cancer*. Epub 2012 Jan 23. PMID: 22277350.
85. Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). *Ann Oncol*. Epub 2012 Mar 19. PMID: 22431703.
86. Stintzing S, Hoffmann RT, Heinemann V, et al. Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. *Eur J Cancer*. 2010 Apr;46(6):1026-32. PMID: 20153959.
87. Nace GW, Steel JL, Amesur N, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. *Int J Surg Oncol*. 2011;2011:571261. PMID: 22312513. Epub 2011 Mar 20.
88. Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead(R), drug-eluting bead loaded with irinotecan: results of a phase II clinical study. *Anticancer Res*. 2011 Dec;31(12):4581-7. PMID: 22199334.
89. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. *J Vasc Interv Radiol*. 2008 Aug;19(8):1187-95. PMID: 18656012.
90. Nishiofuku H, Tanaka T, Aramaki T, et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. *Clin Colorectal Cancer*. 2010 Dec;9(5):305-10. PMID: 21208845.

91. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. *Cochrane Database Syst Rev*. 2009(3):CD007823. PMID: 19588444.
92. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. *BMC Health Serv Res*. 2004 Dec 22;4(1):38. PMID: 15615589.
93. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using Yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. *Int J Radiat Oncol Biol Phys*. 2007;68(1):13-23. PMID: 17448867.
94. Bouchahda M, Levi F, Adam R, et al. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. *Eur J Cancer*. 2011 Dec;47(18):2681-90. PMID: 21783358.
95. Fong Y. Surgical therapy of hepatic colorectal metastasis. *Ca-A Cancer Journal for Clinicians*. 1999;49(4):231-55.
96. Sweet BV, Schwemm AK, Parsons DM. Review of the processes for FDA oversight of drugs, medical devices, and combination products. *J Manag Care Pharm*. 2011 Jan-Feb;17(1):40-50. PMID: 21204589.
97. Gliklich RE, Dreyer NA. *Registries for Evaluating Patient Outcomes: A User's Guide*. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality; 2007.

Introduction

Background

This report aims to compare the effectiveness and harms of several local hepatic therapies for unresectable colorectal cancer (CRC) metastases to the liver. In the sections that follow, we describe CRC and its diagnosis and treatment to orient the reader to the disease. This is followed by a discussion of the treatment of CRC liver metastasis. The local hepatic therapies included in the review are described in detail.

Condition

CRC is the third most frequently diagnosed cancer and the second leading cause of cancer death in the United States.¹ It is a cancer that forms in the tissues of the colon and the rectum. Most colorectal cancers are adenocarcinomas, meaning that they are a cancer of the epithelium originating from glandular tissue. Adenocarcinomas develop from adenomas, which are noncancerous tumors in the epithelial tissue. Over time, adenomas can become cancerous. This progression from adenoma to adenocarcinoma occurs through a sequential process of accumulating genetic changes.² Although the most common type of CRC is adenocarcinoma, squamous carcinoma and adenosquamous carcinoma have been reported infrequently.³

An elevated risk of CRC has been associated with obesity, low physical activity, high dietary intake of refined sugars, low dietary intake of fiber, consumption of meat, and consumption of more than two alcoholic drinks per day.⁴ A reduction in risk has been linked to the intake of dietary calcium and diets high in fiber and potassium.^{5,6}

Diagnosis and Treatment of Colorectal Cancer

The diagnosis of CRC requires pathologic review to characterize and stage the tumor. The Tumor, Node, and Metastases (TNM) staging system is recommended for the staging of CRC, but other staging systems, such as Dukes and Astler-Coller, are widely used.⁷

Approximately 39 percent of new cases are diagnosed in the localized state, (i.e., no metastases or spread to regional lymph nodes); 36 percent present with regional spread to lymph nodes; 20 percent present with distant, metastatic cancer; and 5 percent present with unstaged disease.⁸ The 5-year survival rate estimated by the National Cancer Institute Surveillance Epidemiology and End Results program (SEER) data analysis was found to be 74.1 percent for stage I, 64.5 percent for stage IIA, 51.6 percent for stage IIB, 32.3 percent for stage IIC, 74 percent for IIIA, 45 percent for IIIB, 33.4 percent for IIIC, and 6 percent for stage IV.⁹ Survival declines with increasing depth of tumor penetration, increasing tumor stage, and patient age. For the 20 percent of patients who are initially diagnosed with distant (i.e., metastatic) disease, the 5-year survival rate is 10 percent or less with treatment. Patients with untreated liver metastases have 5-year survival rate of less than 3 percent.¹⁰ Survival differs by the extent of liver metastases. Patients with a solitary metastasis have a median survival of 21 months; those with multiple metastases confined to one lobe have median survival of 15 months; and those with widespread bilobar disease have a median survival of less than 12 months.¹⁰

Treatment of Localized Disease

For the 39 percent of patients who are diagnosed with localized disease, the cornerstone of treatment is surgery.⁸ Advances in surgical technique, such as total mesorectal excision

(dissection of the entire intact vascular, lymphatic, and fatty tissues) rather than blunt dissection, have improved local recurrence rates. Local recurrence rates have decreased from as high as 50 percent to less than 10 percent in some cases.¹¹ Patients whose disease was entirely removed through surgery may be offered adjuvant (i.e., after surgery) chemotherapy or radiation therapy to lower their risk of cancer recurrence. In the past 20 years, adjuvant therapy has evolved from experimental treatment to standard of care. For example, patients with stage III colon cancer who received postsurgical FOLFOX chemotherapy had a 3-year survival rate of 75 percent compared with 25 percent in the pre-adjuvant chemotherapy era.¹¹ Trials are currently being undertaken to determine if adjuvant treatment also improves overall survival compared with surgery alone.

Treatment of Distant Disease

CRC is the most common malignancy that metastasizes to the liver: 25 percent of colon cancer patients present with primary CRC and synchronous liver metastases (i.e., the primary disease and liver metastases are diagnosed at the same time), and another 50 percent develop metachronous disease (i.e., liver metastases develop after the initial diagnosis).¹² For some proportion of patients, the liver may be the only site of metastasis. Autopsy studies have shown that 38 percent of patients who died of metastatic CRC had liver-only metastasis.¹³ Thus, therapies directed at the liver (“local hepatic therapies”) have been used with the goal of extending survival in these patients.¹⁴

Surgical Resection

Although the prognosis for patients with metastatic CRC to the liver has been historically quite poor, advances in surgical technique have improved outcomes for patients with liver-confined metastases. In some situations, treatment of limited liver-only metastases may be curative. For example, in patients with resectable liver-only metastases, several studies have demonstrated durable long-term survival in selected patients, with 5-year survival estimates ranging between 30 percent and 58 percent.¹⁵⁻²¹ CRC liver metastases are defined as resectable when it is anticipated that disease can be completely resected with negative margins, two adjacent liver segments can be spared, adequate vascular inflow and outflow and biliary drainage can be preserved, and adequate liver volume (20 to 25 percent) will remain postsurgery.^{22, 23} Approximately 20 to 30 percent of patients with CRC liver metastases are candidates for this approach. Some patients with lesions not well suited for resection may also receive radiofrequency ablation at the time of surgery.

In cases where patients may not have resectable liver metastases at diagnosis, systemic chemotherapy may be used to shrink the tumor and “convert” it to resectable disease.²⁴ Similar to patients with initially resectable liver metastases, these patients may also experience promising 5-year survival rates or approximately 30 percent. Hepatotoxicity from preoperative chemotherapy (e.g., steatohepatitis, sinusoidal injury) is an important concern in these patients.

Local Nonsurgical Treatment Strategies

Despite improved surgical techniques and systemic chemotherapy options, many patients may remain ineligible for resection because of anatomic constraints (tumor location or extent of metastatic lesions), inadequate hepatic functional reserve, or concurrent medical comorbidities such as poor performance status (functional impairment typically defined by a higher Eastern Cooperative Oncology Group [ECOG] grade or a lower Karnofsky score) and cardiac insufficiency.²⁵

For patients with unresectable metastatic disease, local hepatic therapy may be used in an attempt to prolong survival or to palliate symptoms (e.g., pain) in patients for whom a cure is no longer within reach. Local hepatic therapy may be used for the following care scenarios:

1. Patients with unresectable, liver-dominant metastases (i.e., majority of disease located in the liver) who are not eligible for continued systemic chemotherapy because their disease is refractory (i.e., they have experienced disease progression while on therapy). These patients generally have large-volume disease and may be offered treatment to debulk the tumor and palliate symptoms when present.²⁶ Regardless of the local hepatic therapy, patients should have liver-only metastases or liver-dominant metastases. In general, it is acceptable to have minimal extrahepatic disease (e.g., a single lung nodule) and remain a treatment candidate.
2. Patients with unresectable liver metastases at diagnosis or with limited unresectable hepatic recurrence after previous resection and who are candidates for local hepatic therapy.²⁷ In these patients, local hepatic therapies can be used as an adjunct to systemic chemotherapy with curative intent. The volume of disease in these patients is small, either in terms of lesion size or number of lesions.²⁸ These treatments are only appropriate when the entire tumor can be ablated with clear margins. To be considered a candidate for ablation or radiation therapy, patients treated in this setting should have no extrahepatic spread.

Several local hepatic therapies have been developed to treat patients with hepatic metastases of CRC. In the continuum of care, use of a local hepatic therapy may occur before or after the use of systemic chemotherapy, but it is administered most often in conjunction with systemic chemotherapy. Local hepatic therapies are divided into three groups: (1) ablation (destruction of tissue through procedures involving heating or cooling); (2) embolization (the selective blockage of blood vessels, often with agents that carry a drug to the occluded site); and (3) radiotherapy (directed radiation to destroy abnormal cells). Table 1 presents a list of the 12 interventions and their mechanisms of action, the setting in which treatment is performed, who performs the intervention, and the specific harms reported for each. The table presents these interventions grouped by type of ablation, embolization, and radiotherapy approach.

In patients with unresectable hepatic metastases, local hepatic therapy represents an opportunity to treat the major site of disease without exposing patients to the side effects of chronic systemic chemotherapy. Similarly, patients who have exhausted all palliative chemotherapeutic options may benefit from local hepatic therapy as a means of delaying disease progression and, in turn, delaying or preventing liver function deterioration and liver failure. Although nonsurgical local hepatic therapies are not generally considered to be curative options, selected patients may experience effective symptom palliation and, in some cases, long-term disease control.

Guidelines from the National Comprehensive Cancer Network for metastatic CRC state that ablative therapy for the metastases can be considered when all measurable metastatic disease can in fact be treated.²⁹ However, the group provides no guidance on which ablative therapy is optimal or on the comparative benefits and harms of the various palliative treatments.²⁹ A perception of clinical equipoise and limited RCT data comparing local hepatic therapies^{30,31} contribute to uncertainty regarding which techniques, either alone or in combination, may be preferable for certain patient groups.

Table 1. Local nonsurgical therapies for CRC liver metastases reviewed in this report

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|----------|-------------------------------|--|---|-------------------------------------|---|
| Ablation | Cryosurgical ablation | The mechanism of action is based on the rapid formation of intracellular ice crystals during the freezing process. The procedure uses repetitive freezing and thawing of the tissue to produce necrosis and irreversible tissue damage, which occurs at temperatures between -20 and -40°C. ^{32,33} | This type of treatment typically does not require a hospital stay if the percutaneous method is used. An open procedure requires an abdominal incision under general anesthesia and results in a longer recovery period. | Interventional Radiologist | Serious complications are uncommon but are possible, and for cryosurgical ablation include cryoshock phenomenon (acute renal failure, acute respiratory distress syndrome, disseminated intravascular coagulation, and liver failure); myoglobinuria leading to renal failure; bile leakage; hepatic abscess; pleural effusion; consumptive coagulopathy; thrombocytopenia; hepatic iceball fracture; organ failure; and biliary fistula. ^{34,35} |
| | Radiofrequency ablation (RFA) | RFA is performed by generating an alternating current between at least two electrodes in the radiofrequency range that generates heat without muscle contraction. The procedure generates tissue temperatures of 90 to 100°C, which causes protein denaturation and coagulative necrosis. ²³ | The procedure is performed under intravenous narcotics for the percutaneous awake approach and does not require a hospital stay. For laparoscopic or open RFA, the procedure is performed under general anesthesia and results in a longer recovery period. ³⁶ Each RFA takes approximately 10 to 30 minutes, with additional time required if multiple ablations are performed. The entire procedure is usually completed within 1 to 3 hours. ³⁷ | Interventional Radiologist, Surgeon | Possible side effects after RFA therapy include abdominal pain, mild fever, increase in liver enzymes due to damage to the bile ducts, abscess, infection in the liver, skin burns, and bleeding into the chest cavity or abdomen. Serious complications are uncommon but are possible, including hepatic failure, hydrothorax, bile duct leaks, intraperitoneal bleeding, and tumor seeding (spill of tumor cells and subsequent growth in an adjacent site). ^{34,37} |
| | Microwave ablation (MWA) | MWA uses high-frequency electromagnetic radiation to create heat through the excitation of water molecules. ²³ The heat causes thermal damage that leads to coagulation necrosis. | This type of treatment typically does not require a hospital stay if the percutaneous method is used. An open procedure requires an abdominal incision under general anesthesia and results in a longer recovery period. | Interventional Radiologist | Very little has been published about complications associated with MWA. ³⁵ Many patients experience a low-grade fever and pain for a few days following MWA. Major complications include liver abscess, bile duct injury, pleural effusion, intestinal obstruction, infections, bleeding and skin burn, and potential inadvertent injury to adjacent structures. ^{34,35} |

Table 1. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--|--|--|---|----------------------------|---|
| Embolization and Transarterial Therapy | Transarterial embolization (TAE) | TAE uses an embolizing agent for selective catheterization and obstruction of the arterial vessel that supplies blood to the tumor. ³⁸ | Most patients can be discharged several hours after treatment with TAE, but an overnight stay is typically required if postembolization syndrome occurs. | Interventional Radiologist | Side effects differ depending on the type of embolization used. Common complications reported are postembolization syndrome (fever, pain, extreme fatigue, nausea/vomiting); infection in the liver; hepatic abscess; gallbladder inflammation; and blood clots in the main blood vessels of the liver. Serious complications are uncommon but possible. Embolization also reduces some of the blood supply to normal liver tissue. This may be dangerous in patients with underlying diseases such as hepatitis or cirrhosis. ³⁹ |
| | Transarterial chemoembolization (TACE) | TACE involves administering a chemotherapeutic agent directly to the liver tumor to cause ischemia. A chemotherapeutic solution (frequently doxorubicin or cisplatin) is suspended in lipiodol (an oily contrast medium selectively retained within the tumor) and is injected via a catheter into the hepatic arteries that are directly supplying the tumor. Simultaneously, the feeding hepatic arteries are obstructed with an embolizing agent. Tumor ischemia raises the drug concentration, extends retention of the chemotherapeutic agent, and reduces systemic toxicity. | Most patients can be discharged several hours after treatment with TACE, but an overnight stay is typically required if postembolization syndrome occurs. | Interventional Radiologist | Same as above. |

Table 1. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--|-------------------------------|--|---|---|--|
| Embolization and Transarterial Therapy (continued) | Hepatic artery infusion (HAI) | HAI uses a pump to deliver higher doses of chemotherapy to the tumor compared with systemic chemotherapy, while maintaining low levels of toxicity in the normal tissue. This is achieved by exploiting the unique blood supply to the liver: normal hepatocytes are perfused by the portal vein, whereas the metastases derive most of their blood supply via the hepatic artery. The first-pass effect (a phenomenon of drug metabolism whereby the concentration of a drug is greatly reduced before it reaches the systemic circulation) of drugs delivered to the liver is high. ^{12,34} | A surgeon intraoperatively places the hepatic artery pump as an indwelling device. The pump delivers chemotherapeutic agent at a slow, fixed rate over a period of several weeks. The pump drug chamber can be refilled percutaneously. Successful hepatic arterial infusion is dependent on surgeon experience with the procedure. ⁴⁰ | Interventional Radiologist, Surgeon for placement of pump | <p>Complications related to insertion of the pump are rare;⁴⁰ however, hepatic artery thrombosis, catheter displacement, hematomas, infections, and liver perfusion are all reported as pump-related complications.</p> <p>The side effects will differ depending upon the type of embolization used. The most common complications reported are postembolization syndrome (fever, pain, extreme fatigue, nausea/vomiting); infection in the liver; hepatic abscess; chemical hepatitis; biliary sclerosis; peptic ulceration; gallbladder inflammation; and blood clots in the main blood vessels of the liver. Serious complications are uncommon but possible.</p> <p>Embolization also reduces some of the blood supply to normal liver tissue. This may be dangerous in patients with underlying diseases such as hepatitis or cirrhosis.³⁹</p> |

Table 1. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--|--|---|---|----------------------------|--|
| Embolization and Transarterial Therapy (continued) | Radioembolization or selective internal radiation therapy (SIRT) | SIRT involves loading the radionuclide Yttrium-90 into microspheres, which are then placed within the microvasculature of the liver metastases, thus targeting multiple hepatic metastases in a single procedure. ⁴¹ The loaded microspheres deliver high localized doses of β -radiation to the tumor while minimizing radiation exposure to the surrounding tissue. ⁴¹⁻⁴³ | Patients are required to undergo a ^{99m} Tc-macro-aggregated albumin (MAA) scan prior to SIRT to assess eligibility. ⁴⁴ The SIRT procedure takes approximately 90 minutes, and patients can typically return home 4 to 6 hours following treatment. | Interventional Radiologist | <p>The side effects will differ depending on the type of embolization used. The most common complications reported are postembolization syndrome (fever, pain, extreme fatigue, nausea/vomiting); infection in the liver; hepatic abscess; gallbladder inflammation; and blood clots in the main blood vessels of the liver. Serious complications are uncommon but possible.³⁹</p> <p>Acute toxicity events include gastritis, ulceration, or pancreatitis due to microsphere deposition in vessels serving these organs.⁴⁴ Radiation-induced liver disease (jaundice, weight gain, painful hepatomegaly and elevated liver enzymes); thrombocytopenia; encephalopathy; elevated results of liver function tests; ascites; and hypoalbuminemia.</p> |
| | Drug-eluting beads (DEB) | This transarterial embolization system uses a drug-loaded (typically with doxorubicin or cisplatin), superabsorbent polymer microsphere to release drug gradually into the tumor, allowing longer intratumoral exposure and less systemic exposure to the drug. ⁴⁵ | Most patients can be discharged several hours after treatment, but an overnight stay is typically required if postembolization syndrome occurs. | Interventional Radiologist | <p>The side effects will differ depending on the type of embolization used. The most common complications reported are postembolization syndrome (fever, pain, extreme fatigue, nausea/vomiting); infection in the liver; hepatic abscess; gallbladder inflammation; and blood clots in the main blood vessels of the liver. Serious complications are uncommon but possible.³⁹</p> |

Table 1. Local nonsurgical therapies for CRC liver metastases reviewed in this report (continued)

| Therapy | Treatment Strategy | Mechanism of Cell Death | Setting | Performed By | Specific Harms |
|--------------|--|--|---|--|---|
| Radiotherapy | External-beam three-dimensional conformal radiation therapy (3D-CRT) | This type of radiotherapy uses computer-assisted tomography scans (CT or CAT scans), magnetic resonance imaging scans (MR or MRI scans), or both to create detailed, 3D representations of the tumor and the surrounding organs. The radiation oncologist uses these computer-generated images to shape radiation beams to the exact size and shape of the tumor, which is intended to spare nearby healthy tissues from exposure. | Each treatment lasts only a few minutes, although the setup time usually takes longer. Most often, radiation treatments are given 5 days a week for several weeks. The patient's diagnosis determines the total duration of treatment. ^{46,47} | Radiation Oncologist, Medical Physicist, Dosimetrist, Radiation Therapist, and Radiation Therapy Nurse | Possible side effects of external radiation therapy include sunburn-like skin problems, nausea, vomiting, and fatigue. These typically subside post-treatment. Radiation might also make the side effects of chemotherapy worse. ³⁹ Radiation-induced liver disease is the major dose-limiting toxicity. ⁴⁸ |
| | External-beam intensity-modulated radiotherapy (IMRT) | This approach to radiotherapy allows the radiation oncologist to vary both the intensity of a radiation beam and the angle at which it is delivered to the patient. This is intended to deliver a high dose of radiation to the tumor while significantly reducing the exposure of surrounding normal tissue. IMRT offers more refined radiation dosing compared with traditional 3D-CRT. | Same as 3D-CRT, but IMRT requires slightly longer daily treatment times and additional planning and safety checks before the patient can start the treatment. ⁴⁹ | Same as 3D-CRT | Same as 3D-CRT |
| | Stereotactic body radiation therapy (SBRT) | This type of external-beam radiation therapy delivers a high dose of radiation with high targeting accuracy to an extracranial target within the body, in either a single dose or a small number of fractions. ⁵⁰ | Before treatment, patients may be asked to undergo placement of a fiducial marker (an object used in concert with imaging to provide precise location information), which is commonly performed as an outpatient procedure. SBRT typically consists of one to five treatment sessions over the course of 1 to 2 weeks, and is usually performed as an outpatient procedure. ⁵¹ | Same as above | Same as above |

Scope and Key Questions

Scope of the Review

The objective of this systematic review is to characterize the comparative effectiveness and harms of various local hepatic therapies for liver metastases from unresectable CRC in two distinct patient populations:

- Patients with unresectable, liver-dominant (i.e., majority of disease located in the liver) metastases who are not eligible for continued systemic chemotherapy because their disease is refractory (i.e., they have experienced disease progression while on therapy).
- Patients who are candidates for local liver therapies as an adjunct to systemic chemotherapy.

Patients whose liver metastases are resectable, who have unresectable liver metastases treated with first-line chemotherapy in combination with local hepatic therapy for downstaging of disease, or who are treated with a first-line local hepatic therapy alone are outside the scope of this review.

Patients with unresectable liver metastasis are a heterogeneous group, in which careful patient selection may offer opportunities for successful treatment. Patient selection criteria are a key issue; the definition of medically or technically inoperable patients is crucial.⁵² All patients in the studies included in this review have been classified as having unresectable disease based on either the extent of the tumor or patient characteristics (e.g., poor surgical candidate). As noted, we focus on two distinct patient populations that have different underlying prognoses; thus, we make treatment comparisons within, rather than across, these populations. We considered studies with any length of followup and performed in all inpatient and outpatient settings. Table 2 lists the relevant populations, interventions, comparators, outcomes, timing of assessment, and settings (PICOTS) relevant for this review.

Table 2. PICOTS (Population, Intervention, Comparator, Outcome, Timing, and Setting) for the Key Questions

| PICOTS | KQs 1 and 2 | KQs 3 and 4 |
|---------------------|--|--|
| Population | <p>Patients with unresectable liver metastases from primary CRC who are refractory to systemic chemotherapy but are candidates for local hepatic therapy.</p> <ul style="list-style-type: none"> • Patients whose hepatic metastases are unresectable due to medical comorbidities, such as low hepatic reserve, cardiac insufficiency, or poor performance status • Patients whose hepatic metastases are unresectable because of certain characteristics of the metastases • Patients with no or minimal extrahepatic disease | <p>Patients with unresectable liver metastases from primary CRC who receive systemic chemotherapy with local hepatic therapy.</p> <ul style="list-style-type: none"> • Patients whose hepatic metastases are unresectable because of medical comorbidities, such as low hepatic reserve, cardiac insufficiency, or poor performance status • Patients whose hepatic metastases are unresectable because of certain characteristics of the metastases • Patients who have synchronous hepatic metastases • Patients whose hepatic metastases have recurred after resection • Patients with no extrahepatic disease |
| Intervention | <ul style="list-style-type: none"> • Cryosurgical ablation • Radiofrequency ablation (RFA) • Microwave ablation (MWA) • Transarterial embolization (TAE) • Transarterial chemoembolization (TACE) • Hepatic arterial infusion (HAI) • Radioembolization or selective internal radiation therapy (SIRT) • Drug-eluting beads (DEB) • External beam with 3D-CRT or IMRT • Stereotactic body radiation therapy (SBRT) | Same as KQs 1 and 2. |
| Comparator | All the therapies listed above compared with the intervention in question for patients not eligible for systemic chemotherapy for CRC | All the therapies listed above compared with the intervention in question for patients receive systemic chemotherapy for CRC. |
| Outcome | <p>KQ1: <u>Ultimate outcomes:</u> Survival and quality of life <u>Intermediate outcomes:</u> Time to progression, and local recurrence, length of stay</p> <p>KQ2: <u>Adverse outcomes:</u> biloma, hepatic abscess, hepatic hemorrhage, elevated alkaline phosphatase, elevated bilirubin, elevated transaminases, injury to adjacent organ(s), liver failure, rare adverse events, and steatohepatitis.</p> | <p>KQ3: <u>Ultimate outcomes:</u> Same as KQs 1 and 2 <u>Intermediate outcomes:</u> Time to recurrence, and local recurrence, length of stay</p> <p>KQ4: <u>Adverse outcomes:</u> Same as KQs 1 and 2</p> |
| Timing | The relevant periods occur at the time of treatment of CRC hepatic metastases through followup over months or years. | Same as KQs 1 and 2. |
| Setting | Inpatient and outpatient. | Same as KQs 1 and 2. |

3D-CRT = three-dimensional conformal radiotherapy; CRC = colorectal cancer; IMRT = intensity-modulated radiation therapy; KQ = Key Question

Key Questions

KQ1. What is the comparative effectiveness of the various liver-directed therapies in patients whose disease is refractory to systemic therapy for unresectable CRC metastases to the liver and who have minimal evidence of extrahepatic disease?

KQ2. What are the comparative harms of the various liver-directed therapies in patients whose disease is refractory to systemic therapy for unresectable CRC metastases to the liver and who have minimal evidence of extrahepatic disease?

KQ3. What is the comparative effectiveness of the various liver-directed therapies in patients who are candidates for liver-directed therapy as an adjunct to systemic therapy for unresectable CRC metastases to the liver and have no evidence of extrahepatic disease?

KQ4. What are the comparative harms of the various liver-directed therapies in patients who are candidates for liver-directed therapy as an adjunct to systemic therapy for unresectable CRC metastases to the liver and have no evidence of extrahepatic disease?


Analytic Frameworks

We developed the analytic frameworks (Figure 1 and Figure 2) based on clinical expertise and refined it with input from our key informants and technical expert panel (TEP). These diagrams are revised versions of those posted with the review protocol; the revisions are intended to make the core elements of our final analyses clearer, given the actual literature available for the review.

Figure 1 outlines potential areas in which patients who are unable to receive systemic chemotherapy are using local hepatic therapy. These therapies may affect intermediate health outcomes such as time to progression, local recurrence, and length of stay, as well as the ultimate outcomes of quality of life and overall survival (KQ1).


Figure 2 outlines potential areas in which patients receive local hepatic therapy and concomitant systemic chemotherapy. These therapies may affect intermediate health outcomes such as time to recurrence, local recurrence, and length of stay, as well as ultimate outcomes of quality of life and overall survival (KQ3). In both frameworks, we attempted to assess the occurrence of adverse effects due to local hepatic therapies (KQ2 and KQ4).

Figure 1. Analytic framework for comparative effectiveness of local hepatic therapies for unresectable CRC metastases to the liver in patients whose metastatic disease is refractory to systemic chemotherapy and who have no or minimal extrahepatic disease



3D-CRT = three-dimensional conformal radiotherapy; KQ = Key Question; IMRT = intensity-modulated radiation therapy

Figure 2. Analytic framework for comparative effectiveness of local hepatic therapies for unresectable colorectal cancer metastases to the liver in patients receiving local hepatic therapy as an adjunct to systemic chemotherapy and who have no extrahepatic disease



3D-CRT = Three-dimensional conformal radiotherapy; IMRT = Intensity-modulated radiation therapy; KQ = Key Question

Organization of This Evidence Report

The Methods chapter describes our processes, including our search strategy, inclusion and exclusion criteria, approach to abstract and full text review, and methods for extraction of data into evidence tables and then compiling evidence. In addition, we describe the procedures for evaluating bias in individual studies and describing the strength of the body of evidence.

The Results chapter presents the findings of the literature search and the review of the evidence by key question, synthesizing the findings by strategies.

The Discussion chapter presents the key findings and discusses their relationship to other published findings and the applicability of the findings of this report. We also outline challenges for future research in the field.

The report includes a number of appendixes to provide further details about our methods and the studies assessed. The appendixes are as follows:

- Appendix A: Search Strategy
- Appendix B: Contacted Authors
- Appendix C: DistillerSR Screening and Abstraction Forms
- Appendix D: Evidence Tables
- Appendix E: Abbreviations and Acronyms
- Appendix F: Excluded Studies

Uses of This Evidence Report

We anticipate that this report will be of primary value and interest to health care providers who treat patients with CRC and CRC metastases to the liver. Treatment is generally provided by medical oncologists, radiation oncologists, interventional radiologists, and surgeons. This report can bring providers up to date on the current state of the evidence, and it provides a quality assessment of the risk of bias in individual studies that report the outcomes of treatment for unresectable CRC metastases to the liver. It will also be of interest to patients with unresectable CRC liver metastases and their families who are concerned about their health and are facing treatment choices.

Finally, this presentation of the evidence will be of value to researchers, who can obtain a concise analysis of the current state of knowledge in the field and information about gaps in knowledge. The report will help prepare them to conduct research in areas that are needed to advance research methods, understand patient selection, and optimize the effectiveness and safety of treatment for unresectable CRC metastases to the liver.

Methods

In this chapter, we document the procedures that the Blue Cross and Blue Shield EPC used to produce a CER on the effectiveness and comparative effectiveness of local hepatic therapies for CRC metastases to the liver. The methods for this CER follow the methods suggested in the AHRQ Methods Guide for Effectiveness and Comparative Effectiveness Reviews (available at www.effectivehealthcare.ahrq.gov/methodsguide.cfm).

The main sections in this chapter reflect the elements of the protocol established for the CER; certain methods map to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist.⁵³ We first describe the topic refinement process and the construction of the review protocol. We then present our strategy for identifying articles relevant to our KQs, our inclusion and exclusion criteria, and the process we used to extract information from the included articles and generate our evidence tables. In addition, we discuss our method for grading the quality of individual articles, rating the strength of the evidence, and assessing the applicability of individual studies and the body of evidence for each KQ. Finally, we describe the peer review process. All methods and analyses were determined a priori and documented in a research protocol that was publically posted by AHRQ for comments.

Given the clinical complexity of this topic and the evolution of the scope and the KQs, we sought input from the TEP throughout the process. In some cases, this was done through joint teleconferences; in other cases, we contacted TEP members individually to draw on each member's particular expertise.

Topic Refinement and Review Protocol

The topic for this report was nominated in a public process. With input from technical experts, the EPC drafted the initial KQs and, after approval from AHRQ, posted them to a public Web site. The KQs were posted for 4 weeks for public comment. We modified the KQs and the key elements of PICOTS based on these comments and discussion with the TEP.

When the KQs were first written, both the questions and the interventions were stratified by intent of treatment (palliative or curative). However, this stratification seemed clinically inappropriate and potentially confusing because some interventions could be applied to palliate symptoms and to eliminate (i.e., cure) the liver metastases. Thus, the final KQs are distinguished by the population receiving local hepatic therapy. KQs 1 and 2 apply to patients whose CRC is refractory to systemic chemotherapy (i.e., their disease had progressed), and KQs 3 and 4 apply to patients who are receiving local hepatic therapy and systemic chemotherapy. To be consistent with clinical practice, we modified KQs 1 and 2 to include patients with minimal extrahepatic disease. In addition, we categorized the 12 interventions to apply to all KQs, we removed some interventions, and we added SBRT. Finally, we expanded the list of harms to be considered to include elevated alkaline phosphatase, elevated bilirubin, elevated transaminases, liver failure, and rare adverse events that had not been considered originally.

Literature Search Strategy

Search Strategy

We searched MEDLINE and Embase and the Cochrane Library. Our search strategy used the National Library of Medicine's Medical Subject Heading (MeSH[®]) keyword nomenclature developed for MEDLINE and adapted for use in other databases. We limited the searches to the

English language⁵⁴ but did not limit the search by geographic location of the study. Evidence suggests that language restrictions do not change the results of systematic reviews for conventional medical interventions.⁵⁵ We also restricted the searches to articles that treated patients between January 1, 2000, and June 27, 2012, primarily to ensure the applicability of the interventions and outcomes data to current clinical practice. Prior to 2000 some interventions were in their infancy and based on current standards used outdated regimens.⁵⁶⁻⁵⁸ Thermal therapies were not used significantly until late 1990s and major changes in proton beam and stereotactic therapy occurred during the same period.⁵⁹ Chemoembolization drugs and embolic mixtures have also changed a great deal in the last ten years and are more standard now. For these reasons which were strongly supported by the TEP we excluded studies where patient treatment preceded 2000.

We searched for the following publication types: RCTs, nonrandomized comparative studies, and case series. We used the following search terms for the diseases in question: CRC, metastases, and unresectable liver tumors. Appendix A gives the major search strings, including all the terms used for the interventions of interest.

We searched the gray literature for clinical trials, material published on the U.S. Food and Drug Administration Web site, and relevant conference abstracts identified by TEP members (from the American Society of Clinical Oncology, American Society of Clinical Oncology Gastrointestinal Cancers, Surgical Society of Oncology, and Radiosurgery Society). We also reviewed scientific information packets that the Scientific Resource Center had requested and obtained from relevant pharmaceutical or device firms.

Originally, we had intended to contact study authors only if the EPC staff believed that the evidence could meaningfully affect results (i.e., alter eventual grades of the strength of evidence). However, because of the limited number of studies included in this report, we elected to contact authors for any article lacking complete information on patient characteristics, interventions, or outcomes. A listing of the contacted authors is included in Appendix B.

Inclusion and Exclusion Criteria

Table 3 lists the inclusion/exclusion criteria we selected based on our understanding of the literature, key informant and public comments gathered during the topic refinement phase, input from the TEP, and established principles of systematic review methods.

Table 3. Inclusion and exclusion criteria

| Category | Criteria |
|-----------------------|---|
| Study population | Patients with primary CRC and unresectable liver metastases due to lesion characteristics or underlying comorbidity <ul style="list-style-type: none"> • For KQ1 and KQ2, patients refractory to systemic chemotherapy • For KQ3 and KQ4, patients receiving local hepatic therapy as an adjunct to systemic chemotherapy |
| Time period | Studies with treatment dates after 2000 to represent current interventional approaches to local hepatic therapies |
| Publication languages | English only |
| Admissible evidence | <u>Study designs</u> <ul style="list-style-type: none"> • All study designs • Case reports that report on a rare adverse event <u>Other criteria</u> <ul style="list-style-type: none"> • Extrahepatic disease permitted only if it is liver dominant • Studies must involve one or more of the interventions listed in the PICOTS • Studies must include at least one outcome measure listed in the PICOTS and the outcome must be extractable from data presented in the articles • To allow for the inclusion of all potentially relevant evidence, studies that deviated from our inclusion criteria by less than 10% were included (e.g., 5% of patients were HCC, or 9% of patients had documented extrahepatic disease) |

CRC = colorectal cancer; KQ = Key Question; PICOTS = population, intervention, comparator, outcome, timing, setting

Study Selection

Search results were transferred to EndNote[®] and subsequently into DistillerSR (Evidence Partners Inc., Ottawa, Canada) for selection. Using the study selection criteria for screening titles and abstracts, each citation was marked as: (1) eligible for review as full-text articles or (2) ineligible for full-text review. Reasons for article exclusions at this level were not noted. The first-level title-only screening was performed in duplicate. To be excluded, a study needed to be independently excluded by both team members. In cases where there was disagreement, second-level abstract screening was completed by two independent reviewers.

Discrepancies were decided by consensus opinion and a third reviewer was consulted when necessary. All team members were trained using a set of 50 abstracts to ensure uniform application of screening criteria. Full-text review was performed if it was unclear whether the abstract met article-selection criteria.

Full-text articles were reviewed in the same fashion to determine their inclusion in the systematic review. Records of the reason for exclusion for each paper retrieved in full-text, but excluded from the review, were maintained in the DistillerSR database. Although an article may have been excluded for multiple reasons, only the first reason identified was recorded.

Development of Evidence Tables and Data Extraction

Evidence tables were constructed by clinical content experts and staff at the EPC. Tables were designed to provide sufficient information and enable readers to understand the studies and determine their quality. Emphasis was given to data elements essential to our KQs. Evidence table templates were identical for KQ1 and KQ3 and KQ2 and KQ4. The format of our evidence tables was based on examples from prior systematic reviews.

Data extraction was performed directly into tables created in DistillerSR, with elements defined in an accompanying data dictionary. All team members extracted a training set of five articles into evidence tables to ensure uniform extraction procedures and test the utility of the table design. All data extractions were performed in duplicate, with discrepancies resolved by

consensus. The full research team met regularly during the period of article extraction to discuss any issues related to the extraction process. Extracted data included patient and treatment characteristics, outcomes related to intervention effectiveness, and information on harms. Harms included specific negative effects, including the narrower definition of adverse effects. Data extraction forms used during this review are presented in Appendix C.

The final evidence tables are presented in their entirety in Appendix D. Studies are presented in the evidence tables by study design, then year of publication alphabetically by the last name of the first author. Abbreviations and acronyms used in the tables are listed as table notes and are presented in Appendix E.

Risk of Bias Assessment of Individual Studies

For the assessment of risk of bias in individual studies, we followed the Methods Guide³⁸ where applicable. Our assessment of risk of bias in the included case-series intervention studies was based on a set of study characteristics proposed by Carey and Boden.⁶⁰ These characteristics include: clearly defined study questions, well-described study population, well-described intervention, use of validated outcome measures, appropriate statistical analyses, well-described results, discussion and conclusion supported by data, and acknowledgement of the funding source. The Carey and Boden assessment tool does not conclude with an overall score of the individual study. We created thresholds for converting the Carey and Boden⁶⁰ risk assessment tool into AHRQ standard quality ratings (good, fair, and poor) to differentiate case-series studies of varied quality. These distinctions are to be used for differentiation within the group of case-series studies, but not for the overall body of evidence described below. The classification into these categories (i.e., good, fair, poor) is distinct for a specific study design. Other study designs are evaluated according to their own strengths and weaknesses.

For a study to be ranked as good quality, each of the Carey and Boden⁶⁰ criteria must have been met. For a fair quality rank, one criterion was not met, and a rank of poor quality was given to studies with more than one criterion not met. These quality ranking forms can be found in Appendix D.

Data Synthesis

Evidence tables were completed for all included studies, and data are presented in summary tables. Evidence is also presented in text organized by outcome and intervention. No direct comparisons are made. We considered whether formal data synthesis (e.g., meta-analysis) would be possible from the set of included studies. Because the literature was so heterogeneous in terms of the populations (e.g., prior treatments, reason for unresectability and number and size of lesions) and interventions (e.g., drugs and dose) studied, we concluded that pooling data would be inappropriate for this review. Thus, all data synthesis is based on qualitative summaries and analyses.

Strength of the Body of Evidence

We graded the strength of the overall body of evidence for overall survival, quality of life, and harms for the four KQs. We used the EPC approach (developed for the EPC program and referenced in the Methods Guide^{38,61}), which is based on a system developed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group.⁶² This

system explicitly addresses four required domains: risk of bias, consistency, directness, and precision.

The overall strength of evidence could be graded as “high” (indicating high confidence that the evidence reflects the true effect, and that further research is very unlikely to change our confidence in the estimate of effect); “moderate” (indicating moderate confidence that the evidence reflects the true effect, and that further research may change our confidence in the estimate of effect and may change the estimate); “low” (indicating low confidence that the evidence reflects the true effect, and that further research is likely to change our confidence in the estimate of effect and is likely to change the estimate); or “insufficient” (indicating that evidence is either unavailable or does not permit estimation of an effect).

Two independent reviewers rated all studies on domain scores and resolved disagreements by consensus discussion; the same reviewers also used the domain scores to assign an overall strength of evidence grade. When evidence was available but the effects could not be estimated from the body of evidence, the overall strength of evidence was rated as “insufficient.” If we could estimate comparative effects, we graded the evidence as “low,” indicating our low level of confidence in the estimates. This decision was based in large part on the biases inherent in a literature base comprising case-series studies. In this review, consistency of the body of literature was graded as “not applicable.” The direction of effect cannot be assessed in noncomparative studies; therefore, consistency in the direction of effect across case series cannot be discerned. In the absence of a comparator, we do not know if the observed estimate is better or worse; therefore, we concluded that consistency was not applicable. Directness pertains to the whether the evidence links the interventions directly to a health outcome. Due to the absence of direct comparisons precision will be rated imprecise.

Assessing Applicability

Applicability of the results presented in this review was assessed in a systematic manner using the PICOTS framework. Assessment included both the design and execution of the studies, as well as their relevance to the target populations, interventions, and outcomes of interest.

Results

In this chapter, we present the results of our systematic review of the literature and synthesis of the extracted data on outcomes on the effectiveness and comparative effectiveness of local hepatic therapy for unresectable CRC metastases to the liver. The Key Questions (KQs) for this review are: KQ1 (effectiveness) and KQ2 (harms) of local hepatic therapy for unresectable CRC metastases to the liver in patients whose disease is refractory to systemic chemotherapy and who have no or minimal extrahepatic disease; and KQ3 (effectiveness) and KQ4 (harms) of local hepatic therapy for unresectable CRC metastases to the liver in patients who are also receiving systemic chemotherapy and have no extrahepatic disease.


We first describe the results of our literature searches and then present the results for KQ1 and KQ2, which include a list of key points, an overview of the included literature, and a detailed synthesis of the data. This is followed by the same for KQ3 and KQ4. We identified 937 nonduplicate titles or abstracts with potential relevance, and of these, 189 proceeded to full-text review (Figure 3). Thirty-one articles were included in the review, including one hand-searched article and five articles from gray literature identified through other sources (the American Society of Clinical Oncology, American Society of Clinical Oncology Gastrointestinal Cancers, Surgical Society of Oncology, and Radiosurgical Society). The 31 arms represent 30 distinct studies: 1 RCT, 12 prospective case series, and 17 retrospective case series. Twenty-three studies pertain to KQ1, 23 studies to KQ2, 7 studies to KQ3, and 7 studies to KQ4.

Results of Literature Searches

Of the 937 records identified through the literature search, we excluded 913 at various stages of screening and included 24 records.⁶³⁻⁸⁶ We included one hand-searched article,⁸⁷ two published studies from scientific information packets,^{88,89} and three articles from conference abstracts.⁹⁰⁻⁹² A total of 30 articles were included in this report: 29 case-series and one RCT⁸⁷ for which a single arm was abstracted as a case series. This RCT compared RFA with systemic chemotherapy to systemic chemotherapy alone. The scope of the review was liver-directed therapy versus liver-directed therapy. Systemic chemotherapy alone was not a relevant intervention or comparator for this review. Only the RFA combined with systemic chemotherapy arm was abstracted and included in this report as it is relevant for KQ3 and KQ4.

The PRISMA diagram (Figure 3) depicts the flow of search screening and study selection.⁵³ A list of full-text studies with reason for exclusion is presented in Appendix F.

Figure 3. PRISMA diagram for identified published literature



Our searches of various gray literature sources yielded five published studies that we added to the articles identified in the search of publications databases and that were included in the analyses presented in this evidence review.⁸⁸⁻⁹²

We evaluated the results of the gray literature search as follows:

- **Regulatory information:** The search yielded six results, but no new studies were identified from this source.
- **Clinical trial registries (ClinicalTrials.gov):** The search yielded 259 clinical trials; we excluded 219 trials during the title and abstract screen. Twenty-five of the remaining 40 trials were excluded. Among the 15 trials remaining, 2 contained too little information to make a conclusion about their relevance to the KQs of this report. Of the remaining 13 studies, three had been terminated, seven were ongoing or recruiting, and three had been completed. We found no publications for the three completed trials. All terminated studies cited low recruitment as the reason for study termination.
- **Abstracts and conference papers:** The search yielded 174 citations, and we excluded 132 during the title and abstract screen. Of the remaining 42 items, two were duplicates

and 37 did not meet inclusion criteria after full-text review. The three remaining references met all inclusion criteria and were included in this report.⁹⁰⁻⁹²

- **Manufacturer database:** Scientific information packets were received from Accuray (manufacturers of the CyberKnife[®] SBRT system) and SIRTEX (manufacturers of the Yttrium-90–infused SIR-Spheres microspheres). The submissions consisted of 55 published references, listings of clinical trials, or conference abstracts. Of the 55 references, we excluded 53 during the abstract and title screen. The remaining two references met the inclusion criterion and were included in this report.^{88,89}

Overview of the Literature

Thirty-one arms within 30 studies met our inclusion criteria and addressed local hepatic therapy for unresectable CRC metastases to the liver. Nine studies were conducted in the United States, four in Italy, four in Germany, three in Australia, three in Japan, two in the United Kingdom, two in Korea, and one study each in France, the Netherlands, and Turkey (Table 4). The number of patients in each study ranged from 6 to 140.

Table 4. Characteristics of studies included in this review by intervention

| Characteristic | RFA | TACE | HAI | RE | DEB | SBRT | RFA With SC | HAI With SC | RE With SC | Total Arms* |
|-------------------------------|-----|----------------|-----|-----------------|-----|------|----------------|-------------|------------|-------------|
| Total | 1 | 2 ^a | 2 | 13 ^a | 3 | 3 | 3 | 2 | 2 | 31 |
| Study Design | | | | | | | | | | |
| Prospective Case Series | 0 | 0 | 0 | 6 | 2 | 1 | 2 ^b | 1 | 1 | 13 |
| Retrospective Case Series | 1 | 2 | 2 | 7 | 1 | 2 | 1 | 1 | 1 | 18 |
| Outcomes Reported | | | | | | | | | | |
| Overall Survival | 1 | 2 | 2 | 13 | 3 | 3 | 3 | 2 | 2 | 31 |
| Quality of Life | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Time to Recurrence | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Length of Stay | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Local Recurrence | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 6 |
| Adverse Events | 1 | 2 | 2 | 13 | 3 | 3 | 3 | 2 | 2 | 31 |
| Study Population | | | | | | | | | | |
| United States | 0 | 2 | 0 | 7 | 1 | 0 | 0 | 0 | 0 | 10 |
| Europe | 1 | 0 | 1 | 4 | 2 | 2 | 1 | 0 | 1 | 12 |
| Australia | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 3 |
| Asia | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 6 |
| Total Participants (N) | 68 | 142 | 67 | 454 | 157 | 43 | 101 | 36 | 159 | 1,227 |

DEB = drug-eluting beads; HAI = hepatic arterial infusion; RE = radioembolization; N = number; RFA = radiofrequency ablation, SBRT = stereotactic body radiotherapy; SC = systemic chemotherapy; TACE = transarterial chemoembolization
 Note: No studies reporting on cryosurgical ablation, MWA, TAE, 3D-CRT, or IMRT met inclusion criteria for this review.

*The total number of articles included in this review is 30.

^aHong et al. reports on both TACE and RE interventions.

^bThe study by Ruers et al. is an RCT that was extracted as a case series.

All 30 studies had clearly defined questions and well-described interventions, used validated outcome measures, and had conclusions that were supported by the data. Studies varied on how well they described the study population, how well they described their results, and

acknowledgement of sponsorship and funding. Fifteen studies did not have well-described patient populations,^{63,65,67,70,74,78,79,81,83-86,88,89,91} and three studies lacked well-described results.^{67,70,74}

Fifteen studies were rated as good quality,^{64,66,68,69,71-73,75-77,80,82,87,90,92} 12 studies as fair quality,^{57,63,65,78,79,81,84-86,88,89,91} and three as poor quality.^{67,70,74}

Key Questions 1 and 2: Effectiveness and Harms of Therapies in Patients Refractory to Systemic Chemotherapy

KQs 1 and 2 focus on the comparative effectiveness (KQ1) and harms (KQ2) of the various local hepatic therapies in patients with unresectable colorectal cancer (CRC) metastases to the liver and who have minimal evidence of extrahepatic disease and whose disease is refractory to systemic therapy (i.e., are not eligible to receive systemic chemotherapy).

Key Points

- The evidence is insufficient to draw conclusions about overall survival, quality of life, or adverse events. Due to the absence of comparative data, we are limited in drawing conclusions regarding the efficacy and effectiveness of these interventions. Risk of bias is a primary concern in observational studies. Intended effects are likely to be biased by preferential prescribing of the intervention based on the patients' prognosis.
- All studies were case series. Carey and Boden quality rankings were converted into AHRQ "good," "fair," and "poor" ratings. Eleven studies were rated as good quality,^{66,68,69,71,73,75-77,82,90,92} nine studies as fair quality,^{63,65,78,83,84,86,88,89,91} and three as poor quality.^{67,70,74}
- The assessment of applicability of the study findings to clinical practice is limited by the poor characterization of the patient populations (e.g., number and size of metastases, performance status) and variability in the delivery of the interventions (e.g., surgical approach, dose and drugs delivered).

Description of Included Studies

Twenty-three case series^{63,65-71,73-78,82-84,86,88-92} met inclusion criteria to address KQ1 and KQ2. Of the 23 case series, nine were prospective^{66,67,70,73-76,78,88} and 14 were retrospective.^{63,65,68,69,71,77,82-84,86,89-92} The total number of patients for whom data were abstracted from the 23 studies was 932. Three studies included patients treated with TACE with DEB;^{67,75,90} and two articles reported on TACE alone;^{63,68} three on SBRT;^{71,82,88} thirteen on RE;^{65,66,68,70,73,76-78,84,86,89,91,93} two on HAI,^{83,92} and one on RFA.⁶⁹ All studies initiated treatment in patients after January 1, 2000, except for the study by Albert and colleagues²¹ on TACE. We included this study because it reported on relatively large numbers of patients treated, and analyses showed no differences in outcomes before and after 2000. Table 5 shows the summary of the study and patient characteristics, including number of patients enrolled, study design, intervention period, and intervention, and patient demographics.

Patients ranged in age from 30 to 91 years, but they were generally in their late 50s or early 60s. Thirteen studies reported rates of previous resection that ranged from 2.6 to 83.5 percent.^{63,64,66,68-70,75,82,84,88,89,91,92} Five studies reported median ECOG scores of 0-1, with a range of 0-3.^{66,67,73,75,77} In all but two studies,^{72,81} patients had been treated with prior lines of systemic

chemotherapy, and 11 studies reported patient experience with prior local hepatic therapy.^{63,68-70,75,78,82,84,88,89,91} Lines of previous systemic chemotherapy are presented in Appendix D.

The included evidence is clinically diverse with respect to the number of patients undergoing previous resection and local hepatic therapy. Variations are also present in the treatments—in terms of the drugs or dosage—within a given intervention.

Data on tumor characteristics were inconsistently reported across studies and are detailed in Table 6. Synchronous or metachronous disease status was reported in eight studies and synchronous disease ranged from 17 to 73 percent.^{66,68,71,75,83,91,92,94} Bilobar or unilobar disease was reported in six studies and bilobar disease ranged from 66.7 to 95.1 percent.^{65,66,68,73,76,86} Eight studies reported liver involvement, but used nonuniform measurements.^{65,67,70,73,75-77,90} Four studies reported mean or median number of hepatic lesions.^{69,71,75,82} Six studies reported the mean size of hepatic lesions, which ranged from 2.9 to 12cm.^{66,68,69,82,90,94} Presence of extrahepatic metastases were reported by five studies and ranged from 33 to 81 percent of patients.^{63,66,68,91,92} Although extrahepatic disease was reported by these studies, the patients were all described as having liver-dominant disease (i.e., majority of the disease is confined to the liver).

Table 5. Local hepatic therapies for CRC metastases to the liver: Summary of study characteristics KQ1 and KQ2

| Study N° (% CRC) Rating | Study Design | Intervention Period | Intervention | Median Age (Range) | Previous Resection % | Median ECOG Score (Range) | Previous Local Hepatic Therapy % |
|---|------------------------------|------------------------|---|--------------------------|-------------------------|------------------------------------|---------------------------------------|
| Martin et al., 2012 ^{86,a} 24 (100) Fair | Retrospective case series | 02/2005– 02/2009 | RE with Y90 via hepatic artery catheter infusion | 63 (35–83) | NR | NR | NR |
| Kucuk et al., 2011 ⁸⁴ 78 (44.9) Fair | Retrospective case series | 06/2006– 10/2010 | SIRT with Y90 via hepatic artery catheter under intermittent fluoroscopic visualization | Mean: 62.4 | 2.6 | NR | RFA: 7.7 Chemoembolization: 2.6 |
| Aliberti et al., 2011 ⁹⁰ 82 (100) Good | Retrospective case series | 12/2005– 09/2011 | TACE with irinotecan (100–2000 mg) in DC Beads (2–4 ml of beads) | 61.8 (46–82) | NR | 1 (0–2) | NR |
| Martin et al., 2011 ⁷⁵ 55 (100) Good | Prospective case series | 10/2006– 08/2008 | Intervention: TACE with DEB; Drug: irinotecan; Dose: median 185 mg, range 150–650 mg; Site: femoral or axillary artery | 60 (34–82) | 20 | 1 (0–2) | Ablation: 9.1 |
| Vautravers- Dewas et al., 2011 ⁸² 42 (66.7) Good | Retrospective case series | 07/2007– 04/2009 | Intervention: SBRT; Radiation dose: 40 Gy and 45 Gy; Site: noninvasive | (23–82) | 51.1 | NR | RFA: 7 |
| Albert et al., 2011 ⁶³ 121 (100) Fair | Retrospective case series | 03/1992– 07/2008 | Intervention: TACE; Drug: mitomycin C, doxorubicin, cisplatin; Site: femoral artery | Mean: 61.9 | 17 | 0 (0 -) | RFA: 17 |
| Nace et al., 2011 ⁸⁹ 51 (100) Fair | Retrospective case series | 08/2002– 05/2008 | RE with Y90 (delivery dose 50 Gy) via hepatic artery | 64 (37–83) | 23.5 | NR (0–1) | RFA: 21.6; HAI 9.8 |
| Stintzing et al., 2010 ⁸⁸ 6 (100) Fair | Prospective case series | NR | Radiosurgery (24 Gy) for a single session | 66.5 (51–76) | 83.5 | NR | RFA: 17.6 |

Table 5. Local hepatic therapies for CRC metastases to the liver: Summary of study characteristics KQ1 and KQ2 (continued)

| Study N° (% CRC) Rating | Study Design | Intervention Period | Intervention | Median Age (Range) | Previous Resection % | Median ECOG Score (Range) | Previous Local Hepatic Therapy % |
|--|------------------------------|------------------------|---|--------------------------|----------------------------|------------------------------------|---|
| Nishiofuku et al., 2010 ⁹² 55 (100) Good | Retrospective case series | 04/2005– 03/2008 | HAI of 5-FU (1000 mg/m ²) via continuous 5-hour infusion once a week; Catheter inserted from left subclavian artery or right femoral artery | 62 (30–78) | 22 | 1 (0–3) | NR |
| Nishiofuku et al., 2010 ⁹² 55 (100) Good | Retrospective case series | 04/2005– 03/2008 | HAI of 5-FU (1000 mg/m ²) via continuous 5-hour infusion once a week; Catheter inserted from left subclavian artery or right femoral artery | 62 (30–78) | 22 | 1 (0–3) | NR |
| Cosimelli et al., 2010 ⁶⁶ 50 (100) Good | Prospective case series | 05/2005– 08/2007 | Intervention: RE; Drug: Y90; Site: hepatic artery | 67 (34–85) | 24 | 0 (0–3) | NR |
| Kim et al., 2009 ⁷¹ 9 (100) Good | Retrospective case series | 06/2004– 12/2006 | Intervention: SBRT; Radiation dose: median 42 Gy, range 36–51 Gy; Site: noninvasive | 57 (35–74) | NR | NR (1–2) | NR |
| Cianni et al., 2009 ⁶⁵ 41 (100) Fair | Retrospective case series | 02/2005– 01/2008 | Intervention: RE; Y90 dose: mean 1.82 GBq; Site: hepatic artery | NR (33–77) | NR | 0.7 (0 -) | TACE: 4.8; RFA or cryosurgical ablation: 19.5 |
| Mulcahy et al., 2009 ⁷⁶ 72 (100) Good | Prospective case series | 2003–2007 | Intervention: RE; Y90 dose: median 118 Gy; Site: hepatic artery | 61 (54–86) | NR | 0 (0–2) | NR |
| Jakobs et al., 2008 ⁹¹ 41 (100) Fair | Retrospective case series | 10/2003– 04/2007 | Intervention: RE; Y90 dose: mean 1.9 GBq (range 0.7–2.8 GBq). | NR | NR | NR | NR |
| Sato et al., 2008 ⁷⁸ 137 (37.2) Fair | Prospective case series | 2002–2006 | Intervention: RE; Y90 dose: median 1.83 GBq, range 0.7–6.9 GBq, median 112.8 Gy, range 27–180 Gy; Site: hepatic artery | NR | NR | 0 (0–3) | Local hepatic therapy (unspecified): 16 |

Table 5. Local hepatic therapies for CRC metastases to the liver: Summary of study characteristics KQ1 and KQ2 (continued)

| Study N° (% CRC) Rating | Study Design | Intervention Period | Intervention | Median Age (Range) | Previous Resection % | Median ECOG Score (Range) | Previous Local Hepatic Therapy % |
|--|------------------------------|-----------------------------------|--|--------------------------|----------------------------|------------------------------------|--|
| Vogl et al., 2008 ⁸³ 55 (21.8) Fair | Retrospective case series | 2002–2006 | Intervention: HAI; Drug: mitomycin C, gemcitabine; Site: femoral artery | 63.5 (54–80) | NR | NR | NR |
| Hong et al., 2009 ⁶⁸ 21 (100) Good | Retrospective case series | 01/2001– 03/2006 | Intervention: TACE; Drug: cisplatin, doxorubicin, mitomycin C; Site: femoral artery | 67 (32–88) | 23 | NR | Cryosurgical ablation: 4.8, Radiation: 4.8, RFA: 9.5 |
| | | | Intervention: RE; Y90 dose: median 112.9 Gy/tx, median 113.0 Gy/pt; Site: femoral artery | 67 (51–80) | 20 | NR | RFA: 6.7, TACE: 13.3 |
| Rowe et al., 2007 ⁷⁷ 24 (29.2) Good | Retrospective case series | 07/2004– 11/2005 | Intervention: RE; Y90 dose: median 103 Gy, range 41–145 Gy, median 1.8 GBq, range 1.5–2.0 GBq; Site: hepatic artery | 57 (53 – 68) | NR | 1 (0–2) | NR |
| Jiao et al., 2007 ⁷⁰ 21 (47.6) Poor | Prospective case series | 06/2004 – NR | Intervention: RE; Y90 dose: mean 1.9 GBq, range 1.2–2.5 GBq; Site: femoral catheter or hepatic artery port | NR (40–75) | 31 | NR | RFA: 48 |
| Fiorentini et al., 2007 ⁶⁷ 20 (100) Poor | Prospective case series | 11/2005 – ongoing (06/2007) | Intervention: TACE with DEB; Drug: irinotecan; Site: hepatic artery | NR | NR | 1 (0–2) | NR |
| Jakobs et al., 2006 ⁶⁹ 68 (100) Good | Retrospective case series | 01/2000– 06/2004 | Intervention: RFA; Site: percutaneous | (38–87) | 16 | NR | HAI: 3, TACE: 3 |

Table 5. Local hepatic therapies for CRC metastases to the liver: Summary of study characteristics KQ1 and KQ2 (continued)

| Study N^o (% CRC) Rating | Study Design | Intervention Period | Intervention | Median Age (Range) | Previous Resectio n % | Median ECOG Score (Range) | Previous Local Hepatic Therapy % |
|--|-------------------------|--------------------------------|---|-----------------------------------|--------------------------------------|--|---|
| Lewandowski et al., 2005 ⁷³ 27 (100) Good | Prospective case series | 06/2001–12/2003 | Intervention: RE; Y90 dose: range 135–150 Gy; Site: lobar | 68 (54–86) | NR | 0 (0–2) | NR |
| Lim et al., 2005 ⁷⁴ 30 (100) Poor | Prospective case series | 01/2002–03/2004 | Intervention: RE; Drug: Y90 | 61.7 (36 – 77) | NR | 0 (0 – 2) | NR |

CRC = colorectal cancer; DEB = drug-eluting bead; ECOG = Eastern Cooperative Oncology Group; GBq = Gigabecquerel; Gy = Gray; HAI = hepatic arterial infusion; Mets = Metastases; NR = not reported; RE = radioembolization; RFA = radiofrequency ablation; SBRT = stereotactic body radiation therapy; SIRT = selective internal radiotherapy; TACE = transarterial chemoembolization; tx = treatment; pt = patient; Y90 = Yttrium-90

^aData on patient characteristics from this case series include patients with extrahepatic disease; information on outcomes is for patients with non-extrahepatic disease.

^oThis N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

Table 6. Local hepatic therapies for CRC metastases to the liver: Summary of tumor characteristics KQ1 and KQ2

| Study N^o (% CRC) Rating | Synchronous (%) | Bilobar (%) | Median Liver Involvement (%) (Range) | Mean and Median Number of Hepatic Lesions (Range) | Mean Size of Hepatic Lesion(s) (cm) (Range) | Other Liver Involvement % |
|---|----------------------------|------------------------|---|--|--|---|
| Martin et al., 2012 ^{86,d} 24 (100) Fair | NR | 67 | NR | NR | NR | Extrahepatic metastasis 45.8 |
| Kucuk et al., 2011 ⁸⁴ 78 (44.9) Fair | NR | NR | NR | NR | NR | NR |
| Aliberti et al., 2011 ⁹⁰ 82 (100) Good | NR | NR | 33 (25–50) | NR | 12 (6.5–32) | NR |
| Martin et al., 2011 ⁷⁵ 55 (100) Good | 30.9 | NR | NR | Median: 4 (1–20) | NR | 50 Percent liver involvement : 30.9 |
| Vautravers- Dewas et al., 2011 ⁸² 42 (66.7) Good | NR | NR | NR | Mean: 1.4 (1–4) | 3.4 (.7–10) | WHO 0: 94.4; WHO 1: 11.1; WHO 2: 2.2; WHO 3: 2.2 |
| Albert et al., 2011 ⁶³ 121 (100) Fair | 49 | NR | NR | NR | NR | Extrahepatic metastasis 46 |
| Nace et al., 2011 ⁸⁹ 51 (100) Fair | NR | NR | NR | NR | NR | NR |
| Stintzing et al., 2010 ⁸⁸ 6 (100) Fair | NR | NR | NR | NR | NR | NR |

Table 6. Local hepatic therapies for CRC metastases to the liver: Summary of tumor characteristics KQ1 and KQ2 (continued)

| Study N ^o (% CRC) Rating | Synchronous (%) | Bilobar (%) | Median Liver Involvement (%) (Range) | Mean and Median Number of Hepatic Lesions (Range) | Mean Size of Hepatic Lesion(s) (cm) (Range) | Other Liver Involvement % |
|---|--------------------|----------------|--|---|--|--|
| Nishiofuku et al., 2010 ⁹² 55 (100) Good | 65.5 | NR | NR | NR | NR | limited extrahepatic disease 81.8 |
| Cosimelli et al., 2010 ⁶⁶ 50 (100) Good | 72 | 70 | NR | NR | (5–.8) | ≤4 hepatic mets: 42; >4 hepatic mets: 58 |
| Kim et al., 2009 ^{71,a} 9 (100) Good | 55.6 | NR | NR | Mean: 1.4 Median: 1 (1–2) | NR | NR |
| Cianni et al., 2009 ^{65,b} 41 (100) Fair | NR | 95.1 | NR | NR | NR | 50 Percent liver involvement : 24.3 |
| Mulcahy et al., 2009 ⁷⁶ 72 (100) Good | NR | 83 | NR | NR | NR | Liver replacement ≤25 percent: 78; Liver replacement 26–50 percent: 19; Liver replacement ≥50 percent: 3 |
| Jakobs et al., 2008 ⁹¹ 41 (100) Fair | 73 | NR | NR | NR | NR | Limited extrahepatic disease 17 |
| Sato et al., 2008 ⁷⁸ 137 (37.2) Fair | NR | NR | NR | NR | NR | Tumor burden 0–25 percent: 80; Tumor burden 26–50 percent: 15; Tumor burden 51–75 percent: 5 |
| Vogl et al., 2008 ^{83,c} 55 (21.8) Fair | 17 | NR | NR | NR | NR | Tumor burden 50–75 percent: 16.7 |
| Hong et al., 2009 ⁶⁸ 21 (100) Good | 66.7 | 66.7 | NR | NR | 9.3 (5–16) | Extrahepatic spread: 43 |
| | 53.3 | 86.7 | NR | NR | 8.2 (2–19) | Extrahepatic spread: 33 |

Table 6. Local hepatic therapies for CRC metastases to the liver: Summary of tumor characteristics KQ1 and KQ2 (continued)

| Study N^o (% CRC) Rating | Synchronous (%) | Bilobar (%) | Median Liver Involvement (%) (Range) | Mean and Median Number of Hepatic Lesions (Range) | Mean Size of Hepatic Lesion(s) (cm) (Range) | Other Liver Involvement % |
|---|----------------------------|------------------------|---|--|--|---|
| Rowe et al., 2007 ⁷⁷ 24 (29.2) Good | NR | NR | 25 (3–49) | NR | NR | NR |
| Jiao et al., 2007 ⁷⁰ 21 (47.6) Poor | NR | NR | NR | NR | NR | Tumor Volume <25 percent:14, Tumor Volume 25-50 percent:81, Tumor Volume >51 percent:5 |
| Fiorentini et al., 2007 ⁶⁷ 20 (100) Poor | NR | NR | 40 (20–70) | NR | NR | NR |
| Jakobs et al., 2006 ⁶⁹ 68 (100) Good | NR | NR | NR | Mean: 2.7 (1–5) | 2.3 (.5–5) | NR |
| Lewandowski et al., 2005 ⁷³ 27 (100) Good | NR | 78 | NR | NR | NR | Liver replacement by tumor ≤25 percent: 78; 26–50 percent: 19; >50 percent: 3 |
| Lim et al., 2005 ⁷⁴ 30 (100) Poor | NR | NR | NR | NR | NR | NR |

CRC = colorectal cancer; Mets = metastases; NR = not reported; WHO = World Health Organization

^oThis N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

^aTotal liver tumor volume: median, 72.8 ml (range 3.4–271.1 ml).

^bAll patients had multiple lesions and four patients (9.7%) had other metastatic involvement (pathologic lymph nodes and bone metastases).

^cMedian tumor volume: 79.2 ml (range 6.6–1,384.4 ml).

^dData on patient characteristics from this case series include patients with extrahepatic disease; information on outcomes is for patients with non-extrahepatic disease.

Detailed Synthesis

Table 7 displays the outcomes reported. All studies reported overall survival. All studies reported on adverse events, but four studies aggregated these events by multiple primary cancer sites, which did not permit us to extract CRC-specific adverse events.^{69,70,77,78} Eight studies also reported progression-free survival.^{63,65,66,71,75,90,92,93} Three studies reported on both liver-specific progression-free survival and overall progression-free survival;^{63, 75, 92} no studies reported on liver-specific progression-free survival alone; and the remaining five studies reported overall progression-free survival alone.^{65,66,71,74,90} Jakobs et al. (2006)⁶⁹ attempted to calculate the time to recurrence statistic but were unable to do so because of the low rate of recurrence (18%). Two studies reported on length of stay,^{63,67} and two studies reported on quality of life.^{66,67} We report data on individual outcomes, except for results on overall progression-free survival and liver-specific progression-free survival, which are located in Appendix D.

Table 7. Outcomes reported for Key Questions 1 and 2

| Study N ^o (% CRC) Rating | OS | QOL | TTR | LOS | LR | AE |
|--|----|-----|----------------|-----|----|----------------|
| Albert et al., 2011 ⁶³ 121 (100) Fair | • | NR | NR | • | NR | • |
| Aliberti et al., 2011 ⁹⁰ 82 (100) Good | • | NR | NR | NR | NR | • |
| Cianni et al., 2009 ⁶⁵ 41 (100) Fair | • | NR | NR | NR | NR | • |
| Cosimelli et al., 2010 ⁶⁶ 50 (100) Good | • | • | NR | NR | NR | • |
| Fiorentini et al., 2007 ⁶⁷ 20 (100) Poor | • | • | NR | • | NR | • |
| Hong et al., 2009 ⁶⁸ 21 (100) Good | • | NR | NR | NR | NR | • |
| Jakobs et al., 2006 ⁶⁹ 68 (100) Good | • | NR | • ^a | NR | • | • ^a |
| Jakobs et al., 2008 ⁹¹ 41 (100) Fair | • | NR | NR | NR | NR | • |
| Jiao et al., 2007 ⁷⁰ 21 (47.6) Poor | • | NR | NR | NR | NR | • ^a |
| Kim et al., 2009 ⁷¹ 9 (100) Good | • | NR | NR | NR | • | • |
| Kucuk et al., 2011 ⁸⁴ 78 (44.9) Fair | • | NR | NR | NR | NR | • |
| Lewandowski et al., 2005 ⁷³ 27 (100) Good | • | NR | NR | NR | NR | • |

Table 7. Outcomes reported for Key Questions 1 and (continued)

| Study N [ⓐ] (% CRC) Rating | OS | QOL | TTR | LOS | LR | AE |
|---|----|-----|-----|-----|----|----------------|
| Lim et al., 2005 ⁷⁴ 30 (100) Poor | • | NR | NR | NR | NR | • |
| Martin et al., 2011 ⁷⁵ 55 (100) Good | • | NR | NR | NR | NR | • |
| Martin et al., 2012 ⁸⁶ 24 (100) Fair | • | NR | NR | NR | NR | • |
| Mulcahy et al., 2009 ⁷⁶ 72 (100) Good | • | NR | NR | NR | NR | • |
| Nace et al., 2011 ⁸⁹ 51 (100) Fair | • | NR | NR | NR | NR | • |
| Nishiofuku et al., 2010 ⁹² 55 (100) Good | • | NR | NR | NR | NR | • |
| Rowe et al., 2007 ⁷⁷ 24 (29.2) Good | • | NR | NR | NR | NR | • |
| Sato et al., 2008 ⁷⁸ 137 (37.2) Fair | • | NR | NR | NR | NR | • ^a |
| Stintzing et al., 2010 ⁸⁸ 6 (100) Fair | • | NR | NR | NR | • | • |
| Vautravers-Dewas et al., 2011 ⁸² 42 (66.7) Good | • | NR | NR | NR | NR | • |
| Vogl et al., 2008 ⁸³ 55 (21.8) Fair | • | NR | NR | NR | NR | • |

AE = adverse events; CRC = colorectal cancer; LOS = length of stay; LR = local recurrence; NR = not reported; OS = overall survival; QOL = quality of life; TTR = time to recurrence

[ⓐ]This N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

“•” indicates that this outcome was reported in the article.

^aPaper reported an outcome of interest but these were grouped with multiple primary presentation sites, which did not permit us to identify CRC-specific data.

Overall Survival

All studies reported on outcomes related to overall survival (Table 8, which is organized by intervention). One RFA study by Jakobs et al. (2006)⁶⁹ did not report mean or median survival measures, but did report 1-, 2-, and 3-year survival rates of 96 percent, 71 percent, and 68 percent, respectively, from the time of study treatment. Three studies in our report used TACE with DEB. Median survival was reported by two^{75,90} studies and ranged from 19 to 25 months from study treatment. Florentini et al. (2007) reported only a 1-year survival rate of 61 percent.⁶⁷ Two studies reported on TACE alone.^{63,68} Both studies reported median survival from time of diagnosis of liver metastases, which ranged from 26.3 to 27 months. Thirteen studies of RE with Yttrium-90 were included in this review.^{65,66,68,70,73,74,76-78,84,86,89,91} One of these studies involved

systemic chemotherapy in addition to RE and is therefore not presented in this summary of results.³⁰ Eight studies reported survival from study treatment; median survival ranged from 4 to 15.2 months.^{70,73,77,78,84,86,89,91} One of these studies⁸⁴ did not reach median survival at a follow up of 3 years. Three studies reported survival starting from diagnosis of liver metastases, which ranged from 31 to 34.6 months.^{66,68,76} Two studies did not indicate the time point from which survival was measured.^{65,74} HAI was used in two studies in our review,^{83,92} and reported median survival from the start of study treatment as 6.7 and 9.7 months.^{83,92} Three studies reported SBRT in this review and all defined survival from time of study treatment.^{71,82,88} Median survival values reported in two studies were 17 and 25 months.^{71,88} The third SBRT study only reported 1- and 2-year survival rates of 95 percent and 58 percent, respectively.⁸²

Direct comparisons of overall survival cannot be made from the published data because there are no comparative studies and the studies measured survival from different starting points (i.e., time of diagnosis or time of treatment).

Quality of Life

Two studies reported on quality of life.^{66,67} Cosimelli and colleagues used a battery of questionnaires to assess both cancer and disease-specific quality of life (The European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ] C30, EORTC QLQ C38, and EORTC QLQ LMC-21).⁶⁶ They also assessed anxiety and depression (Hamilton Rating Scale for Depression [HAM-D]) and patient satisfaction (EORTC QLQ SAT-32). They reported quality of life measures on 14 of 50 enrolled subjects. The study authors provided no insight as to why only 14 of the participants had available data on quality of life. Six weeks after treatment, the quality of life of 14 patients treated with RE was not adversely affected, and patients' anxiety levels were significantly reduced from pretreatment levels. No significant difference was observed in depression score pre- and post-treatment. In a study of chemoembolization with irinotecan-eluting beads, Fiorentini and colleagues stated that 18 of 20 patients reported improvement in quality of life post-treatment.⁴¹ They used the Edmonton Symptom Assessment System in this study, but only reported qualitatively that these patients had improved without providing any metrics.

Length of Stay

Mean length of stay was reported by two studies^{63,67} of TACE and ranged from 1.3 to 3 days. No direct comparisons can be made based on the published studies.

Time to Progression

Time to progression was not reported in any of the included studies.

Local Recurrence

Outcomes related to local recurrence are summarized in Table 9. In this report, local recurrence is defined as recurrence of the liver metastases in the area previously treated. This constitutes a treatment failure or failure to treat the entire lesion and is considered an adverse event. One RFA study reported a local recurrence rate of 18 percent.⁶⁹ Local recurrence was also reported in two studies of SBRT, both of which reported a rate of 33.3 percent.^{71,88}

Adverse Events

Twenty-four studies reported on adverse events with varying levels of detail and are presented in Table 9 by intervention. One TACE study reported a patient who developed a hepatic abscess.⁶⁷ Liver failure was reported in three studies, two on RE^{65,66} and one⁷⁵ on TACE with DEB intervention. Two studies—one on TACE⁶³ and one on RE⁷⁶—reported elevated alkaline phosphatase levels. Elevated bilirubin was reported in five studies, one on TACE with DEB⁹⁰, one on TACE⁶³, two on RE^{76,91}, and one on HAI⁹². Elevated transaminase levels were reported in one RE article,⁷⁶ which also reported elevated bilirubin and alkaline phosphatase. Although these results from liver function tests could point to disease progression, in the time period following a local hepatic therapy they are more likely to reflect an adverse effect of the treatment. Only Aliberti et al. reported liver function test results immediately after treatment.⁹⁰ Other liver function tests were evaluated as acute or late toxicity^{76,91} or were not reported^{63,92} at the time adverse events were evaluated. Two authors indicated that liver function toxicity was likely a result of progressive disease or biliary obstruction.^{76,91} One TACE with DEB study reported one death from myocardial infarction⁷⁵ and one TACE study reported a 30-day mortality rate of 3.6 percent.⁶³ A description of rare adverse events is included in Table 9. No study reported on injury to adjacent organs, hepatic hemorrhage, or steatohepatitis.

Table 8. Local hepatic therapies for CRC metastases to the liver: Outcomes related to overall survival KQ1 and KQ2

| Intervention | Survival Time From | Mean or Median Overall Survival (95% CI) | 1-Year Survival (%) | 2-Year Survival (%) | 3-Year Survival (%) | 5-Year Survival (%) | Study N ^o (% CRC) Rating |
|---|-------------------------|--|---------------------|---------------------|---------------------|---------------------|---|
| RFA | Study Treatment | NR | 96 | 71 | 68 | NR | Jakobs et al., 2006 ^{69,f} 68 (100) Good |
| Intervention: TACE with DEB; Drug: irinotecan | Study Treatment | Median: 25 | ~78 ^g | ~52 ^g | ~21 ^g | NR | Aliberti et al., 2011 ⁹⁰ 82 (100) Good |
| | Study Treatment | Median: 19 | 75 | NR | NR | NR | Martin et al., 2011 ^{75,a} 55 (100) Good |
| | NR | NR | 61* | NR | NR | NR | Fiorentini et al., 2007 ^{67,b} 20 (100) Poor |
| Intervention: TACE; Drug: mitomycin C, doxorubicin, cisplatin | Diagnosis of Liver Mets | Median: 27 | 85 | 55 | NR | 6 | Albert et al., 2011 ^{63,a} 121 (100) Fair |
| Intervention: TACE; Drug: cisplatin, doxorubicin, mitomycin C; Site: femoral artery | Diagnosis of Liver Mets | Median: 26.3 | NR | NR | NR | NR | Hong et al., 2009 ⁶⁸ 21 (100) Good |
| Intervention: RE; Drug: Y90 | Study Treatment | Median: 11.9 (4.1 to 25.7) | NR | NR | NR | NR | Martin et al., 2012 ^{86,f} 24 (100) Fair |
| | Study Treatment | Median not reached | ~88 ^g | ~77 ^g | ~77 ^g | NR | Kucuk et al., 2011 ⁸⁴ 78 (44.9) Fair |
| | Study Treatment | Mean: 14.4 Median: 10.2 (7.5 to 13.0) | NR | NR | NR | NR | Nace et al., 2011 ⁸⁹ 51 (100) Fair |
| | Diagnosis of Liver Mets | Median: 31 (29 to 34) | 50.4 | 19.6 | NR | NR | Cosimelli et al., 2010 ^{66,b} 50 (100) Good |
| | NR | Median: 11.8 | NR | NR | NR | NR | Cianni et al., 2009 ^{65,b} 41 (100) Fair |
| | Diagnosis of Liver Mets | Median: 34.6 (24.4 to 41.8) | NR | NR | NR | 17.7 | Mulcahy et al., 2009 ⁷⁶ 72 (100) Good |
| | Study Treatment | Mean: 13.9 Median: 15.2 | 53.7 | 26.7 | NR | NR | Sato et al., 2008 ^{78,b} 137 (37.2) Fair |

Table 8. Local hepatic therapies for CRC metastases to the liver: Outcomes related to overall survival KQ1 and KQ2 (continued)

| Intervention | Survival Time From | Mean or Median Overall Survival (95% CI) | 1-Year Survival (%) | 2-Year Survival (%) | 3-Year Survival (%) | 5-Year Survival (%) | Study N ^o (% CRC) Rating |
|--|-------------------------|--|---------------------|---------------------|---------------------|---------------------|--|
| Intervention: RE; Drug: Y90 (continued) | Diagnosis of Liver Mets | Median: 32.8 | NR | NR | NR | NR | Hong et al., 2009 ^{68,a} 15 (100) Good |
| | Study Treatment | Median: 10.5 | ~40 ^g | ~27 ^g | ~16 ^g | NR | Jakobs et al., 2008 ⁹¹ 41 (100) Fair |
| | Study Treatment | Median: ~4 ^g | ~23 ^g | 14.3 | NR | NR | Jiao et al., 2007 ^{70,d} 21 (47.6) Poor |
| | Study Treatment | Mean: 11.1 Median: 9 | ~27 ^g | ~20 ^g | NR | NR | Rowe et al., 2007 ^{77,b} 24 (29.2) Good |
| | NR | NR | ~20 ^g | NR | NR | NR | Lim et al., 2005 ⁷⁴ 30 (100) Poor |
| | Study Treatment | Median: 9.4 (7.3 to 13.5) | NR | NR | NR | NR | Lewandowski et al., 2005 ^{73,c} 27 (100) Good |
| Intervention: HAI; Drug: mitomycin C, gemcitabine | Study Treatment | Median: 9.7 | ~48 ^g | ~30 ^g | NR | NR | Vogl et al., 2008 ^{83,a} 55 (21.8) Fair |
| Intervention: HAI; Drug: 5-FU 1000 mg/m ² | Study Treatment | Median: 6.7 (5 to 8.3) | ~18 ^g | ~5 ^g | NR | NR | Nishiofuku et al., 2010 ⁹² 55 (100) Good |

Table 8. Local hepatic therapies for CRC metastases to the liver: Outcomes related to overall survival KQ1 and KQ2 (continued)

| Intervention | Survival Time From | Mean or Median Overall Survival (95% CI) | 1-Year Survival (%) | 2-Year Survival (%) | 3-Year Survival (%) | 5-Year Survival (%) | Study N ^g (% CRC) Rating |
|---|--------------------|--|---------------------|---------------------|---------------------|---------------------|--|
| Intervention: SBRT; Radiation dose: 40 Gy and 45 Gy; Site: noninvasive | Study Treatment | NR | ~95 ^g | 58 | NR | NR | Vautravers-Dewas et al., 2011 ⁸² 42 (66.7) Good |
| | Study Treatment | Median: 25 | 53 | 40 | 40 | NR | Kim et al., 2009 ⁷¹ 9 (100) Good |
| Intervention: SBRT; Radiation dose: 24 Gy to the 70% isodose; Site: noninvasive | Study Treatment | Mean: 18.3 Median: 17.0 | NR | NR | NR | NR | Stintzing et al., 2010 ⁸⁸ 6 (100) Fair |

CI = confidence interval; CRC = colorectal cancer; Gy = Gray; HAI = hepatic arterial infusion; Mets = metastases; NR = not reported; RE = radioembolization; SBRT = stereotactic body radiation therapy; TACE = transarterial chemoembolization

^gThis N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

^aTreatment through the femoral or axillary artery.

^bTreatment through the hepatic artery.

^cLobar treatment site.

^dFemoral catheter or hepatic artery port.

^eSite: percutaneous and intraoperatively.

^fSite: percutaneous.

^gSurvival estimates were extracted by the EPC from survival curves presented in the article.

^hData on this outcome are for patients with non-extrahepatic disease (n=11).

Table 9. Local hepatic therapies for unresectable CRC metastases to the liver: Adverse events KQ1 and KQ2

| Intervention | Local Recurrence N (%) | Biloma (%) | Liver Failure (%) | Elevated Alkaline Phosphatase N (%) | Elevated Bilirubin N (%) | Rare Adverse Events | Study N ^o (% CRC) Rating |
|--|------------------------|------------|-------------------|---|--------------------------|--|---|
| RFA | 12 (18) | NR | NR | NR | NR | No major complications. | Jakobs et al., 2006 ⁶⁹ 68 (100) Good |
| Intervention: TACE with DEB; Drug: irinotecan; | NR | NR | NR | NR | 41 (50) | NR | Aliberti et al., 2011 ⁹⁰ 82 (100) Good |
| | NR | NR | 3 | NR | NR | All AE are from the number of DEB treatments (99) and not from the total 55 patients. 3% of patients had severe liver dysfunction, 1 patient died. 1% had cholecystitis, 1% had gastritis, and 1% had myocardial infarction, which was the cause of death in 1 patient. | Martin et al., 2011 ⁷⁵ 55 (100) Good |
| | NR | NR | NR | NR | NR | Liver abscess: 5% (1 patient) | Fiorentini et al., 2007 ⁶⁷ 20 (100) Poor |
| Intervention: TACE; Drug: mitomycin C, doxorubicin, cisplatin | NR | NR | NR | Grade 1:10% Grade 2: 7% Grade 3: 2% | Grade 1: 1% | Prolonged in-hospital visits after major complications occurred in 11% (20) of the 174 treatments. These included hepatic infarction in 4, hematoma at the site of catheterization in 3, infection in 3, acute edema in 2, myocardial infarction in 2, pulmonary embolism in 1, transient ischemic attack in 1, hypoxia in 1, and abnormal heart rhythm in 1. Thirty-day mortality was 3.6%. | Albert et al., 2011 ⁶³ 121 (100) Fair |
| Intervention: TACE; Drug: cisplatin, doxorubicin, mitomycin C; | NR | NR | NR | NR | NR | 1 (2.7%) pulmonary embolism in the CE group. | Hong et al., 2009 ⁶⁸ 21 (100) Good |
| Intervention: RE; Drug: Y90 | NR | NR | NR | NR | NR | No major complications. | Martin et al., 2012 ⁸⁶ 24 (100) Fair |
| | NR | NR | NR | NR | NR | No major complications. | Kucuk et al., 2011 ⁸⁴ 78 (44.9) Fair |
| | NR | NR | 0 | NR | NR | Ventricular tachycardia: 1 (2%) | Nace et al., 2011 ⁸⁹ 51 (100) Fair |

Table 9. Local hepatic therapies for unresectable CRC metastases to the liver: Adverse events KQ1 and KQ2 (continued)

| Intervention | Local Recurrence N (%) | Biloma (%) | Liver Failure (%) | Elevated Alkaline Phosphatase N (%) | Elevated Bilirubin N (%) | Rare Adverse Events | Study N ⁹ (% CRC) Rating |
|---|------------------------|--------------------|-------------------|-------------------------------------|--------------------------|--|--|
| Intervention: RE; Drug: Y90 (continued) | R | NR | 2 | NR | NR | NR | Cosimelli et al., 2010 ⁶⁶ 50 (100) Good |
| | NR | NR | 2.4 | NR | NR | NR | Cianniet al., 2009 ⁶⁵ 41 (100) Fair |
| | NR | NR | NR | 6 (8) | 9 (13) | GI ulcer | Mulcahy, et al., 2009 ⁷⁶ 72 (100) Good |
| | NR | Nonspecific to CRC | NR | NR | Nonspecific to CRC | Included non-CRC patients in this article and did not report specific adverse events for CRC mets to the liver Significant toxicity included grade 3 or 4 bilirubin toxicity, 1 GI ulceration, 1 radiation-induced cholecystitis, 2 bilomas, and 1 hepatic abscess. | Sato et al., 2008 ^{78,b} 137 (37.2) Fair |
| | NR | NR | NR | NR | NR | 1 (2.7%) pulmonary embolism | Hong et al., 2009 ⁶⁸ 15 (100) Good |
| | NR | NR | NR | NR | 8 (10) | One patient (2.4%) presented with acute grade 4 cholecystitis 4 weeks after radioembolization and was referred for surgery. | Jakobs et al., 2008 ⁹¹ 41 (100) Fair |
| | NR | NR | NR | NR | NR | Gastric/duodenal ulceration: 4 (13%); severe disabling pain, anorexia, and nausea: 1 (3.3%); radiation hepatitis: 1 (3.3%) | Lim et al., 2005 ⁹³ 30 (100) Poor |
| | NR | NR | NR | NR | NR | Included non-CRC patients in this article and did not report specific adverse events for CRC mets to the liver. Four rare adverse events occurred post-SIRT: 1 cholecystitis followed by fibrosis and portal hypertension; 1 peptic ulceration in the lesser curvature of the stomach; and 2 radiation hepatitis. | Jiao et al., 2007 ^{70,c} 21 (47.6) Poor |

Table 9. Local hepatic therapies for unresectable CRC metastases to the liver: Adverse events KQ1 and KQ2 (continued)

| Intervention | Local Recurrence N (%) | Biloma (%) | Liver Failure (%) | Elevated Alkaline Phosphatase N (%) | Elevated Bilirubin N (%) | Rare Adverse Events | Study N ^o (% CRC) Rating |
|--|------------------------|------------|-------------------|-------------------------------------|--------------------------|---|--|
| Intervention: RE; Drug: Y90 (continued) | NR | NR | NR | NR | NR | Toxicity data were only available for 14 of 24 patients and not reported specifically for CRC mets to the liver. One patient had a symptomatic gastric ulcer postsurgery and 1 patient had a femoral artery plaque rupture with thromboembolism in the lower extremity. | Rowe et al., 2007 ^{77,b} 24 (29.2) Good |
| | NR | NR | NR | NR | NR | One case of radiation-induced ulceration caused by technical error and 1 case of right plural effusion 1 month after treatment. | Lewandowski et al., 2005 ⁷³ 27 (100) Good |
| Intervention: HA; Drug: mitomycin C, gemcitabine | NR | NR | NR | NR | NR | No common toxicity criteria grade III, IV, or V adverse events were observed. | Vogl et al., 2008 ^{83,a} 55 (21.8) Fair |
| Intervention: HAI; Drug: 5-FU 1000 mg/m ² | NR | NR | NR | NR | 1 (1.8) | NR | Nishiofuku et al., 2010 ⁹² 55 (100) Good |
| Intervention: SBRT | 2 (33.3%) | NR | NR | NR | NR | NR | Stintzing et al., 2010 ⁸⁸ 6 (100) Fair |
| | NR | NR | NR | NR | NR | One patient had cirrhotic failure at 5 months; 1 patient had gastric ulceration; 1 patient had esophagitis; and 1 patient had grade 3 epidermitis. No grade 4 toxicity was observed. | Vautravers-Dewas et al., 2011 ⁸² 42 (66.7) Good |
| | 3 (33.3%) | NR | NR | NR | NR | No grade 3 or 4 acute complications | Kim et al., 2009 ⁷¹ 9 (100) Good |

CE = chemoembolization; DEB = drug-eluting beads; HAI = hepatic arterial infusion; NR = not reported; RE = radioembolization; SBRT = stereotactic body radiation therapy; TACE = transarterial chemoembolization.

^oThis N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

^aTreatment through the femoral or axillary artery.

^bTreatment through the hepatic artery.

^cFemoral catheter or hepatic artery port.

Multivariate Analyses

Univariate or multivariate analyses of prognostic factors for overall survival including, but not limited to, ECOG score, presence of extrahepatic disease, and treatment response, were variously reported in six case series^{63,73,76,78,91,92} of local hepatic therapies. All analyses reported on overall survival as the dependent variable.

Among the patient or tumor characteristics found to be associated with improved overall survival were the following: ECOG status (0 vs. ≥ 1 and in another study 0 or 1 vs. ≥ 2), performance status (0 or 1 vs. ≥ 2), number of extrahepatic metastases sites (0 or 1 vs. ≥ 2), number of lines of previous chemotherapy (0–1 vs. ≥ 2), performance status (0 or 1 vs. ≥ 2), carcinoembryonic antigen response (Yes, No), and Response Evaluation Criteria in Solid Tumors (RECIST).

Key Questions 3 and 4

Key Questions 3 and 4 focus on the comparative effectiveness (KQ3) and harms (KQ4) of the various local hepatic therapies in patients who are receiving local hepatic therapy as an adjunct to systemic therapy for unresectable CRC metastases to the liver and who have no evidence of extrahepatic disease.

Key Points

- No conclusions on overall survival, quality of life, length of stay, time to recurrence, local recurrence, or adverse events can be drawn from the body of evidence comparing local hepatic therapies for unresectable CRC metastases to the liver. No comparative studies met the inclusion criteria for this review.
- The literature base for this review is comprised of case series and one RCT⁸⁷ that was abstracted as a case-series study due to a nonrelevant comparator. Four studies were ranked as good quality,^{64,72,80,87} and three were ranked as fair quality.^{79,81,85}
- The assessment of applicability of the study findings to clinical practice is limited by the poor characterization of the patient populations (e.g., number and size of metastases, performance status) and variability in the delivery of the interventions (e.g., surgical approach, dose and drugs delivered)

Description of Included Studies

Table 10, Table 11, and Table 12 show the study, patient, and tumor characteristics, including study design, intervention period, intervention, number of patients enrolled, and patient demographics for studies of local hepatic therapies for patients with unresectable CRC metastases to the liver who are receiving local hepatic therapy as an adjunct to systemic therapy. Table 13 through Table 15 present data on study outcomes. Seven studies were included,^{64,72,79-81,85,87} six of which were case series. One RCT⁸⁷ was included in the review but was abstracted as a case-series study because the comparator, systemic chemotherapy, was an intervention outside the scope of this review. Of the six case series, three were prospective^{64,80,81} and three were retrospective.^{72,79,85} The total number of patients for which data were abstracted from the five studies was 296. Two studies included patients treated with RE with concurrent systemic chemotherapy;^{64,72} three articles reported on RFA with chemotherapy;^{80,85,87} and two reported on

patients treated with HAI and systemic chemotherapy.^{79,81} All studies treated patients after January 1, 2000.

Patients ranged in age from 31 to 84 years, but were generally in their 60s. One study reported the ECOG score, with a median value of 0 and a range of 0 to 2.⁶⁴ Two studies reported rates of resection for previous CRC liver metastases of 15 and 27 percent,^{64,87} and three studies^{64,72,80} reported the proportion of patients who had received prior systemic chemotherapy, which ranged from 0 to 94 percent. One study⁶⁴ reported patient experience with prior local hepatic therapy, with 66 percent of patients having prior RE and 6 percent having had prior ablation.

Tumor characteristics were inconsistently reported across studies, with synchronous or metachronous disease status reported in three studies^{72,85,87}; bilobar or unilobar disease reported in two studies;^{64,85} degree of liver involvement reported in three studies;^{64,72,79} number of hepatic lesions reported by two studies;^{80,87} and lesion size reported in two studies.^{80,85} The details of these characteristics are presented in Table 12.

Table 10. Local hepatic therapies adjunctive to systemic chemotherapy for CRC metastases to the liver: Summary of study characteristics KQ3 and KQ4

| Study N ^o (% CRC) Rating | Study Design | Intervention Period | Intervention |
|--|------------------------------|------------------------|---|
| Ruers et al., 2012 ⁸⁷ 60 (100) Good | RCT ^a | 04/2002– 06/2007 | RFA and systemic treatment with 5-FU/L/oxaliplatin, with bevacizumab added post 10/2005. |
| Lee et al., 2012 ⁸⁵ 28 (100) Fair | Retrospective case series | 07/2002– 04/2008 | Percutaneous RFA performed under real-time sonographic guidance. The radiofrequency current was applied for 12 minutes at 200 W to create a radius of ablation at least 10 mm larger than the largest tumor diameter. |
| Kosmider et al., 2011 ⁷² 19 (100) Good | Retrospective case series | 01/2002– 10/2008 | Intervention: RE with systemic chemotherapy; Drug: FOLFOX or 5-FU; Y90 dose: median 1.96 GBq, mean 2.08 GBq, range 1.60-2.60 GBq; Site: hepatic artery |
| Sgouros et al., 2011 ⁸⁰ 13 (100) Good | Prospective case series | 09/2000– 08/2004 | Intervention: RFA with systemic chemotherapy; Drug: FOLFIRI; Site: percutaneous |
| Chua et al. 2011 ⁶⁴ 140 (100) Good | Prospective case series | 03/2006 - 05/2009 | Intervention: RE with systemic chemotherapy; Drug: Y90 dose: mean 1.8 GBq, median 1.8 GBq, range 0.4-2.6 GBq; Site: femoral or brachial artery |
| Seki et al., 2009 ⁷⁹ 20 (100) Fair | Retrospective case series | 07/2004 - 01/2008 | Intervention: HAI followed by systemic chemotherapy; Drug: 5-FU, FOLFOX4, or FOLFOX6; Site: hepatic artery, IV |
| Tsutsumi et al., 2008 ⁸¹ 16 (100) Fair | Prospective case series | 08/2003 - 09/2006 | Intervention: HAI with concurrent systemic chemotherapy; Drug: 5-FU and I-leucovorin, UFT and UZEL; Site: femoral artery, oral |

5-FU = 5-fluorouracil; CRC = colorectal cancer; HAI = hepatic arterial infusion; RE = radioembolization; RFA = radiofrequency ablation; UFT = tegafur-uracil; UZEL = UFT and leucovorin

^oThis N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

^aData from this RCT were abstracted and treated as case series data because the comparator in the RCT was outside the scope of this review.

**Table 11. Local hepatic therapies adjunctive to systemic chemotherapy for CRC metastases to the liver: Summary of patient characteristics
KQ3 and KQ4**

| Study N^o (% CRC) Rating | Study Design | Median Age (Range) | Previous Resection (%) | ECOG Score Median (Range) | Previous Systemic Chemotherapy (%) | Previous Local Hepatic Therapy (%) |
|--|------------------------------|-------------------------------|-----------------------------------|--|---|---|
| Ruers et al., 2012 ⁸⁷ 60 (100) Good | RCT ^a | 64 (31–79) | 15 | NR | NR | NR |
| Lee et al., 2012 ⁸⁵ 28 (100) Fair | Retrospective case series | 61 (32–82) | NR | NR | NR | NR |
| Kosmider et al., 2011 ⁷² 19 (100) Good | Retrospective case series | 62 (44–75) | NR | 0 (0–1) | 0 | NR |
| Sgouros et al., 2011 ⁸⁰ 13 (100) Good | Prospective case series | 77 (47–84) | NR | NR | 76.9 | NR |
| Chua et al., 2011 ⁶⁴ 140 (100) Good | Prospective case series | 64 (37–85) | 27 | 0 (0–2) | 94 | SIRT: 66, Ablation 6 |
| Seki et al., 2009 ⁷⁹ 20 (100) Fair | Retrospective case series | 49 | NR | NR | NR | NR |
| Tsutsumi et al., 2008 ⁸¹ 16 (100) Fair | Prospective case series | 62 (43–74) | NR | NR | NR | NR |

CRC = colorectal cancer; ECOG = Eastern Cooperative Oncology Group; NR = not reported; SIRT = selective internal radiation therapy

^oThis N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

^aData from this RCT were abstracted and treated as case series data because the comparator in the RCT was outside the scope of this review.

Table 12. Local hepatic therapies adjunctive to systemic chemotherapy for CRC metastases to the liver: Summary of tumor characteristics KQ3 and KQ4

| Study N^⓪ (% CRC) Rating | Synchronous (%) | Bilobar (%) | % Median Liver Involvement (Range) | Median Number of Hepatic Lesions (Range) | Mean Size of Hepatic Lesion(s) (cm) (Range) | Median Size of Hepatic Lesion(s) (cm) | Other Liver Involvement |
|--|----------------------------|------------------------|---|---|--|--|--|
| Ruers et al., 2012 ⁸⁷ 60 (100) Good | 38.3 | NR | NR | 4 (1–9) | NR | NR | NR |
| Lee et al., 2012 ⁸⁵ 28 (100) Fair | 50 | NR | NR | NR | NR | NR | NR |
| Kosmider et al., 2011 ⁷² 19 (100) Good | 95 | NR | 40 (25–65) | NR | NR | NR | NR |
| Sgouros et al., 2011 ⁸⁰ 13 (100) Good | NR | NR | NR | 1 (1–3) | 3 (1.5–5.5) | NR | Sum of the maximum diameters of liver metastases per patient at inclusion in cm; Mean: 4.1, Range: 2–8 |
| Chua et al., 2011 ⁶⁴ 140 (100) Good | NR | 90 | NR | NR | NR | NR | % liver involvement 0–25% (55%); 26–50 (36%); 51–75 (9%) |
| Seki et al., 2009 ⁷⁹ 20 (100) Fair | NR | NR | NR | NR | NR | NR | Liver involvement ≤60%: 85; Liver involvement >60%: 15 |
| Tsutsumi et al., 2008 ⁸¹ 16 (100) Fair | NR | NR | NR | NR | NR | NR | NR |

CRC = Colorectal cancer; NR = not reported

^⓪This N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

Detailed Synthesis

Table 13 displays the outcomes reported by study for KQ3 and KQ4. All studies reported overall survival and adverse events. Four studies reported on overall progression-free survival.^{72, 79, 80, 87} Local recurrence was reported in three studies.^{64, 85, 87} One study reported on quality of life.⁸⁷ We report data on individual outcomes, except for results on overall progression-free survival and liver-specific progression-free survival, which are located in Appendix D. No study reported on median time to recurrence, length of stay, or liver progression-free survival.

Table 13. Outcomes reported for Key Questions 3 and 4

| Study N ⁹ (% CRC) Rating | OS | QOL | LOS | TTR | LR | AE |
|---|----|-----|-----|-----|----|----|
| Ruers et al., 2012 ⁸⁷ 60 (100) Good | • | • | NR | NR | • | • |
| Lee et al., 2012 ⁸⁵ 28 (100) Fair | • | NR | NR | NR | • | • |
| Kosmider et al., 2011 ⁷² 19 (100) Good | • | NR | NR | NR | NR | • |
| Sgouros et al., 2011 ⁸⁰ 13 (100) Good | • | NR | NR | NR | NR | • |
| Chua et al., 2011 ⁶⁴ 140 (100) Good | • | NR | NR | NR | • | • |
| Seki, et al., 2009 ⁷⁹ 20 (100) Fair | • | NR | NR | NR | NR | • |
| Tsutsumi et al., 2008 ⁸¹ 16 (100) Fair | • | NR | NR | NR | NR | • |

AE = adverse events; LOS = length of stay; LR = local recurrence; OS = overall survival; QOL = quality of life; TTR = time to recurrence

⁹This N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

“•”Indicates that this outcome was reported in the article.

Overall Survival

Outcomes related to overall survival are summarized in Table 14, which is organized by intervention. All studies reported median overall survival. No direct comparisons can be made from the published data.

RFA was performed in three studies as an adjunct to systemic chemotherapy for unresectable CRC liver metastases.^{80,85,87} Ruers et al. (2012) reported a median survival of 45.3 months from time of randomization; Lee et al. (2012) reported a median survival of 24 months and Sgouros et al. (2011) reported a median survival of 24 months from study enrollment. Radioembolization was given as an adjunct to systemic chemotherapy in two studies, both of which reported survival from time of study treatment with a range of 9 to 37.8 months.^{64,72} HAI as an adjunct to systemic chemotherapy was reported in two studies. In both studies, the authors did not report the time point from which survival was measured.^{79,81} Survival ranged from 22 to 30.1 months.

Quality of Life

One study by Ruers and colleagues⁸⁷ reported on the outcome of quality of life for patients treated with RFA and concurrent systemic chemotherapy. Quality of life was assessed by the EORTC QLQ-C30 questionnaire at baseline, every 6 weeks during study treatment, and during study followup. A 20-point difference is considered a significant change. Of the 60 patients enrolled, it is unclear how many of them were included in the analysis of quality of life. For those with available data, health-related quality of life declined 27 points following RFA. At 4 to 8 weeks post-RFA, prior to the start of systemic chemotherapy, the scores had risen to approximately 10 points below baseline. No other studies reported on quality of life and no direct comparisons can be made based on the published evidence.

Length of Stay

Mean length of stay was not reported by any studies.

Time to Recurrence

Time to recurrence was not reported in any of the included studies.

Local Recurrence

Outcomes related to local recurrence are summarized in Table 15. In this report, local recurrence is defined as recurrence of the liver metastases in the area previously treated. This constitutes a treatment failure or failure to treat the entire lesion and is considered an adverse event. Three RFA studies reported local recurrence rates between 45 and 81.3 percent.^{64,85,87}

Adverse Events

Outcomes related to adverse events are summarized in Table 15, which is organized by intervention. One study of RE and one study of RFA reported injury to adjacent organs and liver failure.^{72,80} Elevated bilirubin was reported in two studies^{72,87} and elevated alkaline phosphatase and transaminases were reported in one study.⁷² Kosmider et al.⁷² reported elevated liver function test results within 60 days post-treatment that were not related to progressive disease and normalized shortly thereafter; Ruers et al.⁸⁷ did not report when the patients had hepatic dysfunction related to elevated bilirubin. Lee et al. reported one patient (3.6 percent) who suffered from a 10-cm subcapsular hematoma.⁸⁵ Local recurrence was reported by three studies.^{64,85,87} A single postoperative death was reported in two RFA studies.^{80,87} No direct comparisons can be made based on the published evidence.

Table 14. Local hepatic therapies for CRC metastases to the liver: Outcomes related to overall survival for patients receiving local hepatic therapy as an adjunct to systemic therapy KQ3 and KQ4

| Intervention | Survival Time From | Median OS (95% CI) | 1-Year Survival (%) | 2-Year Survival (%) | 3-Year Survival (%) | Study N ^o (% CRC) Rating |
|---|--------------------|------------------------|---------------------|---------------------|---------------------|---|
| Intervention: RE with concurrent systemic chemotherapy; Drug: FOLFOX or 5-FU; Y90 dose: median 1.96 GBq, mean 2.08 GBq, range 1.60-2.60 GBq; Site: hepatic artery | Study Treatment | 37.8 | ~83 ^a | ~73 ^a | ~52 ^a | Kosmider et al., 2011 ⁷² 19 (100) Good |
| Intervention: RE with systemic chemotherapy; Drug: Y90 dose: mean 1.8 GBq, median 1.8 GBq, range 0.4-2.6 GBq; Site: femoral or brachial artery | Study Treatment | 9 (6.4 to 11.3) | 42 | 22 | 20 | Chua et al., 2010 ⁶⁴ 140 (100) Good |
| Intervention: RFA and systemic chemotherapy; Drug: FOLFIRI; Site: percutaneous | Study Enrollment | 24 (17 to 31.1) | NR | NR | NR | Sgouros et al., 2011 ⁸⁰ 13 (100) Good |
| Intervention: RFA and systemic chemotherapy; Drug: FOLFIRI or FOLFOX; Site: percutaneous | Study Treatment | 24 | ~88 ^a | ~54 ^a | ~28 ^a | Lee et al., 2012 ⁸⁵ 28 (100) Fair |
| RFA followed by systemic treatment with 5-FU/L/oxaliplatin, with bevacizumab added post 10/2005 | Randomization | 45.3 (33.1 to NA) | 88.1 | 72.8 | 45.7 | Ruers et al., 2012 ⁸⁷ 60 (100) Good |
| Intervention: HAI followed by systemic chemotherapy; Drug: 5-FU, FOLFOX4 or FOLFOX6; Site: hepatic artery, IV | NR | 30.1 | ~90 ^a | ~72 ^a | ~15 ^a | Seki et al., 2009 ⁷⁹ 20 (100) Fair |
| Intervention: HAI with concurrent systemic chemotherapy; Drug: 5-FU and l-leucovorin, UFT and UZEL; Site: femoral artery, oral | NR | 22.0 (19.2 to 26.2) | NR | NR | NR | Tsutsumi et al., 2008 ⁸¹ 16 (100) Fair |

CRC = colorectal cancer; GBq = Gigabecquerel; HAI = hepatic arterial infusion; NR = not reported; OS = overall survival; RE = radioembolization; RFA = radiofrequency ablation

^oThis N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

^aSurvival estimates were approximated by the EPC from survival curves presented in the manuscript.

Table 15. Local hepatic therapies for unresectable CRC metastases to the liver: Adverse events for patients receiving local hepatic therapy as an adjunct to systemic therapy KQ3 and KQ4

| Intervention | Local Recurrence N (%) | Injury to Organs (%) | Liver Failure (%) | Elevated Alkaline Phosphatase N (%) | Elevated Bilirubin N (%) | Rare AE | Study N ^o (% CRC) Rating |
|---|------------------------|----------------------|-------------------|-------------------------------------|--------------------------|--|---|
| Intervention: RE with concurrent systemic chemotherapy; Drug: FOLFOX or 5-FU; Y90 dose: median 1.96 GBq, mean 2.08 GBq, range 1.60-2.60 GBq; Site: hepatic artery | NR | 5.3 | 5.3 | 5 (26.3) | 5 (26.3) | AEs include extrahepatic metastases and 1 (5.3%) treatment-related death from hepatic failure (presumed to be radiation hepatitis). Gastroduodenitis was present in 3 patients (15.8%) and 1 (5.3%) grade 3 anorexia was observed. | Kosmider et al., 2011 ⁷² 19 (100) Good |
| Intervention: RE with systemic chemotherapy; Y90 dose: mean 1.8 GBq, median 1.8 GBq, range 0.4-2.6 GBq; Site: femoral or brachial artery | NR | 1 | NR | NR | NR | Three patients (2%) developed radiation-induced liver dysfunction. | Chua et al., 2011 ⁶⁴ 13 (100) Good |
| Intervention: RFA and systemic chemotherapy; Drug: FOLFIRI; Site: percutaneous | (81.3) | NR | NR | NR | NR | One patient discontinued chemotherapy early after developing bacterial endocarditis that required a prolonged course of antibiotics. Another patient died suddenly during treatment. The cause of death was determined postmortem as acute cardiomyopathy thought to be related to 5-FU toxicity. | Sgouros et al., 2011 ⁸⁰ 140 (100) Good |
| Intervention: RFA and systemic chemotherapy; Drug: FOLFIRI or FOLFOX; Site: percutaneous | 22 (78.6) | NR | NR | NR | NR | One patient (3.6%) suffered from a 10-cm subcapsular hematoma. | Lee et al., 2012 ⁸⁵ 28 (100) Fair |
| Intervention: RFA with concurrent systemic chemotherapy; Drug: FOLFOX 4; Site: laparoscopic or percutaneous | 27 (45) | 3.5 | 1.8 | NR | 3 (5.3) | Respiratory failure: 1 (1.8%); wound infection: 3 (5.3%); postoperative death: 1 (1.8%); need for reoperation: 3 (5.3%); Tolerance to systemic chemotherapy (Grade 3-4), neutropenia: 14 (27.5%); cardiotoxicity 5 (9.8%); diarrhea: 10 (19.6%); vomiting: 5 (9.8%); nausea: 7 (13.7%); other gastrointestinal toxicity: 4 (7.8%); pulmonary: 3 (5.9); renal 1 (2); neuropathy: 9 (17.6); fatigue: 7 (13.7); hypertension: 2 (3.9) | Ruers et al., 2012 ⁸⁷ 60 (100) Good |

Table 15. Local hepatic therapies for unresectable CRC metastases to the liver: Adverse events for patients receiving local hepatic therapy as an adjunct to systemic therapy KQ3 and KQ4 (continued)

| Intervention | Local Recurrence N (%) | Injury to Organs (%) | Liver Failure (%) | Elevated Alkaline Phosphatase N (%) | Elevated Bilirubin N (%) | Rare AE | Study N ^o (% CRC) Rating |
|--|---------------------------|----------------------------|----------------------|---|-----------------------------|--|---|
| Intervention: HAI followed by systemic chemotherapy; Drug: 5-FU, FOLFOX4 or FOLFOX6; Site: hepatic artery, IV | NR | NR | NR | NR | NR | 1 patient resected post HAI, and 1 patient discontinued treatment during HAI therapy due to grade 3 hypersensitivity and sensory neuropathy. No grade 4 toxicity was reported. | Seki et al., 2009 ⁷⁹ 20 (100) |
| Intervention: HAI with concurrent systemic chemotherapy; Drug: 5-FU and I-leucovorin, UFT and UZEL; Site: femoral artery, oral | NR | NR | NR | NR | NR | Only grade 1 and 2 toxicity was reported. No hematologic toxicity was encountered. | Tsutsumi et al., 2008 ⁸¹ 16 (100) Fair |

CRC = colorectal cancer; GBq = Gigabecquerel; HAI = hepatic arterial infusion; NR = not reported; OS = overall survival; RE = radioembolization; RFA = radiofrequency ablation

^oThis N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.

^aSurvival estimates were approximated by the EPC from survival curves presented in the manuscript.

Multivariate Analyses

Relevant univariate or multivariate analyses of prognostic factors for overall survival including, but not limited to, ECOG score, presence of extra hepatic disease, and treatment response, were reported in one case-series study⁵² of RE for unresectable CRC metastasis to the liver among patients who are candidates for local hepatic therapy as an adjunct to systemic therapy (Appendix D). These analyses reported on overall survival as the dependent variable; none evaluated factors associated with frequency of adverse events. Among the patient or tumor characteristics found to be associated with overall survival were extrahepatic disease (no vs. yes) and treatment response (complete vs. partial). Although these analyses may be hypothesis generating, they do not address the comparative benefit of radiotherapy techniques.

Overall Conclusions for Key Questions 1–4

- The body of evidence is insufficient to assess effectiveness or comparative effectiveness based on overall survival, quality of life, length of stay, time to progression, local recurrence, and adverse events for local hepatic therapy for the treatment of unresectable CRC metastases to the liver among patients whose disease is refractory to systemic therapy.
- The body of evidence is insufficient to assess effectiveness or comparative effectiveness based on overall survival, quality of life, length of stay, time to recurrence, local recurrence and adverse events for local hepatic therapy as an adjunct to systemic therapy for the treatment of unresectable CRC metastases to the liver.
- The assessment of applicability of the study findings to clinical practice is limited by the poor characterization of the patient populations (e.g., number and size of metastases, performance status) and variability in the delivery of the interventions (e.g., surgical approach, dose and drugs delivered).

For all Key Questions, we could only find case-series evidence that met inclusion criteria. There were no comparative studies, which limits our ability to draw conclusions for all key questions.

Discussion

Key Findings and Strength of Evidence

No comparative studies met the inclusion criteria for any of the four KQs about local hepatic therapy for the treatment of unresectable CRC metastases to the liver. Thirty-one studies met our inclusion criteria and addressed local hepatic therapy for unresectable CRC metastases to the liver.

We assessed the strength of evidence for all KQs for the primary health outcomes of overall survival and quality of life and for the intermediate outcomes of length of stay, local recurrence, and adverse events. In addition strength of evidence was assessed for the intermediate outcomes of time to progression (KQs 1 and 2) and time to recurrence (KQs 3 and 4). We judged the strength of evidence to be insufficient to draw conclusions for effectiveness outcomes (overall survival, quality of life, length of stay, time to progression, time to recurrence, and local recurrence) and for adverse events for all KQs (Table 16 and Table 17). The body of evidence provided no comparative information about differences in effectiveness by type of intervention. Indirect comparisons were not considered because of the heterogeneity in the patient population, intervention characteristics, and outcome definitions, as well as the biases inherent in observational studies.

Table 16. Strength of evidence for KQ1 and KQ2

| Outcome | Intervention | Strength of Evidence | Conclusion |
|------------------|---------------|----------------------|---|
| Overall Survival | TACE with DEB | Insufficient | Three studies reported overall survival for this intervention. ^{67,75,90} Two studies ^{75a,86} defined survival from time of study treatment and reached a median survival of 25 and 19 months. One study ^{67b} did not report the time point from which survival was measured, but reported a 1-year survival rate of 61%. |
| | TACE | Insufficient | Two studies reported overall survival for this intervention. ^{63,68} Both studies defined survival time from diagnosis of liver metastases and reported median survival times of 27 and 26.3 months. Albert and colleagues presented overall survival data out to 5 years and reported a 6% survival rate. |
| | SBRT | Insufficient | Three studies reported overall survival for this intervention and all defined survival from time of study treatment. ^{71,82,88} Two studies reported median survival of 25 and 17 months. ^{67,84} One study did not report median survival but recorded a 2-year survival rate of 58%. ⁸² |
| | HAI | Insufficient | Two studies reported overall survival for this intervention and both defined survival from time of study treatment. ^{83,92} Median survival was 9.7 and 6.7 months (95% CI 5 to 8.3 months). |
| | RE | Insufficient | Eight studies reported survival from time of study treatment. One study did not reach median survival but reported a 3-year survival rate of 77%. ⁸⁰ In the other seven studies, median survival ranged from 4 to 15.2 months. ^{70,73,77,78,84,86,89,91} Three studies reported overall survival from diagnosis of liver metastases, with median survival ranging from 31 to 34.6 months. ^{66,68,76} Two studies did not report the time point from which survival was defined. One reported a median survival of 11.8 months. ⁶¹ The other study reported a 1-year survival rate of 20%. ⁷⁰ |
| | RFA | Insufficient | Only one RFA study reported data on overall survival. Survival was defined from the time of study treatment and the 3-year survival rate was 68%. ⁶⁹ |

Table 16. Strength of evidence for KQ1 and KQ2 (continued)

| Outcome | Intervention | Strength of Evidence | Conclusion |
|------------------|---------------|----------------------|---|
| Quality of Life | TACE with DEB | Insufficient | The authors reported qualitatively that 18 or 20 patients reported improvement in quality of life post-treatment. ⁶⁷ |
| | RE | Insufficient | This study reported quality of life data for 14 of 50 participants using the EORTC QLQ and HAM-D. No information was given to explain why only 14 patients were given a quality of life assessment was given. Quality of life was not adversely affected after RE and anxiety was significantly reduced from pretreatment levels. No significant difference was observed in depression score pre- and post-treatment. ⁶⁶ |
| Length of Stay | TACE | Insufficient | Mean length of stay ranged from 1.3 to 3 days. ^{63,67} |
| Local Recurrence | SBRT | Insufficient | Both studies reported a local recurrence rate of 33.3%. ^{71,88} |
| | RFA | Insufficient | One RFA study reported local a recurrence rate of 18%. ⁶⁵ |
| Adverse Events | TACE with DEB | Insufficient | A 3% liver failure rate was reported in one study of this intervention. ⁷⁵ Elevated bilirubin was reported in 50% of patients in one study. Other adverse events are listed in Table 9. |
| | TACE | Insufficient | One study reported elevated alkaline phosphatase of varying severity in 19% of patients and grade 1 elevated bilirubin in 1%. ⁶³ Other adverse events are reported in Table 9. |
| | SBRT | Insufficient | One study reported no major complications. ⁷¹ Other adverse events are reported in Table 9. |
| | HAI | Insufficient | One HAI study reported no major complications. ⁸³ One study reported elevated bilirubin in 1.8% of patients. ⁹² |
| | RE | Insufficient | Two studies reported no major complications. ^{84,86} Liver failure was reported in 2% and 2.4% of patients in two studies. ^{65,66} Elevated alkaline phosphatase was reported in 8% of patients in one study. ⁷⁶ Two studies reported elevated bilirubin in 10% and 13% of patients. ^{76,91} All other adverse events are listed in Table 9. |
| | RFA | Insufficient | One RFA study reported no major complications. ⁶⁹ |

DEB = drug-eluting beads; EORTC = European Organization for Research and Treatment of Cancer; HAI = hepatic arterial infusion; HAM-D = Hamilton Rating Scale for Depression; QLQ = quality of life questionnaire; RE = radioembolization; RFA = radiofrequency ablation; SBRT = stereotactic body radiation therapy TACE = transarterial chemoembolization

Table 17. Strength of evidence for KQ3 and KQ4

| Outcome | Adjunctive Therapy | Overall Grade | Conclusion |
|-------------------------|--------------------|---------------|---|
| Overall Survival | RFA | Insufficient | One study reported overall survival from study enrollment with a median survival of 24 months. ⁸⁰ One study reported overall survival from study treatment with a median survival of 24 months. ⁸⁵ One study reported overall survival from randomization with a median survival of 45.3 months. ⁸⁷ |
| | RE | Insufficient | Two studies reported overall survival from study treatment with a median overall survival of 9 and 37.8 months. ^{64,72} |
| | HAI | Insufficient | Two HAI studies did not report the point from which overall survival was measured. Median overall survival was 30.1 and 22 months. ^{79, 81} |
| Quality of Life | RFA | Insufficient | One study by Ruers et al. reported quality of life based on EORTC QLQ-C30. A 20-point difference is considered a significant change. Of the 60 patients enrolled, it is unclear how many were included in the analysis of quality of life. For those with available data, health-related quality of life declined 27 points following RFA. At 4 to 8 weeks post-RFA, prior to the start of systemic chemotherapy, the scores had risen to approximately 10 points below baseline. |
| Local Recurrence | RFA | Insufficient | All RFA studies reported local recurrence. Rates of recurrence were 45%, ⁸⁷ 78.6%, ⁸⁵ and 81.3%. ⁸⁰ |
| Adverse Events | RFA | Insufficient | One study reported injury to organs of 3.5% and liver failure of 1.8%. ⁸⁷ This study also reported elevated bilirubin in 5.3% of patients. ⁸⁷ Other adverse events are given in Table 15. |
| | RE | Insufficient | Two studies reported injury to organs of 1 to 5.3%. ^{64,72} Liver failure was reported in one study of 5.3%. ⁷² This study also reported elevated alkaline phosphatase and bilirubin in 26.3% of patients. ⁷² Other adverse events are given in Table 15. |
| | HAI | Insufficient | One study reported no major adverse events. ⁸¹ Other adverse events are given in Table 15. |

EORTC = European Organization for Research and Treatment of Cancer; HAI = hepatic arterial infusion; QLQ = quality of life questionnaire RE = radioembolization; RFA = radiofrequency ablation

Findings in Relationship to What Is Already Known

We are not aware of any published systematic reviews of the comparative effectiveness of local hepatic therapies for CRC metastases to the liver, and the literature base does not contain studies that compare one local hepatic therapy with another. Some systematic reviews of single local hepatic therapies have been published. Although the reviews vary in quality, they generally agree that evidence is insufficient to demonstrate the effectiveness of these modalities, particularly in terms of survival benefit.⁹⁵⁻⁹⁹ Earlier reviews conforming to a high quality standard interpreted their findings similarly to the present review; that is, evidence was insufficient to permit conclusions.^{31,100}

This review sought evidence on the comparative benefits and harms of local hepatic therapies in two patient groups for CRC metastasis to the liver. Although we did not find this evidence the strength of this present review is in the identification of this important evidence gap. While distinct patient groups exist within the population receiving local hepatic therapies, data to analyze these differences are limited. In our review, we addressed two distinct patient populations: those receiving local hepatic therapies as an adjunct to systemic chemotherapy and those whose disease is refractory to systemic treatment. Because we focused on patient groups rather than a specific intervention, we were able to present the outcomes for a wide range of local hepatic therapies for each target population.

Applicability

It is challenging to comment on the applicability of findings from our CER because we found that the available evidence was insufficient for us to draw conclusions. The degree to which the data presented in this report are applicable to clinical practice hinges on the degree to which the populations in the included studies represent the patient populations receiving clinical care in diverse settings, as well as the availability of the interventions. We comment below on the relevance of included studies for PICOTS elements. The PICOTS format provides a practical and useful structure to review applicability in a systematic manner and is employed in the subsections that follow.¹⁰¹

Population and Settings

The question of which subgroups of patients with CRC metastases to the liver may benefit from any particular local hepatic therapy compared with another remains unanswered. This uncertainty is reflected in the heterogeneity of the patient populations included in the published literature. Patient characteristics were often poorly characterized and not uniformly reported. Patients with varying degrees of resectability, extrahepatic disease, portal vein tumor thrombosis, and size and number of lesions are often grouped together and reported on as one group, even though it is uncertain whether these factors are likely to affect outcomes. Patient heterogeneity, combined with poor reporting of stratified or patient-level data, limited our ability to compare patient groups in any meaningful way. As a result, we are currently unable to determine which patients should be receiving which local hepatic therapies.

The setting in which treatment occurs is a major factor in the outcomes of local hepatic therapy. Expertise of both clinicians and centers varies. Based on the available clinical expertise and technology, the choice of a local hepatic therapy may be limited to one option in many centers. Local hepatic therapies, such as radioembolization¹⁰² and hepatic arterial infusion,¹⁰³ often require high levels of training and familiarity with the procedure. Lack of experience may not only affect patient outcomes but also result in adverse effects; patients treated by less-experienced clinicians and centers will likely experience poorer outcomes.

Detailed analysis of differences in outcomes by center has important implications for the relevance of the findings in the literature. Unfortunately, these data were unavailable as part of our systematic review of the published literature.

Interventions

Even for a single local hepatic therapy, variations in how the procedure is performed may be substantial. For instance, variations may occur in the approach (open vs. percutaneous), the choice of chemotherapy drugs delivered, and the schedule of delivery of chemotherapy and radiation therapy. Given the lack of comparative data, the present review did not allow for a more rigorous and systematic comparison of the relative performance of local hepatic therapies stratified by these factors. How these factors may alter health outcomes remains unclear.

Additional heterogeneity exists for the context in which the intervention was delivered. Patients often receive more than one local hepatic therapy over time or more than one session of the same therapy. This often results in variations of prior therapy at study enrollment. The complex treatment history of each patient can further limit the conclusions that can be drawn about the benefits attributable to any one component of the treatment plan.

Comparators

All studies in this review are observational (including the arm of one RCT that was extracted as a case-series); as such, they report on the experience of a particular center with one or more local hepatic therapies. Although case series can be useful for hypothesis generation, this approach cannot provide the comparative data the field needs for evaluating effectiveness. The applicability of any case series to another study group is very limited.

Outcomes

Little controversy exists regarding the most appropriate direct health outcomes to measure in a study of local hepatic therapies for CRC metastases to the liver. Overall survival is the ultimate outcome; it was reported in all of the studies included in this review. Quality of life is also a very important patient-centered outcome, but was not routinely reported in the literature in this review.

The importance of outcomes such as disease-free survival or local progression-free survival can be debated. Outcomes such as progression-free survival may not accurately predict changes in overall survival. However, these clinical events may mark changes in therapies and treatment that may be important to patients. Few experts would suggest that these outcomes replace the need for data on overall survival.

Studies of a comparative design are needed to measure accurately the differences in overall survival, quality of life, and harms that may be attributed to a local hepatic therapy.

Timing

The timing of followup assessment was appropriate given the natural history of unresectable CRC liver metastases and the primary outcome of overall survival. Median survival was reached in 21 of 24 studies. We judged this to be an appropriate length of assessment. In addition, two of the studies that did not reach median survival followed patients for up to 3 years to assess overall survival rates.

Implications for Clinical and Policy Decisionmaking

The goal of any local hepatic therapy for unresectable CRC metastases to the liver is to prolong life by eliminating the metastases if possible or to palliate symptoms such as pain. This report has reviewed the literature on local hepatic therapies to achieve these goals.

Due to the noncomparative nature of the literature base, both clinicians and policymakers are limited in their ability to apply the published literature base to decisions on effectiveness and comparative effectiveness of these interventions. Survival estimates from individual studies of local hepatic therapies suggest that local hepatic therapies may provide some benefit in terms of survival and symptom relief for some patients, but without comparative data, it is not possible to choose the therapy that will produce the best outcomes for specific patients. Several ongoing clinical trials pertaining to the interventions and population of interest to this review were identified through clinicaltrials.gov and are presented in Appendix D. None of these trials compares a local hepatic therapy with another local hepatic therapy.

Limitations of the Comparative Effectiveness Review Process

Determination of the scope of this review was a lengthy process that began in topic development but did not end until the CER was well underway. The topic was initially broader, encompassing other primary tumors metastasizing to the liver and hepatocellular carcinoma, a primary liver cancer. Although these liver tumors are all treated with a subset of the local hepatic therapies reviewed here, the evidence of their effectiveness is distinct, as are the clinical circumstances. During the scoping process, the review was narrowed to focus solely on unresectable CRC metastases to the liver. After the scope was set and inclusion and exclusion criteria were refined and reviewed by clinical experts, the literature search revealed an evidence base comprised of case-series studies. The decision was made to complete the report with its limitations. CRC metastases to the liver are a common condition and patients and providers may need to choose from many treatment options. The evaluation of the quality of the body of literature to assess our KQs and the identification of research needs are important contributions to the field.

Limitations of the Evidence Base

Limitations of the present review are related largely to the lack of comparative evidence. Because of the limited number of patients and clinical heterogeneity, we did not systematically review doses, regimens, or treatment-specific characteristics. A very large sample size with uniform data collection of these variables would be required to assess whether specific treatment characteristics were associated with survival differences. We did abstract from the literature information on patient characteristics such as performance status (degree of physical impairment typically assessed by an instrument such as ECOG or Karnofsky scale), number of lesions, and size of lesions. However, because of limitations of these data, the association between these variables and overall survival, quality of life, or adverse effects could not be assessed.

Evaluation of comparative effectiveness requires an intervention and a comparator. Case-series do not use comparators. Therefore, comparative effectiveness cannot be assessed using this type of literature. Further, factors that may affect the effectiveness of the interventions within these populations were not controlled for in the included studies. Control may be achieved either through randomized design or statistically through careful adjustment in the analysis. Studies that aim to determine the effectiveness or comparative effectiveness of local treatment for unresectable CRC metastases to the liver should use randomized designs. If randomization is not possible, care should be taken to control for covariates such as size and number of hepatic lesions, extrahepatic lesion number, CEA, treatment characteristics prior to local hepatic therapy (i.e. number of lines of previous chemotherapy), and performance status through regression analysis as these have been shown to impact survival outcomes.

Research Gaps

In this section, we first present a set of gaps focused on issues in the body of literature. Then we discuss the use of RCTs and observational studies to address these gaps, followed by an example of how a registry might overcome the drawbacks of single-center case series.

Gaps

This systematic review attempted to compare outcomes of local hepatic therapies for patients treated for unresectable CRC metastases to the liver. The review focused on two patient populations: those patients whose disease is refractory to systemic chemotherapy and patients who are receiving local hepatic therapy as an adjunct to systemic chemotherapy. Evidence on patient outcomes is limited, and the strength of evidence is insufficient for us to draw conclusions on effectiveness or harms for either patient population. As detailed above under applicability, there are specific evidence gaps that, if addressed, could enhance this literature base.

We identified four broad evidence gaps during this review organized by PICOTS framework. No gaps were identified for timing and setting.

- **Populations:** An objective of comparative effectiveness research is to understand the comparative effects for different population subgroups. To achieve this, we must fully delineate the population subgroups of interest. As detailed in the population and setting section above, these data are limited. Future studies must present data by subgroups of interest so that evidence can be interpreted by these variables. Based on published multivariate analyses examples of patient or tumor characteristics found to be associated with improved overall survival include: ECOG status (0 vs. ≥ 1 and in another study 0 or 1 vs. ≥ 2), performance status (0 or 1 vs. ≥ 2), number of extrahepatic metastases sites (0 or 1 vs. ≥ 2), number of lines of previous chemotherapy (0–1 vs. ≥ 2), performance status (0 or 1 vs. ≥ 2), carcinoembryonic antigen response (Yes, No), and Response Evaluation Criteria in Solid Tumors (RECIST). These variables should be considered when designing future studies. Because there are so many variables being collated, clinical risk scores may be particularly beneficial as a summary measure.¹⁰⁴
- **Intervention:** There can be substantial variation in the role of local hepatic therapy in the overall treatment strategy for patient populations with unresectable CRC liver metastases reviewed in this report. A thorough delineation of prior and concurrent treatment is necessary to assess the incremental benefit of local hepatic therapy and the comparative outcomes of these therapies for the reviewed patient populations. All other therapies, systemic and local, should be taken into account when evaluating the effectiveness of the intervention under study, as these therapies may have an effect on patient survival. Previous resections and other local hepatic therapies were often not reported in the studies included in this review.
- **Comparator:** A major limitation of the current evidence review was that there was no comparative evidence at the time of publication of this report comparing the various liver-directed therapies with one another.
- **Outcomes:** Outcomes of interest to patients and their physicians include survival, quality of life, and adverse effects such as radiation-induced liver disease, liver failure, and local recurrence (i.e., treatment failure). Evidence comparing these outcomes of local hepatic therapies in the populations of interest for the review are needed. For survival and other time-to-event outcomes, it is essential for authors to report the time point from which the event was measured (e.g., time from liver-directed therapy, time from CRC diagnosis, time from diagnosis of metastases). Collection and reporting of quality-of-life data (e.g., pain) using standard measurement tools was inconsistently reported in the literature included in this review. These data are

particularly important for the population of patients in which palliation of symptoms, rather than cure, is the intent of therapy.

Study Designs To Address These Gaps

RCTs are the gold standard of clinical evaluation and there is an absence of randomized controlled clinical trial evidence on the use of local hepatic therapies for the included indications. Because we were unable to find evidence to answer any of our key questions, we conducted additional discussions with members of our TEP to elicit ideas that could address the gaps in the literature. TEP members identified common barriers to conducting RCTs that would answer our key questions, including limited sources of research funding to support RCTs, reluctance of physicians to randomize patients, and the reluctance of patients to be randomized.

In addition to the resistance to randomize, consensus around the most compelling hypothesis for a comparative RCT is lacking. Clinical investigators have competing hypotheses of which treatment is best suited for which patients, and these hypotheses are often based on their own institution's experience. TEP members agreed that certain broad categories of patients with CRC metastasis to the liver, such as the populations included in this review, may well benefit from local hepatic therapies, but they also recognized that the published literature did not permit analysis of patient subgroups to identify characteristics more favorable to one local hepatic therapy over another. RCTs with well-documented patient and treatment characteristics could address the lack of comparative evidence. Lack of funding sources will continue to be an issue under the current regulatory structure. Under this system, the FDA does not require the same level of evidence for device approval as it does for drug approval. Because device companies can obtain approval without data from RCTs, they have very little incentive to provide funding.¹⁰⁵

Regardless of the study design, we suggest that studies aiming to address the effectiveness or comparative effectiveness of local hepatic therapies take care to address potential confounders and effect measure modification that could obscure the results. This is particularly important for patient characteristics such as size and number of metastases and performance status, which could serve as both modifiers of the effectiveness and factors that are considered when choosing the best local hepatic therapy.

Although RCTs may not be possible for all comparisons in all centers, well done multivariate analyses from existing case series can aid in identifying additional factors that should be documented and potentially controlled for in the comparative analysis of these data. These analyses can enhance the design of future RCTs or observational studies.

Patient Registries

In the absence of consensus regarding the most salient comparative research question, observational data could be useful in driving the generation and prioritization of hypotheses for future research. One approach is the use of a registry to systematically collect observational data. According to the Agency for Healthcare Research and Quality publication on registries for evaluating patient outcomes, patient registries are often constructed to study patient outcomes, the natural history of disease, and disease management under various treatment scenarios.¹⁰⁶ Registries need to be created with a question in mind, which will then guide the identification of the target patient population, the interventions of interest (e.g., a local hepatic therapy), the outcomes of interest, the number of patients (to be adequately powered for future analysis), and the length of followup.

The KQs from this CER could serve as guide for designing one or more registries focused on this clinical area. The aim would be to establish a prospective registry that tracks the outcomes, quality of life, and adverse events in those who receive local nonsurgical treatment for unresectable metastatic CRC to the liver in order to identify the most effective local hepatic therapy strategies. The effectiveness of any one local hepatic therapy is expected to vary by patient subgroup. TEP members also indicated that the provider experience with the local hepatic therapy is also an important factor in patient outcomes.

We have identified a core set of variables or core dataset, defined as the information set needed to address the critical questions the registry is developed to answer. This is presented in Table 18, organized by PICOTS.

Table 18. Core dataset elements for local hepatic therapy registry by PICOTS

| Population | Intervention | Comparators | Outcomes | Timing | Setting |
|--|--|----------------------|--|---------|--|
| Patient Characteristics Age Sex Race Ethnicity Performance status LDH CEA Clinical risk scores (e.g., Fong) ¹⁰⁴ Tumor Characteristics Location of tumor Size of lesions Number of lesions Number of extrahepatic metastases Tumor volume Portal vein obstruction Course of disease(stabilization, rapid progression) Other Treatments Number, dose, and duration for lines of prior therapy by drug Number, dose, and duration for lines of adjunctive therapy by drug Previous liver-directed therapy | Type of Local Hepatic Therapy Cryosurgical ablation RFA MWA TAE TACE HAI RE DEB 3D-CRT IMRT SBRT Characteristics of Local Hepatic Therapy Dose Duration Surgical site | Same as Intervention | Overall survival Quality of life Response (e.g., complete, partial, no response) Recovery time Length of stay Adverse effects (Short-term and long-term harms) Treatment holidays* | Ongoing | Hospital type Number of procedures by practitioner Type of practitioner Local hepatic therapy availability Inpatient or outpatient procedure |

3D-CRT = three-dimensional conformal radiation therapy; CEA = carcinoembryonic antigen; DEB = drug-eluting bead; HAI = hepatic artery infusion; IMRT = intensity-modulated radiation therapy; LDH = lactate dehydrogenase; RE = radioembolization; RFA = radiofrequency ablation; SBRT = stereotactic body radiation therapy; TACE = transarterial chemoembolization; TAE = transarterial embolization;

*Treatment holidays refer to time away from systemic chemotherapy and may vary based on the success of treatment with a local hepatic therapy.

Conclusions

Due to the absence of published comparative data, the evidence is insufficient for us to draw conclusions about the comparative effectiveness of local hepatic therapies for unresectable CRC metastases to the liver for the patient populations addressed in this review. Important outcomes of therapy include overall survival, quality of life, and adverse effects (harms). A patient registry is one tool for future research that may generate hypotheses for clinical trials or observational evidence on the comparative effectiveness of local hepatic therapies.

References

1. Bruckner HW. Adenocarcinoma of the colon and rectum. In: Bast RC, Kufe DW, Pollock RE, eds. *Holland-Frei Cancer Medicine* 5th edition. Ontario: B C Decker; 2000.
2. Tierney RP, Ballantyne GH, Modlin IM. The adenoma to carcinoma sequence. *Surg Gynecol Obstet*. 1990 Jul;171(1):81-94. PMID: 2163117.
3. Minsky BD, Cohen AM, Enker WE, et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. *Int J Radiat Oncol Biol Phys*. 1997 Jan 15;37(2):289-95. PMID: 9069299.
4. Steinbach G, Heymsfield S, Olansen NE, et al. Effect of caloric restriction on colonic proliferation in obese persons: implications for colon cancer prevention. *Cancer Res*. 1994 Mar 1;54(5):1194-7. PMID: 8118805.
5. DeCosse JJ, Tsioulis GJ, Jacobson JS. Colorectal cancer: Detection, treatment, and rehabilitation. *CA Cancer J Clin*. 1994 Jan-Feb;44(1):27-42. PMID: 8281470.
6. Wargovich MJ. New dietary anticarcinogens and prevention of gastrointestinal cancer. *Dis Colon Rectum*. 1988 Jan;31(1):72-5. PMID: 3284725.
7. American Joint Committee on Cancer. In *Manual for Staging of Cancer*. 2nd ed. Philadelphia: Lippincott.
8. Surveillance Epidemiology and End Results. Cancer of the Colon and Rectum - SEER Stat Fact Sheet. 2012. seer.cancer.gov/statfacts/html/colorect.html. Accessed on August 3rd 2012.
9. American Joint Committee on Cancer. *AJCC Cancer Staging Manual*. 7 ed: Springer; 2010.
10. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. *Ann Surg*. 1984 May;199(5):502-8. PMID: 6721600.
11. Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. *Mayo Clin Proc*. 2007 Jan;82(1):114-29. PMID: 17285793.
12. Flanders VL, Gervais DA. Ablation of liver metastases: Current status. *J Vasc Interv Radiol*. 2010;21(8 Suppl):S214-S22. PMID: 20656231
13. Gilbert HA, Kagan AR. Metastases: incidence, detection, and evaluation without histologic confirmation. In: Weiss L, ed *Fundamental Aspects of Metastasis*. Netherlands: North Holland Publishing Co; 1976:385-405.
14. Feliberti EC, Wagman LD. Radiofrequency ablation of liver metastases from colorectal carcinoma. *Cancer Control*. 2006 Jan;13(1):48-51. PMID: 16508626.
15. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg*. 2004 Jun;239(6):818-25; discussion 25-7. PMID: 15166961.
16. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. *Ann Surg*. 2002 Jun;235(6):759-66. PMID: 12035031.
17. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. *Ann Surg*. 2009 Sep;250(3):440-8. PMID: 19730175.
18. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). *Ann Surg*. 2004 Sep;240(3):438-47; discussion 47-50. PMID: 15319715.
19. Fong Y, Blumgart LH, Cohen AM. Surgical treatment of colorectal metastases to the liver. *CA Cancer J Clin*. 1995 Jan-Feb;45(1):50-62. PMID: 7804899.

20. Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. *Br J Surg*. 2010 Jul;97(7):1110-8. PMID: 20632280.
21. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. *Association Francaise de Chirurgie. Cancer*. 1996 Apr 1;77(7):1254-62. PMID: 8608500.
22. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? *Ann Surg*. 2004 May;239(5):722-30; discussion 30-2. PMID: 15082977.
23. Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. *J Surg Oncol*. 2009;100(8):619-34. PMID: 20017157
24. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *J Clin Oncol*. 2009 Aug 1;27(22):3677-83. PMID: 19470929.
25. Burak KW. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge? *Oncology (Williston Park)*. 2011 Mar;25(3):296, 8, 300. PMID: 21548474.
26. Evans J. Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM). *Eur J Surg Oncol*. 2007;33(Suppl 2):S64-S75. PMID: 18061390
27. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. *Arch Surg*. 2002 June 1, 2002;137(6):675-81. PMID: 12049538
28. Alsina J, Choti MA. Liver-Directed Therapies in Colorectal Cancer. *Semin Oncol*. 2011;38(4):561-7. PMID: 21810515
29. Benson AB, Engstrom P, Venook A, et al. National Comprehensive Cancer Network Guidelines Colon Cancer Version 3.2012. 2012.
30. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol*. 2010 Aug 10;28(23):3687-94. PMID: 20567019.
31. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. *J Clin Oncol*. 2010 Jan 20;28(3):493-508. PMID: 19841322.
32. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. *Cryobiology*. 1998;37(3):171-86. PMID: 9787063
33. Gage AA, Guest K, Montes M, et al. Effect of varying freezing and thawing rates in experimental cryosurgery. *Cryobiology*. 1985;22(2):175-82. PMID: 3979086
34. Gueorguiev AL, Mackey R, Kowdley GC, et al. Minimally invasive evaluation and treatment of colorectal liver metastases. *Int J Surg Oncol*. 2011;2011:686030. PMID: 22312518.
35. Blazer DG, Anaya DA, Abdalla EK. Destructive therapies for colorectal cancer metastases. In: Vauthey JN, Audisio RA, Hoff PM, Poston G, eds. *Liver Metastases*. London: Springer-Verlag; 2009:39-49.
36. Nguyen KT, Geller DA. Radiofrequency ablation of hepatocellular carcinoma. In: Carr BI, ed *Hepatocellular Carcinoma, Diagnosis and Treatment*. New York, New York: Humana Press; 2010:421-51.
37. Radiologyinfo. Radiofrequency Abalation (RFA) of Liver Tumors. 2011. www.radiologyinfo.org/en/info.cfm?pg=rfaliver. Accessed on May, 10 2012.
38. Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. *Ann Surg*. 2011;253(3):453-69 PMID: 21263310
39. American Cancer Society. Embolization therapy for liver cancer. 2012. www.cancer.org/Cancer/LiverCancer/DetailGuides/liver-cancer-treating-embolization-therapy. Accessed on May 10 2012.

40. Leonard GD, Kemeny NE. Hepatic Directed Therapy. In: Cassidy J, Johnston P, Van Cutsem E, eds. Colorectal Cancer. Informa Healthcare; 2007:253-85.
41. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. *Int J Radiat Oncol Biol Phys.* 2004;60(5):1552-63. PMID: 15590187
42. Campbell AM, Bailey IH, MA. B. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. *Phys Med Biol.* 2001;46(2):487-98. PMID: 11229728
43. Lau WY, Leung T, Ho S, et al. Diagnostic pharmaco-scintigraphy with hepatic intraarterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma. *Br J Radiol.* 1994;67(794):136-9. PMID: 8130973
44. Coldwell DM, Kennedy AS. Internal radiation for the treatment of liver metastases. In: Vauthey JN, Audisio RA, Hoff PM, Poston G, eds. *Liver Metastases.* London: Springer-Verlag; 2009:98-109.
45. Meza-Junco J, Montano-Loza AJ, Liu DM, et al. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? *Cancer Treat Rev.* 2011;In Press, Corrected Proof. PMID: 21726960
46. Radiologyinfo. External Beam Therapy (EBT). "American College of Radiology and the Radiological Society of North America"; 2012. www.radiologyinfo.org/en/info.cfm?pg=ebt. Accessed on May 10 2012.
47. American Cancer Society. Radiation therapy for liver cancer. 2012. www.cancer.org/Cancer/LiverCancer/DetailGuides/liver-cancer-treating-radiation-therapy. Accessed on May 10 2012.
48. Blazer DG, Anaya DA, Abdalla EK. Destructive therapies for colorectal cancer metastases. In: Vauthey JN, ed *Liver Metastases.* London: Springer-Verlag; 2009:39-50.
49. Radiologyinfo. Intensity-Modulated Radiation Therapy (IMRT). "American College of Radiology and the Radiological Society of North America"; 2012. www.radiologyinfo.org/en/info.cfm?pg=imrt. Accessed on May 10 2012.
50. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. *Clin Ther.* 2010 Dec;32(13):2117-38. PMID: 21316532.
51. Radiologyinfo. Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT). "American College of Radiology and the Radiological Society of North America"; 2012. www.radiologyinfo.org/en/info.cfm?pg=stereotactic. Accessed on May 10 2012.
52. Chua TC, Liauw W, Koong H-N, et al. Surgical therapies in metastatic colorectal cancer with a potential for cure. *Am J Clin Oncol.* 2011;34(3):326-31 PMID: 20498587
53. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009 Jul 21;6(7):e1000097. PMID: 19621072.
54. Moher D, Pham B, Lawson ML, et al. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. *Health Technol Assess.* 2003;7(41):1-90. PMID: 14670218.
55. Pham B, Klassen TP, Lawson ML, et al. Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. *J Clin Epidemiol.* 2005 Aug;58(8):769-76. PMID: 16086467.
56. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? *J Clin Oncol.* 2009 Apr 10;27(11):1829-35. PMID: 19273699.
57. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. *J Clin Oncol.* 2001 May 15;19(10):2687-95. PMID: 11352961.

58. Kern W, Beckert B, Lang N, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. *Ann Oncol*. 2001 May;12(5):599-603. PMID: 11432616.
59. Meyers MO, Sasson AR, Sigurdson ER. Locoregional strategies for colorectal hepatic metastases. *Clin Colorectal Cancer*. 2003 May;3(1):34-44. PMID: 12777190.
60. Carey TS, SD B. A critical guide to case series reports. *Spine*. 2003;28:1631-4. PMID: 12897483
61. Baba Y, Noshio K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. *American Journal of Pathology*. 2010 May;176 (5):2292-301. PMID: 2010268740.
62. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: Grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol*. 2010;63:513-23. PMID: 19595577
63. Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. *Cancer*. 2011 Jan 15;117(2):343-52. PMID: 20830766.
64. Chua TC, Bester L, Saxena A, et al. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. *J Cancer Res Clin Oncol*. 2011 May;137(5):865-73. PMID: 20859640.
65. Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. *Cardiovasc Intervent Radiol*. 2009 Nov;32(6):1179-86. PMID: 19680720.
66. Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. *Br J Cancer*. 2010 Jul 27;103(3):324-31. PMID: 20628388.
67. Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study. *In Vivo*. 2007;21(6):1085-92.
68. Hong K, McBride JD, Georgiades CS, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. *J Vasc Interv Radiol*. 2009 Mar;20(3):360-7. PMID: 19167245.
69. Jakobs TF, Hoffmann RT, Trumm C, et al. Radiofrequency ablation of colorectal liver metastases: Mid-term results in 68 patients. *Anticancer Research*. 2006;26(1 B):671-80.
70. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. *Eur J Surg Oncol*. 2007 Jun;33(5):597-602. PMID: 17433608.
71. Kim MS, Kang JK, Cho CK, et al. Three-fraction stereotactic body radiation therapy for isolated liver recurrence from colorectal cancer. *Tumori*. 2009 Jul-Aug;95(4):449-54. PMID: 19856655.
72. Kosmider S, Tan TH, Yip D, et al. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. *J Vasc Interv Radiol*. 2011 Jun;22(6):780-6. PMID: 21515072.
73. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. *J Vasc Interv Radiol*. 2005 Dec;16(12):1641-51. PMID: 16371530.

74. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. *BMC Cancer*. 2005;5:132. PMID: 16225697.
75. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. *Ann Surg Oncol*. 2011 Jan;18(1):192-8. PMID: 20740319.
76. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. *Cancer*. 2009 May 1;115(9):1849-58. PMID: 19267416.
77. Rowe BP, Weiner R, Foster J, et al. 90Yttrium microspheres for nonresectable liver cancer: the University of Connecticut Health Center experience. *Conn Med*. 2007 Oct;71(9):523-8. PMID: 17966721.
78. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. *Radiology*. 2008 May;247(2):507-15. PMID: 18349311.
79. Seki H, Ozaki T, Shiina M. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. *Cardiovasc Intervent Radiol*. 2009 Jul;32(4):679-86. PMID: 19296157.
80. Sgouros J, Cast J, Garadi KK, et al. Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases. *World J Gastrointest Oncol*. 2011 Apr 15;3(4):60-6. PMID: 21528091.
81. Tsutsumi S, Yamaguchi S, Tsuboi K, et al. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer. *Hepatogastroenterology*. 2008 Jul-Aug;55(85):1419-22. PMID: 18795703.
82. Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: Is there a dose response relationship? *Int J Radiat Oncol Biol Phys*. 2011 Mar 4; PMID: 21377292.
83. Vogl TJ, Zangos S, Eichler K, et al. Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. *Eur Radiol*. 2008 Mar;18(3):468-76. PMID: 17938935.
84. Kucuk ON, Soydal C, Lacin S, et al. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. *World J Surg Oncol*. 2011;9:86. PMID: 21819613.
85. Lee KH, Kim HO, Yoo CH, et al. Comparison of radiofrequency ablation and resection for hepatic metastasis from colorectal cancer. *Korean J Gastroenterol*. 2012 Mar;59(3):218-23. PMID: 22460570.
86. Martin LK, Cucci A, Wei L, et al. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. *Clin Colorectal Cancer*. 2012 Jan 23; PMID: 22277350.
87. Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). *Ann Oncol*. 2012 Mar 19; PMID: 22431703.
88. Stintzing S, Hoffmann RT, Heinemann V, et al. Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. *Eur J Cancer*. 2010 Apr;46(6):1026-32. PMID: 20153959.
89. Nace GW, Steel JL, Amesur N, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: A single institution experience. *Int J Surg Oncol*. 2011;2011:571261. PMID: 22312513.

90. Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead(R), drug-eluting bead loaded with irinotecan: results of a phase II clinical study. *Anticancer Res.* 2011 Dec;31(12):4581-7. PMID: 22199334.
91. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. *J Vasc Interv Radiol.* 2008 Aug;19(8):1187-95. PMID: 18656012.
92. Nishiofuku H, Tanaka T, Aramaki T, et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. *Clin Colorectal Cancer.* 2010 Dec;9(5):305-10. PMID: 21208845.
93. Lim L, Gibbs P, Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. *Intern Med J.* 2005 Apr;35(4):222-7. PMID: 15836500.
94. Veltri A, Sacchetto P, Tosetti I, et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. *Cardiovasc Intervent Radiol.* 2008 Sep-Oct;31(5):948-56. PMID: 18506519.
95. Pasetto LM, Merenda R, Pilati P, et al. Hepatic metastases of colorectal cancer: locoregional intra-arterial treatment. *Anticancer Res.* 2006 Nov-Dec;26(6C):4785-92. PMID: 17214342.
96. Skitzki JJ, Chang AE. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. *Surg Oncol.* 2002 Nov;11(3):123-35. PMID: 12356508.
97. Sutherland LM, Williams JA, Padbury RT, et al. Radiofrequency ablation of liver tumors: a systematic review. *Arch Surg.* 2006 Feb;141(2):181-90. PMID: 16490897.
98. Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: An update. *Eur Radiol.* 2007 Apr;17(4):1025-34. PMID: 16944163.
99. Wu YZ, Li B, Wang T, et al. Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: A meta-analysis. *World J Gastroenterol.* 2011 Sep 28;17(36):4143-8. PMID: 22039331.
100. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. *Cochrane Database Syst Rev.* 2009(3):CD007823. PMID: 19588444.
101. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. *BMC Health Serv Res.* 2004 Dec 22;4(1):38. PMID: 15615589.
102. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using Yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. *Int J Radiat Oncol Biol Phys.* 2007;68(1):13-23. PMID: 17448867
103. Bouchahda M, Levi F, Adam R, et al. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. *Eur J Cancer.* 2011 Dec;47(18):2681-90. PMID: 21783358.
104. Fong Y. Surgical therapy of hepatic colorectal metastasis. *Ca-A Cancer Journal for Clinicians.* 1999;49(4):231-55.
105. Sweet BV, Schwemm AK, Parsons DM. Review of the processes for FDA oversight of drugs, medical devices, and combination products. *J Manag Care Pharm.* 2011 Jan-Feb;17(1):40-50. PMID: 21204589.
106. Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes : a user's guide. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality; 2007.

Abbreviations and Acronyms

| | |
|--------|--|
| 3D | three-dimensional |
| AE | adverse events |
| AHRQ | Agency for Healthcare Research and Quality |
| CEA | carcinoembryonic antigen |
| CER | comparative effectiveness review |
| CRC | colorectal cancer |
| CRT | conformal radiotherapy |
| DEB | drug-eluting beads |
| DEBIRI | drug-eluting bead, irinotecan |
| ECOG | Eastern Cooperative Oncology Group |
| EORTC | European Organization for Research and Treatment of Cancer |
| EPC | Evidence-based Practice Center |
| FU | fluorouracil |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| Gy | Gray |
| HAI | hepatic artery infusion |
| HAM-D | Hamilton rating scale for depression |
| IMRT | intensity-modulated radiation therapy |
| KQ(s) | Key Question(s) |
| LDH | lactic dehydrogenase |
| LDT | liver-directed therapy(ies) |
| MAA | ^{99m} Tc-macro-aggregated albumin scan |
| MWA | microwave ablation |
| N | number; no. |
| NA | not available |
| No | number |
| PICOTS | Population, Intervention, Comparator, Outcomes, Timing, Setting |
| PFS | progression-free survival |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| QOL | quality of life |
| RCT | randomized controlled trial |
| RE | radioembolization |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RFA | radiofrequency ablation |
| SBRT | stereotactic body radiation |
| SIRT | selective internal radiotherapy |
| TACE | transarterial chemoembolization |
| TAE | transarterial embolization |
| TEP | technical expert panel |
| TTR | time to recurrence |

Appendix A. Search Strategy

We searched MEDLINE® for RCTs, nonrandomized comparative studies, and case series by using the following string of search terms:

1. "Liver Neoplasms"[Mesh] OR ((hepatic OR liver) AND (cancer OR cancers OR oncology OR neoplasms))
 2. "Colorectal Neoplasms"[Mesh] OR colon OR colorectal OR rectal OR intestinal OR rectum OR intestine*
 3. "secondary "[Subheading] OR metastatic OR metastasis OR metastases
 4. Unresectable OR nonresectable OR inoperable OR irresectable
 5. "Ablation Techniques"[Mesh] OR "Embolization, Therapeutic"[Mesh] OR "Chemoembolization, Therapeutic"[Mesh] OR "Radiotherapy"[Mesh] OR "radiotherapy "[Subheading] OR "drug therapy "[Subheading] OR "Drug Therapy"[Mesh] OR "radiofrequency ablation" OR (radiofrequency AND ablation) OR RFA OR cryoablation OR cryosurgical OR cryosurgery OR "microwave ablation" OR (microwave AND ablation) OR ((percutaneous OR intralesional) AND (ethanol OR acetic acid)) OR embolization OR embolisation OR embolize* OR embolise* OR "transarterial chemoembolization" OR "transarterial chemoembolisation" OR TACE OR "transarterial embolization" OR "transarterial embolisation" OR TAE OR radioembolization OR radioembolisation OR radiotherapy OR radiation OR "external beam" OR "3D conformal" OR "3-D Conformal" OR "intensity modulated radiotherapy" OR IMRT OR "intraluminal brachytherapy" OR "liver-directed chemotherapy" OR "hepatic artery infusion" OR HAI OR chemotherapy OR "drug-eluting beads"
- ((((1 AND 2) AND 3) AND 4) AND 5)
Limits: Humans, English

We searched Embase® for RCTs, nonrandomized comparative studies, and case series by using the following string of search terms:

1. ((hepatic OR 'liver'/exp) AND ('cancer'/exp OR 'cancers'/exp OR 'oncology'/exp OR 'neoplasms'/exp))
2. ('colorectal neoplasms'/exp OR (('colon'/exp OR colorectal OR 'rectal'/exp OR intestinal OR 'rectum'/exp OR 'intestine'/exp OR 'intestines'/exp) AND ('cancer'/exp OR 'carcinoma'/exp OR primary)))
3. secondary OR metastatic OR 'metastasis'/exp OR 'metastases'/exp
4. unresectable OR nonresectable OR inoperable OR irresectable

5. 'ablation techniques'/exp OR 'therapeutic embolization' OR 'therapeutic chemoembolization' OR 'drug therapy'/exp OR 'radiofrequency ablation'/exp OR ('radiofrequency'/exp AND ablation) OR rfa OR 'cryoablation'/exp OR cryosurgical OR 'cryosurgery'/exp OR 'microwave ablation'/exp OR ('microwave'/exp AND ablation) OR (percutaneous OR 'intralesional'/exp AND ('ethanol'/exp OR acetic) AND 'acid'/exp) OR 'embolization'/exp OR 'embolisation'/exp OR embolize* OR embolise* OR 'transarterial chemoembolization' OR 'transarterial chemoembolisation' OR 'tace'/exp OR 'transarterial embolization' OR 'transarterial embolisation' OR tae OR radioembolization OR radioembolisation OR 'radiotherapy'/exp OR 'radiation'/exp OR 'external beam' OR '3d conformal' OR '3-d conformal' OR 'intensity modulated radiotherapy'/exp OR 'imrt'/exp OR 'intraluminal brachytherapy' OR 'liver-directed chemotherapy' OR 'hepatic artery infusion' OR hai OR 'chemotherapy'/exp OR 'drug-eluting beads'

((((1 AND 2) AND 3) AND 4) AND 5)

Limits: Human, English and not MEDLINE.

Regulatory Information

FDA

Source: www.FDA.gov

Date searched: 4/3/2012

Search strategy: key word "colorectal metastases"

Records: 6

Clinical trial registries

NIH database

Source: <http://clinicaltrials.gov/>

Date searched: 4/03/2012

Search strategy: Colorectal AND "Liver metastases"

Records: 259

Conference papers and abstracts

Specific conferences and association meetings

Source – number of results returned for search strategy:

Annual meeting of American Society of Clinical Oncology (ASCO) - 98

Annual meeting of American Society of Clinical Oncology Gastrointestinal (ASCO GI) - 56

Annual meeting of Surgery Society of Oncology (SSO) - 14

Annual meeting of Radiosurgical Society - 6

Date searched: 4/04/2012

Search strategy: KW: "liver metastases" in the title

Records: 174

Manufacturer database

Source: Accuray Incorporated

Date posted: 3/19/2012

Date searched: 4/05/2012

Search strategy: Not applicable

Records: 20

Source: Sirtex SIR-Spheres Pty Limited
Date posted: 3/21/2012
Date searched:4/05/2012
Search strategy: Not applicable
Records:35

Appendix B. Contacted Authors

Table D-1. List of authors contacted with questions during this review and the question resolution

| Author | Response from Authors Sufficient for Issue Resolution | Question/Resolution |
|--------------------------------------|---|--|
| Chua - 2010 ¹ | Yes | Time from which survival is measured? / Measured from date of RE to date of death or last FU |
| Albert – 2011 ² | No | Need to determine number of patients received 0 lines of previous systemic chemotherapy / None |
| Hendlisz – 2010 ³ | Yes | Need to clarify why patients were given further chemotherapy / Chemotherapy given for disease progression. Include study and use time to liver progression statistics. |
| Meijerink - 2011 ⁴ | No | Uncertain if patients were refractory to chemotherapy. / Study excluded due to small sample size and potential contamination. |
| Stintzing – 2011 ⁵ | Yes | Did any of the CRC liver mets. Patients refuse treatment? / None of these patients refused treatment |
| Vautravers-Dewas - 2011 ⁶ | No | Uncertain about extrahepatic metastases in patients. / None |
| Murthy - 2007 ⁷ | No | Uncertain about treatment dates for this study / None |
| Ritz – 2007 ⁸ | No | Uncertain if patients are refractory / None |
| Martin – 2011 ⁹ | No | Do survival statistics correspond to complete responders alone? / No response but study included and assumed that issue resulted from a typographical error in table creation. |
| Tsutsumi - 2008 ¹⁰ | No | Article does not give survival starting point / None |
| Cianni – 2009 ¹¹ | Yes | Article does not give survival starting point, potential overlap in study populations / Author clarified that this was from time of treatment and that this was not a duplicated patient population. |
| Hong - 2009 ¹² | No | Discrepancy in table statistics / none |
| Lim - 2005 ¹³ | Yes | Article does not give survival starting point / Author clarified that this was from study treatment. |
| Fiorentini – 2007 ¹⁴ | No | Article does not give survival starting point / None |

1. Chua TC, Bester L, Akther J, et al. Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases. *Anticancer Res.* 2010 Jul;30(7):3005-7. PMID: 20683046.
2. Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. *Cancer.* 2011 Jan 15;117(2):343-52. PMID: 20830766.
3. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol.* 2010 Aug 10;28(23):3687-94. PMID: 20567019.
4. Meijerink MR, van den Tol P, van Tilborg AA, et al. Radiofrequency ablation of large size liver tumours using novel plan-parallel expandable bipolar electrodes: initial clinical experience. *Eur J Radiol.* 2011 Jan;77(1):167-71. PMID: 19616911.
5. Stintzing S, Hoffmann RT, Heinemann V, et al. Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. *Eur J Cancer.* 2010 Apr;46(6):1026-32. PMID: 20153959.
6. Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: Is there a dose response relationship? *Int J Radiat Oncol Biol Phys.* 2011 Mar 4; PMID: 21377292.
7. Murthy R, Eng C, Krishnan S, et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. *J Vasc Interv Radiol.* 2007 Dec;18(12):1588-91. PMID: 18057297.
8. Ritz JP, Lehmann KS, Reissfelder C, et al. Bipolar radiofrequency ablation of liver metastases during laparotomy. First clinical experiences with a new multipolar ablation concept. *Int J Colorectal Dis.* 2006 Jan;21(1):25-32. PMID: 15875202.
9. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. *Ann Surg Oncol.* 2011 Jan;18(1):192-8. PMID: 20740319.
10. Tsutsumi S, Yamaguchi S, Tsuboi K, et al. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer. *Hepatogastroenterology.* 2008 Jul-Aug;55(85):1419-22. PMID: 18795703.
11. Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. *Cardiovasc Intervent Radiol.* 2009 Nov;32(6):1179-86. PMID: 19680720.
12. Hong K, McBride JD, Georgiades CS, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. *J Vasc Interv Radiol.* 2009 Mar;20(3):360-7. PMID: 19167245.
13. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. *BMC Cancer.* 2005;5:132. PMID: 16225697.
14. Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study. *In Vivo.* 2007;21(6):1085-92.

Appendix C. DistillerSR Screening and Abstraction Forms

Title Screening

Is the article published in English?
Does the article report primary data?
Are the participants in the article human?
Is unresectable colorectal cancer the primary focus of the article?

Abstract Screening

Is the article published in English?
Does the article report primary data?
Are the participants in the article human?
Is unresectable colorectal cancer the primary focus of the article?

CRC Full-text Screening

Is article published in English?
Is treatment date prior to January 1, 2000?
Is the study of relevant design?
Are the study participants human?
Does the article report on the correct patient population?
Did the study employ a relevant intervention?
Did the study report a relevant outcome?

STUDY DESCRIPTION

First Author (Last name):

Year of Publication:

Study design:

What key question(s) does this article address?

Descriptors of Treatment (e.g., drug(s) used, route, etc)

Enrollment Start Date (mm/yyyy)

Enrollment End Date (mm/yyyy)

Number in Group

Outcomes

Setting

Patient population with CRC (%)

Previous Treatment

Previous resection: % yes

Previous systemic chemotherapy: % yes

Previous liver-directed therapy: Therapy: %, Therapy2: ...

Previous LDT: select all that apply

DIAGNOSIS

Adenocarcinoma

Mucinous

Synchronous

Mean Liver

Median Liver

Min Liver

Max Liver

Mean N Hepatic

Median N Hepatic

Min N Hepatic

Max N Hepatic

Other Liver Involvement: Name: %, Name2: ...

PATHOLOGY

Mean Size of Hepatic (cm) Lesion(s)

Median Size of Hepatic (cm) Lesion(s)

Min Size of Hepatic Lesion(s)
Max Size of Hepatic Lesion(s)
% Unilobar Hepatic Lesion(s)
% Bilobar Hepatic Lesion(s)
Other noted lesion characteristics

PATIENT CHARACTERISTICS

Sex (% Male)
Mean Age
Median Age
Min Age
Max Age
RACE: White (%)
RACE: Black (%)
RACE: Asian (%)
RACE: Hispanic (%)
Child-pugh score: Mean
Child-pugh score: Median
Child-pugh score: Min
Child-pugh score: Max
Child-pugh class (A, B, or C)
ECOG Performance Score: Mean
ECOG Performance Score: Median
ECOG Performance Score: Min
ECOG Performance Score: Max
Karnofsky Score: Mean
Karnofsky Score: Median
Karnofsky score: Min
Karnofsky Score: Max

ABTRACTOR COMMENTS: If you would like to leave a comment pertaining to the information above indicate your name below:

Outcomes Form

FOLLOW-UP

Follow-up assessed?
Length of Follow-up (weeks)
N Subjects Lost to Follow-up

OUTCOMES

Survival outcome definition:
Median Overall Survival (months)
95% CI: Lower limit
95% CI: Upper limit
Mean Overall Survival (months)
95% CI: Lower limit
95% CI: Upper limit

Survival by Year

% survived at year 1
% survived at year 2
% survived at year 3
% survived at year 4
% survived at year 5

Progression Free Survival

Progression free survival definition:
Liver PFS
Median (months)
95% CI: Lower Limit

95% CI: Upper Limit
Liver PFS
Mean (months)
95% CI: Lower Limit
95% CI: Upper Limit
Overall PFS
Median (months)
95% CI: Lower Limit
95% CI: Upper Limit
Overall PFS
Mean (months)
95% CI: Lower Limit
95% CI: Upper Limit

Outcomes Continued

Local Recurrence N
Local Recurrence %
Pain, Instrument
Mean Pain Score
Min Pain Score
Max Pain Score
Pain Score p-value

QOL, Instrument
Min QOL Score
Max QOL Score
QOL Score p-value
Mean LOS (days)
Min LOS (days)
Max LOS (days)
LOS p-value

Hepatic Abscess (%)
Hepatic Hemorrhage (%)
Biloma (%)
Steatohepatitis (%)
Injury to adjacent organ(s) (%)
Liver failure (%)
Increased alkaline phosphatase (N)
Increased alkaline phosphatase (%)
Increased bilirubin (N)
Increased bilirubin (%)
Increased transaminases (N)
Increased transaminases (%)

Please describe any rare adverse events which do not fit into the categorizations above:

ABSTRACTOR COMMENTS: If you would like to leave a comment pertaining to the information above indicate your name below:

Study Quality

Comparative Studies Quality Assessment (USPSTF)
Initial assembly of comparable groups
Maintenance of comparable groups (includes attrition, crossovers, adherence, and contamination)
Avoidance of important differential loss to followup or overall high loss to followup.
Measurements reliable, valid, equal (includes masking of outcome assessment)
Interventions comparable/ clearly defined

All important outcomes considered
Appropriate analysis of results (adjustment for potential confounders and intention-to-treat analysis)
Funding/ sponsorship source acknowledged
Overall Rating

Non-Randomized Comparative-Deeks and colleagues

Prospective sample definition and selection
Clearly described inclusion/exclusion criteria
Representative Sample
Attempt to balance groups by design
Comparable groups as baseline, including clearly described prognostic characteristics
Clearly specified interventions
Participants in treatment groups recruited within the same time period
Attempt to allocate participants to treatment groups to minimize bias
Concurrent treatment(s) given equally to all treatment groups
Valid, reliable, and equal outcome measures
Blinded outcome assessment
Adequate length of follow-up
Attrition below an overall high level(<20%)
Difference in attrition between treatment groups below a high level (<15%)
Adjusted for confounders in statistical analysis

Carey and Boden case series quality assessment tool
Clearly Defined Question
Well-described study population
Well-described intervention
Use of Validated Outcome Measures
Appropriate Statistical Analysis
Well-Described Results
Discussion/Conclusions Supported by Data
Funding/Sponsorship Source Acknowledged

Appendix D. Evidence Tables

Tables Related to Key Questions 1 and 2

Appendix Table D-1. Local therapies for colorectal cancer metastases to the liver, study quality Carey and Boden Case Series quality Assessment

| Reference | Clearly Defined Question | Well-Described Study Population | Well-Described Intervention | Use of Validated Outcome Measures | Appropriate Statistical Analysis | Well-Described Results | Discussion/Conclusions Supported by Data | Rank* |
|-------------------------|--------------------------|---------------------------------|-----------------------------|-----------------------------------|----------------------------------|------------------------|--|-------|
| Albert – 2011 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Aliberti – 2011 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Cianni – 2009 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Cosimelli - 2010 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Fiorentini – 2007 | Yes | No | Yes | Yes | Yes | No | Yes | Poor |
| Hong – 2009 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Jakobs – 2006 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Jakobs – 2008 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Jiao – 2007 | Yes | No | Yes | Yes | Yes | No | Yes | Poor |
| Kim – 2009 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Kucuk – 2011 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Lewandowski – 2005 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Lim – 2005 | Yes | No | Yes | Yes | Yes | No | Yes | Poor |
| Martin – 2011 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Martin – 2012 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Mulcahy - 2009 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Nace – 2011 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Nishiofuku - 2010 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Rowe - 2007 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Sato - 2008 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Stintzing – 2010 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Vautravers-Dewas - 2011 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Vogl - 2008 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |

* A rank of good indicates that all Carey and Boden criteria are fulfilled, a rank of fair indicates that one criterion was unfulfilled or it was not possible to assess a criterion given the published information, a rank of poor indicates that two or more criteria were unfulfilled or it was not possible to assess two or more criteria given the published information.

Table Appendix Table D-2. Local therapies for unresectable colorectal cancer metastases to the liver—Summary of multivariable analyses in single-arm studies

| Author - Year | Independent Variable | Model | Age (<64, ≥64) | Gender | ECOG Status (0, ≥1) | Primary Site (Colon, Rectum) | Number of Radioembolization Treatments (1, 2) | Extent of liver metastases (0-25%, 26-50%, 51-75%) | Hepatic lobar involvement (unilobar, bilobar) | Prior liver resection (No, Yes) | Prior ablation (No, Yes) | Extrahepatic disease (No, Yes) | Number of lines of chemotherapy (<2, ≥2) | Radiation dose (<2, ≥2) | Chemo-SIRT (No, Yes) | Treatment Response (Unfavorable, favorable) | CRC Stage at Liver Metastases Diagnosis (2/3, 4) | Tumor Burden (0%-25%, 26%-50%, 51%-75%) | Tumor replacement (<3cm, ≥3cm) | Liver Metastases Diameter (<3cm, ≥3cm) | ECOG status (0 or 1/≥ 2) | CEA Response (Yes, No) | RECIST Response (PR, SD, PD) |
|-------------------|--|--|----------------|--------|---------------------|------------------------------|---|--|---|---------------------------------|--------------------------|--------------------------------|--|-------------------------|----------------------|---|--|---|--------------------------------|--|--------------------------|------------------------|------------------------------|
| Albert - 2011 | Overall Survival Since Time of First Treatment | Log-rank test (univariate) | - | - | <0.001 | - | - | - | - | - | - | 0.48 | 0.03 | - | - | - | - | - | - | - | - | - | - |
| | | Hazard Ratio (95% CI) (univariate) | - | - | 0.466 (0.15 - 0.61) | - | - | - | - | - | - | 0.80 (0.52-1.17) | - | - | - | - | - | - | - | - | - | - | - |
| Nishiofuku – 2010 | Overall Survival Since Time of First Treatment | Hazard Ratio (95% CI) p value (univariate) | N | S | - | - | - | - | - | N | S | 0-1 vs ≥2* | - | - | - | - | - | - | - | - | 7.9 (3.5 – 11.8) | - | - |
| | | Hazard Ratio (95% CI) p value (multivariate) | - | - | - | - | - | - | - | - | - | 8.3 (3.6 – 19) | - | - | - | - | - | - | - | - | 2.5 (1.3 – 4.6) | - | - |

| Author - Year | Indepen- dent Variable | Model | Age (<64, >64) | Gender | ECOG Status (0, 1) | Primary Site (Colon, Rectum) | Number of Radioembolization Treatments (1, 2) | Extent of liver metastases (0-25%, 26- 50%, 51-75%) | Hepatic lobar involvement (unilobar, bilobar) | Prior liver resection (No, Yes) | Prior ablation (No, Yes) | Extrahepatic disease (No, Yes) | Number of lines of chemotherapy (<2, >2) | Radiation dose (<2, ≥2) | Chemo-SIRT (No, Yes) | Treatment Response (Unfavorable, favorable) | CRC Stage at Liver Metastases Diagnosis (2/3, 4) | Tumor Burden (0%-25%, 26%-50%, 51%-75%) | Tumor replacement (<3cm, ≥3cm) | Liver Metastases Diameter (<3cm, ≥3cm) | ECOG status (0 or 1/≥ 2) | CEA Response (Yes, No) | RECIST Response (PR, SD, PD) |
|-------------------------|---|-------------------------------|-------------------|--------|-----------------------|------------------------------|---|--|--|---------------------------------|--------------------------|--------------------------------|---|----------------------------|----------------------|--|---|--|-----------------------------------|---|--------------------------|------------------------|------------------------------|
| 5 | | | | | | | | | | | | | | | | | | | | | | | |
| Mulcahy - 2009 | Overall Surviv- al Since Time of First Y90 Treatm- ent | Log-rank test (univariate) | - | - | <0.00 01 | - | - | - | 0.09 53 | - | - | 0.0004 | - | - | - | <.00 01 | 0.16 91 | - | <0.00 01 | - | - | - | - |
| Jakobs – 2008 | Overall Surviv- al Since Time of First Treatm- ent | Log-rank test (univariate) | N S | N S | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | p= 0.00 01 | p= 0.00 01 | |
| Sato -2008* | Overall Surviv- al | Log-rank test (univariate) | - | - | <0.00 1 | - | - | - | - | - | - | - | - | - | - | - | - | 0.0 0 1 | - | - | - | - | - |
| Lewandows- ki - 2005 | Overall Surviv- al Since First Treatm- ent | Log-rank test (univariate) | - | - | 0.12 | - | - | - | 0.11 | - | - | - | 0. 2 | - | - | - | - | - | 0.002 | - | -- | - | - |

“-” indicates not reported or not analyzed

“NS” indicates a non-significant p value of ≥ 0.05 , exact p value not reported

- Indicates a p value ≤ 0.05

◇ indicates a non-significant p value of ≥ 0.05

* Sato et al. report data on a population which contains non-CRC patients. In their multivariate analysis some variables (Age, Gender, Primary Diagnosis, Angiographic vascularity, CT vascularity, and more than four lesions) were aggregated with these non-CRC patients and not presented in this table.

‡This study looked ECOG status categories of 0, 1 and 2

ΔThis study looked at previous lines of chemotherapy categories of 0-1, 2 and 3-5

□This study also reported NS for lymphatic metastasis at diagnosis, metachronous vs. synchronous metastasis, history of other metastases at time of treatment, and solitary lesions vs. multiple lesions

Appendix Table D-3. Follow up assessment for KQ 1 and 2

| First Author | Study Design | Group | Followup assessed? | Followup Weeks | Lost to followup |
|-------------------------|----------------------------|--|--------------------|---|------------------|
| Albert - 2011 | Retrospective case series | TACE | No | NR | 5 |
| Aliberti - 2011 | Retrospective case series | TACE w/ DEB | Yes | Median: 166, Range: 28-192 | NR |
| Cianni - 2009 | Retrospective case series | RE | No | Last survival outcome documented at ~610 days | NR |
| Cosimelli - 2010 | Prospective case series | RE | Yes | Median: 44, Range: 8-116 | NR |
| Fiorentini - 2007 | Prospective case series | TACE with DEB | Yes | Median: 28.6, range: 12.9-54.3 | NR |
| Hong - 2008 | Retrospective case series | TACE RE | Yes | Mean: 25.2 Mean: 22.8 | NR |
| Jakobs - 2006 | Retrospective case series | RFA | Yes | Mean: 85.6, SD: 42.4, Range: 24-152 | NR |
| Jakobs - 2008 | Retrospective case series | RE | Yes | Median: 31.6, (5.2-153.2) | 2 |
| Jiao - 2007 | Prospective case series | SIRT | Yes | Pts. followed every 3 months for 2 years (from OS curve) | NR |
| Kim - 2009 | Retrospective case series | SBRT | Yes | Median: 48, Range: 28 - 196 | NR |
| Kucuk | Retrospective Case Series | RE | No | NR | NR |
| Kosmider - 2011 | Retrospective case series | RE with concurrent Systemic Chemotherapy | Yes | Median: 74.4, Range: 12.8-314 *These are from all pts. inc extra-hepatic mets | NR |
| Lewandowski - 2005 | Prospective case series | RE | Yes | All pts. followed through December 12, 2003 | 8 |
| Lim - 2005 | Prospective case series | SIRT | Yes | Median: 18.3 | NR |
| Martin - 2011 | Prospective case series | TACE with DEB | Yes | Median: 72, Range: 48-160 | NR |
| Martin - 2012 | Retrospective Case Series | RE | No | NR | NR |
| Mulcahy - 2009 | Prospective case series | RE | Yes | Median: 26.2 | NR |
| Nace - 2011 | Retrospective case series | RE | Yes | NR | NR |
| Nishiofuku - 2010 | Retrospective case series | HAI | Yes | Median: 21.4, 2-110 | NR |
| Rowe - 2007 | Retrospective case series | SIRT | No | NR | NR |
| Sato - 2008 | Prospective case series | RE | Yes | Mean: 41 (all pts.) | NR |
| Stintzing - 2010 | Prospective case series | Radiosurgery | Yes | Median: 15.6, Mean: 15.3, Range: 8-20.7 | NR |
| Vautravers-Dewas - 2011 | Retrospective case control | SBRT | Yes | Median: 57.2, Range: 12-92 *all pts. | NR |
| Vogl - 2008 | Retrospective case series | HAI | Yes | 108 | 0 |

DEB: drug eluting bead; HAI: hepatic arterial infusion; NR: not reported; OS: overall survival; RE: radioembolization; RFA: radiofrequency ablation; SBRT: stereotactic body radiation therapy; SD: standard deviation; SIRT: selective internal radiation therapy; TACE: transarterial chemoembolization

Tables related to Key Question 3 and 4

Appendix Table D-4. Local therapies for colorectal cancer metastases to the liver, study quality Carey and Boden Case Series quality Assessment

| Reference | Clearly Defined Question | Well-Described Study Population | Well-Described Intervention | Use of Validated Outcome Measures | Appropriate Statistical Analysis | Well-Described Results | Discussion/Conclusions Supported by Data | Rank* |
|-----------------|--------------------------|---------------------------------|-----------------------------|-----------------------------------|----------------------------------|------------------------|--|-------|
| Chua - 2010 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Kosmider - 2011 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Lee – 2012 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Ruers - 2012 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Seki - 2009 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |
| Sguoros - 2011 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Tsutsumi - 2008 | Yes | No | Yes | Yes | Yes | Yes | Yes | Fair |

* A rank of good indicates that all Carey and Boden criteria are fulfilled, a rank of fair indicates that one criterion was unfulfilled or it was not possible to assess a criterion given the published information, a rank of poor indicates that two or more criteria were unfulfilled or it was not possible to assess two or more criteria given the published information.

Appendix Table D-5. Local therapies for unresectable colorectal cancer metastases to the liver—Summary of multivariable analyses in single-arm studies

| Author - Year | Independent Variable | Model | Age (<64, 4 | Gender 4 | ECOG Status (0, 4 | Primary Site (Colon, Rectum) 8 | Number of Radioembolization Treatments (1, 8 | Extent of liver metastases (0-25%, 26- 50%, 51-75%) 5 | Hepatic lobar involvement (unilobar, bilobar) 3 | Prior liver resection (No, Yes) 9 | Prior ablation (No, Yes) 1 | Extrahepatic disease (No, Yes) 3 | Number of lines of chemotherapy (<2, >2) 6 | Radiation dose (<2, 5 | Chemo-SIRT (No, Yes) 7 | Treatment Response (Unfavorable, favorable) 1 | CRC Stage at Liver Metastases Diagnosis (2/3, 4) - | Tumor Burden (0%-25%, 26%- 50%, 51%-75%, - | Tumor replacement (Liver Metastases Diameter (≤3cm, >3cm) - |
|------------------|----------------------|-------------------------------|----------------|-------------|----------------------|-----------------------------------|--|---|---|--------------------------------------|-------------------------------|-------------------------------------|--|--------------------------|---------------------------|---|--|--|---|
| Chua - 2011 | Overall Survival | Log-rank test (univariate) | 0.46 4 | 0.03 4 | 0.14 4 | 0.00 8 | 0.04 8 | 0.00 5 | 0.66 3 | 0.85 9 | 0.32 1 | 0.06 3 | 0.00 6 | 0.96 5 | 0.01 7 | <0.00 1 | - | - | - |
| | Overall Survival | Cox regression (multivariate) | - | 0.27 5 | - | 0.01 9 | 0.25 3 | 0.51 2 | - | - | - | 0.03 3 | 0.13 4 | - | 0.44 9 | <0.00 1 | - | - | - |

CRC: colorectal cancer; ECOG: Eastern cooperative oncology group; SIRT: selective internal radiation therapy

Appendix Table D-6. Follow up assessment for KQ 3 and 4

| First Author | Study Design | Group | Followup assessed? | Followup Weeks | Lost to followup |
|-----------------|----------------------------|--|--------------------|---|------------------|
| Chua - 2010 | Prospective case series | RE with systemic chemotherapy | Yes | Median: 36, range: 4-172 | NR |
| Kosmider - 2011 | Retrospective case series | RE with concurrent Systemic Chemotherapy | Yes | Median: 74.4, Range: 12.8-314 *These are from all pts. inc extra-hepatic mets | NR |
| Lee – 2012 | Retrospective case series | RFA plus systemic chemotherapy | Yes | Median: 92 (4.8 – 248) | NR |
| Ruers - 2012 | RCT | RFA plus systemic treatment | Yes | 211 weeks | 2 |
| Seki - 2009 | Retrospective case control | HAI followed by systemic chemotherapy | Yes | Mean:111.7, Range:37.3-194.6 | NR |
| Sguoros - 2011 | Prospective case series | RFA and chemotherapy | No | NR | NR |

KQ: Key Question; HAI: hepatic arterial infusion; NR: not reported; RCT: randomized controlled trial; RE: radioembolization; RFA: radiofrequency ablation

Appendix Table D-7. Progression free survival outcomes for KQ 1 and 2

| Author, Year | Intervention | Progression Definition | Liver PFS Median (months) (95% CI) | Overall PFS Median (months) (95% CI) |
|-------------------------|---------------|------------------------|------------------------------------|--------------------------------------|
| Albert - 2011 | TACE | Study Treatment | 5 | 3 |
| Martin - 2011 | TACE with DEB | Study Treatment | 15 | 11 |
| Vautravers-Dewas - 2011 | SBRT | NR | NR | NR |
| Nace - 2011 | RE | NR | NR | NR |
| Aliberti - 2011 | TACE w/ DEB | Study Treatment | NR | 23 |
| Cosimelli - 2010 | RE | Study Treatment | NR | 3.7 (2.6 to 4.9) |
| Stintzing - 2010 | SBRT | NR | NR | NR |
| Nishiofuku - 2010 | HAI | Study Treatment | 4.6 (2.8 to 6.3) | 2.8 (2 to 3.6) |
| Kim - 2009 | SBRT | Study Treatment | NR | 10 |
| Cianni - 2009 | RE | Study Treatment | NR | 9.3 |
| Mulcahy - 2009 | RE | NR | NR | NR |
| Martin - 2012 | RE | Study Treatment | 5.1 (2.4 to 5.9) | NR |
| Hong - 2009 | TACE | NR | NR | NR |
| Sato - 2008 | RE | NR | NR | NR |
| Vogl - 2008 | HAI | NR | NR | NR |
| Jakobs - 2008 | RE | NR | NR | NR |
| Rowe - 2007 | SIRT | NR | NR | NR |
| Jiao - 2007 | SIRT | NR | NR | NR |
| Fiorentini - 2007 | TACE with DEB | NR | NR | NR |
| Jakobs - 2006 | RFA | NR | NR | NR |
| Lewandowski - 2005 | RE | NR | NR | NR |
| Lim - 2005 | SIRT | Study Treatment | NR | 5.3 |

CI: confidence interval; DEB: drug eluting bead; KQ: Key Question; HAI: hepatic arterial infusion; NR: not reported; pFS: Progression free survival; RE: radioembolization; RFA: radiofrequency ablation; SBRT: stereotactic body radiation therapy; SIRT: selective internal radiation therapy; TACE: transarterial chemoembolization

Appendix Table D-8. Progression free survival outcomes for KQ 3 and 4

| Author, Year | Intervention | Progression Definition | Liver PFS Median (months) (95% CI) | Overall PFS Median (months) (95% CI) |
|-----------------|---|------------------------|------------------------------------|--------------------------------------|
| Ruers - 2012 | RFA plus systemic treatment | Randomization | NR | 16.8 (11.7 to 22.1) |
| Lee – 2012 | RFA plus systemic chemotherapy | NR | NR | NR |
| Kosmider - 2011 | RE with concurrent Systemic Chemotherapy | Study Treatment | NR | 10.4 |
| Sguoros - 2011 | RFA and chemotherapy | Study enrollment | NR | 13 (3.1 to 22.9) |
| Chua - 2010 | RE with systemic chemotherapy | NR | NR | NR |
| Seki - 2009 | HAI followed by systemic chemotherapy | NR | NR | 5.1 |
| Tsutsumi - 2008 | HAI with concurrent systemic chemotherapy | NR | NR | 9.2 (7.9 to 10.5) |

CI: confidence interval; PFS: progression free survival; RFA: radiofrequency ablation; RE: adioembolization; HAI: hepatic arterial infusion; NR: not reported

Appendix Table D-9. Recently completed (without results posted) or ongoing clinical trials

| Trial Name | NCT Number | Status | Sponsor |
|--|-------------------|---------------|---|
| <u>Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer</u> | NCT00869271 | Completed | Fudan University |
| <u>Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver</u> | NCT00023868 | Completed | American College of Radiology Imaging Network |
| <u>Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer</u> | NCT00200200 | Ongoing | Memorial Sloan-Kettering Cancer Center |
| <u>Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer</u> | NCT00868569 | Recruiting | Fudan University |
| <u>FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer</u> | NCT00724503 | Recruiting | Sirtex Medical |
| <u>A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver</u> | NCT01098422 | Recruiting | University of California, San Diego |
| <u>Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors</u> | NCT01177007 | Recruiting | Sidney Kimmel Comprehensive Cancer Center |
| <u>Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer</u> | NCT01483027 | Recruiting | Nordion (Canada) Inc. |
| <u>TheraSphere for the Treatment of Liver Metastases</u> | NCT00511862 | Completed | Nordion (Canada) Inc. |
| <u>Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases</u> | NCT01290536 | Completed | Nicholas Fidelman |

Appendix D-10: Previous lines of chemotherapy KQ 1 and KQ 2

| Author | Median lines of previous therapy | Range Lines of Previous Chemotherapy |
|--|----------------------------------|--------------------------------------|
| Albert, et al. 2011 ² 121 (100) Poor | 0-1 | 0 to 5 |
| Aliberti, et al. 2011 ¹⁵ 82 (100) Fair | NR | 2+ |
| Cianni, et al. 2009 ^{11 b} 41 (100) Poor | NR | 3+ |
| Cosimelli, et al. 2010 ¹⁶ 50 (100) Fair | 4+ | 3 to 5 |
| Fiorentini, et al. 2007 ¹⁴ 20 (100) Poor | 2 | 2 |
| Hong, et al. 2009 ¹² 21 (100) Fair | NR | 1+ |
| Jakobs, et al. 2006 ¹⁷ 68 (100) Fair | NR | NR |
| Jakobs, et al. 2008 ¹⁸ 41 (100) Poor | Mean: 2.8 | 1 to 5 |
| Jiao, et al. 2007 ¹⁹ 21 (47.6) Poor | NR | 2+ |
| Kim, et al. 2009 ^{20 a} 9 (100) Fair | NR | NR |
| Kucuk, et al. 2011 ²¹ 78 (44.9) Poor | NR | 1+ |
| Lewandowski, et al. 2005 ²² 27 (100) Poor | NR | NR |
| Lim, et al. 2005 ¹³ 30 (100) Poor | 1 | 1 + |
| Martin 2011 ⁹ 55 (100) Good | 2 | 1 to 3 |
| Martin, et al. 2012 ^{23d} 24 (100) Poor | 3 | 0-7 |
| Mulcahy, et al. 2009 ²⁴ 72 (100) Fair | 2 | 0-3 |
| Nace, et al. 2011 ²⁵ 51 (100) Fair | 2 | 1 to 4 |
| Nishiofuku, et al. 2010 ²⁶ 55 (100) Fair | 2 | 2+ |
| Rowe, et al. 2007 ²⁷ 24 (29.2) Fair | NR | 1+ |
| Sato, et al. 2008 ²⁸ 137 (37.2) Fair | NR | 1+ |
| Stintzing, et al. 2010 ⁵ 6 (100) | 1 | 1 to 2 |

| Author | Median lines of previous therapy | Range Lines of Previous Chemotherapy |
|---|----------------------------------|--------------------------------------|
| Poor | | |
| Vautravers-Dewas, et al. 2011 ⁶ 42 (66.7) Fair | NR | 0 + |
| Vogl, et al. 2008 ^{29 c} 55 (21.8) Poor | NR | 1+ |

NR: not reported

Appendix E. Abbreviations and Acronyms

| | |
|--------|--|
| 3D | three-dimensional |
| AE | adverse events |
| AHRQ | Agency for Healthcare Research and Quality |
| CEA | carcinoembryonic antigen |
| CER | comparative effectiveness review |
| CRC | colorectal cancer |
| CRT | conformal radiotherapy |
| DEB | drug-eluting beads |
| DEBIRI | drug-eluting bead, irinotecan |
| ECOG | Eastern Cooperative Oncology Group |
| EORTC | European Organization for Research and Treatment of Cancer |
| EPC | Evidence-based Practice Center |
| FU | fluorouracil |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| Gy | Gray |
| HAI | hepatic artery infusion |
| HAM-D | Hamilton rating scale for depression |
| IMRT | intensity-modulated radiation therapy |
| KQ(s) | Key Question(s) |
| LDH | lactic dehydrogenase |
| LDT | liver-directed therapy(ies) |
| MAA | ^{99m} Tc-macro-aggregated albumin scan |
| MWA | microwave ablation |
| N | number; no |
| NA | not available |
| No | number |
| PICOTS | Population, Intervention, Comparator, Outcomes, Timing, Setting |
| PFS | progression free survival |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| QOL | quality of life |
| RCT | randomized, controlled trial |
| RE | radioembolization |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RFA | radiofrequency ablation |
| SBRT | stereotactic body radiation |
| SIRT | selective internal radiotherapy |
| TACE | transcatheter arterial chemoembolization |
| TAE | transarterial embolization |
| TEP | Technical Expert Panel |
| TTR | Time to recurrence |

Appendix F. Excluded Studies

Level 1, Form Title Screening, Does the article report primary data? -> Exclude (No)

S. Y. Ong. Neoadjuvant chemotherapy in the management of colorectal metastases: A review of the literature. *Ann Acad Med Singapore* 2003 32(2): 205-11.

T. P. Pwint, R. Midgley and D. J. Kerr. Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. *Semin Oncol* 2010 37(2): 149-59.

J. L. Van Laethem. Adjuvant treatment for colorectal cancer. *Acta Gastroenterol Belg* 2001 64(3): 263-7.

J. B. Ammori and N. E. Kemeny. Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. *Semin Oncol* 2010 37(2): 139-48.

M. J. Eadens and A. Grothey. Curable metastatic colorectal cancer. *Curr Oncol Rep* 2011 13(3): 168-76.

L. Crocetti and R. Lencioni. Radiofrequency ablation of pulmonary tumors. *Eur J Radiol* 2010 75(1): 23-7.

G. Gravante, J. Overton, R. Sorge, N. Bhardwaj, M. S. Metcalfe, D. M. Lloyd and A. R. Dennison. Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies. *J Gastrointest Surg* 2011 15(2): 378-87.

J. N. Primrose. Surgery for colorectal liver metastases. *Br J Cancer* 2010 102(9): 1313-8.

U. P. Neumann, D. Seehofer and P. Neuhaus. The surgical treatment of hepatic metastases in colorectal carcinoma. *Dtsch Arztebl Int* 2010 107(19): 335-42.

H. R. Alexander, Jr. and C. C. Butler. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. *Cancer J* 2010 16(2): 132-41.

J. M. Hubbard and S. R. Alberts. Treatment of liver-limited metastatic colorectal cancer. *Cancer J* 2010 16(3): 235-40.

T. R. Halfdanarson, M. L. Kendrick and A. Grothey. The role of chemotherapy in managing patients with resectable liver metastases. *Cancer J* 2010 16(2): 125-31.

D. J. Gallagher and N. Kemeny. Metastatic colorectal cancer: from improved survival to potential cure. *Oncology* 2010 78(3-4): 237-48.

S. C. Mayo and T. M. Pawlik. Thermal ablative therapies for secondary hepatic malignancies. *Cancer J* 2010 16(2): 111-7.

N. Kemeny. The management of resectable and unresectable liver metastases from colorectal cancer. *Curr Opin Oncol* 2010 22(4): 364-73.

D. G. Power and N. E. Kemeny. Role of adjuvant therapy after resection of colorectal cancer liver metastases. *J Clin Oncol* 2010 28(13): 2300-9.

M. N. Kulaylat and J. F. Gibbs. Thermoablation of colorectal liver metastasis. *J Surg Oncol* 2010 101(8): 699-705.

S. Robinson, D. M. Manas, I. Pedley, D. Mann and S. A. White. Systemic chemotherapy and its implications for resection of colorectal liver metastasis. *Surg Oncol* 2011 20(2): 57-72.

M. N. Kulaylat and J. F. Gibbs. Regional treatment of colorectal liver metastasis. *J Surg Oncol* 2010 101(8): 693-8.

M. E. Barugel, C. Vargas and G. Krygier Waltier. Metastatic colorectal cancer: recent advances in its clinical management. *Expert Rev Anticancer Ther* 2009 9(12): 1829-47.

L. Crocetti, T. de Baere and R. Lencioni. Quality improvement guidelines for radiofrequency ablation of liver tumours. *Cardiovasc Intervent Radiol* 2010 33(1): 11-7.

N. H. Nicolay, D. P. Berry and R. A. Sharma. Liver metastases from colorectal cancer: radioembolization with systemic therapy. *Nat Rev Clin Oncol* 2009 6(12): 687-97.

S. L. Wong, P. B. Mangu, M. A. Choti, T. S. Crocenzi, G. D. Dodd, 3rd, G. S. Dorfman, C. Eng, Y. Fong, A. F. Giusti, D. Lu, T. A. Marsland, R. Michelson, G. J. Poston, D. Schrag, J. Seidenfeld and A. B. Benson, 3rd. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. *J Clin Oncol* 2010 28(3): 493-508.

O. Dawood, A. Mahadevan and K. A. Goodman. Stereotactic body radiation therapy for liver metastases. *Eur J Cancer* 2009 45(17): 2947-59.

D. G. Power and N. E. Kemeny. Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection? *Ann Surg* 2009 250(4): 654-5; author reply 655.

M. W. Saif. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. *World J Gastroenterol* 2009 15(31): 3855-64.

H. Shimada, K. Tanaka, I. Endou and Y. Ichikawa. Treatment for colorectal liver metastases: a review. *Langenbecks Arch Surg* 2009 394(6): 973-83.

S. Benoist and B. Nordlinger. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. *Ann Surg Oncol* 2009 16(9): 2385-90.

N. Bhardwaj, A. D. Strickland, F. Ahmad, A. R. Dennison and D. M. Lloyd. Liver ablation techniques: a review. *Surg Endosc* 2010 24(2): 254-65.

C. Van De Wiele, L. Defreyne, M. Peeters and B. Lambert. Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. *Q J Nucl Med Mol Imaging* 2009 53(3): 317-24.

S. K. Reddy, A. S. Barbas and B. M. Clary. Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management?. *Ann Surg Oncol* 2009 16(9): 2395-410.

R. N. Berri and E. K. Abdalla. Curable metastatic colorectal cancer: recommended paradigms. *Curr Oncol Rep* 2009 11(3): 200-8.

D. Vriens, L. F. de Geus-Oei, W. T. van der Graaf and W. J. Oyen. Tailoring therapy in colorectal cancer by PET-CT. *Q J Nucl Med Mol Imaging* 2009 53(2): 224-44.

E. C. Bellavance and H. R. Alexander, Jr.. TNF-based isolated hepatic perfusion. *Front Biosci* 2009 14(): 1771-84.

C. Boutros, P. Somasundar, S. Garrean, A. Saied and N. J. Espat. Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis. *Surg Oncol* 2010 19(1): e22-32.

Y. S. Chun, A. Laurent, D. Maru and J. N. Vauthey. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. *Lancet Oncol* 2009 10(3): 278-86.

B. Nordlinger, E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, P. Rougier, A. Sobrero and M. Ychou. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. *Ann Oncol* 2009 20(6): 985-92.

M. Van den Eynde and A. Hendlisz. Treatment of colorectal liver metastases: a review. *Rev Recent Clin Trials* 2009 4(1): 56-62.

S. R. Alberts. Updated options for liver-limited metastatic colorectal cancer. *Clin Colorectal Cancer* 2008 7 Suppl 2(): S58-62.

R. Lencioni, L. Crocetti, M. C. Pina and D. Cioni. Percutaneous image-guided radiofrequency ablation of liver tumors. *Abdom Imaging* 2009 34(5): 547-56.

S. Sharma, C. Camci and N. Jabbour. Management of hepatic metastasis from colorectal cancers: an update. *J Hepatobiliary Pancreat Surg* 2008 15(6): 570-80.

J. M. Gasent Blesa and L. A. Dawson. Options for radiotherapy in the treatment of liver metastases. *Clin Transl Oncol* 2008 10(10): 638-45.

A. Gillams. Tumour ablation: current role in the liver, kidney, lung and bone. *Cancer Imaging* 2008 8 Spec No A(): S1-5.

G. Garcea, S. L. Ong and G. J. Maddern. Inoperable colorectal liver metastases: a declining entity?. *Eur J Cancer* 2008 44(17): 2555-72.

A. Jones and H. R. Alexander, Jr.. Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies. *Surg Oncol Clin N Am* 2008 17(4): 857-76, x.

E. Hoti and R. Adam. Liver transplantation for primary and metastatic liver cancers. *Transpl Int* 2008 21(12): 1107-17.

G. J. Poston, J. Figueras, F. Giuliente, G. Nuzzo, A. F. Sobrero, J. F. Gigot, B. Nordlinger, R. Adam, T. Gruenberger, M. A. Choti, A. J. Bilchik, E. J. Van Cutsem, J. M. Chiang and M. I. D'Angelica. Urgent need for a new staging system in advanced colorectal cancer. *J Clin Oncol* 2008 26(29): 4828-33.

D. G. Power, B. R. Healey-Bird and N. E. Kemeny. Regional chemotherapy for liver-limited metastatic colorectal cancer. *Clin Colorectal Cancer* 2008 7(4): 247-59.

R. B. Jagad, M. Koshariya, J. Kawamoto, P. Papastratis, H. Kefalourous, V. Patris, C. Tzouma and N. J. Lygidakis. Management of rectal cancer: strategies and controversies. *Hepatogastroenterology* 2008 55(81): 82-92.

C. Pozzo, C. Barone and N. E. Kemeny. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. *Cancer Treat Rev* 2008 34(4): 293-301.

E. Topkan, H. C. Onal and M. N. Yavuz. Managing liver metastases with conformal radiation therapy. *J Support Oncol* 2008 6(1): 9-13, 15.

K. P. de Jong. Review article: Multimodality treatment of liver metastases increases suitability for surgical treatment. *Aliment Pharmacol Ther* 2007 26 Suppl 2(): 161-9.

N. Andromanos, D. Filippou, V. Papadopoulos, G. Kouraklis, E. Christianakis and A. Kostakis. New concepts in the therapeutic options of liver metastases from colorectal cancer. *J BUON* 2007 12(4): 445-52.

J. Evans. Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM). *Eur J Surg Oncol* 2007 33 Suppl 2(): S64-75.

T. C. Schirmang and D. E. Dupuy. Image-guided thermal ablation of nonresectable hepatic tumors using the Cool-Tip radiofrequency ablation system. *Expert Rev Med Devices* 2007 4(6): 803-14.

A. Ganeshan, S. Upponi, L. Q. Hon, D. Warakaulle and R. Uberoi. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. *Ann Oncol* 2008 19(5): 847-51.

R. Small, N. Lubezky and M. Ben-Haim. Current controversies in the surgical management of colorectal cancer metastases to the liver. *Isr Med Assoc J* 2007 9(10): 742-7.

D. A. Wicherts, R. J. de Haas and R. Adam. Bringing unresectable liver disease to resection with curative intent. *Eur J Surg Oncol* 2007 33 Suppl 2(): S42-51.

S. Benoist and B. Nordlinger. Neoadjuvant treatment before resection of liver metastases. *Eur J Surg Oncol* 2007 33 Suppl 2(): S35-41.

R. Lencioni and L. Crocetti. Radiofrequency ablation of liver cancer. *Tech Vasc Interv Radiol* 2007 10(1): 38-46.

E. Lim, B. N. Thomson, S. Heinze, M. Chao, D. Gunawardana and P. Gibbs. Optimizing the approach to patients with potentially resectable liver metastases from colorectal cancer. *ANZ J Surg* 2007 77(11): 941-7.

R. R. White and W. R. Jarnagin. The role of aggressive regional therapy for colorectal liver metastases. *Cancer Invest* 2007 25(6): 458-63.

N. Kemeny. Presurgical chemotherapy in patients being considered for liver resection. *Oncologist* 2007 12(7): 825-39.

T. M. Pawlik and M. A. Choti. Surgical therapy for colorectal metastases to the liver. *J Gastrointest Surg* 2007 11(8): 1057-77.

E. Leen and P. G. Horgan. Radiofrequency ablation of colorectal liver metastases. *Surg Oncol* 2007 16(1): 47-51.

A. J. Bremers and T. J. Ruers. Prudent application of radiofrequency ablation in resectable colorectal liver metastasis. *Eur J Surg Oncol* 2007 33(6): 752-6.

N. Moosmann and V. Heinemann. Cetuximab in the treatment of metastatic colorectal cancer. *Expert Opin Biol Ther* 2007 7(2): 243-56.

Y. Abdulaal, P. Ross and N. Heaton. Intra arterial hepatic chemotherapy for unresectable colorectal metastases: (review). *Gulf J Oncolog* 2007 1(1): 77-92.

K. K. Tanabe. New techniques of liver surgery. *Semin Oncol* 2006 33(6 Suppl 11): S39-41.

M. Golling and W. Bechstein. Surgical resection of colorectal liver metastases--the current standard therapy (review). *Rozhl Chir* 2006 85(8): 381-9.

G. Schumacher, R. Eisele, A. Spinelli and P. Neuhaus. The surgical approach for radiofrequency ablation of liver tumors. *Recent Results Cancer Res* 2006 167(): 53-68.

A. McKay, E. Dixon and M. Taylor. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. *Br J Surg* 2006 93(10): 1192-201.

B. N. Fahy and W. R. Jarnagin. Evolving techniques in the treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, microwave coagulation, hepatic arterial chemotherapy, indications and contraindications for resection, role of transplantation, and timing of chemotherapy. *Surg Clin North Am* 2006 86(4): 1005-22.

M. Lise, P. Pilati, P. Da Pian, S. Mocellin, D. Nitti and S. Corazzino. Treatment options for liver metastases from colorectal cancer. *J Exp Clin Cancer Res* 2003 22(4 Suppl): 149-56.

J. Tol and C. J. Punt. Treatment of liver metastases from colorectal cancer. *Neth J Med* 2006 64(5): 133-5.

Y. J. Chua and D. Cunningham. Neoadjuvant treatment of unresectable liver metastases from colorectal cancer. *Clin Colorectal Cancer* 2006 5(6): 405-12.

T. B. Gibson. Radiofrequency ablation for patients with colorectal cancer and unresectable liver metastasis. *Clin Colorectal Cancer* 2006 5(5): 318-20.

E. C. Feliberti and L. D. Wagman. Radiofrequency ablation of liver metastases from colorectal carcinoma. *Cancer Control* 2006 13(1): 48-51.

J. Homsí and C. R. Garrett. Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. *Cancer Control* 2006 13(1): 42-7.

J. N. Vauthey, D. Zorzi and T. M. Pawlik. Making unresectable hepatic colorectal metastases resectable--does it work?. *Semin Oncol* 2005 32(6 Suppl 9): S118-22.

S. A. Curley. Outcomes after surgical treatment of colorectal cancer liver metastases. *Semin Oncol* 2005 32(6 Suppl 9): S109-11.

J. N. Vauthey and E. K. Abdalla. Unresectable hepatic colorectal metastases: need for new surgical strategies. *Ann Surg Oncol* 2006 13(1): 5-6.

E. Vibert, L. Canedo and R. Adam. Strategies to treat primary unresectable colorectal liver metastases. *Semin Oncol* 2005 32(6 Suppl 8): 33-9.

H. Shimada, K. Tanaka, K. Matsuo and S. Togo. Treatment for multiple bilobar liver metastases of colorectal cancer. *Langenbecks Arch Surg* 2006 391(2): 130-42.

T. J. Ruers, K. P. de Jong and J. N. Ijzermans. Radiofrequency for the treatment of liver tumours. *Dig Surg* 2005 22(4): 245-53.

P. Wang, Z. Chen, W. X. Huang and L. M. Liu. Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: a literature review of randomized control trials. *World J Gastroenterol* 2005 11(25): 3817-22.

M. Lise, S. Mocellin, P. Pilati and D. Nitti. Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches. *Front Biosci* 2005 10(): 3042-57.

A. R. Gillams. The use of radiofrequency in cancer. *Br J Cancer* 2005 92(10): 1825-9.

G. D. Leonard, B. Brenner and N. E. Kemeny. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. *J Clin Oncol* 2005 23(9): 2038-48.

D. T. Ruan and R. S. Warren. Liver-directed therapies in colorectal cancer. *Semin Oncol* 2005 32(1): 85-94.

D. J. Bentrem, R. P. Dematteo and L. H. Blumgart. Surgical therapy for metastatic disease to the liver. *Annu Rev Med* 2005 56: 139-56.

A. Grover and H. R. Alexander, Jr.. The past decade of experience with isolated hepatic perfusion. *Oncologist* 2004 9(6): 653-64.

C. J. Punt. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. *Ann Oncol* 2004 15(10): 1453-9.

F. D. Barber, G. Mavligit and R. Kurzrock. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. *Cancer Treat Rev* 2004 30(5): 425-36.

J. Whisenant and A. Venook. Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer. *Oncology (Williston Park)* 2004 18(6): 762-8; discussion 769-73.

H. W. van Laarhoven and C. J. Punt. Systemic treatment of advanced colorectal carcinoma. *Eur J Gastroenterol Hepatol* 2004 16(3): 283-9.

F. Berr. Photodynamic therapy for cholangiocarcinoma. *Semin Liver Dis* 2004 24(2): 177-87.

L. A. Dawson and T. S. Lawrence. The role of radiotherapy in the treatment of liver metastases. *Cancer J* 2004 10(2): 139-44.

D. M. Elaraj and H. R. Alexander. Current role of hepatic artery infusion and isolated liver perfusion for the treatment of colorectal cancer liver metastases. *Cancer J* 2004 10(2): 128-38.

R. Adam, V. Lucidi and H. Bismuth. Hepatic colorectal metastases: methods of improving resectability. *Surg Clin North Am* 2004 84(2): 659-71.

D. Elias, T. de Baere, L. Sideris and M. Ducreux. Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. *Surg Clin North Am* 2004 84(2): 607-25.

G. Folprecht and C. H. Kohne. The role of new agents in the treatment of colorectal cancer. *Oncology* 2004 66(1): 1-17.

L. M. Pasetto, E. Rossi, M. K. Paris, S. Lonardi and S. Monfardini. Common management of primary rectal carcinoma in patients with stage IV disease at the diagnosis. *Anticancer Res* 2003 23(6D): 4999-5004.

D. A. Subar, A. J. Sheen and D. J. Sherlock. Cryoablation for liver tumors - is there clinical utility?. *MedGenMed* 2003 5(4): 19.

H. Rhim, G. D. Dodd, 3rd, K. N. Chintapalli, B. J. Wood, D. E. Dupuy, J. L. Hvizda, P. E. Sewell and S. N. Goldberg. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. *Radiographics* 2004 24(1): 41-52.

L. M. Pasetto, E. Rossi and S. Monfardini. Liver metastases of colorectal cancer: medical treatments. *Anticancer Res* 2003 23(5b): 4245-56.

A. D. Cohen and N. E. Kemeny. An update on hepatic arterial infusion chemotherapy for colorectal cancer. *Oncologist* 2003 8(6): 553-66.

V. Donckier, J. L. Van Laethem, B. Ickx, D. Van Gansbeke, S. Goldman and M. Gelin. Local ablative treatments for liver metastases: the current situation. *Acta Chir Belg* 2003 103(5): 452-7.

L. A. Dawson, C. J. McGinn and T. S. Lawrence. Conformal chemoradiation for primary and metastatic liver malignancies. *Semin Surg Oncol* 2003 21(4): 249-55.

M. Eriguchi, F. Levi, T. Hisa, H. Yanagie, Y. Nonaka and Y. Takeda. Chronotherapy for cancer. *Biomed Pharmacother* 2003 57(Suppl 1): 92s-95s.

G. Fusai and B. R. Davidson. Strategies to increase the resectability of liver metastases from colorectal cancer. *Dig Surg* 2003 20(6): 481-96.

M. Nikfarjam and C. Christophi. Interstitial laser thermotherapy for liver tumours. *Br J Surg* 2003 90(9): 1033-47.

B. Nordlinger, F. Peschard and R. Malafosse. Resection of liver metastases from colorectal cancer—how can we improve results?. *Colorectal Dis* 2003 5(5): 515-7.

Z. Krastev, V. Koltchakov, B. Tomov and J. W. Koten. Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2. *Hepatogastroenterology* 2003 50(52): 1006-16.

T. Hehr, P. Wust, M. Bamberg and W. Budach. Current and potential role of thermoradiotherapy for solid tumours. *Onkologie* 2003 26(3): 295-302.

H. J. Wilke and E. Van Cutsem. Current treatments and future perspectives in colorectal and gastric cancer. *Ann Oncol* 2003 14 Suppl 2(): ii49-55.

R. Adam. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. *Ann Oncol* 2003 14(Suppl 2): ii13-6.

G. Fusai and B. R. Davidson. Management of colorectal liver metastases. *Colorectal Dis* 2003 5(1): 2-23.

M. O. Meyers, A. R. Sasson and E. R. Sigurdson. Locoregional strategies for colorectal hepatic metastases. *Clin Colorectal Cancer* 2003 3(1): 34-44.

T. N. Lau, R. H. Lo and B. S. Tan. Colorectal hepatic metastases: Role of radiofrequency ablation. *Ann Acad Med Singapore* 2003 32(2): 212-8.

C. L. Scaife and S. A. Curley. Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. *Surg Oncol Clin N Am* 2003 12(1): 243-55.

R. Adam, E. Huguet, D. Azoulay, D. Castaing, F. Kunstlinger, F. Levi and H. Bismuth. Hepatic resection after down-staging of unresectable hepatic colorectal metastases. *Surg Oncol Clin N Am* 2003 12(1): 211-20, xii.

A. J. Bilchik. Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update. *Surg Oncol Clin N Am* 2003 12(1): 193-210.

D. P. Braccia and N. Heffernan. Surgical and ablative modalities for the treatment of colorectal cancer metastatic to the liver. *Clin J Oncol Nurs* 2003 7(2): 178-84.

L. X. Liu, W. H. Zhang and H. C. Jiang. Current treatment for liver metastases from colorectal cancer. *World J Gastroenterol* 2003 9(2): 193-200.

H. Muller and R. Hilger. Curative and palliative aspects of regional chemotherapy in combination with surgery. *Support Care Cancer* 2003 11(1): 1-10.

C. Topham and R. Adam. Oncosurgery: a new reality in metastatic colorectal carcinoma. *Semin Oncol* 2002 29(5 Suppl 15): 3-10.

R. J. Canter and N. N. Williams. Surgical treatment of colon and rectal cancer. *Hematol Oncol Clin North Am* 2002 16(4): 907-26.

J. J. Skitzki and A. E. Chang. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. *Surg Oncol* 2002 11(3): 123-35.

M. Kemeny. Hepatic artery infusion of chemotherapy as a treatment for hepatic metastases from colorectal cancer. *Cancer J* 2002 8 Suppl 1(): S82-8.

H. R. Alexander, Jr.. Surgical approaches to liver metastases. *Cancer J* 2002 8 Suppl 1(): S68-81.

E. S. Casper. Gastrointestinal stromal tumors. *Curr Treat Options Oncol* 2000 1(3): 267-73.

L. X. Liu, H. C. Jiang and D. X. Piao. Radiofrequency ablation of liver cancers. *World J Gastroenterol* 2002 8(3): 393-9.

H. Bleiberg and A. Hendlisz. Advanced colorectal cancer treatment in Europe: what have we achieved?. *Anticancer Drugs* 2002 13(5): 461-71.

Y. Ku, M. Tominaga, T. Iwasaki, T. Fukumoto and Y. Kuroda. Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors. *Int J Clin Oncol* 2002 7(2): 82-90.

N. M. Carroll and H. R. Alexander, Jr.. Isolation perfusion of the liver. *Cancer J* 2002 8(2): 181-93.

T. Ruers and R. P. Bleichrodt. Treatment of liver metastases, an update on the possibilities and results. *Eur J Cancer* 2002 38(7): 1023-33.

S. Giacchetti. Chronotherapy of colorectal cancer. *Chronobiol Int* 2002 19(1): 207-19.

D. M. Weinreich and H. R. Alexander. Transarterial perfusion of liver metastases. *Semin Oncol* 2002 29(2): 136-44.

G. B. Makin, D. J. Breen and J. R. Monson. The impact of new technology on surgery for colorectal cancer. *World J Gastroenterol* 2001 7(5): 612-21.

G. Biasco and E. Gallerani. Treatment of liver metastases from colorectal cancer: what is the best approach today?. *Dig Liver Dis* 2001 33(5): 438-44.

R. Malafosse, C. Penna, A. Sa Cunha and B. Nordlinger. Surgical management of hepatic metastases from colorectal malignancies. *Ann Oncol* 2001 12(7): 887-94.

P. Moroz, S. K. Jones and B. N. Gray. Status of hyperthermia in the treatment of advanced liver cancer. *J Surg Oncol* 2001 77(4): 259-69.

N. Neeleman, T. Wobbes, G. J. Jager and T. J. Ruers. Cryosurgery as treatment modality for colorectal liver metastases. *Hepatogastroenterology* 2001 48(38): 325-9.

G. Fiorentini, D. B. Poddie, M. Cantore, P. Giovanis, S. Guadagni, U. De Giorgi, A. Cariello, C. Dazzi and D. Turci. Locoregional therapy for liver metastases from colorectal cancer: the possibilities of intraarterial chemotherapy, and new hepatic-directed modalities. *Hepatogastroenterology* 2001 48(38): 305-12.

C. Proye. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. *World J Surg* 2001 25(6): 685-8.

A. Brouquet, A. Andreou and J. N. Vauthey. The management of solitary colorectal liver metastases. *Surgeon* 2011 9(5): 265-72.

J. M. Davies and R. M. Goldberg. Treatment of metastatic colorectal cancer. *Semin Oncol* 2011 38(4): 552-60.

K. Tanaka, Y. Ichikawa and I. Endo. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. *Int J Clin Oncol* 2011 (); .

S. Pathak, R. Jones, J. M. Tang, C. Parmar, S. Fenwick, H. Malik and G. Poston. Ablative therapies for colorectal liver metastases: a systematic review. *Colorectal Dis* 2011 13(9): e252-65.

T. de Baere and F. Deschamps. Arterial therapies of colorectal cancer metastases to the liver. *Abdom Imaging* 2011 36(6): 661-70.

Curing patients with liver metastases from colorectal cancer. *Drug Ther Bull* 2011 49(4): 42-5; quiz i-ii.

A. Kobayashi and S. Miyagawa. Advances in therapeutics for liver metastasis from colorectal cancer. *World J Gastrointest Oncol* 2010 2(10): 380-9.

D. G. Power and N. E. Kemeny. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. *Crit Rev Oncol Hematol* 2011 79(3): 251-64.

S. Carter and R. C. Martin Ii. Drug-eluting bead therapy in primary and metastatic disease of the liver. *HPB (Oxford)* 2009 11(7): 541-50.

O. Dudeck and J. Ricke. Advances in regional chemotherapy of the liver. *Expert Opinion on Drug Delivery* 2011 8(8): 1057-1069.

A. E. Merrick, E. J. Ilett and A. A. Melcher. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. *Current Opinion in Investigational Drugs* 2009 10(12): 1372-1382.

J. F. H. Geschwind. The future of catheter guided cancer therapy. *CardioVascular and Interventional Radiology* 2009 32(): 262-264.

E. K. Abdalla. Surgical management of colorectal liver metastases. *Community Oncology* 2009 6(8): 349-357.

M. D'Angelica, Y. Fong, R. P. DeMatteo and W. R. Jarnagin. Hepatic arterial infusion chemotherapy for metastases from colorectal cancer: Is it really the end of an era?. *Journal of Clinical Oncology* 2008 26(16): 2788-2789.

S. Mocellin and D. Nitti. In reply. *Journal of Clinical Oncology* 2008 26(16): 2789-2790.

M. A. Choti. New paradigm in the treatment of hepatic colorectal metastases: A surgeon's perspective. *Community Oncology* 2008 5(6 SUPPL. 6): 9-14.

C. A. Arciero and E. R. Sigurdson. Diagnosis and Treatment of Metastatic Disease to the Liver. *Seminars in Oncology* 2008 35(2): 147-159.

G. Kennedy and H. Nelson. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases - Invited critique. *Archives of Surgery* 2008 143(4): 358.

C. H. Kohne. Neoadjuvant chemotherapy in a patient with metastatic colorectal cancer. *Community Oncology* 2007 4(5 SUPPL.): 8-11.

D. L. Bartlett, J. Berlin, G. Y. Lauwers, W. A. Messersmith, N. J. Petrelli and A. P. Venook. Chemotherapy and regional therapy of hepatic colorectal metastases: Expert consensus statement. *Annals of Surgical Oncology* 2006 13(10): 1284-1292.

K. K. Tanabe. Emerging therapies for metastatic carcinoma to the liver. *Community Oncology* 2006 3(9): 567-573.

D. J. Kerr. Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?: Commentary. *Nature Clinical Practice Oncology* 2006 3(9): 480-481.

S. Garrean and N. Joseph Espot. Yttrium-90 internal radiation therapy for hepatic malignancy. *Surgical Oncology* 2005 14(4): 179-193.

F. Meriggi. Surgical therapy of colorectal metastases— State of the art. *Romanian Journal of Gastroenterology* 2004 13(3): 233-235.

D. T. Ruan and R. S. Warren. Palliative techniques for hepatic cancer. *Surgical Oncology Clinics of North America* 2004 13(3): 505-516.

R. Adam. Current surgical strategies for the treatment of colorectal cancer liver metastases. *European Journal of Cancer, Supplement* 2004 2(7): 21-26.

Y. Ku, M. Tominaga, T. Iwasaki, T. Fukumoto, N. Kusunoki, S. Ogata and Y. Kuroda. Regional treatment for unresectable malignant hepatic tumors: An overview of isolated hepatic perfusion. *Chirurgische Gastroenterologie Interdisziplinär* 2003 19(4): 370-376.

L. Frich, T. Mala, B. Edwin, I. Gladhaug, O. Mathisen and A. Bergan. Malignant liver tumors. A review of current surgical treatment options. Experience from a Norwegian hepatobiliary center. *Gastroenterologia Polska* 2003 10(4): 349-356.

S. Alberts and G. Poston. OncoSurge: A strategy for long-term survival in metastatic colorectal cancer. *Colorectal Disease* 2003 5(SUPPL. 3): 20-28.

A. P. Venook. Induction therapy in patients with metastatic colorectal cancer. *Seminars in Oncology* 2003 30(4 SUPPL. 12): 25-29.

N. E. Kemeny and M. Galsky. Hepatic artery infusion for liver metastases. *Seminars in Colon and Rectal Surgery* 2002 13(4): 293-304.

J. F. Gigot and P. Goffette. Commentary. *HPB* 2002 4(1): [d]27-28.

D. L. Bartlett. Systemic chemotherapy of liver tumors. *Seminars in Surgical Oncology* 2000 19(2): 116-124.

Alexander H.R., Jr., D. L. Bartlett and S. K. Libutti. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. *Oncologist* 2000 5(5): 416-424.

M. Lorenz, S. Heinrich, E. Staib-Sebler, C. Gog, G. Vetter, H. Petrowsky and H. H. Muller. Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. *Swiss Surgery* 2000 6(1): 11-22.

Level 1, Form Title Screening, Are the participants in the article h... -> Exclude (No)

P. Ortega-Deballon, O. Facy, D. Consolo, G. Magnin, H. Tixier, M. Simonet, P. Rat and B. Chauffert. Hypoxic single-pass isolated hepatic perfusion of hypotonic Cisplatin: safety study in the pig. *Ann Surg Oncol* 2010 17(3): 898-906.

S. R. Cai, J. R. Garbow, R. Culverhouse, R. D. Church, W. Zhang, W. D. Shannon and H. L. McLeod. A mouse model for developing treatment for secondary liver tumors. *Int J Oncol* 2005 27(1): 113-20.

Level 1, Form Title Screening, Is unresectable colorectal cancer the... -> Exclude (No)

D. Goere, S. Gaujoux, F. Deschamp, F. Dumont, A. Souadka, C. Dromain, M. Ducreux and D. Elias. Patients operated on for initially unresectable colorectal liver metastases with missing metastases experience a favorable long-term outcome. *Ann Surg* 2011 254(1): 114-8.

S. Sogabe, Y. Komatsu, S. Yuki, T. Kusumi, K. Hatanaka, M. Nakamura, T. Kato, T. Miyagishima, A. Hosokawa, I. Iwanaga, Y. Sakata and M. Asaka. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. *Jpn J Clin Oncol* 2011 41(4): 490-7.

T. Karasaki, K. Sano, T. Takamoto, H. Kinoshita, R. Tateishi, T. Takemura and M. Makuuchi. Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports. *Hepatogastroenterology* 2010 57(104): 1526-8.

K. Tanaka, K. Nojiri, T. Kumamoto, K. Takeda and I. Endo. R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy. *Eur J Surg Oncol* 2011 37(4): 336-43.

L. Vasic. Osteolysis of hand bones due to metastatic deposits from colon cancer--a case report. *Med Pregl* 2010 63(9-10): 719-22.

H. C. Kim, J. W. Chung, S. An, N. J. Seong, K. R. Son, H. J. Jae and J. H. Park. Transarterial chemoembolization of a colic branch of the superior mesenteric artery in patients with unresectable hepatocellular carcinoma. *J Vasc Interv Radiol* 2011 22(1): 47-54.

C. R. Azevedo, L. Cezana, E. S. Moraes, M. D. Begnami, T. F. Paiva Junior, A. L. Dettino and M. F. Fanelli. Synchronous thyroid and colon metastases from epidermoid carcinoma of the lung: case report. *Sao Paulo Med J* 2010 128(6): 371-4.

F. Deschamps, P. Rao, C. Teriitehau, A. Hakime, D. Malka, V. Boige, M. Ducreux, D. Elias, D. Goere and T. de Baere. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. *J Vasc Interv Radiol* 2010 21(11): 1681-8.

C. Garufi, A. Torsello, S. Tumolo, G. M. Ettorre, M. Zeuli, C. Campanella, G. Vennarecci, M. Mottotese, I. Sperduti and F. Cognetti. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. *Br J Cancer* 2010 103(10): 1542-7.

Y. Sakamoto, S. Fujita, T. Akasu, S. Nara, M. Esaki, K. Shimada, S. Yamamoto, Y. Moriya and T. Kosuge. Is surgical resection justified for stage IV colorectal cancer patients having bilobar hepatic metastases?--an analysis of survival of 77 patients undergoing hepatectomy. *J Surg Oncol* 2010 102(7): 784-8.

T. C. Chua, L. Bester, J. Akther and D. L. Morris. Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases. *Anticancer Res* 2010 30(7): 3005-7.

W. H. Li, J. J. Peng, J. Q. Xiang, W. Chen, S. J. Cai and W. Zhang. Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. *World J Gastroenterol* 2010 16(26): 3318-24.

M. Bower, T. Metzger, K. Robbins, D. Tomalty, V. Valek, J. Boudny, T. Andrasina, C. Tatum and R. C. Martin. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. *HPB (Oxford)* 2010 12(1): 31-6.

S. Pini, C. Pinto, B. Angelelli, E. Giampalma, A. Blotta, F. Di Fabio, D. Santini, R. Golfieri and A. A. Martoni. Multimodal sequential approach in colorectal cancer liver metastases: hepatic resection after yttrium-90 selective internal radiation therapy and cetuximab rescue treatment. *Tumori* 2010 96(1): 157-9.

T. Beppu, N. Hayashi, T. Masuda, H. Komori, K. Horino, H. Hayashi, H. Okabe, Y. Baba, K. Kinoshita, C. Akira, M. Watanebe, H. Takamori and H. Baba. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. *Anticancer Res* 2010 30(3): 1015-20.

S. M. Tochetto, P. Rezai, M. Rezvani, P. Nikolaidis, S. Berggruen, B. Atassi, R. Salem and V. Yaghamai. Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET? *Radiology* 2010 255(1): 164-72.

H. Komori, T. Beppu, Y. Baba, K. Horino, C. Imsung, T. Masuda, H. Hayashi, H. Okabe, R. Ootao, M. Watanabe, H. Takamori, K. Iyama and H. Baba. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. *Int J Clin Oncol* 2010 15(3): 263-70.

D. Goere, I. Deshaies, T. de Baere, V. Boige, D. Malka, F. Dumont, C. Dromain, M. Ducreux and D. Elias. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. *Ann Surg* 2010 251(4): 686-91.

C. Cellini, S. R. Hunt, J. W. Fleshman, E. H. Birnbaum, A. J. Bierhals and M. G. Mutch. Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?. *World J Surg* 2010 34(5): 1102-8.

Y. Watayo, H. Kuramochi, K. Hayashi, G. Nakajima, H. Kamikozuru and M. Yamamoto. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. *Jpn J Clin Oncol* 2010 40(4): 360-4.

- Y. S. Chun, J. N. Vauthey, P. Boonsirikamchai, D. M. Maru, S. Kopetz, M. Palavecino, S. A. Curley, E. K. Abdalla, H. Kaur, C. Charnsangavej and E. M. Loyer. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. *JAMA* 2009 302(21): 2338-44.
- G. Folprecht, T. Gruenberger, W. O. Bechstein, H. R. Raab, F. Lordick, J. T. Hartmann, H. Lang, A. Frilling, J. Stoeckmacher, J. Weitz, R. Konopke, C. Stroszczynski, T. Liersch, D. Ockert, T. Herrmann, E. Goekkurt, F. Parisi and C. H. Kohne. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. *Lancet Oncol* 2010 11(1): 38-47.
- M. Karoui, A. Soprani, A. Charachon, C. Delbaldo, L. Vigano, A. Luciani and D. Cherqui. Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer. *Eur J Surg Oncol* 2010 36(1): 58-64.
- K. Muneoka, Y. Shirai, M. Sasaki, T. Wakai, J. Sakata and K. Hatakeyama. Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX). *Int J Clin Oncol* 2009 14(5): 457-9.
- Y. Takakura, S. Ikeda, M. Yoshimitsu, T. Hinoi, D. Sumitani, H. Takeda, Y. Kawaguchi, M. Shimomura, M. Tokunaga, M. Okajima and H. Ohdan. Retroperitoneal abscess complicated with necrotizing fasciitis of the thigh in a patient with sigmoid colon cancer. *World J Surg Oncol* 2009 7: 74.
- T. Shinjo, Y. Kondo, K. Harada, J. Yamazaki and M. Okada. Treatment of malignant enterovesical fistula with octreotide. *J Palliat Med* 2009 12(10): 965-7.
- R. Whitney, C. Tatum, M. Hahl, S. Ellis, C. R. Scoggins, K. McMasters and R. C. Martin. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. *J Surg Res* 2011 166(2): 236-40.
- A. Chiappa, E. Bertani, M. Makuuchi, A. P. Zbar, G. Contino, G. Viale, G. Pruneri, M. Bellomi, P. Della Vigna, M. G. Zampino, N. Fazio, M. L. Travaini, G. Trifiro, C. Corbellini and B. Andreoni. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. *Hepatogastroenterology* 2009 56(91-92): 829-34.
- Y. Fujimoto, T. Akasu, S. Yamamoto, S. Fujita and Y. Moriya. Long-term results of hepatectomy after hepatic arterial infusion chemotherapy for initially unresectable hepatic colorectal metastases. *J Gastrointest Surg* 2009 13(9): 1643-50.
- B. Mailey, C. Truong, A. Artinyan, J. Khalili, N. Sanchez-Luege, J. Denitz, H. Marx, L. D. Wagman and J. Kim. Surgical resection of primary and metastatic hepatic malignancies following portal vein embolization. *J Surg Oncol* 2009 100(3): 184-90.
- K. Okoshi, S. Nagayama, M. Furu, Y. Mori, A. Yoshizawa, J. Toguchida and Y. Sakai. A case report of pathologically complete response of a huge rectal cancer after systemic chemotherapy with mFOLFOX6. *Jpn J Clin Oncol* 2009 39(8): 528-33.
- A. Zonta, T. Pinelli, U. Prati, L. Roveda, C. Ferrari, A. M. Clerici, C. Zonta, G. Mazzini, P. Dionigi, S. Altieri, S. Bortolussi, P. Bruschi and F. Fossati. Extra-corporeal liver BNCT for the treatment of diffuse metastases: what was learned and what is still to be learned. *Appl Radiat Isot* 2009 67(7-8 Suppl): S67-75.
- E. Skof, M. Rebersek, Z. Hlebanja and J. Ocvirk. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. *BMC Cancer* 2009 9: 120.
- J. Cardoso, S. Nievas, M. Pereira, A. Schwint, V. Trivillin, E. Pozzi, E. Heber, A. Monti Hughes, P. Sanchez, E. Bumaschny, M. Itoiz and S. Liberman. Boron biodistribution study in colorectal liver metastases patients in Argentina. *Appl Radiat Isot* 2009 67(7-8 Suppl): S76-9.

- A. Brouquet, S. Benoist, C. Julie, C. Penna, A. Beauchet, P. Rougier and B. Nordlinger. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. *Surgery* 2009 145(4): 362-71.
- G. Masi, F. Loupakis, L. Pollina, E. Vasile, S. Cupini, S. Ricci, I. M. Brunetti, R. Ferraldeschi, G. Naso, F. Filippini, A. Pietrabissa, O. Goletti, G. Baldi, L. Fornaro, M. Andreuccetti and A. Falcone. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. *Ann Surg* 2009 249(3): 420-5.
- C. W. Hsu, T. M. King, C. H. Lin, H. T. Wang, W. C. Ou and J. H. Wang. Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis. *Int J Colorectal Dis* 2009 24(4): 377-83.
- S. Komatsu, T. Sonoyama, T. Ochiai, D. Ichikawa, H. Ikoma, H. Okamura and E. Otsuji. Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy. *Int J Clin Oncol* 2008 13(6): 567-70.
- D. A. Wicherts, R. Miller, R. J. de Haas, G. Bitsakou, E. Vibert, L. A. Veilhan, D. Azoulay, H. Bismuth, D. Castaing and R. Adam. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. *Ann Surg* 2008 248(6): 994-1005.
- V. Pamecha, B. Nedjat-Shokouhi, K. Gurusamy, G. K. Glantzounis, D. Sharma and B. R. Davidson. Prospective evaluation of two-stage hepatectomy combined with selective portal vein embolisation and systemic chemotherapy for patients with unresectable bilobar colorectal liver metastases. *Dig Surg* 2008 25(5): 387-93.
- J. W. Huh, Y. A. Park, E. J. Jung, K. Y. Lee, J. E. Kwon and S. K. Sohn. Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay. *J Korean Med Sci* 2008 23(5): 916-9.
- T. Bara, S. Bancu, I. Gyorgy-Fazahas, M. Muresan, T. Bara, Jr., D. Podeanu and S. Muresan. Two-step hepatectomy with right portal branch ligation for a right lobe metastasis. *Hepatogastroenterology* 2008 55(85): 1370-2.
- M. R. Weihrauch, D. Stippel, J. W. Fries, D. Arnold, H. Bovenschulte, O. Coutelle and U. Hacker. Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment. *Onkologie* 2008 31(8-9): 464-7.
- J. Trojan, N. Lubomierski, T. Lehnert, K. Engels, S. Zeuzem and W. O. Bechstein. Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. *Z Gastroenterol* 2008 46(8): 776-9.
- T. Bara, S. Bancu, I. Gyorgy-Fazakas, M. Muresan, T. Bara, Jr., D. Podeanu and S. Muresan. Two-step hepatectomy with right portal branch ligation for a right lobe metastasis. *Hepatogastroenterology* 2008 55(84): 1071-2.
- M. C. Etienne-Grimaldi, J. L. Formento, M. Francoual, E. Francois, P. Formento, N. Renee, P. Laurent-Puig, M. Chazal, D. Benchimol, J. R. Delperro, C. Letoublon, D. Pezet, J. F. Seitz and G. Milano. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. *Clin Cancer Res* 2008 14(15): 4830-5.
- I. Iwanicki-Caron, F. Di Fiore, I. Roque, E. Astruc, M. Stetiu, A. Duclos, D. Tougeron, S. Saillard, S. Thureau, J. Benichou, B. Paillot, J. P. Basuyau and P. Michel. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. *J Clin Oncol* 2008 26(22): 3681-6.

A. Bajwa, N. Blunt, S. Vyas, I. Suliman, J. Bridgewater, D. Hochhauser, J. A. Ledermann and A. O'Bichere. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. *Eur J Surg Oncol* 2009 35(2): 164-7.

M. Ducreux, J. L. Raoul, P. Marti, Y. Merrouche, J. M. Tigaud, C. Rebischung and V. Boige. High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?. *Oncology* 2008 74(1-2): 17-24.

D. W. Wong, S. C. Lupton, L. Bhatt, L. Gross, P. Tanriere, D. R. Peake, D. Spooner and J. I. Geh. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience. *Clin Oncol (R Coll Radiol)* 2008 20(7): 517-22.

L. Mueller, C. Hillert, L. Moller, G. Krupski-Berdien, X. Rogiers and D. C. Broering. Major hepatectomy for colorectal metastases: is preoperative portal occlusion an oncological risk factor?. *Ann Surg Oncol* 2008 15(7): 1908-17.

G. Galizia, E. Lieto, M. Orditura, P. Castellano, V. Imperatore, M. Pinto and A. Zamboli. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. *Arch Surg* 2008 143(4): 352-8; discussion 358.

U. Coskun, S. Buyukberber, E. Yaman, A. Uner, O. Er, M. Ozkan, M. Dikilitas, M. Oguz, R. Yildiz, D. Y. B, A. O. Kaya and M. Benekli. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. *Neoplasma* 2008 55(1): 65-70.

K. E. Tsimogiannis, G. K. Pappas-Gogos, K. Nikas, S. Stefanaki-Nikou, K. Gossios and E. C. Tsimoyiannis. Two-stage surgical treatment of unresectable obstructive rectal cancer with synchronous hepatic metastases. *Am Surg* 2007 73(12): 1218-23.

B. S. Min, N. K. Kim, J. B. Ahn, J. K. Roh, K. S. Kim, J. S. Choi, S. H. Cha and H. Kim. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. *Onkologie* 2007 30(12): 637-43.

P. Kornprat, W. R. Jarnagin, R. P. DeMatteo, Y. Fong, L. H. Blumgart and M. D'Angelica. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. *Arch Surg* 2007 142(11): 1087-92.

T. Iguchi, Y. Arai, Y. Inaba, H. Yamaura, Y. Sato, M. Miyazaki and H. Shimamoto. Hepatic arterial infusion chemotherapy through a port-catheter system as preoperative initial therapy in patients with advanced liver dysfunction due to synchronous and unresectable liver metastases from colorectal cancer. *Cardiovasc Intervent Radiol* 2008 31(1): 86-90.

R. Adam, T. Aloia, F. Levi, D. A. Wicherts, R. J. de Haas, B. Paule, M. P. Bralet, M. Bouchahda, D. Machover, M. Ducreux, V. Castagne, D. Azoulay and D. Castaing. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. *J Clin Oncol* 2007 25(29): 4593-602.

E. F. Leitch, M. Chakrabarti, J. E. Crozier, R. F. McKee, J. H. Anderson, P. G. Horgan and D. C. McMillan. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. *Br J Cancer* 2007 97(9): 1266-70.

H. Z. Malik, S. Farid, A. Al-Mukthar, A. Anthoney, G. J. Toogood, J. P. Lodge and K. R. Prasad. A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study. *Ann Surg Oncol* 2007 14(12): 3519-26.

C. Barone, G. Nuzzo, A. Cassano, M. Basso, G. Schinzari, F. Giuliani, E. D'Argento, N. Trigila, A. Astone and C. Pozzo. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. *Br J Cancer* 2007 97(8): 1035-9.

M. Karoui, A. Charachon, C. Delbaldo, J. Loriau, A. Laurent, I. Sobhani, J. Tran Van Nhieu, J. C. Delchier, P. L. Fagniez, P. Piedbois and D. Cherqui. Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration. *Arch Surg* 2007 142(7): 619-23; discussion 623.

W. Y. Lau and E. C. Lai. Hepatic resection for colorectal liver metastases. *Singapore Med J* 2007 48(7): 635-9.

S. Olmi, A. Scaini, G. Cesana, M. Dinelli, A. Lomazzi and E. Croce. Acute colonic obstruction: endoscopic stenting and laparoscopic resection. *Surg Endosc* 2007 21(11): 2100-4.

A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crino, G. Benedetti, W. Evangelista, L. Fanchini, E. Cortesi, V. Picone, S. Vitello, S. Chiara, C. Granetto, G. Porcile, L. Fioretto, C. Orlandini, M. Andreuccetti and G. Masi. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. *J Clin Oncol* 2007 25(13): 1670-6.

G. Nuzzo, F. Giuliani, F. Ardito, M. Vellone, C. Pozzo, A. Cassano, I. Giovannini and C. Barone. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. *J Gastrointest Surg* 2007 11(3): 318-24.

E. Berber and A. E. Siperstein. Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. *Surg Endosc* 2007 21(4): 613-8.

S. Takahashi, Y. Kuroki, K. Nasu, S. Nawano, M. Konishi, T. Nakagohri, N. Gotohda, N. Saito and T. Kinoshita. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. *Anticancer Res* 2006 26(6C): 4705-11.

N. Baize, B. Gerard, H. Bleiberg, F. Caroli-Bosc, F. Berthier, H. Legendre, J. C. Pector and A. Hendlitz. Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. *Gastroenterol Clin Biol* 2006 30(12): 1349-53.

M. Minagawa, J. Yamamoto, S. Miwa, Y. Sakamoto, N. Kokudo, T. Kosuge, S. Miyagawa and M. Makuuchi. Selection criteria for simultaneous resection in patients with synchronous liver metastasis. *Arch Surg* 2006 141(10): 1006-12; discussion 1013.

M. A. Maluccio, A. M. Covey, J. Schubert, L. A. Brody, C. T. Sofocleous, G. I. Getrajdman, R. DeMatteo and K. T. Brown. Treatment of metastatic sarcoma to the liver with bland embolization. *Cancer* 2006 107(7): 1617-23.

L. Capussotti, A. Muratore, M. M. Mulas, P. Massucco and M. Aglietta. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. *Br J Surg* 2006 93(8): 1001-6.

N. Selzner, B. C. Pestalozzi, Z. Kadry, M. Selzner, S. Wildermuth and P. A. Clavien. Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. *Br J Surg* 2006 93(5): 587-92.

E. Goshen, T. Davidson, S. T. Zwas and D. Aderka. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. *Technol Cancer Res Treat* 2006 5(1): 37-43.

D. Elias, D. Manganas, E. Benizri, F. Dufour, P. Menegon, T. El Harroudi and T. de Baere. Trans-metastasis hepatectomy: results of a 21-case study. *Eur J Surg Oncol* 2006 32(2): 213-7.

- G. Masi, S. Cupini, L. Marcucci, E. Cerri, F. Loupakis, G. Allegrini, I. M. Brunetti, E. Pfanner, M. Viti, O. Goletti, F. Filippini and A. Falcone. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. *Ann Surg Oncol* 2006 13(1): 58-65.
- K. Muneoka, Y. Shirai, N. Yokoyama, T. Wakai and K. Hatakeyama. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. *Int J Clin Oncol* 2005 10(6): 441-3.
- J. Aparicio, C. Fernandez-Martos, J. M. Vincent, I. Maestu, C. Llorca, I. Busquier, J. M. Campos, D. Perez-Enguix and M. Balcells. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. *Clin Colorectal Cancer* 2005 5(4): 263-7.
- D. Elias, D. Manganas, E. Benizri, F. Dufour, P. Menegon, T. El Harroudi and T. de Baere. The trans-metastasis hepatectomy (through metastases previously ablated with radiofrequency): results of a 13-case study of colorectal cancer. *J Surg Oncol* 2006 93(1): 8-12.
- L. R. Jiao, G. Navarra, J. C. Weber, R. Havlik, J. P. Nicholls and N. A. Habib. Radiofrequency assisted liver resection—a novel technique. *Hepatogastroenterology* 2005 52(66): 1685-7.
- M. W. Saif, S. Sellers and S. Russo. Gemcitabine-related radiation recall in a patient with pancreatic cancer. *Anticancer Drugs* 2006 17(1): 107-11.
- G. P. Stathopoulos, S. K. Rigatos, J. G. Stathopoulos, J. P. Xynotroulas and E. Dimou. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluorouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluorouracil and leucovorin. *Am J Clin Oncol* 2005 28(6): 565-9.
- W. M. Ho, B. Ma, T. Mok, W. Yeo, P. Lai, R. Lim, J. Koh, Y. Y. Wong, A. King, C. K. Leow and A. T. Chan. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. *Med Oncol* 2005 22(3): 303-12.
- S. Togo, Y. Nagano, H. Masui, K. Tanaka, Y. Miura, D. Morioka, I. Endo, H. Sekido, H. Ike and H. Shimada. Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer. *Hepatogastroenterology* 2005 52(63): 913-9.
- D. Elias, O. Baton, L. Sideris, V. Boige, D. Malka, G. Libérale, M. Pocard and P. Lasser. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. *J Surg Oncol* 2005 90(1): 36-42.
- T. Delaunoit, S. R. Alberts, D. J. Sargent, E. Green, R. M. Goldberg, J. Krook, C. Fuchs, R. K. Ramanathan, S. K. Williamson, R. F. Morton and B. P. Findlay. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. *Ann Oncol* 2005 16(3): 425-9.
- Z. L. Ji, S. Y. Peng, A. J. Yuan, P. J. Li, W. Zhang and Y. Yu. Hepatic resection for metastasis from colorectal cancer. *Tech Coloproctol* 2004 8 Suppl 1(): s47-9.
- S. R. Grobmyer, Y. Fong, M. D'Angelica, R. P. Dematteo, L. H. Blumgart and W. R. Jarnagin. Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases. *Arch Surg* 2004 139(12): 1326-30.
- M. C. Etienne, J. L. Formento, M. Chazal, M. Francoual, N. Magne, P. Formento, A. Bourgeon, J. F. Seitz, J. R. Delpero, C. Letoublon, D. Pezet and G. Milano. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. *Pharmacogenetics* 2004 14(12): 785-92.

D. Jaeck, E. Oussoultzoglou, E. Rosso, M. Greget, J. C. Weber and P. Bachellier. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. *Ann Surg* 2004 240(6): 1037-49; discussion 1049-51.

G. Masi, G. Allegrini, S. Cupini, L. Marcucci, E. Cerri, I. Brunetti, E. Fontana, S. Ricci, M. Andreuccetti and A. Falcone. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. *Ann Oncol* 2004 15(12): 1766-72.

D. Elias, R. Santoro, J. F. Ouellet, L. Osmak, T. de Baere and A. Roche. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. *Hepatogastroenterology* 2004 51(60): 1788-91.

A. S. Serralta, F. R. Sanjuan, A. H. Moya, F. C. Orbis, R. Lopez-Andujar, E. I. Pareja, J. C. Vila, M. Rayon, M. B. Juan and J. P. Mir. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. *Eur J Gastroenterol Hepatol* 2004 16(11): 1237-9.

R. Adam, V. Delvart, G. Pascal, A. Vaeleanu, D. Castaing, D. Azoulay, S. Giacchetti, B. Paule, F. Kunstlinger, O. Ghemard, F. Levi and H. Bismuth. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. *Ann Surg* 2004 240(4): 644-57; discussion 657-8.

G. Garcea, N. Polemonivi, E. O'Leary, T. D. Lloyd, A. R. Dennison and D. P. Berry. Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases. *Eur J Surg Oncol* 2004 30(7): 759-64.

C. Pozzo, M. Basso, A. Cassano, M. Quirino, G. Schinzari, N. Trigila, M. Vellone, F. Giuliani, G. Nuzzo and C. Barone. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. *Ann Oncol* 2004 15(6): 933-9.

A. Julianov, A. Karashmalakov, I. Rachkov and H. Hristov. Treatment of colorectal cancer with synchronous bilobar liver metastases with simultaneous bowel and liver resection plus radiofrequency ablation. *Hepatogastroenterology* 2004 51(57): 643-5.

H. S. Ho and H. S. Ong. A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex). *Surg Endosc* 2004 18(2): 347.

S. Evrard, Y. Becouarn, M. Fonck, R. Brunet, S. Mathoulin-Pelissier and V. Picot. Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination. *Eur J Surg Oncol* 2004 30(4): 399-406.

D. H. Palmer, V. Mautner, D. Mirza, S. Oliff, W. Gerritsen, J. R. van der Sijp, S. Hubscher, G. Reynolds, S. Bonney, R. Rajaratnam, D. Hull, M. Horne, J. Ellis, A. Mountain, S. Hill, P. A. Harris, P. F. Searle, L. S. Young, N. D. James and D. J. Kerr. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. *J Clin Oncol* 2004 22(9): 1546-52.

D. Elias, O. Youssef, L. Sideris, C. Dromain, O. Baton, V. Boige and M. Ducreux. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. *J Surg Oncol* 2004 86(1): 4-9.

P. Rutkowski, P. Nyckowski, U. Grzesiakowska, Z. I. Nowecki, A. Nasierowska-Guttmejer, A. Pienkowski, K. Dudek, M. Krawczyk and W. Ruka. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). *Neoplasma* 2003 50(6): 438-42.

- T. M. Pawlik, F. Izzo, D. S. Cohen, J. S. Morris and S. A. Curley. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. *Ann Surg Oncol* 2003 10(9): 1059-69.
- S. Takahashi, K. Inoue, M. Konishi, T. Nakagouri and T. Kinoshita. Prognostic factors for poor survival after repeat hepatectomy in patients with colorectal liver metastases. *Surgery* 2003 133(6): 627-34.
- T. Livraghi, L. Solbiati, F. Meloni, T. Ierace, S. N. Goldberg and G. S. Gazelle. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". *Cancer* 2003 97(12): 3027-35.
- A. W. Hemming, A. I. Reed, R. J. Howard, S. Fujita, S. N. Hochwald, J. G. Caridi, I. F. Hawkins and J. N. Vauthey. Preoperative portal vein embolization for extended hepatectomy. *Ann Surg* 2003 237(5): 686-91; discussion 691-3.
- C. Louvet, F. Carrat, F. Mal, M. Mabro, K. Beerblock, J. C. Vaillant, J. Cady, T. Andre, E. Gamelin and A. de Gramont. Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). *Cancer Invest* 2003 21(1): 14-20.
- D. Jaeck, P. Bachellier, H. Nakano, E. Oussoultzoglou, J. C. Weber, P. Wolf and M. Greget. One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. *Am J Surg* 2003 185(3): 221-9.
- A. Roche, B. V. Girish, T. de Baere, E. Baudin, V. Boige, D. Elias, P. Lasser, M. Schlumberger and M. Ducreux. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. *Eur Radiol* 2003 13(1): 136-40.
- M. Rivoire, F. De Cian, P. Meeus, S. Negrier, H. Sebban and P. Kaemmerlen. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. *Cancer* 2002 95(11): 2283-92.
- H. Yoshida, M. Onda, T. Tajiri, K. Akimaru, H. Takasaki, Y. Mamada, N. Taniai, Y. Nakamura, Y. Kawano and T. Takahashi. Successful surgical treatment of peritoneal dissemination of hepatocellular carcinoma. *Hepatogastroenterology* 2002 49(48): 1663-5.
- M. Kornmann and K. H. Link. Conversion of locally inoperable primary rectal cancer with multiple liver metastases to an option for cure after local downstaging and hepatic arterial infusion chemotherapy. *Langenbecks Arch Surg* 2002 387(2): 90-3.
- P. A. Clavien, N. Selzner, M. Morse, M. Selzner and E. Paulson. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. *Surgery* 2002 131(4): 433-42.
- D. Burke, M. M. Davies, J. Zweit, M. A. Flower, R. J. Ott, M. J. Dworkin, C. Glover, V. R. McCready, P. Carnochan and T. G. Allen-Mersh. Continuous angiotensin II infusion increases tumour: normal blood flow ratio in colo-rectal liver metastases. *Br J Cancer* 2001 85(11): 1640-5.
- K. Tanaka, H. Shimada, S. Togo, M. Ota, S. Yamagichi and H. Ike. Is hepatic resection for multiple liver metastases from colorectal carcinoma acceptable treatment?. *Hepatogastroenterology* 2001 48(39): 803-7.
- T. Utsunomiya, Y. Emi, K. Ikejiri, M. Suzuki, H. Saitsu, S. Yakabe, M. Nonaka, M. Saku, K. Yoshida, M. Shimada and K. Sugimachi. Retrospective study on the effects of lipiodolization before a potentially curative hepatectomy for colorectal liver metastases: long-term results of a pilot study. *Hepatogastroenterology* 2001 48(39): 790-3.
- N. Mizuno, S. Naruse, M. Kitagawa, H. Ishiguro, O. Ito, S. B. Ko, T. Yoshikawa, C. Tanahashi, M. Ito and T. Hayakawa. Insulinoma with subsequent association of Zollinger-Ellison syndrome. *Intern Med* 2001 40(5): 386-90.

R. Adam, E. Avisar, A. Ariche, S. Giachetti, D. Azoulay, D. Castaing, F. Kunstlinger, F. Levi and F. Bismuth. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. *Ann Surg Oncol* 2001 8(4): 347-53.

C. Cha, F. T. Lee, Jr., L. F. Rikkers, J. E. Niederhuber, B. T. Nguyen and D. M. Mahvi. Rationale for the combination of cryoablation with surgical resection of hepatic tumors. *J Gastrointest Surg* 2001 5(2): 206-13.

A. Shankar, P. Leonard, A. J. Renaut, J. Lederman, W. R. Lees, A. R. Gillams, E. Harrison and I. Taylor. Neo-adjuvant therapy improves resectability rates for colorectal liver metastases. *Ann R Coll Surg Engl* 2001 83(2): 85-8.

C. Rosty, M. Chazal, M. C. Etienne, C. Letoublon, A. Bourgeon, J. R. Delperio, D. Pezet, P. Beaune, P. Laurent-Puig and G. Milano. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. *Int J Cancer* 2001 95(3): 162-7.

R. Adam, A. Laurent, D. Azoulay, D. Castaing and H. Bismuth. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. *Ann Surg* 2000 232(6): 777-85.

P. Hellman, M. Andersson, J. Rastad, C. Juhlin, S. Karacagil, B. Eriksson, B. Skogseid and G. Akerstrom. Surgical strategy for large or malignant endocrine pancreatic tumors. *World J Surg* 2000 24(11): 1353-60.

F. Meric, Y. Z. Patt, S. A. Curley, J. Chase, M. S. Roh, J. N. Vauthey and L. M. Ellis. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. *Ann Surg Oncol* 2000 7(7): 490-5.

M. F. Gardiner, W. B. Long, Z. J. Haskal and G. R. Lichtenstein. Upper gastrointestinal hemorrhage secondary to erosion of a biliary Wallstent in a woman with pancreatic cancer. *Endoscopy* 2000 32(8): 661-3.

D. Azoulay, D. Castaing, A. Smail, R. Adam, V. Cailliez, A. Laurent, A. Lemoine and H. Bismuth. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. *Ann Surg* 2000 231(4): 480-6.

H. Isoniemi and P. Osterlund. Surgery combined with oncological treatments in liver metastases from colorectal cancer. *Scand J Surg* 2011 100(1): 35-41.

J. M. Davies and R. M. Goldberg. Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases. *J Surg Oncol* 2010 102(8): 946-54.

A. Brouquet and B. Nordlinger. Neoadjuvant therapy of colorectal liver metastases: lessons learned from clinical trials. *J Surg Oncol* 2010 102(8): 932-6.

N. Snoeren, E. E. Voest, A. M. Bergman, O. Dalesio, H. M. Verheul, R. A. Tollenaar, J. R. van der Sijp, S. B. Schouten, I. H. Rinkes and R. van Hillegersberg. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. *BMC Cancer* 2010 10(): 545.

B. Nordlinger, J. N. Vauthey, G. Poston, S. Benoist, P. Rougier and E. Van Cutsem. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. *Clin Colorectal Cancer* 2010 9(4): 212-8.

P. J. Kneuert, S. K. Maithel, C. A. Staley and D. A. Kooby. Chemotherapy-associated liver injury: impact on surgical management of colorectal cancer liver metastases. *Ann Surg Oncol* 2011 18(1): 181-90.

M. A. Alcala, Jr., K. Park, J. Yoo, D. H. Lee, B. H. Park, B. C. Lee, D. L. Bartlett and Y. J. Lee. Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors. *J Cell Biochem* 2010 110(5): 1073-81.

G. Nasti, A. Ottaiano, M. Berretta, P. Delrio, F. Izzo, A. Cassata, C. Romano, G. Facchini, D. Scala, A. Mastro, G. Romano, F. Perri and R. V. Iaffaioli. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. *Cancer Chemother Pharmacol* 2010 66(2): 209-18.

J. M. Cleary, K. T. Tanabe, G. Y. Lauwers and A. X. Zhu. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. *Oncologist* 2009 14(11): 1095-105.

I. Popescu, S. Alexandrescu, A. Croitoru and M. Boros. Strategies to convert to resectability the initially unresectable colorectal liver metastases. *Hepatogastroenterology* 2009 56(91-92): 739-44.

N. E. Kemeny, F. D. Melendez, M. Capanu, P. B. Paty, Y. Fong, L. H. Schwartz, W. R. Jarnagin, D. Patel and M. D'Angelica. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. *J Clin Oncol* 2009 27(21): 3465-71.

A. Al-Asfoor, Z. Fedorowicz and M. Lodge. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. *Cochrane Database Syst Rev* 2008 (2): CD006039.

B. Nordlinger, E. Van Cutsem, P. Rougier, C. H. Kohne, M. Ychou, A. Sobrero, R. Adam, D. Arvidsson, A. Carrato, V. Georgoulas, F. Giulante, B. Glimelius, M. Golling, T. Gruenberger, J. Tabernero, H. Wasan and G. Poston. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. *Eur J Cancer* 2007 43(14): 2037-45.

R. Adam, R. Miller, M. Pitombo, D. A. Wicherts, R. J. de Haas, G. Bitsakou and T. Aloia. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. *Surg Oncol Clin N Am* 2007 16(3): 525-36, viii.

G. J. Poston, R. Adam, S. Alberts, S. Curley, J. Figueras, D. Haller, F. Kunstlinger, G. Mentha, B. Nordlinger, Y. Patt, J. Primrose, M. Roh, P. Rougier, T. Ruers, H. J. Schmoll, C. Valls, N. J. Vauthey, M. Cornelis and J. P. Kahan. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. *J Clin Oncol* 2005 23(28): 7125-34.

C. Belluco, E. Mammano, E. Petricoin, L. Prevedello, V. Calvert, L. Liotta, D. Nitti and M. Lise. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. *Clin Chim Acta* 2005 357(2): 180-3.

G. Folprecht, A. Grothey, S. Alberts, H. R. Raab and C. H. Kohne. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. *Ann Oncol* 2005 16(8): 1311-9.

S. Sadahiro, T. Suzuki, K. Ishikawa, T. Nakamura, Y. Tanaka, K. Ishizu, S. Yasuda, H. Makuuchi and C. Murayama. Estimation of the time of pulmonary metastasis in colorectal cancer patients with isolated synchronous liver metastasis. *Jpn J Clin Oncol* 2005 35(1): 18-22.

D. K. Rajan, M. C. Soulen, T. W. Clark, R. A. Baum, Z. J. Haskal, R. D. Shlansky-Goldberg and D. B. Freiman. Sarcomas metastatic to the liver: Response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. *J Vasc Interv Radiol* 2001 12(2): 187-93.

M. Karoui, F. Roudot-Thoraval, F. Mesli, E. Mitry, T. Aparicio, G. Desguetz, C. Louvet, B. Landi, E. Tiret and I. Sobhani. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: Results of a multicentric study. *Dis Colon Rectum* 2011 54(8): 930-8.

I. Maroulis, D. D. Karavias and D. Karavias. General principles of hepatectomy in colorectal liver metastases. *Tech Coloproctol* 2011 15(Suppl 1): 1-4.

- R. Wong, D. Cunningham, Y. Barbachano, C. Saffery, J. Valle, T. Hickish, S. Mudan, G. Brown, A. Khan, A. Wotherspoon, A. S. Strimpakos, J. Thomas, S. Compton, Y. J. Chua and I. Chau. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. *Annals of Oncology* 2011 22(9): 2042-2048.
- M. Barra, G. Dabasi, P. Reismann, P. Igaz and K. Racz. A simple semiquantitative technique by analyzing somatostatin receptor scintigraphy to predict therapeutic effect of peptide-receptor-radiotherapy. *Nuclear Medicine Review* 2011 14: A5.
- N. Vassos, A. Agaimy, W. Hohenberger and R. S. Croner. Management of liver metastases of gastrointestinal stromal tumors (GISTs). *Langenbeck's Archives of Surgery* 2011 396(6): 924.
- D. A. Wicherts, R. J. De Haas, P. Andreani, A. Ariche, C. Salloum, G. Pascal, D. Castaing, R. Adam and D. Azoulay. Short- and long-term results of extended left hepatectomy for colorectal metastases. *HPB* 2011 13(8): 536-543.
- A. Bethke, K. Kuhne, I. Platzek and C. Stroszczyński. Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography. *Cancer Imaging* 2011 11(1): 91-99.
- M. O'Malley, L. LaGuardia, C. Burke, M. Kalady and J. Church. Hepatoblastoma: When to screen?. *Hereditary Cancer in Clinical Practice* 2011 9: 19.
- M. Mirarchi, E. De Raffe, S. Vaccari and B. Cola. Rescue ultrasonography-guided liver resection after selective yttrium-90 radioembolization in a case of bilobar colorectal liver metastases. *HPB* 2011 13: 77.
- L. Spelt, P. Norman, L. Tornqvist, B. Tingstedt and R. Andersson. Combined portal embolization and neoadjuvant chemotherapy prior to liver resection for colorectal liver metastases. *HPB* 2011 13: 52-53.
- R. E. Brown, M. R. Bower, T. L. Metzger, C. R. Scoggins, K. M. McMasters, M. J. Hahl, C. Tatum and R. C. G. Martin. Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: Is it safe? *HPB* 2011 13(2): 91-95.
- R. T. Jones, J. J. French, J. Scott, D. M. Manas and R. M. Charnley. Radiofrequency ablation resulting in left lobe hypertrophy and improved resectability. *Case Reports in Gastroenterology* 2011 5(1): 132-135.
- A. Stein, J. Russel, S. Peinert and D. Arnold. The role of peri-operative treatment in resectable liver metastases of colorectal cancer. *Therapeutic Advances in Medical Oncology* 2010 2(6): 389-398.
- I. Nikolic, S. Pavin, B. Kukic, B. Bogdanovic, M. Ilic, I. Majdevac, T. Petrovic and T. Ivkovic-Kapic. Bevacizumab in neoadjuvant treatment of patients with liver metastases from colorectal carcinoma. *Archives of Oncology* 2010 18(3): 75-78.
- S. K. Reddy and B. M. Clary. A new era in defining indications for resectability of colorectal cancer liver metastases. *Current Colorectal Cancer Reports* 2010 6(2): 89-96.
- M. Sereno Moyano, E. Casado Saenz, J. De Castro-Carpeno and C. Belda-Iniesta. The combination of FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer. *Anti-Cancer Drugs* 2009 20(SPEC. ISS. 1): S4-S6.
- J. S. Gold and R. P. DeMatteo. Combined surgical and molecular therapy: The gastrointestinal stromal tumor model. *Annals of Surgery* 2006 244(2): 176-184.
- B. Fioole, M. C. Jansen, F. H. van Duijnhoven, R. van Hillegersberg, T. M. van Gulik and I. H. M. Borel Rinkes. Combining partial liver resection and local ablation of liver tumours: A preliminary Dutch experience. *World J Surg Oncol*. 2006 4:46.

M. T. Milano, S. J. Chmura, M. C. Garofalo, C. Rash, J. C. Roeske, P. P. Connell, O. H. Kwon, A. B. Jani and R. Heimann. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome. *International Journal of Radiation Oncology Biology Physics* 2004 59(2): 445-453.

A. Takamura, H. Saito, T. Kamada, K. Hiramatsu, S. Takeuchi, M. Hasegawa and N. Miyamoto. Intraluminal low-dose-rate ¹⁹²Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. *International Journal of Radiation Oncology Biology Physics* 2003 57(5): 1357-1365.

P. Rutkowski, Z. I. Nowecki, A. Nowak-Dement, A. Nasierowska-Guttmejer, T. Tuziak, P. R. Pawel Nyckowski, U. Grzesiakowska, M. Tacikowska, Z. Zurawski, W. Dziewirski, M. Salamacha, M. Krawczyk, W. Ruya and A. Kopacz. Gastrointestinal stromal tumors - Clinical and morphological features. *Polski Przegląd Chirurgiczny* 2003 75(4): 374-384.

K. Seymour, R. M. Charnley, J. D. G. Rose, C. J. Baudouin and D. Manas. Preoperative portal vein embolisation for primary and metastatic liver tumours: Volume effects, efficacy, complications and short-term outcome. *HPB* 2002 4(1): 21-26.

P. Economopoulos and C. Christopoulos. Glucagonoma. *Annals of Gastroenterology* 2001 14(2): 99-108.

S. Van Ruth, E. Mutsaerts, F. A. N. Zoetmulder and F. Van Coevorden. Metastasectomy for liver metastases of non-colorectal primaries. *European Journal of Surgical Oncology* 2001 27(7): 662-667.

C. Chao, M. Goldberg and J. P. Hoffman. Surgical salvage therapy: Abdominoperineal resection for recurrent anal carcinoma, metastasectomy of recurrent colorectal cancer, and esophagectomy after combined chemoradiation. *Current Opinion in Oncology* 2000 12(4): 353-356.

Level 2, Form Abstract Screening, Exclude if the answer to any of these... -> EXCLUDE

G. Colucci, F. Giuliani, C. Garufi, R. Mattioli, L. Manzione, A. Russo, M. Lopez, P. Parrella, S. Tommasi, M. Copetti, B. Daniele, S. Pisconti, G. Tuveri, N. Silvestris and E. Maiello. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. *Oncology* 2010 79(5-6): 415-22.

P. M. Krieger, D. Tamandl, B. Herberger, P. Faybik, E. Fleischmann, J. Maresch and T. Gruenberger. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. *Ann Surg Oncol* 2011 18(6): 1644-50.

Y. Cui, H. Li, Q. Wu, T. Zhang, D. Kong, T. Song, T. Ru, P. Chen and Q. Li. Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities. *J Gastrointest Surg* 2011 15(2): 285-93.

K. Homayounfar, T. Liersch, M. Niessner, J. Meller, T. Lorf, H. Becker and B. M. Ghadimi. Multimodal treatment options for bilobar colorectal liver metastases. *Langenbecks Arch Surg* 2010 395(6): 633-41.

D. A. Wicherts, R. J. de Haas, P. Andreani, D. Sotirov, C. Salloum, D. Castaing, R. Adam and D. Azoulay. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. *Br J Surg* 2010 97(2): 240-50.

R. Zhao, J. Zhu, X. Ji, J. Cai, F. Wan, Q. Li, B. Zhong, S. Tucker and D. Wang. A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. *Jpn J Clin Oncol* 2010 40(1): 10-6.

R. Adam, D. A. Wicherts, R. J. de Haas, O. Ciaccio, F. Levi, B. Paule, M. Ducreux, D. Azoulay, H. Bismuth and D. Castaing. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. *J Clin Oncol* 2009 27(11): 1829-35.

A. N. Tse, N. Wu, D. Patel, D. Haviland and N. Kemeny. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. *Cancer Chemother Pharmacol* 2009 64(5): 935-44.

H. J. Lenz. First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. *Cancer Treat Rev* 2008 34 (Suppl 2): S3-7.

P. Flamen, B. Vanderlinden, P. Delatte, G. Ghanem, L. Ameye, M. Van Den Eynde and A. Hendlisz. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. *Phys Med Biol* 2008 53(22): 6591-603.

R. P. Whitehead, C. Rankin, P. M. Hoff, P. J. Gold, K. G. Billingsley, R. A. Chapman, L. Wong, J. H. Ward, J. L. Abbruzzese and C. D. Blanke. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). *Invest New Drugs* 2009 27(5): 469-75.

Y. Ogata, S. Uchida, T. Hisaka, H. Horiuchi, S. Mori, N. Ishibashi, Y. Akagi and K. Shirouzu. Intraoperative thermal ablation therapy for small colorectal metastases to the liver. *Hepatogastroenterology* 2008 55(82-83): 550-6.

A. Duffy, J. Shia, F. D. Huitzil-Melendez, Y. Fong and E. M. O'Reilly. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma. *Clin Colorectal Cancer* 2008 7(2): 140-3.

M. Sugimoto, H. Yasuda, K. Koda, M. Yamazaki, T. Tezuka, T. Takenoue, C. Kosugi, R. Higuchi, S. Yamamoto, Y. Watayo, Y. Yagawa and M. Suzuki. Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency. *Hepatogastroenterology* 2007 54(78): 1684-8.

S. Osada, H. Imai, H. Tomita, Y. Tokuyama, N. Okumura, N. Matsuhashi, F. Sakashita and K. Nonaka. Serum cytokine levels in response to hepatic cryoablation. *J Surg Oncol* 2007 95(6): 491-8.

T. Szyszko, A. Al-Nahhas, R. Canelo, N. Habib, L. Jiao, H. Wasan, M. Pagou and P. Tait. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. *Nucl Med Commun* 2007 28(1): 15-20.

C. J. Simon, D. E. Dupuy, D. A. Iannitti, D. S. Lu, N. C. Yu, B. I. Aswad, R. W. Busuttil and C. Lassman. Intraoperative triple antenna hepatic microwave ablation. *AJR Am J Roentgenol* 2006 187(4): W333-40.

G. D. Leonard and N. E. Kemeny. Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. *Dis Colon Rectum* 2006 49(3): 407-10.

S. R. Alberts, W. L. Horvath, W. C. Sternfeld, R. M. Goldberg, M. R. Mahoney, S. R. Dakhil, R. Levitt, K. Rowland, S. Nair, D. J. Sargent and J. H. Donohue. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. *J Clin Oncol* 2005 23(36): 9243-9.

S. Benoist, K. Pautrat, E. Mitry, P. Rougier, C. Penna and B. Nordlinger. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. *Br J Surg* 2005 92(9): 1155-60.

C. Y. Wong, R. Salem, F. Qing, K. T. Wong, D. Barker, V. Gates, R. Lewandowski, E. A. Hill, H. J. Dworkin and C. Nagle. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. *J Nucl Med* 2004 45(11): 1892-7.

- M. R. Machiavelli, G. Salum, J. E. Perez, E. H. Ortiz, A. O. Romero, F. Bologna, C. T. Vallejo, J. A. Lacava, M. E. Dominguez and B. A. Leone. Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. *Am J Clin Oncol* 2004 27(2): 149-54.
- N. Al-Sanea and W. H. Isbister. Is palliative resection of the primary tumour, in the presence of advanced rectal cancer, a safe and useful technique for symptom control?. *ANZ J Surg* 2004 74(4): 229-32.
- M. Stella, A. Percivale, M. Pasqualini, A. Profeti, N. Gandolfo, G. Serafini and R. Pellicci. Radiofrequency-assisted liver resection. *J Gastrointest Surg* 2003 7(6): 797-801.
- J. King, J. Zhao, P. Clingan and D. Morris. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. *Anticancer Res* 2003 23(1B): 639-45.
- D. Cerretani, F. Roviello, M. Pieraccini, L. Civieli, P. Correale, G. Francini, D. Marrelli, G. De Manzoni, E. Pinto and G. Giorgi. Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases. *Vascul Pharmacol* 2002 39(1-2): 1-6.
- B. S. Langenhoff, W. J. Oyen, G. J. Jager, S. P. Strijk, T. Wobbes, F. H. Corstens and T. J. Ruers. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. *J Clin Oncol* 2002 20(22): 4453-8.
- D. L. Stippel, S. Bohm, K. T. Beckurts, H. G. Brochhagen and A. H. Holscher. Intraoperative radiofrequency ablation using a 3D navigation tool for treatment of colorectal liver metastases. *Onkologie* 2002 25(4): 346-50.
- C. Y. Wong, R. Salem, S. Raman, V. L. Gates and H. J. Dworkin. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. *Eur J Nucl Med Mol Imaging* 2002 29(6): 815-20.
- A. Wein, C. Riedel, F. Kockerling, P. Martus, U. Baum, W. M. Brueckl, T. Reck, R. Ott, J. Hansler, T. Bernatik, D. Becker, T. Schneider, W. Hohenberger and E. G. Hahn. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. *Ann Oncol* 2001 12(12): 1721-7.
- A. I. Sarela, J. A. Guthrie, M. T. Seymour, E. Ride, P. J. Guillou and D. S. O'Riordain. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. *Br J Surg* 2001 88(10): 1352-6.
- T. J. Ruers, J. Joosten, G. J. Jager and T. Wobbes. Long-term results of treating hepatic colorectal metastases with cryosurgery. *Br J Surg* 2001 88(6): 844-9.
- A. Zori Comba, C. Blajman, E. Richardet, S. Bella, M. Vilanova, F. Coppola, M. Van Kooten, J. Rodger, R. Giglio, L. Balbiani, F. Perazzo, M. Montiel, M. Chacon, F. Pujol, E. Mickiewicz, E. Cazap, G. Recondo, F. Lastiri, J. Simon, E. Wasserman and A. Schmilovich. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. *Eur J Cancer* 2001 37(8): 1006-13.
- S. Guadagni, A. Pizzutilli, E. Mancini, A. Varrone, G. Palumbo, G. Amicucci, S. Perri, M. Deraco and G. Fiorentini. Significance of duplex/colour Doppler sonography in hepatic arterial chemotherapy for patients with liver metastases from colorectal carcinoma. *Eur J Surg Oncol* 2000 26(4): 381-6.
- D. Hompes, W. Prevoo and T. Ruers. Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin. *Cancer Imaging* 2011 11(): 23-30.

A. P. Stillwell, Y. H. Ho and C. Veitch. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. *World J Surg* 2011 35(3): 684-92.

T. P. Kingham, M. D'Angelica and N. E. Kemeny. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. *J Surg Oncol* 2010 102(8): 988-95.

J. P. Guenette and D. E. Dupuy. Radiofrequency ablation of colorectal hepatic metastases. *J Surg Oncol* 2010 102(8): 978-87.

F. G. Rocha and M. D'Angelica. Treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, and microwave coagulation. *J Surg Oncol* 2010 102(8): 968-74.

J. Garcia-Foncillas and E. Diaz-Rubio. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. *Clin Transl Oncol* 2010 12(8): 533-42.

J. Herman, W. Messersmith, W. W. Suh, W. Blackstock, B. C. Cosman, M. Mohiuddin, M. M. Poggi, W. F. Regine, L. Saltz, W. Small, Jr., J. Zook and A. A. Konski. ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. *Curr Probl Cancer* 2010 34(3): 201-10.

E. S. Glazer, K. Beaty, E. K. Abdalla, J. N. Vauthey and S. A. Curley. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. *Arch Surg* 2010 145(4): 340-5; discussion 345.

A. Deleporte, P. Flamen and A. Hendlisz. State of the art: radiolabeled microspheres treatment for liver malignancies. *Expert Opin Pharmacother* 2010 11(4): 579-86.

L. S. Poulou, P. D. Ziakas, V. Xila, G. Vakrinos, K. Malagari, K. N. Syrigos and L. Thanos. Percutaneous radiofrequency ablation for unresectable colorectal liver metastases: time for shadows to disperse. *Rev Recent Clin Trials* 2009 4(3): 140-6.

S. Mocellin, S. Pasquali and D. Nitti. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. *Cochrane Database Syst Rev* 2009 (3): CD007823.

M. A. Vente, M. Wondergem, I. van der Tweel, M. A. van den Bosch, B. A. Zonnenberg, M. G. Lam, A. D. van Het Schip and J. F. Nijsen. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. *Eur Radiol* 2009 19(4): 951-9.

A. Tachimori, N. Yamada, R. Amano, M. Ohira and K. Hirakawa. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. *Anticancer Res* 2008 28(2A): 629-38.

D. Hind, P. Tappenden, I. Tumor, S. Eggington, P. Sutcliffe and A. Ryan. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. *Health Technol Assess* 2008 12(15): iii-ix, xi-162.

M. Koshariya, R. B. Jagad, J. Kawamoto, P. Papastratis, H. Kefalourous, T. Porfiris, C. Tzouma and N. J. Lygidakis. An update and our experience with metastatic liver disease. *Hepatogastroenterology* 2007 54(80): 2232-9.

P. Shen, K. R. Geisinger, R. Zagoria and E. A. Levine. Pathologic correlation study of microwave coagulation therapy for hepatic malignancies using a three-ring probe. *J Gastrointest Surg* 2007 11(5): 603-11.

J. Yoo and Y. J. Lee. Effect of hyperthermia on TRAIL-induced apoptotic death in human colon cancer cells: development of a novel strategy for regional therapy. *J Cell Biochem* 2007 101(3): 619-30.

A. S. Kennedy, C. Nutting, D. Coldwell, J. Gaiser and C. Drachenberg. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. *Int J Radiat Oncol Biol Phys* 2004 60(5): 1552-63.

J. Machi, A. J. Oishi, A. J. Mossing, N. L. Furumoto and R. H. Oishi. Hand-assisted laparoscopic ultrasound-guided radiofrequency thermal ablation of liver tumors: a technical report. *Surg Laparosc Endosc Percutan Tech* 2002 12(3): 160-4.

D. A. Litvak, T. F. Wood, G. J. Tsioulis, M. Chung, S. P. Chawla, L. J. Foshag, D. L. Morton, K. P. Ramming and A. J. Bilchik. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. *Ann Surg Oncol* 2002 9(2): 148-55.

V. Muralidharan and C. Christophi. Interstitial laser thermotherapy in the treatment of colorectal liver metastases. 2001 76(1): 73-81.

C. Asseburg, M. Frank, C. H. Kohne, J. T. Hartmann, I. Griebisch, A. Mohr, U. Osowski, J. Schulten and T. Mittendorf. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. *Clin Ther* 2011 33(4): 482-97.

D. Hompes, H. Boot, H. van Tinteren and V. Verwaal. Unresectable peritoneal carcinomatosis from colorectal cancer: A single center experience. *J Surg Oncol* 2011 104(3): 269-73.

V. Goffredo, A. Paradiso, G. Ranieri and C. D. Gadaleta. Yttrium-90 ((90)Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). *Crit Rev Oncol Hematol* 2011 (): .

H. Wasan, A. Kennedy, D. Coldwell, B. Sangro and R. Salem. Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases. *Am J Clin Oncol* 2011 (): .

D. Coldwell, B. Sangro, R. Salem, H. Wasan and A. Kennedy. Radioembolization in the Treatment of Unresectable Liver Tumors: Experience Across a Range of Primary Cancers. *Am J Clin Oncol* 2010 (): .

R. Adam, E. Hoti, G. Folprecht and A. B. Benson. Accomplishments in 2008 in the management of curable metastatic colorectal cancer. *Gastrointest Cancer Res* 2009 3(5 Supplement 2): S15-22.

I. Blasiak-Wal, V. N. Hansen and M. Hawkins. Individualising stereotactic liver radiotherapy for large tumour volumes using liver normal tissue complication probability (NTCP) estimation. *Radiotherapy and Oncology* 2011 99(): S181.

N. Gouvas, L. Vini, A. Silyvidou, E. Diamantidou, C. Dervenis and E. Xynos. Multidisciplinary management of locally recurrent colorectal cancer. *Radiotherapy and Oncology* 2011 99(): S395.

R. Jones, S. Fenwick, G. Poston and H. Malik. Non-expert decision making in the management of metastatic colorectal cancer. *HPB* 2011 13(): 54-55.

. Abstracts of the 9th Congress of the European-African HPBA, E-AHPBA. *HPB* 2011 13(): .

D. Amelie, F. Patrick and H. Alain. State of the art: Radiolabeled microspheres treatment for liver malignancies. *Expert Opinion on Pharmacotherapy* 2010 11(4): 579-586.

S. Bacchetti, E. Pasqual, E. Crozzolo, A. Pellarin and P. P. Cagol. Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: A review of medical devices complications in 3172 patients. *Medical Devices: Evidence and Research* 2009 2(1): 31-40.

O. Nafidi, D. Desy, R. Letoumeau, J. Cote, M. Plasse, F. Vandenbroucke, A. Roy, M. Dagenais and R. W. Lapointe. Hypertrophy of the non-embolized liver after chemotherapy. *HPB* 2009 11(2): 103-107.

T. Yamagami, K. Terayama, R. Yoshimatsu, T. Matsumoto, H. Miura and T. Nishimura. Use of N-butyl cyanoacrylate in implantation of a port-catheter system for hepatic arterial infusion chemotherapy with the fixed-catheter-tip method: Is it necessary?. *American Journal of Roentgenology* 2008 191(5): 1523-1529.

K. A. Paschos and N. Bird. Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis. *Hippokratia* 2008 12(3): 132-138.

S. Mocellin, P. Pilati, M. Lise and D. Nitti. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era?. *Journal of Clinical Oncology* 2007 25(35): 5649-5654.

M. Khodjibekova, T. Szyszko, S. Khan, K. Nijran, P. Tait and A. Al-Nahas. Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours. *Reviews on Recent Clinical Trials* 2007 2(3): 212-216.

H. Seki and M. Shiina. Placement of a long tapered side-hole catheter in the hepatic artery: Technical advantages, catheter stability, and arterial patency. *American Journal of Roentgenology* 2006 187(5): 1312-1320.

N. E. Kemeny. Current approaches for liver-only metastases in colorectal cancer. *Community Oncology* 2006 3(6 SUPPL. 2): 26-35.

G. Biasco, E. Derenzini, S. Fanello and G. Brandi. Liver metastases from colorectal cancer. *European Journal of Oncology* 2005 10(1): 45-54.

N. N. Hanna. Radiofrequency ablation of primary and metastatic hepatic malignancies. *Clinical Colorectal Cancer* 2004 4(2): 92-100.

N. Kemeny. Treatment of liver metastases with hepatic arterial infusion. *European Surgery - Acta Chirurgica Austriaca* 2002 34(1): 40-41.

G. Fiorentini, D. B. Poddie, U. De Giorgi, D. Guglielminetti, P. Giovanis, M. Leoni, W. Latino, C. Dazzi, A. Cariello, D. Turci and M. Marangolo. Global approach to hepatic metastases from colorectal cancer: Indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments. *Medical Oncology* 2000 17(3): 163-173.

S. Y. Abbasi, H. E. Taani, A. Saad, A. Badheeb and A. Addasi. Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes. *Gastrointest Cancer Res* 2011 4(4): 122-7.

M. H. K. Abdelmaksoud, J. D. Louie, G. L. Hwang, N. Kothary, D. R. Minor and D. Y. Sze. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver. *Journal of Vascular and Interventional Radiology* 2012 23(3): 323-330.

A. B. Benson Iii, J. P. Arnoletti, T. Bekaii-Saab, E. Chan, Y. J. Chen, M. A. Choti, H. S. Cooper, R. A. Dilawari, P. F. Engstrom, P. C. Enzinger, J. W. Fleshman Jr, C. S. Fuchs, J. L. Grem, J. A. Knol, L. A. Leong, E. Lin, K. S. May, M. F. Mulcahy, K. Murphy, E. Rohren, D. P. Ryan, L. Saltz, S. Sharma, D. Shibata, J. M. Skibber, W. Small Jr, C. T. Sofocleous, A. P. Venook and C. Willett. Clinical practice guidelines in oncology. *JNCCN Journal of the National Comprehensive Cancer Network* 2011 9(11): 1238-1289.

M. J. Borad, D. Sigal, H. Uronis, J. Stephenson, N. Bahary, M. U. Rarick, L. C. DeMarco, T. J. Finnegan, E. G. Chiorean, D. P. Ryan, A. L. Cohn, B. K. Ulrich, V. C. Harish, E. N. Anderes, W. W. Ma, P. P. Yu, F. Sinicrope, C. Eng, U. K. Sunkara and S. G. Reddy. Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. *Journal of Clinical Oncology* 2011 29(15): .

R. E. Brown, K. M. Gibler, T. Metzger, I. Trofimov, H. Krebs, F. D. Romero, C. R. Scoggins, K. M. McMasters and R. C. G. Martin Ii. Imaged guided transarterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for hepatic metastases from melanoma: Early outcomes from a multi-institutional registry. *American Surgeon* 2011 77(1): 93-98.

J. Bruix, F. Izzo, L. Crocetti, V. Vilgrain, M. Abdel-Rehim, L. Bianchi, J. Ricke, M. Pech and R. Lencioni. Irreversible electroporation for the treatment of early-stage hepatocellular carcinoma. A prospective multicenter Phase 2 study assessing safety and efficacy. *Journal of Hepatology* 2012 56(): S554.

D. A. Bush, Z. Kayali, R. Grove and J. D. Slater. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. *Cancer* 2011 117(13): 3053-9.

D. Castellano, J. Capdevila, R. Salazar, J. Sastre, V. Alonso, M. Llanos, R. Garcia-Carbonero, A. Abad, I. Sevilla and I. Duran. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish neuroendocrine tumor group (GETNE0801). *Neuroendocrinology* 2011 94(): 19-20.

P. G. Claringbold, P. A. Brayshaw, R. A. Price and J. H. Turner. Phase II study of radiopeptide ¹⁷⁷Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. *Eur J Nucl Med Mol Imaging* 2011 38(2): 302-11.

B. G. Czito, C. Willett, P. Kennedy-Newton, D. S. Tyler, H. Hurwitz and H. E. Uronis. A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC). *Journal of Clinical Oncology* 2011 29(4): .

R. Czymek, D. Dinter, S. Loffler, M. Gebhard, T. Laubert, A. Lubienski, H. P. Bruch and A. Schmidt. Electrochemical treatment: An investigation of dose-response relationships using an isolated liver perfusion model. *Saudi J Gastroenterol* 2011 17(5): 335-42.

M. Dahele and S. Senan. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. *Cancer Res Treat* 2011 43(2): 75-82.

X. D. Dong and B. I. Carr. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: A long-term follow-up in 123 patients. *Medical Oncology* 2011 28(SUPPL. 1): S286-S290.

A. Edwards and C. E. Ray. Transarterial therapies for unresectable cholangiocarcinoma: A meta-analysis. *Journal of Vascular and Interventional Radiology* 2012 23(3): S101.

G. Ercolani, A. Cucchetti, M. Cescon, E. Peri, G. Brandi, M. Del Gaudio, M. Ravaioli, M. Zanello and A. D. Pinna. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. *Eur J Cancer* 2011 47(15): 2291-8.

E. M. Gartner, P. Silverman, M. Simon, L. Flaherty, J. Abrams, P. Ivy and P. M. Lorusso. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. *Breast Cancer Res Treat* 2012 131(3): 933-7.

R. T. Grundmann. Current state of surgical treatment of liver metastases from colorectal cancer. *World J Gastrointest Surg* 2011 3(12): 183-96.

A. L. Gueorguiev, R. Mackey, G. C. Kowdley, J. Esquivel and S. C. Cunningham. Minimally invasive evaluation and treatment of colorectal liver metastases. *Int J Surg Oncol* 2011 2011(): 686030.

D. Habermehl, K. Kessel, T. Welzel, H. Hof, A. Abdollahi, F. Bergmann, S. Rieken, J. Weitz, J. Werner, P. Schirmacher, M. W. Buchler, J. Debus and S. E. Combs. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. *Radiation Oncology* 2012 7(1): .

D. Han, G. M. Beasley, D. S. Tyler and J. S. Zager. Minimally invasive intra-arterial regional therapy for metastatic melanoma: Isolated limb infusion and percutaneous hepatic perfusion. *Expert Opinion on Drug Metabolism and Toxicology* 2011 7(11): 1383-1394.

A. R. Haug, B. P. T. Donfack, C. Trumm, C. J. Zech, M. Michl, R. P. Laubender, C. Uebleis, P. Bartenstein, V. Heinemann and M. Hacker. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. *Journal of Nuclear Medicine* 2012 53(3): 371-377.

G. Hery, S. Franchi-Abella, D. Habes, L. Brugieres, H. Martelli, M. Fabre, D. Pariente, F. Gauthier, E. Jacquemin and S. Branchereau. Initial liver transplantation for unresectable hepatoblastoma after chemotherapy. *Pediatric Blood and Cancer* 2011 57(7): 1270-1275.

R. T. Hoffmann, P. M. Paprottka, A. Schon, F. Bamberg, A. Haug, E. M. Durr, B. Rauch, C. T. Trumm, T. F. Jakobs, T. K. Helmberger, M. F. Reiser and F. T. Kolligs. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: Factors associated with prolonged survival. *CardioVascular and Interventional Radiology* 2012 35(1): 105-116.

S. Iqbal, C. Rankin, H. J. Lenz, P. J. Gold, S. A. Ahmad, A. B. El-Khoueiry, M. J. Messino, R. F. Holcombe and C. D. Blanke. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. *Cancer Chemother Pharmacol* 2011 68(6): 1595-602.

H. Iwase, M. Shimada, T. Tsuzuki, K. Ina, M. Sugihara, J. Haruta, M. Shinoda, T. Kumada and H. Goto. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer. *Oncology* 2011 80(1-2): 76-83.

B. J. John and B. R. Davidson. Treatment options for unresectable neuroendocrine liver metastases. *Expert Review of Gastroenterology and Hepatology* 2012 6(3): 357-369.

F. Kanai, H. Yoshida, R. Tateishi, S. Sato, T. Kawabe, S. Obi, Y. Kondo, M. Taniguchi, K. Tagawa, M. Ikeda, C. Morizane, T. Okusaka, H. Arioka, S. Shiina and M. Omata. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. *Cancer Chemother Pharmacol* 2011 67(2): 315-24.

Y. S. Khajanchee, C. W. Hammill, M. A. Cassera, R. F. Wolf and P. D. Hansen. Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis. *Arch Surg* 2011 146(12): 1416-23.

M. V. Kiefer, M. Albert, M. McNally, M. Robertson, W. Sun, D. Fraker, K. Olthoff, K. Christians, S. Pappas, W. Rilling and M. C. Soulen. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. *Cancer* 2011 117(7): 1498-505.

G. P. Kim, M. R. Mahoney, D. Szydlo, T. S. Mok, R. Marshke, K. Holen, J. Picus, M. Boyer, H. C. Pitot, J. Rubin, P. A. Philip, A. Nowak, J. J. Wright and C. Erlichman. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. *Invest New Drugs* 2012 30(1): 387-94.

J. W. Kim, J. Seong, M. Yun, I. J. Lee, H. I. Yoon, H. J. Cho and K. H. Han. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. *International Journal of Radiation Oncology Biology Physics* 2012 82(3): 1172-1178.

I. V. Kolosov and R. V. Ishchenko. [The results of palliative locoregional chemotherapy of primary and metastatic hepatic cancer]. *Klin Khir* 2011 (9): 31-3.

C. Kratochwil, R. Lopez-Benitez, W. Mier, S. Haufe, B. Isermann, H. U. Kauczor, P. L. Choyke, U. Haberkorn and F. L. Giesel. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. *Endocr Relat Cancer* 2011 18(5): 595-602.

M. Kudo, K. Imanaka, N. Chida, K. Nakachi, W. Y. Tak, T. Takayama, J. H. Yoon, T. Hori, H. Kumada, N. Hayashi, S. Kaneko, H. Tsubouchi, D. J. Suh, J. Furuse, T. Okusaka, K. Tanaka, O. Matsui, M. Wada, I. Yamaguchi, T. Ohya, G. Meinhardt and K. Okita. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. *Eur J Cancer* 2011 47(14): 2117-27.

J. B. Kuhlmann, W. Euringer, H. C. Spangenberg, M. Breidert, H. E. Blum, J. Harder and R. Fischer. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. *Eur J Gastroenterol Hepatol* 2012 24(4): 437-43.

S. Lacin, I. Oz, E. Ozkan, O. Kucuk and S. Bilgic. Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response. *Cancer Biother Radiopharm* 2011 26(5): 631-7.

V. W. T. Lam, C. Spiro, J. M. Laurence, E. Johnston, M. J. Hollands, H. C. C. Pleass and A. J. Richardson. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. *Annals of Surgical Oncology* 2012 19(4): 1292-1301.

C. Lance, G. McLennan, N. Obuchowski, G. Cheah, A. Levitin, M. Sands, J. Spain, S. Srinivas, S. Shrikanthan, F. N. Aucejo, R. Kim and K. V. Menon. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. *J Vasc Interv Radiol* 2011 22(12): 1697-705.

I. J. Lee and J. Seong. Radiotherapeutic strategies in the management of hepatocellular carcinoma. *Oncology* 2011 81(SUPPL. 1): 123-133.

I. J. Lee and J. Seong. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. *Gut Liver* 2012 6(2): 139-48.

K. Lehmann, A. Rickenbacher, A. Weber, B. C. Pestalozzi and P. A. Clavien. Chemotherapy before liver resection of colorectal metastases: friend or foe?. *Ann Surg* 2012 255(2): 237-47.

L. Lenoir, M. Pracht, Y. Rolland, J. Edeline, S. Laffont, V. Ardisson, H. Mesbah, P. Poree, J. L. Raoul, E. Boucher and E. Garin. Yttrium-90 microspheres radioembolization in hepatocellular carcinoma with portal vein thrombosis: Results on 40 consecutive patients. *European Journal of Nuclear Medicine and Molecular Imaging* 2011 38(): S95.

H. Y. Lim, J. Lee, H. Chang, J. S. Kim, H. J. Choi, M. A. Lee, J. Jang, H. Jeung, J. H. Kang, H. W. Lee, D. Shin, H. J. Jang, J. Sun, S. H. Park, J. O. Park, Y. Park and W. K. Kang. Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma. *Journal of Clinical Oncology* 2011 29(18): .

Z. Z. Lin, C. Hsu, F. C. Hu, Y. Y. Shao, D. Y. Chang, C. H. Yang, R. L. Hong, C. H. Hsu and A. L. Cheng. Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy. *Oncologist* 2012 (): .

J. Luo, R. P. Guo, E. C. Lai, Y. J. Zhang, W. Y. Lau, M. S. Chen and M. Shi. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. *Ann Surg Oncol* 2011 18(2): 413-20.

F. Maire, C. Lombard-Bohas, D. O'Toole, M. P. Vullierme and P. Ruszniewski. Hepatic arterial embolization versus chemoembolization in patients with liver metastases of digestive neuroendocrine tumors. *Neuroendocrinology* 2011 94(): 34-35.

R. C. Martin, K. Robbins, J. F. Fages, F. D. Romero, L. Rustein, D. Tomalty and R. Monaco. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. *Breast Cancer Res Treat* 2012 132(2): 753-63.

K. Memon, R. J. Lewandowski, M. F. Mulcahy, A. Riaz, R. K. Ryu, K. T. Sato, R. Gupta, P. Nikolaidis, F. H. Miller, V. Yaghmai, V. L. Gates, B. Atassi, S. Newman, R. A. Omary, A. B. R. Benson and R. Salem. Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. *Int J Radiat Oncol Biol Phys* 2012 83(3): 887-894.

P. Merle, A. Abergel, C. Masliah, O. Rosmorduc, J. P. Bronowicki, G. P. Pageaux, J. P. H. Zarski, F. Degos, E. Dorval, G. Pelletier, G. Verset and P. Attali. A randomized phase ii trial of doxorubicintransdrug (trademark) (livatag(registered trademark)) demonstrates significant overall survival increase in inoperable hepatocellular carcinoma (hcc) patients. *Hepatology* 2011 54(): 1388A-1389A.

O. Mir, J. Domont, A. Cioffi, S. Bonvalot, B. Boulet, C. Le Pechoux, P. Terrier, M. Spielmann and A. Le Cesne. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. *European Journal of Cancer* 2011 47(4): 515-519.

M. Moehler, S. Kanzler, C. C. Schimanski, M. A. Worns, U. Denzer, F. Kolligs, M. Ebert, A. Distelrath, S. Zeuzem, F. Lammert, M. Geissler, A. Lohse, M. Dollinger, U. Lindig, M. Durr, N. Lubomierski, M. Kabisch, S. Schadmand-Fischer and P. R. Galle. A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naïve advanced or metastatic biliary tract cancer: First safety and efficacy data. *Onkologie* 2011 34(): 217.

K. Okabe, T. Beppu, T. Masuda, H. Hayashi, H. Okabe, H. Komori, K. Horino, S. I. Sugiyama, T. Ishiko, H. Takamori, T. Yamanaka and H. Baba. Portal vein embolization can prevent intrahepatic metastases to non-embolized liver. *Hepato-Gastroenterology* 2012 59(114): 538-541.

Y. Osaka, M. Shinohara, S. Hoshino, T. Ogata, Y. Takagi, A. Tsuchida and T. Aoki. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. *Anticancer Res* 2011 31(2): 633-8.

L. C. Pagliaro, M. Munsell, D. Harris, R. L. Carolla and A. O. Siefker-Radtke. Gemcitabine, paclitaxel, and doxorubicin for patients (pts) with urothelial carcinoma (UC) and renal insufficiency: Preliminary results of a multicenter phase II study. *Journal of Clinical Oncology* 2011 29(7): .

J. W. Park, R. S. Finn, J. S. Kim, M. Karwal, R. K. Li, F. Ismail, M. Thomas, R. Harris, C. Baudelet, I. Walters and J. L. Raoul. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. *Clin Cancer Res* 2011 17(7): 1973-83.

V. J. Picozzi, M. Nguyen, L. W. Traverso and R. A. Kozarek. The virginia mason pancreatic cancer database. *Journal of Clinical Oncology* 2011 29(4): .

M. Pracht, J. Edeline, L. Lenoir, M. La Tournerie, E. Garin, Y. Rolland, J. Raoul and E. Boucher. Hepatocellular carcinoma with portal vein thrombosis treated with yttrium-90 microsphere radioembolization results on 22 consecutive patients. *Journal of Clinical Oncology* 2011 29(15): .

D. Quan, S. Gallinger, C. Nhan, R. A. Auer, J. J. Biagi, G. G. Fletcher, C. H. Law, C. A. Moulton, L. Ruo, A. C. Wei and R. S. McLeod. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review. *Surgery* 2012 151(6): 860-70.

H. Rajekar, K. Bogammana and R. S. Stubbs. Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: A new and effective modality for treatment. *International Journal of Hepatology* 2011 (): .

T. Ruers. Colorectal cancer with synchronous liver metastases. *European Journal of Cancer* 2012 48(): S2.

R. Sacco, I. Bargellini, M. Bertini, E. Bozzi, A. Romano, P. Petruzzi, E. Tumino, B. Ginanni, G. Federici, R. Cioni, S. Metrangolo, M. Bertoni, G. Bresci, G. Parisi, E. Altomare, A. Capria and C. Bartolozzi. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. *J Vasc Interv Radiol* 2011 22(11): 1545-52.

P. Saletti, C. Sessa, S. De Dosso, T. Cerny, V. Renggli and D. Koeberle. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. *Oncology* 2011 81(1): 50-4.

M. Salhab and R. Canelo. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. *J Cancer Res Ther* 2011 7(4): 463-75.

M. Salhab and R. Canelo. An overview of evidence-based management of hepatocellular carcinoma- A meta-analysis. *Hepatology* 2011 54(): 1395A.

I. Schmid, B. Haberle, M. H. Albert, S. Corbacioglu, B. Frohlich, N. Graf, B. Kammer, U. Kontny, I. Leuschner, H. G. Scheel-Walter, W. Scheurlen, S. Werner, T. Wiesel and D. von Schweinitz. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. *Pediatr Blood Cancer* 2012 58(4): 539-44.

B. A. Seinsträ, L. Defreyne, B. Lambert, M. Lam, L. Verkooijen, K. J. Van Erpecum, B. Van Hoek, A. R. Van Erkel, M. J. Coenraad, I. Al Younis, H. Van Vlierberghe and M. Van Den Bosch. Transarterial RAdioembolization versus ChemoEmbolization for the treatment of HCC: TRACE trial-an international multicenter randomized controlled trial. *Journal of Vascular and Interventional Radiology* 2012 23(3): S150-S151.

E. Seront and M. Van den Eynde. Liver-Directed Therapies: Does It Make Sense in the Current Therapeutic Strategy for Patients With Confined Liver Colorectal Metastases?. *Clin Colorectal Cancer* 2012 (): .

C. S. Shim. Photodynamic therapy for hilar cholangiocarcinoma. *Photodiagnosis and Photodynamic Therapy* 2011 8(2): 218-219.

W. Sun, D. Sohal, D. G. Haller, K. Mykulowycz, M. Rosen, M. C. Soulen, M. Caparro, U. R. Teitelbaum, B. Giantonio, P. J. O'Dwyer, A. Shaked, R. Reddy and K. Olthoff. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. *Cancer* 2011 117(14): 3187-92.

J. J. M. Teunissen, D. J. Kwekkeboom, R. Valkema and E. P. Krenning. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. *Endocr Relat Cancer* 2011 18(SUPPL. 1): S27-S51.

A. Thakur, P. Littrup, E. N. Paul, B. Adam, L. K. Heilbrun and L. G. Lum. Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study. *J Immunother* 2011 34(5): 457-67.

K. R. Tomkovich. Ablation of breast cancer. *CardioVascular and Interventional Radiology* 2011 34(): 415-416.

T. J. Vogl, N. N. N. Naguib, T. Lehnert, N. E. A. Nour-Eldin, K. Eichler, S. Zangos and T. Gruber-Rouh. Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: Indications, outcomes and role in patient's management. *Gynecologic Oncology* 2012 124(2): 225-229.

R. Whitney, V. Valek, J. F. Fages, A. Garcia, G. Narayanan, C. Tatum, M. Hahl and R. C. Martin, 2nd. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. *Oncologist* 2011 16(5): 594-601.

G. Wieners, K. Mohnike, N. Peters, J. Bischoff, A. Kleine-Tebbe, R. Seidensticker, M. Seidensticker, G. Gademann, P. Wust, M. Pech and J. Rieke. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study. *Radiother Oncol* 2011 100(2): 314-9.

Y. V. Wu, G. Tomaszewski, A. Groman, R. Iyer and B. Kuvshinov. Comparison of yttrium-90 microspheres (Y-90) and transarterial chemoembolization (TACE) in the treatment of inoperable metastatic neuroendocrine tumors (NETS). *Annals of Surgical Oncology* 2012 19(): S32.

P. Yarra and A. Rodriguez. A rare etiology of brain metastasis: Squamous cell carcinoma of the esophagus. *American Journal of Gastroenterology* 2011 106(): S187.

J. H. Yi, J. Lee, S. H. Park, J. O. Park, D. S. Yim, Y. S. Park, H. Y. Lim and W. K. Kang. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. *Br J Cancer* 2012 106(9): 1469-74.

J. Yu, X. Meng, J. H. Wang, X. Sun, L. Wang, M. Ye, P. B. Feng, G. Y. Zhu, Y. Lu and S. C. Zhu. KRAS mutation status and toxicity of cetuximab, paclitaxel, cisplatin, and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study. *Journal of Clinical Oncology* 2011 29(15): .

J. Zager and C. Nutting. Chemosaturation therapy with percutaneous hepatic perfusions of melphalan versus standard of care in patients with hepatic metastases from melanoma: A randomized multicenter phase 3 study. *Journal of Vascular and Interventional Radiology* 2012 23(3): S3.

Y. Zhou, J. Huang, L. Yang, G. R. Cai, H. B. Xu, W. J. Wang, K. Y. Shi and Y. Sun. Phase II trial of paclitaxel and cisplatin combination given biweekly as first-line chemotherapy in patients with advanced or metastatic squamous cell carcinoma of esophagus from a single center in China. *Journal of Clinical Oncology* 2011 29(15): .

Level 3, Form CRC Full-textScreening, trtment Exclude

L. B. van Iersel, M. Koopman, C. J. van de Velde, L. Mol, E. L. van Persijn van Meerten, H. H. Hartgrink, P. J. Kuppen, A. L. Vahrmeijer, J. W. Nortier, R. A. Tollenaar, C. Punt and H. Gelderblom. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. *Ann Oncol* 2010 21(8): 1662-7.

P. Pilati, E. Mammano, S. Mocellin, E. Tessari, M. Lise and D. Nitti. Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy. *Anticancer Res* 2009 29(10): 4139-44.

H. R. Alexander, Jr., D. L. Bartlett, S. K. Libutti, J. F. Pingpank, D. L. Fraker, R. Royal, S. M. Steinberg, C. B. Helsabeck and T. H. Beresneva. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal cancer. *Ann Surg Oncol* 2009 16(7): 1852-9.

O. B. Lao, F. Farjah, D. R. Flum and R. S. Yeung. Adverse events after radiofrequency ablation of unresectable liver tumors: a single-center experience. *Am J Surg* 2009 198(1): 76-82.

R. Puls, S. Langner, C. Rosenberg, K. Hegenscheid, J. P. Kuehn, K. Noeckler and N. Hosten. Laser ablation of liver metastases from colorectal cancer with MR thermometry: 5-year survival. *J Vasc Interv Radiol* 2009 20(2): 225-34.

- T. J. Vogl, T. Gruber, J. O. Balzer, K. Eichler, R. Hammerstingl and S. Zangos. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. *Radiology* 2009 250(1): 281-9.
- J. H. Howard, C. W. Tzeng, J. K. Smith, D. E. Eckhoff, J. S. Bynon, T. Wang, J. P. Arnoletti and M. J. Heslin. Radiofrequency ablation for unresectable tumors of the liver. *Am Surg* 2008 74(7): 594-600; discussion 600-1.
- S. S. Ng, S. C. Yu, P. B. Lai and W. Y. Lau. Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies. *Dig Dis Sci* 2008 53(10): 2813-7.
- H. Seki, T. Ozaki and M. Shiina. Side-hole catheter placement for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer: long-term treatment and survival benefit. *AJR Am J Roentgenol* 2008 190(1): 111-20.
- A. Suppiah, T. J. White, S. H. Roy-Choudhury, D. J. Breen, J. Cast, A. Maraveyas, J. E. Hartley and J. R. Monson. Long-term results of percutaneous radiofrequency ablation of unresectable colorectal hepatic metastases: final outcomes. *Dig Surg* 2007 24(5): 358-60.
- S. Bageacu, D. Kaczmarek, M. Lacroix, J. Dubois, J. Forest and J. Porcheron. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. *Eur J Surg Oncol* 2007 33(5): 590-6.
- P. Abitabile, U. Hartl, J. Lange and C. A. Maurer. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. *Eur J Surg Oncol* 2007 33(1): 67-71.
- Y. Van Nieuwenhove, M. Aerts, B. Neyns and G. Delvaux. Techniques for the placement of hepatic artery catheters for regional chemotherapy in unresectable liver metastases. *Eur J Surg Oncol* 2007 33(3): 336-40.
- M. Hoyer, H. Roed, A. Traberg Hansen, L. Ohlhuis, J. Petersen, H. Nellesmann, A. Kiil Berthelsen, C. Grau, S. Aage Engelholm and H. Von der Maase. Phase II study on stereotactic body radiotherapy of colorectal metastases. *Acta Oncol* 2006 45(7): 823-30.
- J. Machi, A. J. Oishi, K. Sumida, K. Sakamoto, N. L. Furumoto, R. H. Oishi and J. W. Kylstra. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. *Cancer J* 2006 12(4): 318-26.
- F. F. Amersi, A. McElrath-Garza, A. Ahmad, T. Zogakis, D. P. Allegra, R. Krasne and A. J. Bilchik. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. *Arch Surg* 2006 141(6): 581-7; discussion 587-8.
- M. Stella, F. Mithieux, P. Meeus, P. Kaemmerlen, C. Lafon and M. Rivoire. Transpleurodiaphragmatic cryosurgical ablation for recurrent unresectable colorectal liver metastases. *J Surg Oncol* 2006 93(4): 268-72.
- C. M. Pacella, D. Valle, G. Bizzarri, S. Pacella, M. Brunetti, R. Maritati, J. Osborn and R. Stasi. Percutaneous laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: Results of a phase II study. *Acta Oncol* 2006 45(1): 77-83.
- T. D. Yan, R. Padang and D. L. Morris. Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastases. *J Am Coll Surg* 2006 202(1): 100-11.
- K. Ishibashi, K. Yoshimatsu, H. Yokomizo, A. Umehara, K. Yoshida, T. Fujimoto, K. Watanabe, T. Katsube, Y. Naritaka and K. Ogawa. Low-dose leucovorin and 5-Fluorouracil for unresectable multiple liver metastasis from colorectal cancer. *Anticancer Res* 2005 25(6C): 4747-52.

E. Ben-Josef, D. Normolle, W. D. Ensminger, S. Walker, D. Tatro, R. K. Ten Haken, J. Knol, L. A. Dawson, C. Pan and T. S. Lawrence. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. *J Clin Oncol* 2005 23(34): 8739-47.

S. Nag, M. DeHaan, G. Scruggs, N. Mayr and E. W. Martin. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. *Int J Radiat Oncol Biol Phys* 2006 64(3): 736-44.

J. Joosten, G. Jager, W. Oyen, T. Wobbes and T. Ruers. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. *Eur J Surg Oncol* 2005 31(10): 1152-9.

N. Kemeny, A. Eid, J. Stockman, M. Gonen, L. Schwartz, E. Tetzlaff and P. Paty. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. *J Surg Oncol* 2005 91(2): 97-101.

B. Qin, K. Kato, K. Mitsugi, M. Nakamura, R. Tanaka, E. Baba, H. Ariyama, T. Kuroiwa, M. Harada and S. Nakano. Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer. *Cancer Chemother Pharmacol* 2006 57(1): 114-9.

P. J. Allen, A. Nissan, A. I. Picon, N. Kemeny, P. Duddrick, L. Ben-Porat, J. Espat, A. Stojadinovic, A. M. Cohen, Y. Fong and P. B. Paty. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. *J Am Coll Surg* 2005 201(1): 57-65.

Y. T. You, C. R. Changchien, J. S. Huang and K. K. Ng. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. *Int J Colorectal Dis* 2006 21(1): 33-7.

G. Navarra, A. Ayav, J. C. Weber, S. L. Jensen, C. Smadga, J. P. Nicholls, N. A. Habib and L. R. Jiao. Short- and long-term results of intraoperative radiofrequency ablation of liver metastases. *Int J Colorectal Dis* 2005 20(6): 521-8.

T. Yamagami, T. Kato, O. Tanaka, T. Hirota and T. Nishimura. Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy. *J Vasc Interv Radiol* 2005 16(4): 549-54.

C. Christophi, M. Nikfarjam, C. Malcontenti-Wilson and V. Muralidharan. Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy. *World J Surg* 2004 28(10): 987-94.

U. Pohlen, U. Mansmann, G. Berger, C. T. Germer, U. Gallkowski, J. Boese-Landgraf and H. J. Buhr. Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases. *Anticancer Res* 2004 24(5B): 3275-82.

S. Kerkar, A. M. Carlin, R. L. Sohn, C. Steffes, J. Tyburski, P. Littrup and D. Weaver. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. *Surgery* 2004 136(4): 770-9.

T. J. White, S. H. Roy-Choudhury, D. J. Breen, J. Cast, A. Maraveyas, E. F. Smyth, J. E. Hartley and J. R. Monson. Percutaneous radiofrequency ablation of colorectal hepatic metastases - initial experience. An adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases. *Dig Surg* 2004 21(4): 314-20.

E. K. Abdalla, J. N. Vauthey, L. M. Ellis, V. Ellis, R. Pollock, K. R. Broglio, K. Hess and S. A. Curley. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004 239(6): 818-25; discussion 825-7.

M. Venturini, E. Angeli, M. Salvioni, F. De Cobelli, M. Ronzoni, L. Aldrighetti, M. Stella, M. Carlucci, C. Staudacher, V. Di Carlo, G. Ferla, E. Villa and A. Del Maschio. Complications after percutaneous transaxillary implantation of a catheter for intraarterial chemotherapy of liver tumors: clinical relevance and management in 204 patients. *AJR Am J Roentgenol* 2004 182(6): 1417-26.

H. Muller, V. Nakchbandi, I. Chatzisavvidis and C. von Voigt. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. *Hepatogastroenterology* 2003 50(54): 1919-26.

J. Rothbarth, M. E. Pijl, A. L. Vahrmeijer, H. H. Hartgrink, F. G. Tijl, P. J. Kuppen, R. A. Tollenaar and C. J. van de Velde. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. *Br J Surg* 2003 90(11): 1391-7.

A. Hamada, K. Yamakado, A. Nakatsuka, N. Tanaka and K. Takeda. Repeated hepatic arterial infusion chemotherapy using an implanted port system in patients with unresectable malignant liver neoplasms: significant factors affecting early hepatic arterial occlusion. *Oncol Rep* 2003 10(6): 1821-7.

T. J. Vogl, M. G. Mack, J. O. Balzer, K. Engelmann, R. Straub, K. Eichler, D. Woitaschek and S. Zangos. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. *Radiology* 2003 229(2): 457-64.

A. Mancuso, R. Giuliani, C. Accettura, M. Palma, G. D'Auria, F. Cecere, L. Paoluzzi, M. Bezzi, B. Massidda and E. Cortesi. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. *Anticancer Res* 2003 23(2C): 1917-22.

D. Fallik, M. Ychou, J. Jacob, P. Colin, J. F. Seitz, J. Baulieux, A. Adenis, J. Y. Douillard, P. Couzigou, R. Mahjoubi, M. Ducreux, M. Mahjoubi and P. Rougier. Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. *Ann Oncol* 2003 14(6): 856-63.

R. J. Bleicher, D. P. Allegra, D. T. Nora, T. F. Wood, L. J. Foshag and A. J. Bilchik. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. *Ann Surg Oncol* 2003 10(1): 52-8.

N. Miyanari, T. Mori, K. Takahashi and M. Yasuno. Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. *Dis Colon Rectum* 2002 45(11): 1503-9.

M. Bloomston, O. Binitie, E. Fraiji, M. Murr, E. Zervos, S. Goldin, B. Kudryk, B. Zwiebel, T. Black, S. Fargher and A. S. Rosemurgy. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. *Am Surg* 2002 68(9): 827-31.

H. R. Alexander, Jr., S. K. Libutti, D. L. Bartlett, J. F. Pingpank, K. Kranda, C. Helsabeck and T. Beresnev. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. *Cancer* 2002 95(4): 730-6.

L. X. Liu, W. H. Zhang, H. C. Jiang, A. L. Zhu, L. F. Wu, S. Y. Qi and D. X. Piao. Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. *World J Gastroenterol* 2002 8(4): 663-7.

I. Popov, S. Lavrnjic, S. Jelic, S. Jezdic and A. Jasovic. Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit. *Neoplasma* 2002 49(1): 43-8.

K. Kosari, M. Gomes, D. Hunter, D. J. Hess, E. Greeno and T. D. Sielaff. Local, intrahepatic, and systemic recurrence patterns after radiofrequency ablation of hepatic malignancies. *J Gastrointest Surg* 2002 6(2): 255-63.

J. Machi, S. Uchida, K. Sumida, W. M. Limm, S. A. Hundahl, A. J. Oishi, N. L. Furumoto and R. H. Oishi. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. *J Gastrointest Surg* 2001 5(5): 477-89.

D. A. Iannitti, D. E. Dupuy, W. W. Mayo-Smith and B. Murphy. Hepatic radiofrequency ablation. *Arch Surg* 2002 137(4): 422-6; discussion 427.

T. Gruenberger, J. Zhao, J. King, T. Chung, P. R. Clingan and D. L. Morris. Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy. *Cancer* 2002 94(6): 1753-9.

A. Huang, J. M. McCall, M. D. Weston, P. Mathur, H. Quinn, D. C. Henderson and T. G. Allen-Mersh. Phase I study of percutaneous cryotherapy for colorectal liver metastasis. *Br J Surg* 2002 89(3): 303-10.

S. L. Wong, M. J. Edwards, C. Chao, D. Simpson and K. M. McMasters. Radiofrequency ablation for unresectable hepatic tumors. *Am J Surg* 2001 182(6): 552-7.

S. Kohnoe, K. Endo, M. Yamamoto, Y. Ikeda, Y. Toh, H. Baba, T. Tajima and T. Okamura. Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. *Surgery* 2002 131(1 Suppl): S128-34.

T. Kimoto, A. Yamanoi, M. Uchida, Y. Makino, T. Ono, H. Kohno and N. Nagasue. Repeated hepatic dearterialization for unresectable carcinomas of the liver: report of a 10-year experience. *Surg Today* 2001 31(11): 984-90.

K. H. Link, E. Sunelaitis, M. Kornmann, M. Schatz, F. Gansauge, G. Leder, A. Formentini, L. Staib, J. Pillasch and H. G. Beger. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival. *Cancer* 2001 92(11): 2746-53.

L. Aldrighetti, M. Arru, M. Ronzoni, M. Salvioni, E. Villa and G. Ferla. Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUDR) for liver metastases from colorectal cancer. *Hepatogastroenterology* 2001 48(41): 1302-7.

H. Muller, W. Nakchbandi, I. Chatzissavvidis and V. Valek. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases. *Eur J Surg Oncol* 2001 27(7): 652-61.

N. J. Lygidakis, G. Sgourakis, G. Dedemadi, M. C. Safioleus and J. Nestoridis. Regional chemoimmunotherapy for nonresectable metastatic liver disease of colorectal origin. A prospective randomized study. *Hepatogastroenterology* 2001 48(40): 1085-7.

M. G. Mack, R. Straub, K. Eichler, K. Engelmann, S. Zangos, A. Roggan, D. Woitaschek, M. Bottger and T. J. Vogl. Percutaneous MR imaging-guided laser-induced thermotherapy of hepatic metastases. *Abdom Imaging* 2001 26(4): 369-74.

R. S. Stubbs, R. J. Cannan and A. W. Mitchell. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. *Hepatogastroenterology* 2001 48(38): 333-7.

R. S. Stubbs, R. J. Cannan and A. W. Mitchell. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. *J Gastrointest Surg* 2001 5(3): 294-302.

M. Lorenz, H. H. Mueller, E. Mattes, H. J. Gassel, T. Junginger, H. D. Saeger, H. Schramm, E. Staib-Sebler, G. Vetter, S. Heinrich and C. H. Kohne. Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. *Ann Oncol* 2001 12(3): 321-5.

M. S. Copur, M. Capadano, J. Lynch, T. Goertzen, T. McCowan, R. Brand and M. Tempero. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. *J Clin Oncol* 2001 19(9): 2404-12.

T. E. Lans, D. L. Bartlett, S. K. Libutti, M. F. Gnant, D. J. Liewehr, D. J. Venzon, E. M. Turner and H. R. Alexander. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. *Clin Cancer Res* 2001 7(4): 784-90.

M. Rivoire, F. De Cian, P. Meeus, B. Gignoux, B. Frering and P. Kaemmerlen. Cryosurgery as a means to improve surgical treatment of patients with multiple unresectable liver metastases. *Anticancer Res* 2000 20(5C): 3785-90.

M. J. Heslin, H. Medina-Franco, M. Parker, S. M. Vickers, J. Aldrete and M. M. Urist. Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival. *Arch Surg* 2001 136(3): 318-23.

J. M. van Riel, C. J. van Groenigen, S. H. Albers, M. Cazemier, S. Meijer, R. Bleichrodt, F. G. van den Berg, H. M. Pinedo and G. Giaccone. Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. *Ann Oncol* 2000 11(12): 1563-70.

D. L. Bartlett, S. K. Libutti, W. D. Figg, D. L. Fraker and H. R. Alexander. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. *Surgery* 2001 129(2): 176-87.

T. de Baere, D. Elias, C. Dromain, M. G. Din, V. Kuoch, M. Ducreux, V. Boige, N. Lassau, V. Marteau, P. Lasser and A. Roche. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. *AJR Am J Roentgenol* 2000 175(6): 1619-25.

J. K. Seifert, T. Achenbach, A. Heintz, T. C. Bottger and T. Junginger. Cryotherapy for liver metastases. *Int J Colorectal Dis* 2000 15(3): 161-6.

L. A. Dawson, C. J. McGinn, D. Normolle, R. K. Ten Haken, S. Walker, W. Ensminger and T. S. Lawrence. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. *J Clin Oncol* 2000 18(11): 2210-8.

A. R. Gillams and W. R. Lees. Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. *Dis Colon Rectum* 2000 43(5): 656-61.

M. Lorenz and H. H. Muller. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. *J Clin Oncol* 2000 18(2): 243-54.

E. Berber and A. Siperstein. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. *Ann Surg Oncol* 2008 15(10): 2757-64.

G. Fiorentini, D. B. Poddie, M. Cantore, S. Rossi, S. Tumolo, P. Dentico, P. Bernardeschi, S. Guadagni, G. Rossi, V. M. Valori and M. De Simone. Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study. *J Chemother* 2004 16 Suppl 5(0): 51-4.

R. Mancini, M. Tedesco, C. Garufi, A. Filippini, S. Arcieri, M. Caterino, G. Pizzi, E. Cortesi, A. Spila, I. Sperduti and M. Cosimelli. Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. *Anticancer Res* 2003 23(2C): 1837-41.

S. Heinrich, H. Petrowsky, I. Schwinnen, E. Staib-Sebler, C. Gog, A. El-Ganainy, C. Gutt, H. H. Muller and M. Lorenz. Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. *Surgery* 2003 133(1): 40-8.

A. J. Bilchik, T. F. Wood, S. P. Chawla, D. M. Rose, M. H. Chung, S. S. Stern, L. J. Foshag and K. P. Ramming. Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. *Clin Colorectal Cancer* 2001 1(1): 36-42.

K. M. Ng, T. C. Chua, A. Saxena, J. Zhao, F. Chu and D. L. Morris. Two Decades of Experience with Hepatic Cryotherapy for Advanced Colorectal Metastases. *Ann Surg Oncol* 2011 (): .

C. W. Hammill, K. G. Billingsley, M. A. Cassera, R. F. Wolf, M. B. Ujiki and P. D. Hansen. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. *Annals of Surgical Oncology* 2011 18(7): 1947-1954.

T. J. Vogl, A. Jost, N. A. Nour-Eldin, M. G. Mack, S. Zangos and N. N. Naguib. Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. *Br J Cancer* 2012 106(7): 1274-9.

Level 3, Form CRC Full-textScreening, Not Relevant Design -> Exclude

T. Iguchi, H. Idani, S. Asami, H. Endo, Y. Inaba, Y. Arai and S. Kanazawa. Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients. *Acta Med Okayama* 2011 65(1): 49-53.

T. Tanida, M. Ohue, S. Noura, Y. Seki, K. Gotoh, M. Motoori, K. Kishi, T. Yamada, I. Miyashiro, H. Ohigashi, M. Yano and O. Ishikawa. Long-term complete response of unresectable liver metastases from colorectal cancer. *Hepatogastroenterology* 2010 57(101): 764-7.

B. Guiu, J. Vincent, S. Guiu, S. Ladoire, P. Ortega-Deballon, J. P. Cercueil, B. Chauffert and F. Ghiringhelli. Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer. *World J Gastroenterol* 2010 16(9): 1150-4.

A. Viudez, J. Rodriguez and I. Gil-Bazo. Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom?. *Cardiovasc Intervent Radiol* 2009 32(3): 603-4.

S. Garrean, A. Muhs, J. T. Bui, M. J. Blend, C. Owens, W. S. Helton and N. J. Espat. Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT. *World J Gastroenterol* 2007 13(21): 3016-9.

L. M. Veenendaal, A. de Jager, G. Stapper, I. H. Borel Rinkes and R. van Hillegersberg. Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. *Photomed Laser Surg* 2006 24(1): 3-9.

M. Milandri, F. Calzolari, A. Passardi, R. Ridolfi, C. Tison, E. Giampalma, R. Golfieri, L. Ridolfi, G. Mura, A. Vagliasindi, M. Fra Marini and G. M. Verdecchia. Intra-arterial chemotherapy for liver metastases from colorectal cancer. *Suppl Tumori* 2005 4(3): S45.

- C. Shibata, X. L. Jin, Y. Funayama, K. Fukushima, K. Takahashi, A. Hashimoto, M. Nagao, S. Haneda, K. Watanabe, S. Matsuno, I. Sasaki and H. Naito. Effect of intra-arterial cisplatin on multiple liver metastases from rectal cancer associated with ulcerative colitis. *Tohoku J Exp Med* 2004 202(1): 57-61.
- Y. Ogata, H. Tsuda, K. Matono, T. Kumabe, H. Saitsu, H. Hara, Y. Akagi, Y. Araki, M. Sata and K. Shirouzu. Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case. *Surg Today* 2003 33(6): 448-53.
- E. Savier, D. Azoulay, E. Huguet, F. Lokiec, M. Gil-Delgado and H. Bismuth. Percutaneous isolated hepatic perfusion for chemotherapy: a phase I study. *Arch Surg* 2003 138(3): 325-32.
- M. A. Sikma, J. L. Coenen, C. Kloosterziel, B. A. Hasselt and T. J. Ruers. A breakthrough in cryosurgery. *Surg Endosc* 2002 16(5): 870.
- S. Jamdar, S. Jegatheeswaran, A. Bandara, A. J. Sheen and A. K. Siriwardena. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases (*Br J Surg* 2010; 97: 240-250). *Br J Surg* 2010 97(6): 958; author reply 958.
- F. A. De Jong, R. H. Mathijssen and J. Verweij. Limited potential of hepatic arterial infusion of irinotecan. *J Chemother* 2004 16 Suppl 5(): 48-50.
- M. Bienert, B. McCook, B. I. Carr, D. A. Geller, M. Sheetz, N. Amesur and N. Avril. Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases. *Eur J Nucl Med Mol Imaging* 2005 32(6): 723.
- A. Seki and S. Hori. Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study. *Int J Clin Oncol* 2011 (): .
- S. Castiglioni, A. Tozzi, P. Mancosu, P. Navarra, S. Pentimalli, F. Alongi, E. Clerici, A. Fogliata, L. Cozzi, G. Torzilli and M. Scorsetti. Sbrt dose escalation phase I study for liver metastases using volumetric modulated arc therapy. *Radiotherapy and Oncology* 2011 99(): S354.
- Y. A. Barsukov, V. A. Aliev, S. I. Tkachev, S. A. Tyulyandin, M. Y. Fedyanin, D. V. Kuzmichev, Z. Z. Mammadli and A. O. Atroshenko. Our experience in treatment rectal cancer patients with synchronous metastases. *European Surgery - Acta Chirurgica Austriaca* 2011 43(): 16.
- Y. A. Barsukov, V. A. Aliev, S. I. Tkachev, S. A. Tyulandin, M. Y. Fedjanin, D. V. Kuzmichev, Z. Z. Mamedli and A. O. Atroshchenko. Our experience in treating patients with synchronous distant metastases of rectal cancer. *European Surgery - Acta Chirurgica Austriaca* 2011 43(): 17.
- N. B. Bhardwaj, W. Ngu, A. Strickland, M. Elabassy and D. L. Loyd. Microwave ablation for unresectable hepatic tumours: Long term clinical results. *HPB* 2011 13(): 73-74.
- S. Evrard, M. Rivoire, J. P. Arnaud, A. Ayav, A. S. Cuhna, J. M. Regimbeau, S. Mathoulin and C. Bellera. Intraoperative radiofrequency ablation combined or not with resection to treat unresectable colorectal metastases. Results of the multicentric phase 2 study: ARF2003. *HPB* 2011 13(): 1.
- P. Manchon Walsh, J. M. Borrás, T. Ferro and J. A. Espinas. Colorectal cancer *OncoGuia*. Clinical and Translational Oncology 2010 12(3): 188-210.
- L. Vlad. Hepatic intraarterial chemotherapy - A therapeutic alternative in unresectable liver tumours. *Romanian Journal of Gastroenterology* 2000 9(3): 193-200.
- D. Ansari and R. Andersson. Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. *World J Gastroenterol* 2012 18(10): 1003-8.

G. Bonomo, P. Della Vigna, L. Monfardini, G. Orgera and F. Orsi. Micro-bland embolization (mb-TAE) may enhance local outcome of RFA in the treatment of complex liver metastases from CRC. *CardioVascular and Interventional Radiology* 2011 34(): 603.

B. A. Boone, D. L. Bartlett and A. H. Zureikat. Isolated Hepatic Perfusion for the Treatment of Liver Metastases. *Current Problems in Cancer* 2012 36(2): 27-76.

R. Cirotchi, S. Trastulli, C. Boselli, A. Montedori, D. Cavaliere, A. Parisi, G. Noya and I. Abraha. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. *Cochrane Database Syst Rev* 2012 6(): CD006317.

S. J. Cohen, A. A. Konski, S. Putnam, D. Ball, J. E. Meyer, J. Q. Yu, I. A. Astsaturov, K. Magalong, D. Cade and N. J. Meropol. A phase I study of capecitabine in combination with yttrium-90 labeled resin microspheres (SIR-Spheres) in patients (pts) with advanced cancer. *Journal of Clinical Oncology* 2011 29(15): .

M. Cosimelli, R. Mancini, L. Carpanese, R. Sciuto, G. Pizzi, G. Pattaro and C. L. Maini. Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer. *Expert Opin Ther Targets* 2012 16 Suppl 2(): S11-6.

L. A. Dawson, A. Swaminath, C. Massey, J. Kim, R. Diniwell, J. Brierley, R. Wong, M. Velec and K. Brock. Stereotactic radiotherapy for liver metastases. *European Journal of Cancer* 2011 47(): S89.

T. De Baere. Transcatheter therapy in hepatic colorectal metastasis has value. *CardioVascular and Interventional Radiology* 2011 34(): 482-483.

M. Ducreux, P. Rougier, D. Smith, C. N. J. Focan, P. F. Innominato, M. Bouchahda, Y. Ajavon, D. Castaing, T. De Baere, A. Karaboue, C. Lepere, V. Boige, R. Adam and F. Levi. Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV-A European multicenter phase II trial. *Journal of Clinical Oncology* 2011 29(15): .

S. Evrard, M. Rivoire, J. P. Arnaud, E. Lermite, C. Bellera, S. Mathoulin-Pelissier, M. Fonck, R. Brunet, Y. Becouarn and C. Lalet. Unresectable colorectal liver metastases treated by intraoperative radiofrequency ablation with or without resection: the ARF2003 study. *European Journal of Cancer* 2011 47(): S393.

G. Fiorentini, C. Aliberti, M. Tilli, A. Mambrini, G. Turrisi, P. Dentico and G. Benea. Evaluation of a phase III clinical trial comparing transarterial chemoembolisation (TACE) using irinotecan-loaded polyvinyl alcohol microspheres (DeBiro) vs systemic chemotherapy Folfiri (CT) for the treatment of unresectable metastases to the liver (LM) in patients with advanced colorectal cancer (MCR). *CardioVascular and Interventional Radiology* 2011 34(): 599.

D. Magge, A. Zureikat, D. Bartlett, M. Holtzman, H. Choudry, J. Beumer, J. L. Holleran, S. Strychor, J. Pingpank and H. J. Zeh. A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases (ILM) from colorectal cancer (CRC). *Annals of Surgical Oncology* 2012 19(): S115.

H. Nishiofuku, T. Tanaka, H. Anai, S. Sueyoshi, M. Matsuoka, T. Otsuji, K. Yamamoto, Y. Inaba, H. Sakaguchi and K. Kichikawa. Phase I/II study of transcatheter arterial chemoembolization with cisplatin powder and degradable starch microspheres for unresectable hepatic metastases from colorectal cancer refractory to systemic standard chemotherapy. *Journal of Clinical Oncology* 2011 29(4): .

F. Orsi, G. Bonomo, P. Della Vigna and L. Monfardini. Combination therapy. CardioVascular and Interventional Radiology 2011 34(): 365-366.

F. Petrelli and S. Barni. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis 2012 (): .

S. C. Rose, E. Roeland, K. Shimabukuro, P. Fanta, B. Parker, Y. Kono and T. Reid. Single center prospective phase II trial of Yttrium-90 radioembolization for treatment of colorectal liver metastases that have failed first line chemotherapy and prior to initiation of second line chemotherapy: Study design and early results. CardioVascular and Interventional Radiology 2011 34(): 502.

M. Scorsetti, S. Castiglioni, A. Tozzi, F. Alongi, S. Pentimalli, A. Ascolese, P. Navarria, S. Arcangeli, P. Mancosu and L. Cozzi. SBRT dose escalation Phase II study for liver metastases using volumetric modulated Arc therapy (VMAT-RapidArc). International Journal of Radiation Oncology Biology Physics 2011 81(2): S346.

Y. Shimada. Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective. J Hepatobiliary Pancreat Sci 2012 (): 1-8.

A. Sobrero and M. Di Benedetto. Neoadjuvant treatment in colon cancer. European Journal of Cancer 2011 47(): S72-S73.

A. Stein, M. Duex, R. Kickuth, A. Petrovitch, S. Pluntke, J. Ricke, C. Stroszczynski, T. J. Vogl, D. Arnold and P. L. Pereira. A randomized phase II trial of irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX) versus systemic treatment with intravenous cetuximab and irinotecan in patients with refractory colorectal liver metastases and Kras wild-type tumors. CardioVascular and Interventional Radiology 2011 34(): 617.

Level 3, Form CRC Full-textScreening, Animal study -> Exclude

M. T. Lee, J. J. Kim, R. Dinniwell, J. Brierley, G. Lockwood, R. Wong, B. Cummings, J. Ringash, R. V. Tse, J. J. Knox and L. A. Dawson. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009 27(10): 1585-91.

Level 3, Form CRC Full-textScreening, Not Relevant Population -> Exclude

L. H. Camacho, S. Garcia, A. M. Panchal, J. Lim, D. S. Hong, C. Ng, D. C. Madoff, S. Fu, I. Gayed and R. Kurzrock. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer 2010 9(5): 311-4.

C. Khouri, B. Guiu, J. P. Cercueil, B. Chauffert, S. Ladoire and F. Ghiringhelli. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. Anticancer Drugs 2010 21(6): 656-61.

R. Cianni, C. Urigo, E. Notarianni, A. Saltarelli, A. D'Agostini, M. Iozzino, T. Dornbusch and E. Cortesi. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med 2010 115(4): 619-33.

R. C. Martin, C. R. Scoggins and K. M. McMasters. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. *Ann Surg Oncol* 2010 17(1): 171-8.

M. R. Meijerink, P. van den Tol, A. A. van Tilborg, J. H. van Waesberghe, S. Meijer and C. van Kuijk. Radiofrequency ablation of large size liver tumours using novel plan-parallel expandable bipolar electrodes: initial clinical experience. *Eur J Radiol* 2011 77(1): 167-71.

A. R. Knudsen, A. S. Kannerup, F. V. Mortensen and D. T. Nielsen. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy. *Acta Radiol* 2009 50(7): 716-21.

G. Poggi, P. Quaretti, C. Minoia, G. Bernardo, M. R. Bonora, R. Gaggeri, A. Ronchi, C. M. Saluzzo, A. Azzaretti, G. Rodolico, M. Montagna, A. Amatu, C. Teragni, I. Palumbo, E. Traverso, S. Tonini, L. Villani, M. Scelsi, P. Baiardi, M. G. Felisi, F. Sottotetti, B. Tagliaferri and A. Riccardi. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. *Anticancer Res* 2008 28(6B): 3835-42.

H. J. Zeh, 3rd, C. K. Brown, M. P. Holtzman, M. J. Egorin, J. L. Holleran, D. M. Potter and D. L. Bartlett. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. *Ann Surg Oncol* 2009 16(2): 385-94.

S. Hofer, C. Oberholzer, S. Beck, C. Looser and C. Ludwig. Ultrasound-guided radiofrequency ablation (RFA) for inoperable gastrointestinal liver metastases. *Ultraschall Med* 2008 29(4): 388-92.

R. B. Jagad, M. Koshariya, J. Kawamoto, P. Papastratis, H. Kefalourous, V. Patris, T. Porfiris, P. Gevriolidis, C. Tzouma and N. J. Lygidakis. Laparoscopic microwave ablation of liver tumors: our experience. *Hepatogastroenterology* 2008 55(81): 27-32.

P. Hildebrand, M. Kleemann, U. Roblick, L. Mirow, M. Birth and H. P. Bruch. Laparoscopic radiofrequency ablation of unresectable hepatic malignancies: indication, limitation and results. *Hepatogastroenterology* 2007 54(79): 2069-72.

K. Liepe, C. Brogsitter, J. Leonhard, G. Wunderlich, R. Hliscs, J. Pinkert, G. Folprecht and J. Kotzerke. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. *Jpn J Clin Oncol* 2007 37(12): 942-50.

G. Schumacher, R. Eisele, A. Spinelli, S. C. Schmidt, D. Jacob, J. Pratschke and P. Neuhaus. Indications for hand-assisted laparoscopic radiofrequency ablation for liver tumors. *J Laparoendosc Adv Surg Tech A* 2007 17(2): 153-9.

J. P. Ritz, K. S. Lehmann, U. Zurbuchen, F. Wacker, F. Brehm, C. Isbert, C. T. Germer, H. J. Buhr and C. Holmer. Improving laser-induced thermotherapy of liver metastases--effects of arterial microembolization and complete blood flow occlusion. *Eur J Surg Oncol* 2007 33(5): 608-15.

S. C. Low, R. H. Lo, T. N. Lau, L. L. Ooi, C. K. Ho, B. S. Tan, A. Y. Chung, W. H. Koo and P. K. Chow. Image-guided radiofrequency ablation of liver malignancies: experience at Singapore General Hospital. *Ann Acad Med Singapore* 2006 35(12): 851-7.

S. Geyik, O. Akhan, O. Abbasoglu, D. Akinci, O. S. Ozkan, E. Hamaloglu and M. Ozmen. Radiofrequency ablation of unresectable hepatic tumors. *Diagn Interv Radiol* 2006 12(4): 195-200.

S. Krishnan, E. H. Lin, G. B. Gunn, A. Chandra, A. S. Beddar, T. M. Briere, P. Das, M. E. Delclos, N. A. Janjan and C. H. Crane. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. *Am J Clin Oncol* 2006 29(6): 562-7.

- O. Cosin, J. I. Bilbao, S. Alvarez, E. de Luis, A. Alonso and A. Martinez-Cuesta. Right gastric artery embolization prior to treatment with yttrium-90 microspheres. *Cardiovasc Intervent Radiol* 2007 30(1): 98-103.
- R. Murthy, H. Xiong, R. Nunez, A. C. Cohen, B. Barron, J. Szklaruk, D. C. Madoff, S. Gupta, M. J. Wallace, K. Ahrar and M. E. Hicks. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. *J Vasc Interv Radiol* 2005 16(7): 937-45.
- S. A. Gulec, T. S. Mountcastle, D. Frey, J. D. Cundiff, E. Mathews, L. Anthony, J. P. O'Leary and J. P. Boudreaux. Cytorreductive surgery in patients with advanced-stage carcinoid tumors. *Am Surg* 2002 68(8): 667-71; discussion 671-2.
- H. C. Jiang, L. X. Liu, D. X. Piao, J. Xu, M. Zheng, A. L. Zhu, S. Y. Qi, W. H. Zhang and L. F. Wu. Clinical short-term results of radiofrequency ablation in liver cancers. *World J Gastroenterol* 2002 8(4): 624-30.
- N. Isambert, M. Correia, J. P. Cercueil, S. Zanetta, L. Osmak, M. Flesch, D. Krause, B. Coudert, P. Fargeot, L. Bedenne and B. Chauffert. Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study. *J Exp Clin Cancer Res* 2001 20(2): 183-8.
- T. Skalicky, V. Treska, A. Sutnar, V. Liska, P. Duras and F. Slauf. Chemo-embolization of inoperable liver tumors. *Bratisl Lek Listy* 2010 111(12): 676-9.
- G. Fiorentini, C. Aliberti, G. Benea, F. Montagnani, A. Mambrini, P. L. Ballardini and M. Cantore. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. *Hepatogastroenterology* 2008 55(88): 2077-82.
- V. Donckier, J. L. Van Laethem, S. Goldman, D. Van Gansbeke, P. Feron, B. Ickx, D. Wikler and M. Gelin. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. *J Surg Oncol* 2003 84(4): 215-23.
- S. A. Gulec, R. R. Suthar, T. C. Barot and K. Pennington. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. *Eur J Nucl Med Mol Imaging* 2011 38(7): 1289-95.
- P. Samaras, S. Breitenstein, S. R. Haile, F. Stenner-Liewen, S. Heinrich, J. Feilchenfeldt, C. Renner, A. Knuth, B. C. Pestalozzi and P. A. Clavien. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. *Ann Surg Oncol* 2011 18(7): 1924-31.
- J. T. Bowling, N. P. Reuter, R. C. G. Martin, K. M. McMasters, C. Tatum and C. R. Scoggins. Prior biliary tree instrumentation does not preclude hepatic arterial therapy for malignancy. *American Surgeon* 2010 76(6): 618-621.
- P. Hildebrand, T. Leibecke, M. Kleemann, L. Mirow, M. Birth, H. P. Bruch and C. Burk. Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome. *European Journal of Surgical Oncology* 2006 32(4): 430-434.
- P. Hildebrand, M. Kleemann, U. J. Roblick, L. Mirow, M. Birth, T. Leibecke and H. P. Bruch. Radiofrequency-ablation of unresectable primary and secondary liver tumors: Results in 88 patients. *Langenbeck's Archives of Surgery* 2006 391(2): 118-123.
- B. Melichar, M. Touskova, M. Blaha, P. Vesely, J. Dvorak, A. Krajina and J. Cerman Jr. Hepatic arterial administration of activated leukocytes in patients with liver metastases. *Cancer Biotherapy and Radiopharmaceuticals* 2002 17(5): 545-552.

J. Votrubova, J. Horejs, M. Peskova, J. Svab and Z. Krska. Radiofrequency thermoablation of hepatic tumours. *Ceska Radiologie* 2002 56(3): 145-150.

J. Bhat and F. Habr. Photodynamic therapy in nonresectable cholangiocarcinoma-is it worth it?. *American Journal of Gastroenterology* 2011 106(): S56-S57.

J. Boda-Hegemann, D. Dinter, C. Weiss, K. Siebenlist, U. Attenberger, A. Frauenfeld, M. Ottstadt, A. Simeonova, F. Schneider, R. Hofheinz, F. Lohr and F. Wenz. Hypofractionated image-guided breath-hold radiotherapy of liver metastases - Clinical results. *Strahlentherapie und Onkologie* 2011 187(): 19.

G. Bonomo, P. Della Vigna, L. Monfardini, G. Orgera, A. Chiappa, P. P. Bianchi, M. G. Zampino and F. Orsi. Combined Therapies for the Treatment of Technically Unresectable Liver Malignancies: Bland Embolization and Radiofrequency Thermal Ablation within the Same Session. *Cardiovasc Intervent Radiol* 2012 (): .

B. Engels, T. Gevaert, H. Everaert, P. De Coninck, A. Sermeus, N. Christian, G. Storme, D. Verellen and M. De Ridder. Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer. *Radiat Oncol* 2012 7(): 34.

M. G. House, N. E. Kemeny, M. Gonen, Y. Fong, P. J. Allen, P. B. Paty, R. P. DeMatteo, L. H. Blumgart, W. R. Jarnagin and M. I. D'Angelica. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusion chemotherapy after hepatic resection for metastatic colorectal cancer. *Ann Surg* 2011 254(6): 851-6.

L. M. Howells, D. P. Berry, P. J. Elliott, E. W. Jacobson, E. Hoffmann, B. Hegarty, K. Brown, W. P. Steward and A. J. Gescher. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. *Cancer Prev Res (Phila)* 2011 4(9): 1419-25.

Y. C. Kim, Y. H. Kim, S. H. Um, Y. S. Seo, E. K. Park, S. Y. Oh, Y. M. Han and J. G. Choe. Usefulness of bremsstrahlung images after intra-arterial Y-90 resin microsphere radioembolization for hepatic tumors. *Nuclear Medicine and Molecular Imaging* 2011 45(1): 59-67.

R. C. Martin, 2nd, C. R. Scoggins, D. Tomalty, M. Schreeder, T. Metzger, C. Tatum and V. Sharma. Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial. *J Gastrointest Surg* 2012 (): .

C. Reissfelder, C. Timke, H. Schmitz-Winnenthal, N. N. Rahbari, M. Koch, F. Klug, F. Roeder, L. Edler, J. Debus, M. W. Buchler, P. Bechthold, P. E. Huber and J. Weitz. A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. *BMC Cancer* 2011 11(): 419.

E. Simoneau, M. Aljiffry, A. Salman, N. Abualhassan, T. Cabrera, D. Valenti, A. El Baage, M. Jamal, P. Kavan, S. Al-Abbad, P. Chaudhury, M. Hassanain and P. Metrakos. Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. *HPB (Oxford)* 2012 14(7): 461-8.

Level 3, Form CRC Full-textScreening, Not Relevant Intervention -> Exclude

A. A. Van Tilborg, M. R. Meijerink, C. Sietses, J. H. Van Waesberghe, M. O. Mackintosh, S. Meijer, C. Van Kuijk and P. Van Den Tol. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. *Br J Radiol* 2011 84(1002): 556-65.

Y. Chen, Z. Yan, J. Wang, X. Wang, J. Luo and Q. Liu. Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. *Anticancer Res* 2010 30(7): 3045-9.

T. Yamaguchi, H. Matsumoto, M. Yasutome, T. Mori and K. Takahashi. Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. *Cancer Chemother Pharmacol* 2011 67(3): 629-35.

R. C. Martin, K. Robbins, D. Tomalty, R. O'Hara, P. Bosnjakovic, R. Padr, M. Rocek, F. Slauf, A. Scupchenko and C. Tatum. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. *World J Surg Oncol* 2009 7(): 80.

G. Wieners, M. Pech, B. Hildebrandt, N. Peters, A. Nicolaou, K. Mohnike, M. Seidensticker, M. Sawicki, P. Wust and J. Ricke. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal "liver-only" metastases: hepatic interstitial brachytherapy plus regional chemotherapy. *Cardiovasc Intervent Radiol* 2009 32(5): 937-45.

C. Verhoef, J. H. de Wilt, F. Brunstein, A. W. Marinelli, B. van Etten, M. Vermaas, G. Guetens, G. de Boeck, E. A. de Bruijn and A. M. Eggermont. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. *Ann Surg Oncol* 2008 15(5): 1367-74.

D. J. Gallagher, M. Capanu, G. Raggio and N. Kemeny. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. *Ann Oncol* 2007 18(12): 1995-9.

V. Boige, D. Malka, D. Elias, M. Castaing, T. De Baere, D. Goere, C. Dromain, M. Pocard and M. Ducreux. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. *Ann Surg Oncol* 2008 15(1): 219-26.

M. Pech, G. Wieners, T. Freund, O. Dudeck, F. Fischbach, J. Ricke and M. D. Seemann. MR-guided interstitial laser thermotherapy of colorectal liver metastases: efficiency, safety and patient survival. *Eur J Med Res* 2007 12(4): 161-8.

R. A. Sharma, G. A. Van Hazel, B. Morgan, D. P. Berry, K. Blanshard, D. Price, G. Bower, J. A. Shannon, P. Gibbs and W. P. Steward. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. *J Clin Oncol* 2007 25(9): 1099-106.

A. S. Kennedy, D. Coldwell, C. Nutting, R. Murthy, D. E. Wertman, Jr., S. P. Loehr, C. Overton, S. Meranze, J. Niedzwiecki and S. Sailer. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. *Int J Radiat Oncol Biol Phys* 2006 65(2): 412-25.

R. C. Martin, 2nd, C. R. Scoggins and K. M. McMasters. A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy. *J Surg Oncol* 2006 93(5): 387-93.

F. H. van Duijnhoven, J. P. Rovers, K. Engelmann, Z. Krajina, S. F. Purkiss, F. A. Zoetmulder, T. J. Vogl and O. T. Terpstra. Photodynamic therapy with 5,10,15,20-tetrakis(m-hydroxyphenyl) bacteriochlorin for colorectal liver metastases is safe and feasible: results from a phase I study. *Ann Surg Oncol* 2005 12(10): 808-16.

M. Ducreux, M. Ychou, A. Laplanche, E. Gamelin, P. Lasser, F. Hussein, F. Quenet, F. Viret, J. H. Jacob, V. Boige, D. Elias, J. R. Delperro and M. Lubinski. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. *J Clin Oncol* 2005 23(22): 4881-7.

N. Kemeny, W. Jarnagin, P. Paty, M. Gonen, L. Schwartz, M. Morse, G. Leonard, M. D'Angelica, R. DeMatteo, L. Blumgart and Y. Fong. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. *J Clin Oncol* 2005 23(22): 4888-96.

J. H. Morgan, 3rd, G. M. Royer, P. Hackett, T. C. Gamblin, B. L. McCampbell, A. Conforti and P. S. Dale. Radio-frequency ablation of large, nonresectable hepatic tumors. *Am Surg* 2004 70(12): 1035-8.

B. van Etten, F. Brunstein, I. M. G. van, A. W. Marinelli, C. Verhoef, J. R. van der Sijp, G. Guetens, G. de Boeck, E. A. de Bruijn, J. H. de Wilt and A. M. Eggermont. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. *Ann Surg Oncol* 2004 11(6): 598-605.

J. Tepel, S. Hinz, H. J. Klomp, M. Kapischke and B. Kremer. Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. *Eur J Surg Oncol* 2004 30(5): 551-5.

M. Onaitis, M. Morse, H. Hurwitz, P. Cotton, D. Tyler, P. Clavien and B. Clary. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. *Ann Surg* 2003 237(6): 782-8; discussion 788-9.

N. Kemeny, M. Gonen, D. Sullivan, L. Schwartz, F. Benedetti, L. Saltz, J. Stockman, Y. Fong, W. Jarnagin, J. Bertino, W. Tong and P. Paty. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. *J Clin Oncol* 2001 19(10): 2687-95.

J. Baumgart, S. Lang and H. Lang. A new method for induction of liver hypertrophy prior to right trisectionectomy: A report of three cases. *HPB* 2011 13(): 71-72.

C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. de Braud, G. Schuch, A. Zubel, I. Celik, M. Schlichting and P. Koralewski. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. *Ann Oncol* 2011 22(7): 1535-46.

G. Bruera, K. Cannita, F. Giuliani, P. L. Baldi, R. Vicentini, P. Marchetti, G. Nuzzo, A. Antonucci, C. Ficarella and E. Ricevuto. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. *Clin Colorectal Cancer* 2012 11(2): 119-26.

G. Bruera, K. Cannita, P. Lanfiuti Baldi, A. Santomaggio, P. Marchetti, G. Nuzzo, A. Antonucci, C. Ficarella and E. Ricevuto. Effectiveness of FIr-B/FOx and liver metastasectomies in liver-only metastatic colorectal cancer (MCRC). *Journal of Clinical Oncology* 2011 29(4): .

J. Cassidy, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, K. Rittweger, F. Gilberg and L. Saltz. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. *Br J Cancer* 2011 105(1): 58-64.

L. Fornaro, F. Loupakis, S. Lonardi, G. Masi, L. Salvatore, C. Cremolini, F. Bergamo, A. Cappetta, V. Zagonel and A. Falcone. FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in combination with panitumumab (P) in the first-line treatment of metastatic colorectal cancer (mCRC) patients (PTS) selected for KRAS, BRAF, nrns and hras mutational status? A Phase II study by the G.O.N.O. group. *European Journal of Cancer* 2011 47(): S420.

M. Frank, C. Asseburg, C. H. Kohne, J. T. Hartmann, J. Schulten, A. Mohr and T. Mittendorf. Exploring the cost-effectiveness of targeted therapy with cetuximab vs bevacizumab in Germany in patients with KRAS wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver. *Onkologie* 2011 34(): 246.

K. M. Galal, Z. Khaled and A. M. Mourad. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. *Indian J Cancer* 2011 48(1): 47-54.

T. Goi, K. Sawai, K. Koneri, K. Katayama and A. Yamaguchi. Results of hepatic arterial infusion chemotherapy in patients with unresectable liver metastases. *Viszeralmedizin: Gastrointestinal Medicine and Surgery* 2011 27(5): 397-401.

H. Hur, N. K. Kim, H. G. Kim, B. S. Min, K. Y. Lee, S. J. Shin, J. H. Cheon and S. H. Choi. Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. *Br J Cancer* 2012 106(1): 53-60.

K. Kataoka, A. Kanazawa, A. Nakajima, A. Yamaguchi, S. Tuyuki, A. Arimoto and Y. Kohno. Feasibility and potential benefit of neoadjuvant chemotherapy for colorectal liver metastasis: A single-centered retrospective study. *Journal of Clinical Oncology* 2011 29(4): .

N. E. Kemeny, W. R. Jarnagin, M. Capanu, Y. Fong, A. N. Gewirtz, R. P. Dematteo and M. I. D'Angelica. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. *J Clin Oncol* 2011 29(7): 884-9.

V. Liska, A. Sutnar, L. H. Jr, J. Vrzalova, V. Treska, T. Skalicky, M. Pesta, S. Kormunda, J. Finek, M. Rousarova and O. Topolcan. Matrix metalloproteinases and their inhibitors in correlation to proliferative and classical tumour markers during surgical therapy of colorectal liver metastases. *Bratisl Lek Listy* 2012 113(2): 108-13.

A. Muratore, G. Zimmiti, D. Ribero, A. Mellano, L. Vigano and L. Capussotti. Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?. *Ann Surg Oncol* 2012 19(4): 1310-5.

T. Takahashi, Y. Shibata, Y. Tojima, K. Tsuboi, E. Sakamoto, K. Kunieda, H. Matsuoka, K. Suzumura, M. Sato, T. Naganuma, J. Sakamoto, S. Morita and K. Kondo. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. *Int J Clin Oncol* 2012 (): .

K. Tanaka, T. Kumamoto, K. Nojiri, K. Takeda and I. Endo. Postchemotherapy histological analysis of major intrahepatic vessels for reversal of attachment or invasion by colorectal liver metastases. *Cancer* 2012 118(9): 2443-2453.

K. Uehara, S. Ishiguro, K. Hiramatsu, H. Nishio, E. Takeuchi, D. Takahari, Y. Yoshioka, Y. Takahashi, T. Ebata, K. Yoshimura, K. Muro and M. Nagino. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer. *Jpn J Clin Oncol* 2011 41(10): 1229-32.

H. Uetake, S. Tanaka, T. Ishikawa, K. Sugihara and S. Arii. Fate of metastatic foci after chemotherapy and usefulness of contrast-enhanced intraoperative ultrasonography to detect minute hepatic lesions. *J Hepatobiliary Pancreat Sci* 2012 (): .

Level 3, Form CRC Full-textScreening, Not Relevant Outcome -> Exclude

G. Poggi, P. Quaretti, B. Montagna, F. Sottotetti, B. Tagliaferri, E. Pozzi, A. Amatu, C. Pagella and G. Bernardo. Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization. *Cardiovasc Intervent Radiol* 2011 34 Suppl 2(): S190-4.

G. Ambrosino, F. Polistina, G. Costantin, P. Francescon, R. Guglielmi, P. Zanco, F. Casamassima, A. Febbraro, G. Gerunda and F. Lumachi. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. *Anticancer Res* 2009 29(8): 3381-4.

R. Murthy, C. Eng, S. Krishnan, D. C. Madoff, A. Habbu, S. Canet and M. E. Hicks. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. *J Vasc Interv Radiol* 2007 18(12): 1588-91.

J. P. Ritz, K. S. Lehmann, C. Reissfelder, T. Albrecht, B. Frericks, U. Zurbuchen and H. J. Buhr. Bipolar radiofrequency ablation of liver metastases during laparotomy. First clinical experiences with a new multipolar ablation concept. *Int J Colorectal Dis* 2006 21(1): 25-32.

L. Lim, P. Gibbs, D. Yip, J. D. Shapiro, R. Dowling, D. Smith, A. Little, W. Bailey and M. Liechtenstein. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. *Intern Med J* 2005 35(4): 222-7.

G. Basdanis, A. Michalopoulos, V. Papadopoulos, I. Tzeveleki, C. Efthimiadis, C. Kosmidis, D. Mekras and N. Harlaftis. Clinical short-term results of radiofrequency ablation in patients with liver metastases from colorectal cancer. *Tech Coloproctol* 2004 8 Suppl 1(): s187-9.

G. N. Bachar, F. Greif, E. Mor, R. Tur-Kaspa and A. Belenky. Radiofrequency ablation for the management of liver tumors. *Isr Med Assoc J* 2003 5(7): 496-500.

T. Tanaka, Y. Arai, Y. Inaba, K. Matsueda, T. Aramaki, Y. Takeuchi and K. Kichikawa. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. *J Vasc Interv Radiol* 2003 14(1): 63-8.

S. Mallach, U. Ramp, A. Erhardt, M. Schmitt and D. Haussinger. An uncommon cause of gastro-duodenal ulceration. *World J Gastroenterol* 2008 14(16): 2593-5.

R. Mancini, L. Carpanese, R. Sciuto, G. Pizzi, R. Golfieri, L. Giampalma, A. Cappelli, M. C. Galaverni, A. Blotta, F. Fiore, F. Izzo, S. Lastoria, A. Mastro, M. Di Marzo, P. P. Cagol, D. Gasparini, O. Geatti, S. Bacchetti, E. Pasqual, M. Zeuli, G. Paoletti, C. Garufi and M. Cosimelli. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. *In Vivo* 2006 20(6A): 711-4.

Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol*. 2010 Aug 10;28(23):3687-94. PMID: 20567019.

S. Evrard, M. Rivoire, J. Arnaud, E. Lermite, C. Bellera, M. Fonck, Y. Becouarn, C. Lalet, M. Puילו and S. Mathoulin-Pelissier. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. *Br J Surg* 2012 99(4): 558-65.

T. C. Lauenstein, T. A. Heusner, M. Hamami, J. Ertle, J. F. Schlaak, G. Gerken, A. Bockisch and G. Antoch. Radioembolization of hepatic tumors: Flow redistribution after the occlusion of intrahepatic arteries. *RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren* 2011 183(11): 1058-1064.

C. Aliberti, M. Tilli, G. Benea and G. Fiorentini. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. *Anticancer Res* 2006 26(5B): 3793-5.

V. Boige, D. Malka, D. Elias, M. Castaing, T. De Baere, D. Goere, C. Dromain, M. Pocard and M. Ducreux. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. *Ann Surg Oncol* 2008 15(1): 219-26.

T. F. Jakobs, R. T. Hoffmann, G. Poepperl, A. Schmitz, J. Lutz, W. Koch, K. Tatsch, A. Lubiensky, M. F. Reiser and T. Helmberger. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. *Eur Radiol* 2007 17(5): 1320-30.

Veltri A, Sacchetto P, Tosetti I, et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. *Cardiovasc Intervent Radiol*. 2008 Sep-Oct;31(5):948-56. PMID: 18506519.